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Abstract 
Title: Biomarker-Guided Clinical Trial Designs 
Author: Miranta Antoniou 
Personalized medicine is a rapidly growing area of research which has attracted 
much attention in recent years in the field of medicine. The ultimate aim of this 
approach is to ensure that the most appropriate treatment which provides clinical 
benefit will be tailored to each patient according their personal characteristics. 
However, testing the effectiveness of a biomarker-guided approach to treatment in 
improving patient health yields challenges both in terms of trial design and analysis. 
Although a variety of biomarker-guided designs have been proposed recently, their 
statistical validity, application and interpretation has not yet been fully explored. 
A comprehensive literature review based on an in-depth search strategy has 
been conducted with a view to providing researchers with clarity in definition, 
methodology and terminology of the various reported biomarker-guided trial 
designs. Additionally, a user-friendly online tool (www.BiGTeD.org) informed by 
our review has been developed to help investigators embarking on such trials decide 
on the most appropriate design. 
Simulation studies for the investigation of key statistical aspects of such trial 
designs and statistical approaches such as the sample size requirement under 
different settings have been performed. 
Furthermore, a strategy has been applied to choose the most optimal design in 
a given setting where a previously proposed clinical trial proved inefficient due to 
the very large sample size that was required. Statistical techniques to calculate the 
corresponding sample size have been applied and an adaptive version of the 
proposed design has been explored through simulations. 
Practical challenges of biomarker-guided trials in terms of funding, ethical and 
regulatory issues, recruitment, monitoring, statistical analysis plan, biomarker 
assessment and data sharing issues are also addressed in this thesis. 
The different biomarker-guided designs proposed so far need to be better 
understood by the research community in terms of analysis and planning and 
practical application as their proper use and choice can increase the probability of 
success of clinical trials which will result in development of personalised treatments 
in the future. Therefore, with this PhD thesis, we contribute to the knowledge 
enhancement of researchers regarding these studies by providing essential 
information and presenting statistical issues arising in their implementation. We 
hope that this work will help scientists to choose the right clinical trial design in the 
era of personalized medicine which is of utmost importance for the translation of 
drug development into the improvement of human health. 
 
iv 
 
List of Tables 
Table 2.1. Characteristics of biomarker-guided adaptive trial designs in Phase II and 
Phase III ................................................................................................................................ 13 
Table 3.1. Types of Biomarker guided non-adaptive designs proposed within the last 
ten years................................................................................................................................ 69 
Table 3.2. Sample size formulae for biomarker-guided clinical trial designs. ........... 88 
Table 5.1. Results for expected number of events and patients, expected total study 
period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 1 of hazard ratios for different percentages of 
information fraction. Number of events and patients from Table C.1 (calculated from 
(5.1) and (5.3) respectively) which achieve 80% power for the first scenario of hazard 
ratios and significance levels are also presented. ......................................................... 209 
Table 6.1. Sample size of the Biomarker-strategy design with treatment 
randomisation in the control arm in each effect size scenario. ................................... 231 
Table 6.2. Sample size of the Marker Stratified design based on the target effect size 
and acamprosate response rate in each biomarker-defined subgroup. .................... 242 
Table 6.3. Sample size of the Sequential Subgroup-Specific design based on the target 
effect size and acamprosate response rate in biomarker-positive subgroup. .......... 247 
Table 6.4. Sample size of the Parallel Subgroup-Specific design based on the target 
effect size and acamprosate response rate in each biomarker-defined subgroup. .. 251 
Table 6.5. Sample size of the Reverse Marker-Based strategy design with treatment 
randomization in the control arm in each effect size scenario. .................................. 256 
Table 6.6. Required total number of patients for four potential designs applied to 
STRONG trial. .................................................................................................................... 258 
v 
 
Table 6.7. Required total number of events and corresponding hazard ratio of the 
Reverse Marker-Based strategy design applied to STRONG trial. ............................ 264 
Table 7.1. Summary of simulation parameters for both binary and time-to-event 
outcomes. ........................................................................................................................... 282 
Table A.1. Characteristics of variations of Biomarker-guided adaptive trial designs
 ............................................................................................................................................. 371 
Table C.1. Accrual rate and number of events and patients (calculated from (5.7), (5.1) 
and (5.3) respectively) which achieve approximate 80% power for different scenarios 
of hazard ratios and significance levels, and the corresponding power of each 
biomarker-defined subgroup yielded from the simulation. ....................................... 386 
Table C.2. Results for expected number of events and patients, expected total study 
period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 2 of hazard ratios for different percentages of 
information fraction. Number of events and patients from Table C.1 (calculated from 
(5.1) and (5.3) respectively) which achieve 80% power for the second scenario of 
hazard ratios and significance levels are also presented. ............................................ 390 
Table C.3. Results for expected number of events and patients, expected total study 
period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 3 of hazard ratios for different percentages of 
information fraction. Number of events and patients from Table C.1 (calculated from 
(5.1) and (5.3) respectively) which achieve 80% power for the third scenario of hazard 
ratios and significance levels are also presented. ......................................................... 393 
Table C.4. Results for expected number of events and patients, expected total study 
period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 4 of hazard ratios for different percentages of 
information fraction. Number of events and patients from Table C.1 (calculated from 
vi 
 
(5.1) and (5.3) respectively) which achieve 80% power for the fourth scenario of 
hazard ratios and significance levels are also presented. ............................................ 396 
Table D.1.1. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the effect-size ratio method and 
O’Brien-Fleming decision boundaries. .......................................................................... 419 
Table D.1.2. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the conditional power method and 
O’Brien-Fleming decision boundaries. .......................................................................... 420 
Table D.1.3. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the effect-size ratio method and 
Pocock decision boundaries. ........................................................................................... 421 
Table D.1.4. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the conditional power method and 
Pocock decision boundaries. ........................................................................................... 422 
Table D.1.5. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the effect-size ratio method 
and O’Brien-Fleming decision boundaries. ................................................................... 423 
Table D.1.6. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the conditional power 
method and O’Brien-Fleming decision boundaries. .................................................... 425 
Table D.1.7. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with effect-size ratio method and 
Pocock decision boundaries. ........................................................................................... 428 
Table D.1.8. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the conditional power 
method and Pocock decision boundaries. ..................................................................... 430 
vii 
 
Table D.2.1. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the effect-size ratio method, 
O’Brien-Fleming efficacy boundaries and Pocock futility boundary. ....................... 433 
Table D.2.2. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the conditional power method, 
O’Brien-Fleming efficacy boundaries and Pocock futility boundary. ....................... 434 
Table D.2.3. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the effect-size ratio method, Pocock 
efficacy boundaries and Pocock futility boundary. ..................................................... 435 
Table D.2.4. Adaptive sample size re-estimation design for binary outcome applied 
to the reverse marker-based strategy design with the conditional power method, 
Pocock efficacy boundaries and Pocock futility boundary. ........................................ 436 
Table D.2.5. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the effect-size ratio method, 
O’Brien-Fleming efficacy boundaries and Pocock futility boundary. ....................... 437 
Table D.2.6. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the conditional power 
method, O’Brien-Fleming efficacy boundaries and Pocock futility boundary. ....... 439 
Table D.2.7. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the effect-size ratio method, 
Pocock efficacy boundaries and Pocock futility boundary. ........................................ 442 
Table D.2.8. Adaptive sample size re-estimation design for time-to-event outcome 
applied to the reverse marker-based strategy design with the conditional power 
method, Pocock efficacy boundaries and Pocock futility boundary. ........................ 444 
 
viii 
 
List of Figures 
Figure 2.1. CONSORT diagram of the review process .................................................... 9 
Figure 2.2. Adaptive signature design. “R” refers to randomization of patients. ..... 23 
Figure 2.3. Outcome-based adaptive randomization design. “R” refers to 
randomization of patients. ................................................................................................. 26 
Figure 2.4. Outcome-based adaptive randomization design. “R” refers to 
randomization of patients. ................................................................................................. 28 
Figure 2.5. Adaptive patient enrichment design. “R” refers to randomization of 
patients. ................................................................................................................................ 31 
Figure 2.6. Adaptive parallel Simon two-stage design. “R” refers to randomization of 
patients. ................................................................................................................................ 33 
Figure 2.7. Multi-arm multi-stage (MAMS) design. “R” refers to randomization of 
patients. ................................................................................................................................ 37 
Figure 2.8. Stratified adaptive design. “R” refers to randomization of patients........ 39 
Figure 2.9. Tandem two stage design. “R” refers to randomization of patients. ....... 42 
Figure 3.1. Flow diagram of the review process. From our search strategy a total 
number of 211 papers have been identified giving information regarding not only the 
biomarker-guided designs but also general information about personalized medicine 
and biomarkers. Before arriving at 211 papers, books, web pages for actual trials and 
papers published before 2005 were excluded. The 211 papers are split into two 
overlapping sets of 100 and 107 papers. The total of 207 is less than 211 due to overlap 
of papers, and also due to the fact that some articles referring to general information 
about personalized medicine and biomarkers and articles which do not provide 
further information on each broad of biomarker-guided designs were excluded. The 
ix 
 
107 papers for biomarker-guided adaptive trial designs were reviewed in our 
published paper Antoniou et al. (2016) [35]. ................................................................... 67 
Figure 3.2. Single arm designs ........................................................................................ 105 
Figure 3.3. Enrichment designs. “R” refers to randomization of patients. ............... 107 
Figure 3.4. Marker Stratified designs. “R” refers to randomization of patients. ..... 115 
Figure 3.5. Sequential Subgroup-Specific design. “R” refers to randomization of 
patients. Uncolored boxes are referred to the first stage of the trial and colored boxes 
are referred to the second stage of the trial. .................................................................. 122 
Figure 3.6. Parallel Subgroup-Specific design. “R” refers to randomization of patients.
 ............................................................................................................................................. 125 
Figure 3.7. Biomarker-positive and overall strategies with parallel assessment. “R” 
refers to randomization of patients. ............................................................................... 127 
Figure 3.8. Biomarker-positive and overall strategies with sequential assessment. “R” 
refers to randomization of patients. Uncolored boxes are referred to the first stage of 
the trial and colored boxes are referred to the second stage of the trial. .................. 129 
Figure 3.9. Biomarker-positive and overall strategies with fall-back analysis. “R” 
refers to randomization of patients. Uncolored boxes are referred to the first stage of 
the trial and colored boxes are referred to the second stage of the trial. .................. 131 
Figure 3.10. Marker Sequential test design (MaST). “R” refers to randomization of 
patients. Uncolored boxes are referred to the first stage of the trial and colored boxes 
are referred to the second stage of the trial. .................................................................. 133 
Figure 3.11. Hybrid design. “R” refers to randomization of patients. ...................... 136 
Figure 3.12. Biomarker-strategy design with biomarker assessment in the control 
arm. “R” refers to randomization of patients. ............................................................... 139 
x 
 
Figure 3.13. Biomarker-strategy design without biomarker assessment in the control 
arm. “R” refers to randomization of patients. ............................................................... 142 
Figure 3.14. Biomarker-strategy design with treatment randomization in the control 
arm. “R” refers to randomization of patients. ............................................................... 145 
Figure 3.15. Reverse Marker-Based strategy design. “R” refers to randomization of 
patients. .............................................................................................................................. 147 
Figure 3.16. Randomized Phase II trial design with biomarkers. “R” refers to 
randomization of patients. CI refers to the confidence interval. Uncolored boxes are 
referred to the first stage of the trial and colored boxes are referred to the second stage 
of the trial. .......................................................................................................................... 150 
Figure 4.1. ‘Pop-up’ box illustration. .............................................................................. 172 
Figure 4.2. Online tool’s homepage ................................................................................ 173 
Figure 4.3. Example of the webpage of a distinct adaptive design ........................... 174 
Figure 4.4. Example of an expanded version of an adaptive trial graphic ............... 175 
Figure 4.5. Example of an expanded version of an adaptive design graphic with the 
‘pop-up’ box showing further information ................................................................... 175 
Figure 4.6. Methodology information in the ‘Details’ section of an adaptive design 
graphic. ............................................................................................................................... 176 
Figure 4.7. Statistical and practical information in the ‘Details’ section of an adaptive 
design graphic. .................................................................................................................. 176 
Figure 4.8. Key references in the ‘Details’ section of an adaptive design graphic. .. 177 
Figure 4.9. ‘Variations’ section of an adaptive design graphic................................... 177 
xi 
 
Figure 4.10. Example of the webpage of a distinct non-adaptive design ................. 178 
Figure 4.11. Example of an expanded version of a shrunken non-adaptive design 
graphic ................................................................................................................................ 179 
Figure 4.12. Example of an expanded non-adaptive design graphic with a ‘pop-up’ 
box showing further information ................................................................................... 179 
Figure 4.13. Utility information in the ‘Details’ section of a non-adaptive graphic 180 
Figure 4.14. Methodology information in the ‘Details’ section of a non-adaptive 
graphic ................................................................................................................................ 180 
Figure 4.15. Sample size formulae in the ‘Details’ section of a non-adaptive graphic
 ............................................................................................................................................. 181 
Figure 4.16. Statistical and practical information in the ‘Details’ section of a non-
adaptive graphic ................................................................................................................ 181 
Figure 4.17. Key references in the ‘Details’ section of a non-adaptive graphic ....... 182 
Figure 4.18. Design-specific webpage of a non-adaptive design divided in different 
sub-categories. ................................................................................................................... 183 
Figure 4.19. Design-specific webpage of a sub-category of a non-adaptive design 183 
Figure 5.1. Parallel Subgroup-Specific design. “R” refers to randomization of patients. 
a refers to the overall significance level between the two biomarker subgroup tests 
such that a = a- + a+. ........................................................................................................ 188 
Figure 5.2. A, B, C represent the required number of events and D, E, F represent the 
required number of patients of each biomarker-defined subgroup which achieve 80% 
power versus the corresponding hazard ratio for each of the three scenarios of 
significance levels. Figure 5.2 A and D corresponds to the significance levels a- =
a+ = 0.0125, Figure 5.2 B and E corresponds to the significance levels a- = 0.015 and 
xii 
 
a+ = 0.010 and Figure 5.2 C and F corresponds to the significance levels a- = 0.010 
and a+ = 0.015. .................................................................................................................. 196 
Figure 5.3. A, B represent the required number of events and C, D represent the 
required number of patients which achieve 80% power versus the hazard ratio in each 
of the three scenarios of significance levels for each biomarker-defined subgroup 
separately. Figure 5.3 A and C corresponds to the biomarker-negative subgroup and 
the following significance levels: (i) a- = 0.0125, (ii) a- = 0.015 and (iii) a- = 0.010. 
Figure 5.3 B and D corresponds to the biomarker-positive subgroup and the following 
significance levels:  (i) a+ = 0.0125, (ii) a+ = 0.010 and (iii) a+ = 0.015. ................. 198 
Figure 5.4. Adaptive Parallel Subgroup-Specific design. “R” refers to randomization 
of patients. D1+ and D1- correspond to the target number of events of the biomarker-
positive subgroup and biomarker-negative subgroup respectively at the first stage of 
the study. D+ and D- correspond to the total required number of events of the 
biomarker-positive subgroup and biomarker-negative subgroup respectively which 
are planned according to the non-adaptive approach. D2+ and D2- correspond to the 
number of events of the biomarker-positive subgroup and biomarker-negative 
subgroup respectively at the second stage of the study. ............................................. 200 
Figure 5.5. Efficacy stopping probability, futility stopping probability and power of 
a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 1 of hazard ratios. Each row of graphs represents the 
different probabilities versus the interim fraction of each biomarker-defined 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) a- =
0.010 and a+ = 0.015 respectively. ................................................................................. 213 
Figure 5.6. Expected number of events and patients in two-stage design and required 
number of events and patients in one-stage design for each biomarker-defined 
subgroup versus the hazard ratios of each biomarker-defined subgroup when the 
interim fraction is 25%. The first two graphical representations in each row of graphs 
represent the number of events versus the hazard ratio of each biomarker-defined 
xiii 
 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) a- =
0.010 and a+ = 0.015 respectively. The remaining graphical representations in each 
row of graphs represent the number of patients versus the hazard ratio of each 
biomarker-defined subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ =
0.010 and (iii) a- = 0.010 and a+ = 0.015 respectively. ............................................... 215 
Figure 6.1. Biomarker-strategy design with treatment randomization in the control 
arm adopted in STRONG trial. “R” refers to randomization of patients. Naltrexone 
corresponds to the experimental treatment (A) and Acamprosate corresponds to the 
control treatment (B). Asp40 + (Asp40 present) corresponds to biomarker-positive 
patients and Asp40 - (Asp40 absent) corresponds to biomarker-negative patients.228 
Figure 6.2. Rate of return to any drinking for acamprosate ....................................... 230 
Figure 6.3. Marker Stratified design adopted in STRONG trial. “R” refers to 
randomization of patients. Naltrexone corresponds to the experimental treatment (A) 
and acamprosate corresponds to the control treatment (B). Asp40 + (Asp40 present) 
corresponds to biomarker-positive patients and Asp40 - (Asp40 absent) corresponds 
to biomarker-negative patients. ...................................................................................... 239 
Figure 6.4. Sequential Subgroup Specific design adopted in STRONG trial. “R” refers 
to randomization of patients. Naltrexone corresponds to the experimental treatment 
(A) and acamprosate corresponds to the control treatment (B). Asp40 + (Asp40 
present) corresponds to biomarker-positive patients and Asp40 - (Asp40 absent) 
corresponds to biomarker-negative patients................................................................. 246 
Figure 6.5. Parallel Subgroup-Specific design adopted in STRONG trial. “R” refers to 
randomisation of patients. Naltrexone corresponds to the experimental treatment (A) 
and acamprosate corresponds to the control treatment (B). Asp40 + (Asp40 present) 
corresponds to biomarker-positive patients and Asp40 - (Asp40 absent) corresponds 
to biomarker-negative patients. ...................................................................................... 249 
xiv 
 
Figure 6.6. Reverse Marker-Based strategy design adopted in STRONG trial. “R” 
refers to randomization of patients. Naltrexone corresponds to the experimental 
treatment and acamprosate corresponds to the control treatment. Asp40 + (Asp40 
present) corresponds to biomarker-positive patients and Asp40 - (Asp40 absent) 
corresponds to biomarker-negative patients................................................................. 254 
Figure 7.1. Type I error versus the information fraction of Simulation study 1. The 
horizontal line represents the level of significance of the non-adaptive design (i.e. 
0.025). .................................................................................................................................. 287 
Figure 7.2. Type I error versus the information fraction of Simulation study 2. The 
horizontal line represents the level of significance of the non-adaptive design (i.e. 
0.025). .................................................................................................................................. 288 
Figure 7.3. Power versus the information fraction under the alternative hypothesis of 
Simulation study 1. The horizontal line represents the power of the non-adaptive 
design (i.e. 80%). ................................................................................................................ 289 
Figure 7.4. Power versus the information fraction under the alternative hypothesis of 
Simulation study 2. The horizontal line represents the power of the non-adaptive 
design (i.e. 80%). ................................................................................................................ 290 
Figure 7.5. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 1. The horizontal line represents the sample size of 
the non-adaptive design. .................................................................................................. 291 
Figure 7.6. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 2. The horizontal line represents the sample size of 
the non-adaptive design. .................................................................................................. 291 
Figure 7.7. Sample size versus the information fraction under the null hypothesis of 
Simulation study 1. The horizontal line represents the sample size of the non-adaptive 
design. ................................................................................................................................. 292 
xv 
 
Figure 7.8. Sample size versus the information fraction under the null hypothesis of 
Simulation study 2. The horizontal line represents the sample size of the non-adaptive 
design. ................................................................................................................................. 293 
Figure 7.9. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 1. ............................................................... 294 
Figure 7.10. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2. ............................................................... 294 
Figure 7.11. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 1. .......................................................................... 295 
Figure 7.12. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2. .......................................................................... 296 
Figure 7.13. Futility stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2. ............................................................... 297 
Figure 7.14. Futility stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2. .......................................................................... 298 
Figure 7.15. Type I error versus the information fraction under the null hypothesis of 
Simulation study 1 for the first scenario of hazard ratio. The horizontal line represents 
the level of significance of the non-adaptive design (i.e. 0.025). ................................ 299 
Figure 7.16. Type I error versus the information fraction under the null hypothesis of 
Simulation study 2 for the first scenario of hazard ratio. The horizontal line represents 
the level of significance of the non-adaptive design (i.e. 0.025). ................................ 299 
Figure 7.17. Type I error versus the information fraction under the null hypothesis of 
Simulation study 1 for the second scenario of hazard ratio. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). ............. 300 
xvi 
 
Figure 7.18. Type I error versus the information fraction under the null hypothesis of 
Simulation study 2 for the second scenario of hazard ratio. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). ............. 300 
Figure 7.19. Type I error versus the information fraction under the null hypothesis of 
Simulation study 1 for the third scenario of hazard ratio. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). ............. 301 
Figure 7.20. Type I error versus the information fraction under the null hypothesis of 
Simulation study 2 for the third scenario of hazard ratio. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). ............. 301 
Figure 7.21. Type I error versus the information fraction under the null hypothesis of 
Simulation study 1 for the fourth scenario of hazard ratio. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). ............. 302 
Figure 7.22. Type I error versus the information fraction under the null hypothesis of 
Simulation study 2 for the fourth scenario of hazard ratio. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). ............. 302 
Figure 7.23. Power versus the information fraction under the alternative hypothesis 
of Simulation study 1 for the first scenario of hazard ratio. The horizontal line 
represents the power of the non-adaptive design. ....................................................... 304 
Figure 7.24. Power versus the information fraction under the alternative hypothesis 
of Simulation study 1 for the second scenario of hazard ratio. The horizontal line 
represents the power of the non-adaptive design. ....................................................... 305 
Figure 7.25. Power versus the information fraction under the alternative hypothesis 
of Simulation study 1 for the third scenario of hazard ratio. The horizontal line 
represents the power of the non-adaptive design. ....................................................... 305 
xvii 
 
Figure 7.26. Power versus the information fraction under the alternative hypothesis 
of Simulation study 1 for the fourth scenario of hazard ratio. The horizontal line 
represents the power of the non-adaptive design. ....................................................... 306 
Figure 7.27. Power versus the information fraction under the alternative hypothesis 
of Simulation study 2 for the first scenario of hazard ratio (i.e. 0.746). The horizontal 
line represents the power of the non-adaptive design. ............................................... 307 
Figure 7.28. Power versus the information fraction under the alternative hypothesis 
of Simulation study 2 for the second scenario of hazard ratio (i.e. 0.807). The 
horizontal line represents the power of the non-adaptive design. ............................ 307 
Figure 7.29. Power versus the information fraction under the alternative hypothesis 
of Simulation study 2 for the third scenario of hazard ratio (i.e. 0.845). The horizontal 
line represents the power of the non-adaptive design. ............................................... 308 
Figure 7.30. Power versus the information fraction under the alternative hypothesis 
of Simulation study 2 for the fourth scenario of hazard ratio (i.e. 0.765). The horizontal 
line represents the power of the non-adaptive design. ............................................... 308 
Figure 7.31. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the first scenario of hazard ratio (i.e. 0.746). . 309 
Figure 7.32. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the first scenario of hazard ratio (i.e. 0.746). . 310 
Figure 7.33. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the second scenario of hazard ratio (i.e. 0.845). 
The horizontal line represents the sample size of the non-adaptive design............. 310 
Figure 7.34. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the second scenario of hazard ratio (i.e. 0.845). 
The horizontal line represents the sample size of the non-adaptive design............. 311 
xviii 
 
Figure 7.35. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the third scenario of hazard ratio (i.e. 0.807). The 
horizontal line represents the sample size of the non-adaptive design. ................... 312 
Figure 7.36. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the third scenario of hazard ratio (i.e. 0.807). The 
horizontal line represents the sample size of the non-adaptive design. ................... 312 
Figure 7.37. Sample size versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the fourth scenario of hazard ratio (i.e. 0.765). 
The horizontal line represents the sample size of the non-adaptive design............. 313 
Figure 7.38. Sample size versus the information fraction under the alternative and 
null hypothesis of Simulation study 2 for the fourth scenario of hazard ratio (i.e. 
0.765). The horizontal line represents the sample size of the non-adaptive design. 314 
Figure 7.39. Sample size versus the information fraction under the null hypothesis of 
Simulation study 1 for the first scenario of hazard ratio. The horizontal line represents 
the sample size of the non-adaptive design. ................................................................. 315 
Figure 7.40. Sample size versus the information fraction under the null hypothesis of 
Simulation study 1 for the second scenario of hazard ratio. The horizontal line 
represents the sample size of the non-adaptive design. .............................................. 316 
Figure 7.41. Sample size versus the information fraction under the null hypothesis of 
Simulation study 1 for the third scenario of hazard ratio. The horizontal line 
represents the sample size of the non-adaptive design. .............................................. 316 
Figure 7.42. Sample size versus the information fraction under the null hypothesis of 
Simulation study 1 for the fourth scenario of hazard ratio. The horizontal line 
represents the sample size of the non-adaptive design. .............................................. 317 
xix 
 
Figure 7.43. Sample size versus the information fraction under the null hypothesis of 
Simulation study 2 for the first scenario of hazard ratio. The horizontal line represents 
the sample size of the non-adaptive design. ................................................................. 318 
Figure 7.44. Sample size versus the information fraction under the null hypothesis of 
Simulation study 2 for the second scenario of hazard ratio. The horizontal line 
represents the sample size of the non-adaptive design. .............................................. 318 
Figure 7.45. Sample size versus the information fraction under the null hypothesis of 
Simulation study 2 for the third scenario of hazard ratio. The horizontal line 
represents the sample size of the non-adaptive design. .............................................. 319 
Figure 7.46. Sample size versus the information fraction under the null hypothesis of 
Simulation study 2 for the fourth scenario of hazard ratio. The horizontal line 
represents the sample size of the non-adaptive design. .............................................. 319 
Figure 7.47. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 1 for the first scenario of hazard ratio. 320 
Figure 7.48. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the first scenario of hazard ratio. 321 
Figure 7.49. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 1 for the second scenario of hazard ratio.
 ............................................................................................................................................. 321 
Figure 7.50. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the second scenario of hazard ratio.
 ............................................................................................................................................. 322 
Figure 7.51. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 1 for the third scenario of hazard ratio.
 ............................................................................................................................................. 322 
xx 
 
Figure 7.52. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the third scenario of hazard ratio.
 ............................................................................................................................................. 323 
Figure 7.53. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 1 for the fourth scenario of hazard ratio.
 ............................................................................................................................................. 323 
Figure 7.54. Efficacy stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the fourth scenario of hazard ratio.
 ............................................................................................................................................. 324 
Figure 7.55. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 1 for the first scenario of hazard ratio. ........... 325 
Figure 7.56. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the first scenario of hazard ratio. ........... 325 
Figure 7.57. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 1 for the second scenario of hazard ratio. ...... 326 
Figure 7.58. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the second scenario of hazard ratio. ...... 326 
Figure 7.59. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 1 for the third scenario of hazard ratio. ......... 327 
Figure 7.60. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the third scenario of hazard ratio. ......... 327 
Figure 7.61. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 1 for the fourth scenario of hazard ratio. ....... 328 
xxi 
 
Figure 7.62. Efficacy stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the fourth scenario of hazard ratio. ....... 328 
Figure 7.63. Futility stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the first scenario of hazard ratio. 329 
Figure 7.64. Futility stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the second scenario of hazard ratio.
 ............................................................................................................................................. 330 
Figure 7.65. Futility stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the third scenario of hazard ratio.
 ............................................................................................................................................. 330 
Figure 7.66. Futility stopping probability versus the information fraction under the 
alternative hypothesis of Simulation study 2 for the fourth scenario of hazard ratio.
 ............................................................................................................................................. 331 
Figure 7.67. Futility stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the first scenario of hazard ratio. ........... 332 
Figure 7.68. Futility stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the second scenario of hazard ratio. ...... 332 
Figure 7.69. Futility stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the third scenario of hazard ratio. ......... 333 
Figure 7.70. Futility stopping probability versus the information fraction under the 
null hypothesis of Simulation study 2 for the fourth scenario of hazard ratio. ....... 333 
Figure B.1. Sequential before–after pharmacogenetic diagnostic study ................... 381 
Figure B.2. Classifier randomization design. “R” refers to randomization of patients.
 ............................................................................................................................................. 382 
xxii 
 
Figure B.3. Modified marker strategy design. “R” refers to randomization of patients.
 ............................................................................................................................................. 383 
Figure B.4. Two-way Stratified design (for validation of prognostic biomarkers). “R” 
refers to randomization of patients. ............................................................................... 385 
Figure C.1. Efficacy stopping probability, futility stopping probability and power of 
a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 2 of hazard ratios. Each row of graphs represents the 
different probabilities versus the interim fraction of each biomarker-defined 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) a- =
0.010 and a+ = 0.015 respectively. ................................................................................. 399 
Figure C.2. Efficacy stopping probability, futility stopping probability and power of 
a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 3 of hazard ratios. Each row of graphs represents the 
different probabilities versus the interim fraction of each biomarker-defined 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) a- =
0.010 and a+ = 0.015 respectively. ................................................................................. 400 
Figure C.3. Efficacy stopping probability, futility stopping probability and power of 
a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 4 of hazard ratios. Each row of graphs represents the 
different probabilities versus the interim fraction of each biomarker-defined 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) a- =
0.010 and a+ = 0.015 respectively. ................................................................................. 401 
Figure C.4. Expected number of events and patients in two-stage design and required 
number of events and patients in one-stage design for each biomarker-defined 
subgroup versus the hazard ratios of each biomarker-defined subgroup when the 
interim fraction is 50%. The first two graphical representations in each row of graphs 
represent the number of events versus the hazard ratio of each biomarker-defined 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 anda+ = 0.010 and (iii) a- = 0.010 
xxiii 
 
and a+ = 0.015 respectively. The remaining graphical representations in each row of 
graphs represent the number of patients versus the hazard ratio of each biomarker-
defined subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) 
a- = 0.010 and a+ = 0.015. ............................................................................................... 402 
Figure C.5. Expected number of events and patients in two-stage design and required 
number of events and patients in one-stage design for each biomarker-defined 
subgroup versus the hazard ratios of each biomarker-defined subgroup when the 
interim fraction is 75%. The first two graphical representations in each row of graphs 
represent the number of events versus the hazard ratio of each biomarker-defined 
subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ = 0.010 and (iii) a- =
0.010 and a+ = 0.015 respectively. The remaining graphical representations in each 
row of graphs represent the number of patients versus the hazard ratio of each 
biomarker-defined subgroup when (i) a- = a+ = 0.0125, (ii) a- = 0.015 and a+ =
0.010 and (iii) a- = 0.010 and a+ = 0.015. ..................................................................... 403 
 
 
  
xxiv 
 
List of Publications 
1. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided Adaptive 
Trial Designs in Phase II and Phase III: A Methodological Review. PLoS ONE. 
2016;11(2):e0149803. doi: 10.1371/journal.pone.0149803. 
2. Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-
Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. Journal 
of Personalized Medicine. 2017;7(1). doi: 10.3390/jpm7010001. 
3. Antoniou M, Jorgensen AL, Kolamunnage-Dona R.  Fixed and adaptive Parallel 
Subgroup-Specific design for survival outcomes: power and sample size. 2017 (Under 
review) 
 
 
 
 
 
 
 
 
 
 
xxv 
 
Contents 
Acknowledgements .............................................................................................................. i 
Abstract ................................................................................................................................ iii 
List of Tables ....................................................................................................................... iv 
List of Figures ................................................................................................................... viii 
List of Publications ........................................................................................................ xxiv 
Contents ............................................................................................................................. xxv 
Chapter 1. Introduction ....................................................................................................... 1 
1.1. Personalized medicine ............................................................................................... 1 
1.1.1. Biomarker-guided clinical trial designs ........................................................... 2 
1.2. Novel insight into Biomarker-guided clinical trial designs ................................. 2 
1.2.1. Creating a user-friendly, interactive web resource ........................................ 3 
1.2.2. Choosing the best trial design ........................................................................... 3 
1.2.3. Guidance on practical challenges ..................................................................... 4 
1.3. References ................................................................................................................... 4 
Chapter 2. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A 
Methodological Review ...................................................................................................... 6 
2.1. Abstract.................................................................... Error! Bookmark not defined. 
2.2. Introduction ................................................................................................................ 6 
2.3. Methods and Findings ............................................................................................... 8 
2.3.1. Adaptive designs ............................................................................................... 10 
2.3.1.1. Definitions and terminology .................................................................... 10 
2.3.1.2. Adaptations to the design ......................................................................... 11 
2.3.1.3. Analysis of adaptive designs .................................................................... 11 
2.3.2. Biomarker-guided adaptive trial designs ...................................................... 12 
xxvi 
 
2.3.2.1. Adaptive signature design ........................................................................ 22 
2.3.2.2. Outcome-based adaptive randomization design .................................. 24 
2.3.2.3. Adaptive threshold sample-enrichment design .................................... 27 
2.3.2.4. Adaptive patient enrichment design ....................................................... 30 
2.3.2.5. Adaptive parallel Simon two-stage design ............................................ 32 
2.3.2.6. Multi-arm multi-stage designs ................................................................. 36 
2.3.2.7. Stratified adaptive design ......................................................................... 39 
2.3.2.8. Tandem two stage design ......................................................................... 41 
2.4. Discussion ................................................................................................................. 44 
2.5. References ................................................................................................................. 46 
Chapter 3. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase 
III: A Methodological Review ......................................................................................... 64 
3.1. Abstract.................................................................... Error! Bookmark not defined. 
3.2. Introduction .............................................................................................................. 64 
3.3. Methods and Findings ............................................................................................. 65 
3.3.1. Single Arm Designs ........................................................................................ 105 
3.3.2. Enrichment Designs ........................................................................................ 106 
3.3.3. Randomize-All Designs.................................................................................. 114 
3.3.3.1. Marker Stratified Designs ....................................................................... 114 
3.3.3.2. Hybrid Designs ......................................................................................... 136 
3.3.4. Biomarker-Strategy Designs .......................................................................... 137 
3.3.4.1. Biomarker-Strategy Design with Biomarker Assessment in the 
Control Arm ........................................................................................................... 138 
3.3.4.2. Biomarker-Strategy Design without Biomarker Assessment in the 
Control Arm ........................................................................................................... 142 
xxvii 
 
3.3.4.3. Biomarker-Strategy Design with Treatment Randomization in the 
Control Arm ........................................................................................................... 143 
3.3.4.4. Reverse Marker-Based Strategy Design ................................................ 147 
3.3.5. Other Designs .................................................................................................. 150 
3.3.5.1. A Randomized Phase II Trial Design with Biomarker Proposed by 
Freidlin et al., 2012 ................................................................................................ 150 
3.4. Discussion ............................................................................................................... 153 
3.5. References ............................................................................................................... 155 
Chapter 4. Online tool to help develop personalized medicine (BiGTeD) .......... 171 
4.1. Introduction ............................................................................................................ 171 
4.2. Key features ............................................................................................................ 172 
4.3. User interface .......................................................................................................... 173 
4.3.1. Homepage ........................................................................................................ 173 
4.3.2. Design-specific webpages: Adaptive Designs ............................................ 174 
4.3.3. Design-specific webpages: Non-Adaptive Designs ................................... 178 
4.4. Discussion ............................................................................................................... 183 
Chapter 5. Fixed and adaptive Parallel Subgroup-Specific design for survival 
outcomes: power and sample size ................................................................................. 186 
5.1. Introduction ............................................................................................................ 186 
5.2. Methods and Findings ........................................................................................... 187 
5.2.1. Parallel Subgroup-Specific design ................................................................ 187 
5.2.1.1. Sample size calculation for time-to-event-outcomes .......................... 189 
5.2.1.2. Simulation Study 1 ................................................................................... 192 
5.2.1.3. Results from simulation study 1 ............................................................ 194 
5.2.2. An adaptive version of the Parallel Subgroup-Specific design ................ 199 
5.2.2.1. Simulation Study 2 ................................................................................... 206 
xxviii 
 
5.2.2.2. Results from simulation study 2 ............................................................ 208 
5.3. Discussion ............................................................................................................... 216 
5.4. References ............................................................................................................... 218 
Chapter 6. Deciding on the best biomarker-guided trial design: a case study .... 220 
6.1. Background to the proposed trial (STRONG trial) ........................................... 220 
6.1.1. Previously proposed randomized controlled trial of a stratified approach 
to Naltrexone treatment ........................................................................................... 226 
6.1.2. Sample size calculation of the previously proposed design ..................... 229 
6.2. Reasons for inefficiency of the previously proposed design ........................... 233 
6.3. Reconsideration of the most appropriate design ............................................... 234 
6.4. Sample size calculations for the STRONG trial assuming different study 
designs ............................................................................................................................ 238 
6.4.1. Using the Marker Stratified design in the STRONG trial .......................... 238 
6.4.1.1. Using a variation of the Marker Stratified design – the Sequential 
Subgroup-Specific design .................................................................................... 245 
6.4.1.2. Using a variation of the Marker Stratified design: the Parallel 
Subgroup-Specific design .................................................................................... 248 
6.4.2. Using the Reverse Marker-Based strategy design in the STRONG trial . 253 
6.5. Discussion ............................................................................................................... 257 
6.5.1. Non-adaptive design with time-to-event outcome .................................... 262 
6.6. References ............................................................................................................... 264 
Chapter 7. Case study - An adaptive approach ........................................................... 270 
7.1. Choosing the type of Sample size re-estimation method ................................. 270 
7.2. Simulation study 1: With the option of early stopping of the trial for efficacy
 ......................................................................................................................................... 272 
7.2.1. Calculation of required sample size ............................................................. 272 
xxix 
 
7.2.2. Target number of patients at the interim stage ........................................... 273 
7.2.3. Variance of outcome ....................................................................................... 273 
7.2.4. Test statistic of the first stage ......................................................................... 274 
7.2.5. Stopping boundaries ....................................................................................... 275 
7.2.6. Sample size adjustment .................................................................................. 277 
7.2.7. Test statistic of the second stage ................................................................... 278 
7.2.8. Final test statistic ............................................................................................. 279 
7.2.9. Simulation parameters ................................................................................... 279 
7.3. Simulation study 2: With the option of early stopping of the trial for efficacy 
and futility ...................................................................................................................... 285 
7.4. Simulation results .................................................................................................. 286 
7.4.1. Binary Outcome ............................................................................................... 286 
7.4.1.1. Control of type I error rate ...................................................................... 286 
7.4.1.2. Power of the study ................................................................................... 288 
7.4.1.3. Sample size of the study .......................................................................... 290 
7.4.1.4. Efficacy stopping probability ................................................................. 293 
7.4.1.5. Futility stopping probability .................................................................. 296 
7.4.2. Time-to-event Outcome ................................................................................. 298 
7.4.2.1. Control of type I error rate ...................................................................... 298 
7.4.2.2. Power of the study ................................................................................... 303 
7.4.2.3. Sample size of the study .......................................................................... 309 
7.4.2.4. Efficacy stopping probability ................................................................. 320 
7.4.2.5. Futility stopping probability .................................................................. 328 
7.5. Discussion ............................................................................................................... 334 
7.6. References ............................................................................................................... 335 
Chapter 8. Challenges in Practice.................................................................................. 337 
xxx 
 
8.1. Examples of clinical trials ..................................................................................... 337 
8.2. Challenges ............................................................................................................... 340 
8.2.1. Funding issues ................................................................................................. 340 
8.2.2. Ethical and Regulatory Issues ....................................................................... 342 
8.2.3. Recruitment ...................................................................................................... 345 
8.2.4. Monitoring samples and labs ........................................................................ 347 
8.2.5. Biomarker assessment .................................................................................... 348 
8.2.6. Data sharing issues ......................................................................................... 349 
8.2.7. Resources .......................................................................................................... 350 
8.3. Recommendations to overcome practical challenges ....................................... 351 
8.4. Discussion ............................................................................................................... 353 
8.5. References ............................................................................................................... 354 
Chapter 9. Conclusions and Future Research ............................................................. 355 
9.1. Future directions .................................................................................................... 359 
9.2. References ............................................................................................................... 360 
Appendix A ....................................................................................................................... 362 
A.1. Variations of biomarker-guided adaptive trial designs .................................. 362 
A.2. Literature review search strategies for both biomarker-guided clinical trial 
designs and for traditional trial designs .................................................................... 378 
Appendix B ........................................................................................................................ 381 
Appendix C ....................................................................................................................... 386 
C.1. Supporting tables and figures ............................................................................. 386 
C.2. R codes .................................................................................................................... 404 
C.2.1. Parallel Subgroup-Specific design ............................................................... 404 
C.2.2. An adaptive version of the Parallel Subgroup-Specific design ............... 412 
Appendix D ....................................................................................................................... 418 
xxxi 
 
D.1. Results for Simulation study 1 ............................................................................ 419 
D.2. Results for Simulation study 2 ............................................................................ 433 
D.3. R codes .................................................................................................................... 447 
D.3.1. Simulation study 1 ......................................................................................... 447 
D.3.2. Simulation study 2 ......................................................................................... 474 
D.3.3. Type I error probabilities .............................................................................. 501 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1. Introduction 
1.1. Personalized medicine 
The idea of personalized medicine first appears in Hippocrates’ time. 
Hippocrates of Cos, an ancient Greek physician who is considered the father of 
medicine said, “It’s far more important to know what person the disease has than 
what disease the person has” [1]. Hence, the concept that a treatment will benefit 
patients who share similar characteristics in the same way and that patients can be 
treated with different drugs depending on their individual characteristics is not new 
and was well understood hundreds of years ago. 
Several definitions have been provided for the term “personalized medicine”, 
however, they all correspond to the idea of “one treatment fits a particular subgroup” 
instead of “one size fits all”, meaning that patients are divided into several 
subpopulations according to their personal characteristics with each subpopulation 
assigned a treatment believed to benefit them the most. The ultimate aim of 
personalized medicine is to maximize benefit and minimize risk by tailoring an 
individual’s treatment according to their personal characteristics. These 
characteristics can be demographic such as age or gender, or biological such as 
genetic or other biomarkers. According to the National Cancer Institute, “a biomarker 
is a biological molecule found in blood, other body fluids, or tissues that is a sign of 
a normal or abnormal process, or of a condition or disease, which may be used to see 
how well the body responds to a treatment for a disease or condition” [3]. 
Demonstrating the efficacy of using a personalized approach to treatment 
requires clinical trials. This thesis is focused on trial designs for identification of 
biomarker-defined subgroups which will derive maximal clinical benefit from a 
given treatment. Such designs have drawn considerable attention in the field of 
medicine as they promise an improved benefit-risk ratio for patients and enhanced 
opportunities for drug development. 
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1.1.1. Biomarker-guided clinical trial designs 
In much the same way as the effectiveness of a treatment must be proven before 
it is prescribed in clinical practice, the effectiveness of using biomarkers to help tailor 
treatment must also be demonstrated before the biomarkers are used to guide 
treatment in practice. Trials that test the effectiveness of a biomarker-guided 
approach to treatment are collectively known as ‘biomarker-guided clinical trials’. 
The concept of personalized medicine has become increasingly popular over recent 
years, and consequently many different biomarker-guided trial designs have been 
proposed in the literature. The varying designs reflect the large variation in types of 
biomarkers and their different properties, with different designs being appropriate 
in different scenarios. For instance, some designs are aimed at the identification of a 
particular biomarker-defined subgroup which will benefit from a specific treatment 
whilst other designs might be aimed at assessing the impact of different biomarkers 
in a single type of disease (e.g. cancer) or testing the effect of a treatment(s) on a single 
biomarker in a variety of a disease types. 
1.2. Novel insight into biomarker-guided clinical trial designs 
The scope of this PhD thesis is to provide novel insights into biomarker-guided 
clinical trial designs. Whilst a number of these designs have been proposed in the 
past decade, there is lack of knowledge and understanding of current designs by 
those working in the field of personalized medicine including clinicians, 
policymakers and researchers. Further, there is very little guidance on which 
biomarker-guided design is appropriate in a particular setting. Consequently, it is 
difficult for investigators embarking on biomarker-guided clinical trials to decide on 
the most appropriate design for their particular setting, and navigating the literature 
to determine this can be difficult.  
With this in mind, a thorough and comprehensive review of the biomarker-
guided trial designs proposed to date is undertaken in order to give an in-depth 
overview of the designs for researchers working in personalised medicine, focussing 
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particularly on providing them with clarity in definition, methodology and 
terminology. For ease of reading, the review is split into two chapters, one focussing 
on adaptive biomarker-guided trial designs (Chapter 2) and the other focussing on 
non-adaptive designs (Chapter 3). Both chapters include key information related to 
utility, methodology, benefits and limitations of each design and examples of real 
studies. 
1.2.1. Creating a user-friendly, interactive web resource 
To enhance the guidance on biomarker-guided clinical trials, we developed 
clear graphical representations of each trial design, with standardized formatting to 
allow easy comparison across various designs. To ensure that the guidance and 
graphical representations are easily accessible to stakeholders, an interactive web 
resource to host this information was also developed. Chapter 4 presents this online 
tool for designing biomarker-guided clinical trials (BiGTeD, www.BiGTeD.org). This 
work is informed by the methodological review presented in Chapter 2 and 3. 
BiGTeD is a user-friendly online tool which provides an easily accessible resource to 
inform on the most optimal design when embarking on a biomarker-guided trial 
including easy to navigate graphical displays of the various trial designs. 
Our review and resulting guidance serves to improve the understanding of 
biomarker-guided trial designs and provides a valuable and much-needed resource 
for those wishing to implement such trials. This, in turn, will expedite the 
development of personalized approaches to treatment for the improvement in 
healthcare. 
1.2.2.  Choosing the best trial design 
One size does not fit all, and investigators should take into consideration the 
implications that each design might have before selecting one. Chapter 5 focuses on 
a popular non-adaptive trial design, Parallel Subgroup-Specific design, for which a 
fixed sample size is required in advance of the study. We also explore an adaptive 
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approach of the same design aiming to assess the efficiency of the study related to the 
cost and time of the trial in general. Several statistical and simulation techniques are 
developed for the calculation of the required number of patients to ensure sufficient 
power for these types of designs.  
Additionally, Chapter 6 reconsiders the most appropriate design for a clinical 
trial previously proposed which was not feasible due to several statistical 
considerations including a very large sample size that was required. Various 
biomarker-guided non-adaptive trial designs are explored and compared to choose 
which of them is more suitable for the purpose of the above trial. To assist in making 
this decision, we develop a series of strategies that could be used in future to decide 
between different trial designs. Sample size calculations are presented for both binary 
and time-to-event outcomes.  
In Chapter 7, we explore an adaptive version of the chosen design through 
simulation studies in order to address a degree of uncertainty that surrounds the 
assumed effect size. 
1.2.3. Guidance on practical challenges 
In Chapter 8, we address the key practical challenges when undertaking 
biomarker-guided clinical trials, with particular focus on their management and 
monitoring. These challenges have been raised and discussed during the ‘Biomarker-
guided trials: challenges in practice’ workshop organized by the author of this thesis 
and the MRC Hubs for Trials Methodology Research Network’s Stratified Medicine 
Working Group (SMWG) at the University of Liverpool in London Campus, 15th 
March 2017. A list of recommendations are drawn to overcome several key 
challenges. 
1.3. References 
1. U.S. Food and Drug Administration. Paving the way for personalized medicine 
2013 [cited 2015 10 Oct]. Available online:  
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3. Institute NC. Biomarker [accessed on 23 August 2017]. Available online: 
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Chapter 2. Biomarker-Guided Adaptive Trial Designs 
in Phase II and Phase III: A Methodological Review 
2.1. Introduction 
The rapidly developing field of ‘personalized medicine’ [1], also known as 
‘individualized medicine’, ‘stratified medicine’, or ‘precision medicine’ is allowing 
scientists to treat patients by providing them with a specific regimen according to 
their demographic or individualized genomic or biological characteristics, known as 
biomarkers [2]. The terms Personalized Medicine and Individualized Medicine often 
create confusion in literature as, in reality, the objective of this approach is to identify 
demographic- or biomarker-defined subgroups. Thus, as it still remains a population 
and not an individualized approach, the terms Stratified or Precision medicine are 
often considered to be more accurate.  
The Biomarkers Definitions Working Group defined a biomarker to be “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [1, 3-6]. Biomarkers related to clinical outcome which are 
measured before treatment can be classified as either prognostic or predictive 
biomarkers. Prognostic biomarkers provide information regarding the likely 
progression of a disease without taking into account any specific treatment, whilst 
predictive biomarkers provide information about the patient’s outcome given a 
certain treatment, i.e. their likely response to the treatment [3, 6-33]. 
Prior to utilizing a patient’s biomarker information in clinical practice, it is 
necessary that they have been robustly tested in terms of analytical validity, clinical 
validity and clinical utility. Specifically, the first term refers to the ability of a genetic 
test to detect and measure the biomarker of interest in a repeatable and reproducible 
way, hence it can  answer the question of whether or not we should trust the results 
of a specific biomarker test. Once a valid test has been developed, the degree to which 
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the biomarker can identify the patients with and without the target disease from the 
whole population is referred to as clinical validity. A biomarker will be used in 
clinical practice only if it improves patient’s health; hence, clinical utility corresponds 
to the assessment of the effectiveness of the biomarker and showing the positive 
effects compared to the risks of doing harm [8, 12, 18, 24]. 
A number of Phase II and Phase III trial designs have been proposed for testing 
the clinical utility of predictive biomarkers and they can be broadly classified into 
adaptive and non-adaptive trial designs. As we enter the new era of personalized 
medicine, there is substantial need for novel trial designs which will (i) demonstrate 
cost benefits and minimize the required time to obtain conclusive results despite an 
increase in the number of subjects needed for the trial; (ii) avoid erroneous 
conclusions and (iii) be more ethical by giving patients more effective treatments. 
Whereas non-adaptive trial designs often result in large and costly Phase III trials of 
long duration, adaptive designs are becoming increasingly attractive in the context 
of biomarker-directed therapies as they allow for additional flexibility during the 
course of the trial. 
In the previous chapter (Chapter 1), we introduced the general concept of 
Personalized medicine and Biomarker-guided clinical trial designs. In the current 
chapter we report current biomarker-guided trial designs based on a comprehensive 
review in order to provide investigators embarking on such trials with useful 
guidance which to our best knowledge has not been performed previously to such an 
extent. This chapter is based on our published paper Antoniou et al. (2016) (see List 
of Publications) and is focused on adaptive trial designs. Key features are the 
graphical representation of each individual trial design with standardized formatting 
to allow easy comparison between them, categorization and presentation of key 
information including advantages and limitations. 
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2.2. Methods and Findings 
We have undertaken a search of the MEDLINE (Ovid) database, restricted to 
published papers in the English language within the previous ten years aiming to 
identify articles which describe and discuss both non biomarker-guided trial designs, 
which we will refer to as ‘traditional’ trial designs, and biomarker-guided trial 
designs. Traditional trial designs are included in our literature review search strategy 
in order to ensure that we do not miss any potential reference to biomarker-guided 
designs, as the finding of the appropriate keywords in Medline database for 
biomarker-guided designs was challenging. Two separate strategies as illustrated in 
Figure 2.1 were used to identify relevant articles, and the keywords utilized in the 
search are presented in Appendix A.2. I screened the available titles and abstracts, 
and my supervisors, Dr Andrea Jorgensen and Dr Ruwanthi Kolamunnage-Dona 
were consulted when it was questionable whether or not a paper should be included. 
Our initial search resulted in 9,412 and 5,024 relevant titles for biomarker-guided 
clinical trial designs and traditional designs respectively. From the 9,412 papers, 104 
articles were included based on their title and abstract. From the 5,024 papers, 40 
articles were included based on their title and abstract and after removing 
inaccessible articles or those already identified in the search for biomarker-guided 
trial designs. A further 57 papers were identified from searching both the reference 
list of included articles and the internet (the internet searches were performed using 
the same keywords as those for the Ovid strategy). Of the 201 included papers, 
biomarker-guided adaptive trial designs were referred to in 107 papers. An extraction 
form was designed to collect all necessary information, and the summary of the 
extracted data was reviewed by my supervisors. If there were any ambiguities or 
confusion as to the extracted data, the second and third authors were consulted. For 
each included paper, the following details were extracted: definition of the trial 
design(s) referred to in the paper, how patients were screened and/or randomized 
based on their biomarker status, treatment groups randomized to, other key 
information relating to the trial design and methodology, advantages and limitations, 
and examples of actual trials which have adopted designs if mentioned together with 
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the proposed methodology and clinical field where the design had been applied. 
There is no evidence of some of the proposed trial designs being used in practice in 
the literature which was used for our review; however, they may well currently be in 
use in ongoing trials. The review of all trial designs which have been implemented in 
practice is beyond the scope of this chapter but if a published description of the 
methodology exists, this would have been captured by our search.  
 
Figure 2.1. Flow diagram of the review process. Keywords are listed in Appendix A.2. 
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2.2.1. Adaptive designs 
Before discussing the specific biomarker-guided adaptive trial designs, we 
consider key aspects of adaptive trial designs in more generality. 
2.2.1.1. Definitions and terminology 
To date, several authors have given different definitions about adaptive designs 
in general [34-36]. Chow et al. (2005) [34] described the adaptive design as a strategy 
that allows adaptations in trial procedures and/or statistical procedures after 
initiation of the trial without undermining the validity and integrity of the trial. In 
2006, the Pharmaceutical Research Manufacturer Association (PhRMA) Working 
Group on Adaptive Design [35] defined an adaptive design as a clinical trial design 
that uses accumulating data to decide how to modify aspects of the study as it 
continues, without undermining the validity and integrity of the trial. 
In 2010, US Food and Drug Administration defined an adaptive design as a 
study that includes a prospectively planned opportunity for modification of one or 
more specified aspects of the study design and hypotheses based on analysis of 
(usually interim) data from subjects in the study [36]. In the context of biomarker-
guided therapies, Chen et al. (2014) [12] defines the biomarker adaptive trial design 
as “designs which identify most suitable target subpopulations with respect to a 
particular treatment, based on either clinical observations or known biomarkers, and 
evaluate the effectiveness of the treatment on that subpopulation in a statistically 
valid manner”. 
Some researchers refer to these approaches as flexible designs [33, 37-40], 
terminology which can cause confusion since some trial designs which allow 
adaptivity are by no means flexible, for example those with pre-specified rules in 
terms of how to proceed based on interim data analyses [41]. Thus, the term ‘flexible 
designs’ can include designs with both planned and unplanned properties [42]. 
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2.2.1.2. Adaptations to the design 
Adaptations based on interim analysis, which are made during the course of an 
adaptive strategy include adding or dropping treatment arms, changes in the 
required sample size, changes in the allocated proportion of the study population in 
order to randomize more patients to treatment arms which are doing better, or 
refinement of the existing study population according to their predictive biomarkers 
[38-40, 43-49]. 
In Personalized Medicine some common adaptations during the 
implementation of adaptive designs refer to changes in randomization probabilities 
within the biomarker-defined subgroups or dropping a biomarker-defined subgroup 
[15, 50]. 
Generally, this type of biomarker-guided approach is appropriate when (i) the 
candidate biomarker is not known at the start of the study; (ii) there are multiple 
experimental treatments and pre-specified biomarker-defined subgroups; (iii) 
existence of well-established analytical validity; (iv) rapid turnaround time for 
biomarker assessment [12, 15, 51]. Finally, it is important to have informative 
endpoints that are observed early. 
2.2.1.3. Analysis of adaptive designs 
Although both a Bayesian and Frequentist framework has been used for the 
analysis of adaptive designs [26, 52-54] the former has been described by many 
authors as a more suitable perspective due to its flexibility as it enables revision of 
knowledge according to prior information. It is common that Bayesian methods are 
used but frequentist operating characteristics are controlled. I-SPY2 and BATTLE 
studies are examples of actual adaptive trials designed with a Bayesian framework 
[48, 49, 55]. Nevertheless, the Bayesian perspective in adaptive designs can cause 
many problems in terms of computational demands, inference making and 
parameter estimations [10, 26, 55, 56]. 
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2.2.2. Biomarker-guided adaptive trial designs 
In our review, we have identified eight main biomarker-guided adaptive 
designs. Four of the eight designs also have variations. Each main design is presented 
graphically in Figures 2.2-2.9. The characteristics and methodology of the eight main 
designs are discussed below and summarized in Table 2.1, whilst information on 
their variations are summarized in Table A.1 in Appendix A.1. 
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 Table 2.1. Characteristics of biomarker-guided adaptive trial designs in Phase II and Phase III 
Types of Biomarker-guided 
adaptive trial designs 
Phase Adaptations Pros Cons 
Adaptive signature design 
(30 papers) [2, 6, 8, 9, 12, 14-
16, 18, 20, 21, 24, 27, 31, 32, 
47, 49, 57, 58-68] 
Also called: Two-stage 
Adaptive Signature design, 
Adaptive Two-stage design, 
Biomarker-Adaptive 
Signature design 
III Identification of 
biomarker-positive 
subpopulation 
Identification of optimal group of patients 
which benefit the most from a specific 
treatment. 
Identification and validation of candidate 
biomarker signature in a single trial. 
Avoids inflation of type I error rate as it does 
not use the individuals on which the 
predictive signature was developed in order to 
test the treatment effect. 
Rapid and efficient approval of the novel 
treatment. 
No modifications in randomization weights or 
in eligibility criteria are made, consequently, it 
Larger sample size may be required, 
especially when there is small difference 
between biomarker-negative and 
biomarker-positive patients. 
Can limit its power when testing the 
treatment effectiveness in the biomarker-
positive subgroup as half of patients are 
used for signature development and half 
for validation of the biomarker. 
Treatment comparisons can only be 
performed when the study is completed. 
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avoids any statistical adjustment needed to 
ensure that there is no introduction of bias. 
Outcome-based adaptive 
randomization design (24 
papers) [14, 26, 29, 32, 37, 40, 
47, 49, 52, 56, 59, 62, 63, 65, 
69, 70-78] 
Also called: Adaptive 
randomization Bayesian 
Adaptive, Bayesian 
Adaptive randomization, 
Combined dynamic multi-
arm, Outcome-Adaptive 
randomization, Outcome-
based Bayesian Adaptive 
Randomization 
II Change in 
randomization ratio 
Smart, novel, and ethical approach 
Permits updating patient’s outcome (it uses 
the accumulated information in order to assign 
patients to different treatment arms; the arm 
which seems to benefit the study population 
the most, is composed of the higher proportion 
of randomized individuals). 
Can result in high probability of success of the 
trial as there is increase in the number of 
patients who receive effective treatments. 
In the Bayesian perspective, Type I and II 
errors can be controlled by carefully 
calibrating the design parameters. 
Can boost patients’ ethics as patients are 
assigned to the best available therapy. 
Complexity in terms of building-up the 
trial design, conduct and analysis of the 
trial. 
Can make incorrect decisions in case of 
incorrect biomarker selection as the design 
is based on the accumulated data about 
how well the biomarker performs. 
Requirement of relatively short biomarker 
and endpoint assessment (quick testing of 
the biomarker is required in order to avoid 
incorrect decision regarding the 
assignment of patients and rapid 
assessment of outcome to randomize 
adaptively according to the updated 
outcome.). 
Likely to introduce bias due to time trends 
in the prognostic mix of individuals 
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enrolled to the study. The evidence 
accumulated during the trial can influence 
clinicians’ decisions regarding which 
patient groups to consider recruiting. 
Adaptive threshold sample-
enrichment design (5 
papers) [18, 20, 21, 63, 79] 
Also called: Threshold 
sample-enrichment 
approach, Two-stage Sample 
Enrichment, Two-stage 
sample-enrichment design 
strategy 
III Change in the 
inclusion criteria of 
the study population 
after the initial stage 
of the study in order 
to broaden the 
targeted patient 
population. 
More cost-effective as it avoids further 
recruitment of patients when there is no 
difference in treatment outcome among the 
biomarker-defined subgroups. 
Researchers can use the data which was 
accumulated during the first stage of the study 
to proceed with further investigation of any 
other potential assumption made at the start of 
the trial. 
Cannot work if there is no information 
about a subset of patients for whom the 
novel treatment is more effective than 
others before the beginning of the trial. 
Adaptive patient 
enrichment design (23 
papers) [3, 6, 7, 14, 18, 20, 21, 
29, 38, 42, 43, 63, 70, 74, 78, 
80-87] 
III 
 
Information obtained 
from interim stage is 
used to decide 
whether the study 
should be narrowed 
Can detect a particular biomarker-defined 
subgroup most likely to respond to the novel 
treatment, thus the efficiency of study design 
can be increased. 
Can be quite complex. 
Can result in biased treatment effect 
estimates. 
Criticised as a design without satisfactory 
operating characteristics in real practice 
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Also called: Adaptive 
accrual, Adaptive accrual 
based on interim analysis 
design, Adaptive 
Enrichment, Adaptive 
Modification of Target 
Population. Adaptive 
Population Enrichment, 
Two-stage Adaptive Design, 
Two-stage adaptive accrual 
to a particular 
subpopulation. 
Can gain that more power than a fixed study 
design under the scenario that the genomic 
biomarker is predictive of treatment effect (i.e. 
the value of effect size indicates that there is 
treatment effect in the biomarker-defined 
subgroup, e.g. the value of 0.4) than in the case 
where the genomic biomarker is prognostic 
(i.e. the scenario where we assume that the 
value of effect size is zero). 
with a lack of generalizability and 
information in subgroups which are 
excluded. 
May augment the duration of the trial 
depending on the prevalence of the 
biomarker for the biomarker–defined 
subgroup which continues to full accrual 
due to recruitment of many more 
biomarker-positive patients. 
Requirement of an appropriate futility 
boundary and rapid and reliable clinical 
endpoint. 
Conservativeness of futility boundaries as 
the futility boundary is set to be in the 
region in which the observed efficacy of 
the standard of care is greater than that for 
the experimental treatment. 
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Assumes complete confidence in the 
biomarker. 
Early termination of the entire trial is not 
permitted. 
Adaptive parallel Simon 
two-stage design (8 papers) 
[6, 76, 85, 88-92] 
Also called: Biomarker-
adaptive parallel two-stage, 
Adaptive parallel, Two-
parallel Simon, Two-stage 
design 
II The design starts with 
two parallel studies 
and according to the 
results of the initial 
stage we enrol 
selected or unselected 
patients during the 
second stage. 
May reduce the required sample size. 
May augment the efficiency of the trial as it 
allows for early understanding that a 
particular experimental treatment is beneficial 
in a specific biomarker-defined subgroup. 
Straightforward and simple strategy with 
reasonable operating characteristics. 
Does not allow early termination of the 
trial for efficacy in biomarker-defined 
subgroups during the first stage of the trial. 
Multi-arm multi-stage 
designs (16 papers) [18, 20, 
40, 56, 63, 69, 89, 93-103] 
Also called: Adaptive 
biomarker-driven design, 
Adaptive Analysis, Adaptive 
II/III Experimental arms 
can be dropped for 
futility from the 
study. 
Promising treatments are tested concurrently 
using a smaller number of patients as some 
treatments arms can be dropped early for 
futility. 
High setting-up time due to the complexity 
caused by logistic issues and collection of 
experimental drugs from different 
companies. 
Operational challenges regarding the 
randomization and the modifications of 
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Multi-stage designs, Multi-
stage 
Reduced costs and time as they assess multiple 
treatments simultaneously. 
Preferable to continue with the investigation of 
promising treatments as compared to the 
conduct of separate single-arm phase II clinical 
trials. 
The simultaneous assessment of multiple 
experimental treatments increases the chance 
of identifying a promising treatment. 
It is unlikely that the trial will stop for futility 
as multiple experimental treatments are tested 
and hence, it is not likely that all experimental 
arms will be ineffective and dropped. 
Can ease the regulatory and administrative 
burden as compared to building–up separate 
trials. 
allocation ratios after the performance of 
an interim analysis. 
19 
 
Unpromising experimental arms can be 
dropped in a quick and reliable way. 
Stratified adaptive design (1 
paper) [89] 
No alternative names found 
for this trial design 
II The number of 
patients and decision 
rules are based on the 
observed response 
rates during the first 
stage of the study. 
Can avoid unethical studies in patients for 
whom the novel treatment is not effective as it 
allows for the identification of efficacy which 
is limited to a particular biomarker-defined 
subgroup. 
The trial can continue to Phase III only with a 
subgroup which is proven to benefit from the 
experimental therapy and not with the entire 
population. 
Less numbers of individuals for whom the 
novel treatment is not effective will be tailored 
to toxic treatments. 
Permits the identification of the actual 
treatment benefit in at least one biomarker-
defined subgroup. 
No information found 
20 
 
Avoids the termination of tailoring a novel 
treatment due to treatment effect dilution in 
the entire population. 
Permits early stopping of efficacy or inefficacy. 
Tandem two stage design (5 
papers) [21, 63, 76, 90, 104] 
Also called: Tandem two-
step phase II trial, Tandem-
two step trial (phase II), 
Tandem two-step phase 2 
trial design, Tandem two-
step 
II Assessment of 
treatment 
effectiveness in the 
entire population at 
the first stage of the 
study to make a 
decision about 
enriching the targeted 
patient population. 
Although the two stages could be run 
separately, i.e. one for the biomarker-positive 
subgroup and the other for the unselected 
patients, the performance of the study in this 
way can increase the duration and costs of the 
trial. Consequently, it will be better to run the 
study in just one trial so as to have a more 
seamless study. 
Allow estimating response rates not only in 
the unselected biomarker-defined patients 
(entire population) but also in the biomarker-
positive subset. 
Identify whether the experimental treatment is 
beneficial in the entire population, and if it is 
not, then can test whether the candidate 
No information found 
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predictor can enrich the responding 
population. 
Allow for simultaneous testing of multiple 
different biomarkers for the same treatment in 
a single parallel multi-arm trial. 
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2.2.2.1. Adaptive signature design 
The adaptive signature design is described in 30 (28%) papers of our review. It 
is a two-stage Phase III non-Bayesian trial design proposed by Freidlin and Simon 
(2005) [105] for settings where an assay or signature that identifies sensitive patients 
(i.e. biomarker-positive patients) is not known at the outset. This trial design permits 
the development and evaluation of a biomarker based on high dimensional data. It 
uses a training set to identify predictive biomarkers and evaluates them in a 
validation set. Generally, this approach is useful when there is no available biomarker 
at the start of the trial or there is a great number of candidate biomarkers which could 
be combined to identify a biomarker-defined subgroup, and the attention is given 
first to the entire study population. Five variations of the adaptive signature design 
have also been identified, with differences occurring mainly in terms of the analysis. 
These variations are the following: i) Adaptive threshold design, ii) Molecular 
signature design, iii) Cross-validated Adaptive Signature design, iv) Generalized 
adaptive signature design and v) Adaptive signature design with subgroup plots. 
Information about each variant can be found in Appendix A.1, section ‘’Variations of 
Adaptive signature design”. 
Design: Figure 2.2 graphically represents the trial design. The design begins 
with a comparison between the experimental treatment and the standard treatment 
in the entire study population at a pre-specified level of significance. In case that the 
overall result is positive, it is considered that the treatment is beneficial, and the trial 
is closed. If the comparison in the overall population is not promising, then the entire 
population is divided in order to develop and validate a biomarker, using a split 
sample strategy. More precisely, a portion of patients is used to detect a biomarker 
signature that best distinguishes subjects for which the novel treatment is better than 
the standard treatment. Hence, this approach (i) identifies patients who are more 
susceptible to a specific treatment during the initial stage of the study (at the interim 
analysis); (ii) it assesses the global treatment effect of the entire randomized study 
population through a powered test, and (iii) finally, it assesses the treatment effect 
for the biomarker-positive subgroup identified during the initial stages of the study 
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but only with patients randomized in the remainder of the trial, the so-called 
‘validation test’. 
 
Figure 2.2. Adaptive signature design. “R” refers to randomization of patients. 
Methodology: The analysis is undertaken as follows: If the overall treatment 
effect is not significant at a reduced level 𝑎1 (< 0.05), the full set of P patients in the 
clinical trial is partitioned into a training set Tr (recruited before interim analysis) and 
a validation set V (recruited after interim analysis). A pre-specified algorithmic 
analysis plan is applied to the training set to generate a classifier Cl(x;Tr) where x is 
a biomarker vector. This classifier is a function that identifies a biomarker-positive 
subgroup of patients who appear to benefit from the experimental treatment E. 
Cl(x;Tr)=1 means that a patient with x is predicted to benefit from E whereas 
Cl(x;Tr)=0 indicates that a patient is not predicted to benefit from E [57]. The 
experimental treatment E is compared with the standard of care (or control) treatment 
in the biomarker-positive subgroup of the validation set using a significance level of 
𝑎2 = 𝑎 − 𝑎1 in order to ensure that the overall likelihood to obtain a false-positive 
conclusion is no greater than 𝑎 (= 0.05). 
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Freidlin and Simon (2005) [105] recommended that a level of 𝑎1 = 0.04 (two-
sided) is allocated to the entire population hypothesis and 𝑎2 = 0.01 (two-sided) is 
allocated to the biomarker-positive subgroup hypothesis. The multiplicity problem 
is a concern with this approach as the statistical test is conducted twice; this is why 
the alpha is split so the total is 0.05. The power of this strategy can be increased using 
K-fold cross-validation as Freidlin and Simon (2005) [105] demonstrated (see the 
Cross-validated adaptive signature design (CVASD) in Appendix A.1 for further 
information). 
Statistical/practical considerations: Although the adaptive signature design 
allows for approval of the novel treatment in a quick and efficient way as it combines 
two trials into one, the main statistical challenges to be taken into account include the 
potential increase in the number of patients and the limited power to assess the 
treatment effect in the biomarker-defined subgroup. However, this approach avoids 
introduction of bias since the adaptations do not involve modifications in allocation 
ratio and eligibility criteria. Further, it prevents the inflation in type I error rate as the 
design does not use the study population which was employed to develop the 
predictive signature for the assessment of the treatment effect. 
2.2.2.2. Outcome-based adaptive randomization design 
The outcome-based adaptive randomization approach is referred to in 24 
(22.4%) papers. In the context of personalized medicine, this design is used when the 
biomarkers are only putative or not known at the beginning of a Phase II trial and is 
also useful when there are multiple targeted treatments and biomarkers to be 
considered. It aims to test simultaneously both biomarkers and treatments while 
providing more patients with effective therapies according to their biomarker 
profiles. Outcome-adaptive randomization is sometimes included under the 
umbrella of “Bayesian clinical trials” but as criticized by Korn and Freidlin (2011) 
[71], there is nothing inherently Bayesian about it. There is a single variant of the 
Outcome-based adaptive randomization design with differences occurring in its 
analysis methodology. This variant is referred to as Bayesian covariate adjusted 
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response-adaptive randomization and information about this approach can be found 
in Appendix A.1, section ‘’Variation of Outcome-based adaptive randomization 
design’’. Two examples of actual trials which use the outcome-based adaptive 
randomization approach are the following: i) BATTLE trial mentioned in [14, 29, 52, 
59, 62, 70, 72-74, 76, 77], ii) ISPY2 mentioned in [29, 32, 49, 62, 72, 75, 76]. 
Design: An illustration of this approach with one biomarker is shown in Figure 
2.3. The trial begins with the assessment of patients’ biomarker status. The design 
permits the modification of patients’ allocation to different treatment arms so that the 
arm(s) which seem(s) to benefit the study population the most, is composed of the 
higher proportion of randomized patients. Consequently, we have randomization 
probabilities which do not stay fixed over time (e.g. change from adaptive 
randomization (AR) ratio 1:1 to AR 2:1, see Figure 2.3). The random assignment of 
patients to treatment arms, according to their biomarker status, depends on the use 
of accumulated patients’ data about how well the biomarker performs as at each 
interim analysis stage. When these accruing outcome data indicate that an 
experimental treatment is more effective as compared to the standard of care (or other 
treatment(s) or control), it is possible that a higher number of patients will be assigned 
to this particular experimental arm. 
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Figure 2.3. Outcome-based adaptive randomization design. “R” refers to randomization of patients. 
Methodology: Zhou et al. (2008) [77] proposed an analysis plan in a Bayesian 
hierarchical framework using the Bayesian probit model to characterize the disease 
control rate for each treatment by biomarker subgroup. Therefore, the estimates for 
the treatment and the biomarker effect are provided by using the adaptive 
randomization design with the incorporation of a hierarchical Bayes model (it is a 
probit model included in the category of generalized linear models which uses the 
probit link function to model categorical or ordinal data). More precisely, the process 
starts with the biomarker profile assessment of all eligible patients and then 
according to the profile of each individual, the study population will be assigned to 
the different biomarker groups (e.g. a patient with a particular biomarker will be 
assigned to a specific biomarker group). Due to the fact that at the beginning of the 
trial we do not know the true disease control rate (i.e. the proportion of patients who 
demonstrate response to a treatment) the trial begins with equal randomization so 
that each treatment by biomarker subgroup is composed of at least one individual 
with a known disease control status (whether the patient will experience progression 
given a certain treatment). Next, the trial continues with adaptive randomization of 
patients; this is achieved by using the Bayesian probit model to calculate the posterior 
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disease control rate. After the posterior rate is found, we define the randomization 
rate as the posterior mean of the disease control rate of each treatment in each 
biomarker-defined subgroup. The adaptive randomization process continuous until 
the last individual is enrolled and can stop early only in case that all treatments are 
dropped due to inefficacy. Whereas in many trial designs the baseline covariate (in 
this case the biomarker) is considered as prognostic, the design proposed by Zhou et 
al. (2008) [77] allows for modelling the treatment by biomarker interactions where the 
biomarker is in fact predictive. The incorporation of the above hierarchical Bayesian 
structure allows ‘borrowing strength’ or information-sharing across patients 
receiving the same treatment but with different biomarker profiles [77]. 
Statistical/practical considerations: Despite the fact that this design can be 
considered successful as an ethical approach where patients can be assigned to the 
most effective treatments according to their biomarker profiles, an issue that raises 
concern is the requirement of a relatively short assessment period of both biomarker 
and endpoint to avoid erroneously not only the assignment of patients but also the 
adjustment of the randomization rate. Also, potential introduction of bias due to time 
trends in the prognostic mix of the patients enrolled to the study should be taken into 
consideration.  
2.2.2.3. Adaptive threshold sample-enrichment design 
Adaptive threshold enrichment design was identified in 5 papers (4.7%) of our 
review. This approach is a two-stage design in a Phase III setting which was proposed 
by Liu et al. (2010) [79] to adaptively modify accrual in order to broaden the targeted 
patient population (see Figure 2.4). 
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Figure 2.4. Outcome-based adaptive randomization design. “R” refers to randomization of patients. 
Design: The design is based on the former knowledge that a specific biomarker-
defined subgroup (biomarker positive) is believed to benefit more from a novel 
treatment as compared to the remainder of the study population (biomarker 
negative). This knowledge can be gained, for example, from previous studies such as 
a large scale comparative trial (Phase III) when there was treatment effect 
heterogeneity among the study population. This design allows the trial to be 
terminated for futility in the biomarker positive subgroup. More precisely, the trial 
proceeds as follows: (i) accrue and randomize only biomarker positive patients; (ii) 
conduct an interim analysis in order to compare the experimental treatment with the 
standard of care within the biomarker positive subgroup; (iii) if the interim result is 
negative, then the accrual stops and the trial is closed without showing a treatment 
benefit; if the result is ‘promising’ for the specific biomarker-positive subgroup, then 
the study continues with this specific biomarker positive subgroup and accrual also 
begins for biomarker negative patients. Thus, the trial continues with patients 
randomized from the entire population. A ‘promising’ result in the biomarker 
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positive subgroup at the interim stage is claimed when the estimated treatment effect 
is above a particular pre-specified threshold. 
Methodology: The analysis is undertaken as follows: At the interim analysis 
stage, the treatment effect of a sample of patients (𝑛1) from the biomarker-positive 
subset is estimated. If an improvement is seen in the experimental treatment arm 
which is greater than a pre-specified threshold value (i.e. the estimated treatment 
difference between the novel treatment arm and the control treatment arm for this 
subpopulation is greater than a threshold value 𝑐 divided by the square root of the 
aforementioned sample size 𝑛1) the trial continues with accrual of patients from the 
entire biomarker-positive subgroup and additional patients are also accrued from the 
biomarker-negative subpopulation; otherwise the trial is stopped for futility. At the 
end of the trial, the treatment effect is estimated for all subpopulations. Researchers 
should choose the sample size 𝑛1 so that a persuasive result can be reached when the 
first stage of the trial is completed. In general, the threshold value 𝑐 can be 
determined so that 𝑐/√𝑛1  is a proportion of the smallest meaningful treatment 
improvement that researchers expect, e.g. it can be set to half of the smallest clinically 
important difference. Other methods also have been proposed [79]. 
Liu et al. (2010) [79] give a detailed description regarding the statistical 
formalization of the Type I error rate of this two-stage test and the power for assessing 
group-specific treatment effects. Also, Liu et al. (2010) [79] give detailed information 
on testing hypotheses based on the overall treatment effect indexed as a weighted 
average of the group-specific treatment effects, where the weight can be specified as 
the prevalence of that particular subgroup. 
Statistical/practical considerations: The Adaptive threshold sample-
enrichment design is not feasible if there is no prior knowledge regarding a subgroup 
of patients which is more susceptible to a particular treatment than others. In 
addition, this approach is considered more cost-effective as there will be no further 
recruitment from the study population when there is no evidence of treatment 
effectiveness. 
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2.2.2.4. Adaptive patient enrichment design 
The adaptive patient enrichment design was included in 23 papers (21.5%). This 
is a two-stage Phase III clinical trial design proposed by Wang et al. (2007) [80]. There 
is a single variant of the adaptive patient enrichment design with differences 
occurring in its methodology. This variant is referred to as Modified Bayesian version 
of the two-stage design of Wang et al. (2007) [80] and information about it can be 
found in Appendix A.1, section ‘’Variation of Adaptive patient enrichment design’’. 
An example of actual trial which incorporates the adaptive patient enrichment design 
is the NCT01001234 trial [42, 87]. 
Design: This approach is used for the comparison of an experimental treatment 
with the standard of care (control) which adaptively modifies accrual to two 
predefined biomarker-defined subgroups based on an interim analysis for futility. 
Figure 2.5 presents the adaptive patient enrichment design, and in general it flows as 
follows: (i) accrue both biomarker-positive and biomarker-negative patients; (ii) 
perform an interim analysis to evaluate the experimental treatment in the biomarker-
negative subgroup; (iii) if the interim result in that subgroup is ‘not promising’, 
defined as the observed efficacy for the control group being greater than that for the 
experimental group and the difference being greater than a futility boundary, then 
accrual of biomarker-negative patients stops; but the strategy continues with 
accruing additional biomarker-positive patients in order to substitute the unaccrued 
biomarker-negative patients until the pre-specified total target sample size is 
achieved; (iv) contrarily, if the interim results are promising in the biomarker-
negative patients, the accrual of both biomarker-negative and biomarker-positive 
patients continues until the total target sample size is achieved. 
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Figure 2.5. Adaptive patient enrichment design. “R” refers to randomization of patients. 
Methodology: A pre-planned total sample size with futility stopping is 
considered for this two-stage adaptive design. The trial assesses the treatment effect 
both in the entire population and in the biomarker-positive population. Wang et al. 
(2007) [80] performed a simulation study testing a composite hypothesis; the 
hypothesis of the global treatment effect and a hypothesis of treatment effect in the 
biomarker-positive subgroup. A bivariate normal model which incorporates the 
correlation between the two test statistics for each hypothesis was used. Furthermore, 
two multiplicity adjustment methods which have a strong control of experimentwise 
false-positive rate (𝑎 = 0.025) were considered in order to test the composite 
hypotheses of no treatment effect; the first method was the equal split-alpha method 
which allocate 𝑎1 = 𝑎2 =  0.0125 [106] and the second method was the Hochberg’s 
method [107] for multiple testing; a special case of partitioning 𝑎 which starts with 
the least significant p-value and investigate the other p-value in a sequential manner 
until it reaches the most significant one (unequal alpha split). 
Statistical/practical considerations: Although a greater power is achieved as 
compared to a non-adaptive trial design (i.e. fixed study) in simulation settings, this 
strategy can yield an important increase in the duration of recruitment depending on 
the prevalence of the biomarker. Additionally, it does not allow for early termination 
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due to efficacy and can lead to biased treatment effect estimates when the results from 
interim analysis are used for  exclusion of a biomarker-defined subgroup. In addition, 
this study design is appropriate when there is rapid outcome assessment relative to 
the accrual rate and assumes complete confidence in the biomarker at the outset. A 
further limitation is that the futility boundary is considered conservative and less 
than optimal. This conservative approach was chosen in order to expose the least 
number of patients possible to a non-beneficial treatment. However, alternative 
options could be considered.   
2.2.2.5. Adaptive parallel Simon two-stage design 
Jones and Holmgren (2007) [85] proposed a Phase II adaptive design (Figure 
2.6) by extending the Simon two-stage design [88]. This strategy does not include a 
control arm yet, consequently it can be considered a single-arm approach exactly like 
the Simon two-stage approach. The biomarker-adaptive parallel Simon two-stage 
design was mentioned in 8 (7.5%) papers of our review. The design aims to test a 
novel treatment which possibly has a different treatment effect in the biomarker-
positive versus the biomarker-negative subgroups. This approach requires a pre-
defined biomarker with well-established prevalence and permits preliminary 
determination of efficacy that may be restricted to a particular subset of patients. An 
example of actual trial which uses this strategy is the NCT00958971 trial [76, 92, 108]. 
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Figure 2.6. Adaptive parallel Simon two-stage design. “R” refers to randomization of patients. 
Design: The design begins with two parallel phase II studies. During the first 
stage, two separate studies are performed in the biomarker-positive and biomarker-
negative subgroups. Next, depending on the interim results of the first stage, the trial 
either stops or continues into a second stage with the enrollment from either the entire 
patient population (unselected patients) or from the biomarker-positive 
subpopulation only (selected patients). If a preliminary efficacy is observed during 
the first stage of the study for the experimental treatment in both the biomarker-
positive and biomarker-negative subset, then additional patients from the general 
patient population will be enrolled in the second stage; if the interim result during 
the first stage of the trial shows that the efficacy is limited to the biomarker-positive 
subjects, then the recruitment of additional biomarker-positive patients only 
continues during the second stage. 
Methodology: If there are sufficient results in both first and second stages, the 
novel treatment can further be explored. More precisely, the strategy is as follows as 
outlined by McShane et al. (2009) [90]: In the first stage of the design, 𝑁1
− biomarker-
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negative individuals and 𝑁1
+ biomarker-positive individuals are recruited. An 
interim analysis is undertaken with its results determining how the design proceeds 
as follows: If the number of responses to the novel treatment in the biomarker-
negative group, in the first stage 𝑋1
−, meets or exceeds a cutoff of 𝑘1
−, then 𝑁𝑢𝑛 
additional unselected individuals are accrued during the second stage (including 𝑋2
− 
biomarker-negative responders and 𝑋1
+ biomarker-positive responders). If 𝑋1
− is less 
than 𝑘1
− but the number of responses in the biomarker-positive group in the first 
stage, 𝑋1
+, meets or exceeds a cutoff of 𝑘1
+, then the design enrolls 𝑁2
+, additional 
biomarker-positive individuals during the second stage (including 𝑋2
+ responders). If 
𝑋1
−is less than 𝑘1
− and 𝑋1
+ is less than 𝑘1
+then the trial stops. Consequently, when the 
second stage is terminated, a total of 𝑁+ and 𝑁− biomarker-positive and biomarker-
negative individuals, respectively, will have been enrolled, whilst a total of 𝑋𝑇
+ 
(biomarker-positive group) and 𝑋𝑇
− (biomarker-negative group) responders will have 
been observed.  
At the end of stage two, treatment benefit is determined as follows: In the case 
where unselected individuals continued to be accrued during the second stage, the 
total number of responders in the biomarker-negative subgroup, 𝑋𝑇
−, is compared to 
a cutoff,  𝑘− whilst the total number of responders in the biomarker-positive 
subgroup, 𝑋𝑇
+, is compared to a cutoff,  𝑘+. If 𝑋𝑇
− ≥  𝑘−, then we conclude that the 
experimental treatment is beneficial in the unselected population; if 𝑋𝑇
+ ≥  𝑘+and 
𝑋𝑇
− <  𝑘− then we conclude that the treatment is beneficial only in the biomarker-
positive population; if 𝑋𝑇
+ <  𝑘+ and 𝑋𝑇
− <  𝑘−, then we conclude no treatment benefit. 
In the case where only biomarker-positive patients continued to be accrued during 
the second stage, 𝑋𝑇
+, is compared to a cutoff, 𝑘2
+. If 𝑋𝑇
+ ≥ 𝑘2
+ then we conclude 
treatment is beneficial in the biomarker-positive subgroup; otherwise we conclude 
no treatment benefit. The trial stage- and subgroup-specific sample 
sizes  𝑁1
−, 𝑁1
+, 𝑁𝑢𝑛, 𝑁2
+and cutoffs 𝑘1
−, 𝑘1
+, 𝑘−,𝑘+, 𝑘2
+ are determined so that they 
control the probability of correct conclusions in the biomarker-positive and 
unselected patient groups.  
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Jones and Holmgren (2007) [85] have used the values 34, 34, 32 and 36 for 
𝑁1
−, 𝑁1
+, 𝑁𝑢𝑛,and 𝑁2
+ respectively and the values 2, 1, 4, 4 and 5 for 𝑘1
−, 𝑘1
+, 𝑘−,𝑘+, and 
𝑘2
+ respectively. As stated by Jones and Holmgren (2007) [85] values for the cutoffs 
𝑘1
−and 𝑘1
+ (equal to 2 and 1 respectively) are obtained from the first stage of the 
optimal Simon two-stage design. Additionally, in the case where there is preliminary 
efficacy of the experimental treatment in the unselected population during the first 
stage of the trial, the study enters the second stage where the values of 𝑘− and 𝑘+ for 
decision making need to be defined. Assuming the total number of biomarker-
positive subjects (𝑁+) enrolled by the end of the second stage is fixed at its expected 
value given a known prevalence, the aforementioned values (𝑘− and 𝑘+) can be 
acquired as the minimum values needed for exclusion of the null value from the 
(1 − 𝑎)   × 100% exact Blythe-Still-Casella confidence interval where 𝑎 ≤ 0.05; these 
values can be found using the StatXact software package. However, if the observed 
total number of biomarker-positive subjects is much different from the expected 
value, then the cut-offs (𝑘− and 𝑘+) can be changed using the confidence interval 
approach aiming to preserve the desired operating features of the design. Moreover, 
the value of 𝑘2
+ needed also during the second stage of the trial for decision making 
can be acquired using either the confidence interval approach or through the 
calculation of exact binomial probabilities. 
Statistical/practical considerations: The Adaptive Parallel Simon two-stage 
design may be considered as a simple approach with reasonable operating 
characteristics which can result in sample size savings as compared to the Simon two-
stage design [88]. Similarly to Simon’s two-stage design, early termination of the 
study is not allowed during the initial stage of the trial for efficacy in a single 
biomarker-defined subgroup. Additionally, this approach requires the pre-
specification of appropriate response rates in both biomarker-positive and 
biomarker-negative subgroups which may be difficult. 
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2.2.2.6.  Multi-arm multi-stage designs 
Multi-arm multi-stage (MAMS) as originally proposed were not for biomarker 
designs. They aimed at testing multiple experimental treatment against a control 
treatment in the same trial. With the current advances, MAMS can be used in 
personalized medicine within the same context, however, they have also the ability 
to assess the impact of different biomarkers; the treatment arm within which a patient 
is included depends on their biomarker status. MAMS were found in 16 (14.9%) 
papers. They have the ability to simultaneously compare multiple experimental 
treatments with the standard treatment in order to achieve more reliable results in 
less time as compared with separate Phase II trials to assess each novel treatment 
individually. Depending on how long the actual endpoint takes to observe, the actual 
or an intermediate endpoint is used to identify both treatments for which there is an 
early sign of effectiveness and treatments that appear ineffective thus allowing the 
study to continue with the promising experimental arms and to stop the investigation 
of insufficient treatments. Generally, MAMS designs, according to Parmar et al. 
(2008) [97], are useful when (i) there are multiple promising treatments in phase II/III 
studies; (ii) there is no strong belief that a treatment will be more beneficial compared 
to another therapy; (iii) availability of adequate funds; (iv) there is an adequate 
number of patients to be enrolled and (v) there is an intermediate outcome measure 
correlated with the primary outcome measure. Parmar et al. (2008) [97] encouraged 
the use of the MAMS strategy in the field of oncology but highlighted that these 
designs should only be used when quick outcome assessment is possible [69]. There 
are two variants referred to as i) Two-stage adaptive seamless design, ii) Group 
Sequential design to the MAMS designs with differences occurring in its 
methodology. Information about these variants can be found in Appendix A.1, 
section ‘’Variations of Multi-arm multi-stage (MAMS) design’’. Some examples of 
actual trials which use the MAMS approach are the following: i) GOG-182 [20, 97, 
102], ii) STAMPEDE [93, 97], iii) ICON6 [93, 97, 109], iv) FOCUS4 trial [69, 103].  
Design: Figure 2.7 illustrates a MAMS design where the first stage of the trial 
(the Phase II stage) involves randomization within one of two arms which 
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simultaneously compare two experimental treatments with the standard of care 
(control) using an intermediate outcome measure (e.g. progression free survival). The 
arm within which a patient is included depends on their biomarker status, for 
example patients positive for biomarker 1 may be randomized in arm 1 to either 
standard of care or experimental treatment 1 whilst patients positive for biomarker 2 
may be randomized in arm 2 to either standard of care or experimental treatment 2. 
At the end of this first stage, an interim analysis is undertaken in each arm, comparing 
the experimental treatment with standard of care. Depending on the outcome of the 
interim analysis, accrual of patients either continues within an arm to the second 
stage of the trial or the accrual of additional patients stops within that arm. Despite 
the fact that some experimental treatments cannot pass the first stage, a secondary 
analysis can be conducted for each of these treatment arms comparing them with the 
standard of care. This approach ensures that patients are randomized to the most 
promising treatments which were selected at the first stage of the study. 
 
Figure 2.7. Multi-arm multi-stage (MAMS) design. “R” refers to randomization of patients. 
Methodology: At the interim stage, in the case where the observed effect size 
in an experimental arm is greater than a predefined critical value, accrual of patients 
continues within that arm to the second stage of the trial until the pre-specified 
number of events on the primary outcome (e.g. overall survival) measure is reached, 
otherwise the accrual of additional patients stops within that arm and the 
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corresponding novel treatment does not enter the second stage of the trial. The 
aforementioned predefined critical value is calculated for each stage of the study in a 
way that takes into account whether the null hypothesis can be rejected at the level 
of the probability of the continuation of the study to the next stage should the null 
hypothesis be true as Parmar et al. (2008) [97] state. 
The stopping thresholds are based on test statistics, resulting in dropping 
experimental arms which do not show effectiveness. The allocation to each remaining 
arm is fixed in MAMS trials, however, it is possible to assign more patients in the 
control treatment group than to the experimental arms which can yield small gains 
in efficiency over balanced randomization as Wason and Trippa (2014) [69] 
highlighted; this strategy has been used in practice with the STAMPEDE trial where 
the control arm is compared with five experimental treatments with the 
corresponding randomization ratio 2:1:1:1:1:1 [93]. MAMS approach could be 
designed with either a fixed sample size by fixing the number of patients enrolled at 
each stage or a fixed number of patients enrolled per arm per stage [69]. 
The methodology has mainly focused on situations where the primary 
endpoint is assumed normally distributed or time-to-event [69]. Two papers discuss 
MAMS designs with the normally distributed endpoint [94, 110], whilst a time-to-
event endpoint is used by Royston et al. (2003) [99]. Freely-available software in Stata 
for calculating sample size was proposed by Barthel et al. (2009) [97] for MAMS trials 
[93]. 
A recent article by Wason et al. (2015) [111] proposed a new Bayesian adaptive 
design for clinical trials with biomarkers and linked treatments in multi-arm phase II 
trials. It is a novel approach combining the methodology used for BATTLE, I-SPY 2 
and FOCUS 4 trial, which results in significant power to identify treatment effects. 
This novel trial design could be used for simultaneously testing several predictive 
biomarkers and new experimental treatments in a more cost-effective and rapid way. 
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Statistical/practical considerations: MAMS designs as compared with testing 
each experimental treatment in separate large-scale two-armed trials not only shorten 
the length of time required and reduce the costs due to the fact that they assess several 
experimental treatments at the same time while using a smaller number of 
individuals as some experimental treatment arms are dropped early. Despite the 
aforementioned benefits, researchers are faced with operational challenges and 
difficulties in building-up such designs. 
2.2.2.7.  Stratified adaptive design 
Tournoux-Facon et al. (2011) [89] proposed a new Adaptive Stratified phase II 
design based on the multiple-stage Fleming design [112]. A single article (0.93%) of 
our review referred to this approach. It is an alternative approach to dealing with 
stratification in a phase II setting and aims to demonstrate whether an experimental 
treatment (no control arm is included, thus it’s about a single arm approach) is 
beneficial for at least one biomarker-defined subgroup rather than the entire study 
population. 
 
Figure 2.8. Stratified adaptive design. “R” refers to randomization of patients. 
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Methodology: Decision making and the number of patients used at the second 
stage of the trial are based on the observed response rates during the first stage of the 
trial. This approach depends on the identification of heterogeneity between the two 
biomarker-defined subgroups (positive and negative subgroups). Heterogeneity is 
identified when the observed response rate in one of the biomarker-defined 
subgroups is less than 𝜋0𝑖 (defined as the probability of response in one of the 
biomarker-defined subsets below which the novel treatment is considered to be a 
low-activity treatment, where 𝑖 denotes each biomarker-defined subgroup; the value 
of 0.25 is used for the 𝜋0𝑖  by Tournoux-Facon et al. (2011) [89]), whereas the other 
subset has a response rate greater than 𝜋0𝑖 . The subset for which the observed 
response rate is less than 𝜋0𝑖  is considered clinically insignificant, and therefore 
cannot continue to the second stage of the trial. Only the subgroup with response rate 
greater than 𝜋0𝑖 therefore enters the second stage where the study can continue as a 
randomized Phase III trial comparing the novel treatment which has proved to be 
effective with the standard of care. More precisely, the identification of heterogeneity 
of responses is performed by calculating the symmetric interval of probability around 
𝜋0𝑖 at each stage (only a symmetric interval is observed due to binomial calculation). 
When the first stage of the design is terminated, in case that the cumulative number 
of responses for one of the biomarker-defined subset is less than/greater than the 
lower/upper boundary of the aforementioned symmetric interval of probability and 
the cumulative number of responses for the other biomarker-defined subgroup is 
greater than/less than the upper/lower boundary of the symmetric interval, then the 
responses between the two subsets are considered heterogeneous; otherwise, the 
treatment effect is similar in the two subsets, consequently, the trial continues 
without selecting any biomarker-defined subset. After the identification of 
heterogeneity of responses, conclusions at the end of the first stage of the trial are 
made according to decision rules based on specific thresholds which are determined 
by iterations using a Fleming two-stage approach [112]; a single-arm design which 
permits early termination of the trial for either efficacy or inefficacy of the treatment. 
The adaptive stratified design has a number of differences from the Adaptive 
Parallel Simon two-stage design proposed by Jones and Holmgren (2007) [85] and the 
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global one-sample test for response rates for stratified phase II clinical trials proposed 
by London and Chang (2005) [113]. First and foremost, the adaptive stratified design 
permits futility or efficacy of the study as it is a strategy based on a Fleming design 
[112]. On the contrary, the two aforementioned methods are based on the Simon 
design and do not make the discontinuation for efficacy or futility of the study 
possible. Additionally, the stratification approach used in the design provided by 
Tournoux-Facon et al. (2011) [89] is utilized in order to target the patients who are 
most likely to respond to a novel treatment, whereas, stratification in the design by 
London and Chang (2005) [113] aims to ameliorate the power of the overall test. 
Statistical/practical considerations: Tournoux-Facon et al. (2011) [89] state 
several benefits, such as the possibility of early termination for efficacy or inefficacy 
of the novel treatment according to the results of the interim analysis (first stage). 
Moreover, this approach can be considered more ethical due to the fact that it 
identifies a particular biomarker-defined subpopulation for which the novel 
treatment can be effective and thus avoids conducting a study with patients exposed 
to toxic treatments. Additionally, this strategy ameliorates targeting of the 
populations entering phase III trials. No statistical challenges have been identified for 
this type of trial design so far. 
2.2.2.8.  Tandem two stage design 
The tandem two-stage design was discussed in 5 (4.7%) papers. It was proposed 
by Pusztai et al. (2007) [104] and it is composed of 2 optimal trials in a Phase II setting 
(Figure 2.9). This design was proposed for rapid biomarker assessment in settings 
where we don’t know the activity of a novel treatment in the unselected population 
but there is at least one candidate predictor of response. This approach can identify 
whether the novel treatment is effective in the unselected patients, and if it is not, can 
tell us if the predictor can enrich the responding population [104]. Only an 
experimental treatment arm is included in this design and not a control treatment 
arm, thus this approach can be considered a single-arm approach. An example of 
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actual trial which uses the tandem two stage approach is the NCT00735917 [90, 92, 
114, 115]. 
 
Figure 2.9. Tandem two stage design. “R” refers to randomization of patients. 
Design: In this design, a predefined biomarker is assumed. In the first stage of 
the trial, patients from the entire population enter the trial irrespective of their 
biomarker status. An interim analysis is then undertaken and if a sufficient number 
of events (defined in terms of clinical benefit rate or response rate) have been 
observed during the first stage, the study proceeds to a second stage whereby further 
patients are accrued from the unselected population to establish the benefit rate more 
precisely in unselected patients. However, if an insufficient number of events have 
been observed during the first stage, rather than stopping accrual for futility, a second 
trial commences whereby its first stage involves continued accrual of biomarker–
positive patients only. An interim analysis is then conducted and if a sufficient 
number of events have been occurred, this second trial continues into a second stage 
of biomarker-marker positive patient accrual. Otherwise, if an insufficient number of 
events have occurred, the predefined biomarker is rejected. 
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Methodology: A second phase in the trial design is considered due to the fact 
that the small number of individuals used in the first phase of the study (typically 
𝑛1 < 25) is likely to include insufficient number of biomarker-positive individuals in 
order to decide whether the novel treatment benefits this particular biomarker-
defined subset. In terms of defining what constitutes a ‘sufficient number’, Pusztai et 
al. (2007) [104] suggest the use of a non-informative prior distribution for clinical 
benefit rate of 𝛽(1, 1) and make recommendations for the early stopping rules. More 
precisely, Pusztai et al. (2007) [104], given a certain value for the targeted level of 
activity of the novel treatment (i.e. 25% clinical benefit rate), suggest that the trial 
should stop early for futility if the conditional power (i.e. the chance to reach the 
aforementioned targeted level of activity) is equal or less than 7.5% in the following 
cases: (i) at the first 9 evaluated patients there is no one who responds to treatment; 
(ii) at the first 15 evaluated patients there is only one individual who responds to 
treatment and (iii) at the first 20 evaluated patients there are only 2 individuals who 
respond to treatment. 
The sample size for this approach is calculated with the same rules as a classic 
two-stage or Bayesian phase II design [104] where criteria for specifying the sample 
size are used (e.g. one criterion is to choose a sample size so that if there is no early 
termination of the trial and the trial accrues the entire population the posterior of the 
experimental treatment success rate reaches a specified degree of precision). The 
sample size calculations are discussed in two papers [116, 117].  
Statistical considerations: The two trials within this design could be conducted 
separately, as two independent trials for the unselected individuals and for the 
biomarker-positive individuals, however, this can result in larger duration and costs, 
therefore it would be better to run the two trials as a single study (see Table 2.1 for 
further details). Additionally, this approach enables the estimation of response rates 
in both biomarker-negative and biomarker-positive patients. 
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2.3. Discussion 
The review has demonstrated ambiguity and confusion regarding biomarker-
guided adaptive designs proposed by different authors. For example, different 
authors described the same trial design by naming it differently (see Table 2.1). In this 
review, we focus on 8 types of such designs. There are several reasons why these 
design strategies are becoming an appealing approach to a great extent. The main 
reason is their application to real clinical practice and their ability to evaluate both 
multiple experimental treatments and biomarkers simultaneously. Hence, multiple 
questions can be answered just in a single trial [48]. During the progression of the 
trial alterations are permitted, and consequently, any potential incorrect hypothesis 
made at the beginning of the trial can be modified. Many authors note that these 
strategies are ethical in terms of safety and efficacy as they attempt to tailor the 
appropriate treatment to the right population at the right time [10, 33, 37, 40, 46, 55, 
70, 118, 119]. The required number of patients needed for the enrollment in the trial 
can be modified according to the results from interim analysis (e.g. stop accrual or 
increase sample size) and the duration of the trial can be minimized as they allow for 
dropping early treatments which show poor performance. Also, due to alterations, 
e.g. if incrementation of the sample size is suggested as the study progresses, higher 
power to demonstrate a treatment effect may be achieved [120]. Furthermore, it has 
been argued that during the adaptation process, preservation of type I and type II 
error rates may be attained through the appropriate choice of statistical parameters 
[26]. 
Despite the aforementioned advantages, there are a considerable number of 
challenges which should be carefully investigated before making a decision. Their 
implementation may be considered a poor choice when there is already a high quality 
retrospective dataset available which includes information both on biomarker status 
and on long-term follow-up, since in such a situation an analysis of this dataset to 
identify a biomarker subgroup would likely be more efficient as a first stage as 
opposed to incorporating this first stage into the trial itself [120]. Also, they can be 
complex in terms of logistic issues such as maintaining trial integrity, minimizing 
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operational bias [33, 45, 48, 52] and the involved perspectives of regulatory agencies 
(e.g. what level of adaptation will be acceptable to the regulatory agencies) [121]. In 
addition, adaptations, of which statistical validity may be challenging, can lead to 
notable modifications yielding a complicated trial totally different from the initial 
study [33, 37, 40]. Consequently, it could diverge from the original question which 
researchers expect to answer. Furthermore, statistical validity of conclusions can be 
influenced to a great extent as unexpected bias or variation may be introduced during 
the course of the trial making the interpretation of results greatly complex [33, 122, 
123]. The inserted operational bias occurred by the modifications in the trial design 
augments the likelihood of making a false conclusion that the treatment is beneficial 
to certain patients [33, 37, 40, 71, 118]. It is necessary that adaptive designs are 
planned in such a way that allows for controlling both Type I and Type II error rates 
[69]. Additionally, from a statistical viewpoint, adaptive designs based on Bayesian 
methods are considered computationally intensive [55] and estimations of Type I 
error rate can be inaccurate. Problems of statistical testing may also arise and 
applying the statistical methods can be very challenging without the availability of 
appropriate software packages to facilitate the implementation of adaptive designs 
(e.g. computational intensive demands of Bayesian methods) [33, 40, 45, 48, 52]. A 
number of obstacles and barriers related to the conduct of adaptive designs in 
practice in Phase III trials is addressed in a recent paper [124]; several key 
stakeholders in clinical trials research have been interviewed and some of the 
highlighted difficulties expressed during this study were the lack of appropriate 
knowledge and familiarity of these designs in the biostatistics community, 
insufficient time and funding structure, additional work required due to the 
complexity of such designs and the needed statistical expertise and appropriate 
software.  
However, adaptive designs will continue to hold a prominent place in the era 
of personalized medicine, and hence, further developments and discussion are of 
utmost importance in order to enhance clinical research. In conducting such further 
developments and discussion, investigators should take account of the following 
points in particular (i) regulatory and logistical issues; (ii) statistical challenges 
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including the control of the false-positive rate, power of the study and treatment 
effect estimation; (iii) the unexpected bias likely to be introduced during the 
adaptation process and (iv) the potential increased cost and time. Further, the 
different designs proposed so far for adaptive trials need to be better understood by 
the research community, as the proper use of such designs can result in a great 
increase in the efficiency of a trial and boost the development of novel treatments. By 
conducting this methodological review, we contribute to the knowledge 
enhancement of researchers regarding the biomarker-guided adaptive trial designs.  
The characteristics and methodology of the eight main designs are discussed 
here, whilst information on their variations are summarized in Table A.1, Appendix 
A.1. Additional references for these variations are provided in [125-142]. 
In the current chapter we presented the adaptive trial designs, whereas in the 
next chapter (Chapter 3) we will focus on the second broad category, the so-called 
non-adaptive trial designs. 
2.4. References 
1. George SL. Statistical issues in translational cancer research. Clinical cancer 
research: an official journal of the American Association for Cancer Research. 2008; 
14(19):5954-8. doi: 10.1158/1078-0432.CCR-07-4537. 
2. Chabner B. Advances and challenges in the use of biomarkers in clinical trials. 
Clinical advances in hematology & oncology: H&O. 2008; 6(1):42-3. 
3. Shi Q, Mandrekar SJ, Sargent DJ. Predictive biomarkers in colorectal cancer: usage, 
validation, and design in clinical trials. Scandinavian journal of gastroenterology. 
2012; 47(3):356-62. doi: 10.3109/00365521.2012.640836. 
4. Pihlstrom BL, Barnett ML. Design, operation, and interpretation of clinical trials. 
Journal of dental research. 2010; 89(8):759-72. doi: 10.1177/0022034510374737. 
 47 
 
5. Rigatto C, Barrett BJ. Biomarkers and surrogates in clinical studies. Methods in 
molecular biology (Clifton, NJ). 2009; 473:137-54. doi: 10.1007/978-1-59745-385-1_8. 
6. Mandrekar SJ, An M-W, Sargent DJ. A review of phase II trial designs for initial 
marker validation. Contemporary clinical trials. 2013; 36(2):597-604. doi: 
10.1016/j.cct.2013.05.001. 
7. Karuri SW, Simon R. A two-stage Bayesian design for co-development of new 
drugs and companion diagnostics. Statistics in medicine. 2012; 31(10):901-14. doi: 
10.1002/sim.4462. 
8. Matsui S. Genomic biomarkers for personalized medicine: development and 
validation in clinical studies. Computational and mathematical methods in medicine. 
2013; 2013:865980-. doi: 10.1155/2013/865980. 
9. Buyse M, Michiels S. Omics-based clinical trial designs. Current opinion in 
oncology. 2013; 25(3):289-95. doi: 10.1097/CCO.0b013e32835ff2fe. 
10. Wu W, Shi Q, Sargent DJ. Statistical considerations for the next generation of 
clinical trials. Seminars in oncology. 2011; 38(4):598-604. doi: 
10.1053/j.seminoncol.2011.05.014. 
11. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive 
marker validation in cancer treatment trials. Journal of clinical oncology: official 
journal of the American Society of Clinical Oncology. 2005; 23(9):2020-7. doi: 
10.1200/JCO.2005.01.112. 
12. Chen JJ, Lu T-P, Chen D-T, Wang S-J. Biomarker adaptive designs in clinical trials. 
Translational Cancer Research. 2014; 3(3):279-92. 
13. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment 
and biomarker evaluation. Journal of clinical oncology: official journal of the 
American Society of Clinical Oncology. 2013; 31(25):3158-61. doi: 
10.1200/JCO.2012.48.3826. 
 48 
 
14. Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for 
biomarker research. Sensors (Basel, Switzerland). 2012; 12(7):8966-86. doi: 
10.3390/s120708966. 
15. Ming-Wen An SJM, Daniel JS. Biomarkers-guided targeted drugs: new clinical 
trials design and practice necessity. Advances in Personalized Cancer Management. 
2011; 30-41. doi: 10.2217/ebo.11.87. 
16. Buyse M. Towards validation of statistically reliable biomarkers. European 
Journal of Cancer Supplements. 2007; 5(5):89-95. doi: 10.1016/S1359-6349(07)70028-9. 
17. Lee CK, Lord SJ, Coates AS, Simes RJ. Molecular biomarkers to individualise 
treatment: assessing the evidence. The Medical journal of Australia. 2009; 190(11):631-
6. 
18. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and 
predictive biomarkers in oncology. Personalized medicine. 2010; 7(1):33-47. doi: 
10.2217/pme.09.49. 
19. Fraser GAM, Meyer RM. Biomarkers and the design of clinical trials in cancer. 
Biomarkers in medicine. 2007; 1(3):387-97. doi: 10.2217/17520363.1.3.387. 
20. Mandrekar SJ, Sargent DJ. Design of clinical trials for biomarker research in 
oncology. Clinical investigation. 2011; 1(12):1629-36. doi: 10.4155/CLI.11.152. 
21. Simon R. Advances in clinical trial designs for predictive biomarker discovery and 
validation. Current Breast Cancer Reports. 2009; 1(4):216-21. doi: 10.1007/s12609-009-
0030-4. 
22. Polley M-YC, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical 
and practical considerations for clinical evaluation of predictive biomarkers. Journal 
of the National Cancer Institute. 2013; 105(22):1677-83. doi: 10.1093/jnci/djt282. 
 49 
 
23. Bradley E. Incorporating biomarkers into clinical trial designs: points to consider. 
Nature biotechnology. 2012; 30(7):596-9. doi: 10.1038/nbt.2296. 
24. Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers 
into oncology clinical development programmes. Nature reviews Drug discovery. 
2011; 10(10):735-48. doi: 10.1038/nrd3550. 
25. Young KY, Laird A, Zhou XH. The efficiency of clinical trial designs for predictive 
biomarker validation. Clinical trials (London, England). 2010; 7(5):557-66. doi: 
10.1177/1740774510370497. 
26. Lee JJ, Xuemin G, Suyu L. Bayesian adaptive randomization designs for targeted 
agent development. Clinical trials (London, England). 2010; 7(5):584-96. doi: 
10.1177/1740774510373120. 
27. Simon R. Clinical trials for predictive medicine: new challenges and paradigms. 
Clinical trials (London, England). 2010; 7(5):516-24. doi: 10.1177/1740774510366454. 
28. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and 
surrogate end points--the challenge of statistical validation. Nature reviews Clinical 
oncology. 20100; 7(6):309-17. doi: 10.1038/nrclinonc.2010.43. 
29. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker 
validation: theoretical considerations and practical challenges. Journal of clinical 
oncology: official journal of the American Society of Clinical Oncology. 2009; 
27(24):4027-34. doi: 10.1200/JCO.2009.22.3701. 
30. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker 
validation: one size does not fit all. Journal of biopharmaceutical statistics. 2009; 
19(3):530-42. doi: 10.1080/10543400902802458. 
31. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for 
targeted agents. Clinical cancer research: an official journal of the American 
 50 
 
Association for Cancer Research. 2008; 14(14):4358-67. doi: 10.1158/1078-0432.CCR-
08-0288. 
32. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right 
patient. Nature reviews Drug discovery. 2012; 11(3):201-14. doi: 10.1038/nrd3651. 
33. Chow S-C. Adaptive clinical trial design. Annual review of medicine. 2014; 65:405-
15. doi: 10.1146/annurev-med-092012-112310. 
34. Chow S-C, Chang M, Pong A. Statistical consideration of adaptive methods in 
clinical development. Journal of biopharmaceutical statistics. 2005; 15(4):575-91. doi: 
10.1081/BIP-200062277. 
35. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive 
designs in clinical drug development--an Executive Summary of the PhRMA 
Working Group. Journal of biopharmaceutical statistics. 2006; 16(3):275-83; 
discussion 85-91, 93-8, 311-2. doi: 10.1080/10543400600614742. 
36. Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, et al. Confirmatory 
adaptive designs with Bayesian decision tools for a targeted therapy in oncology. 
Statistics in medicine. 2009; 28(10):1445-63. doi: 10.1002/sim.3559. 
37. Chow S-C, Tu Y-H. On Two-stage Seamless Adaptive Design in Clinical Trials. 
Journal of the Formosan Medical Association = Taiwan yi zhi. 2008; 107(12 Suppl):52-
60. 
38. Maharaj R. Vasopressors and the search for the optimal trial design. 
Contemporary clinical trials. 2011; 32(6):924-30. doi: 10.1016/j.cct.2011.07.010. 
39. Vandemeulebroecke M. Group sequential and adaptive designs - a review of basic 
concepts and points of discussion. Biometrical journal Biometrische Zeitschrift. 2008; 
50(4):541-57. doi: 10.1002/bimj.200710436. 
 51 
 
40. Chow S-C, Chang M. Adaptive design methods in clinical trials - a review. 
Orphanet journal of rare diseases. 2008; 3:11-. doi: 10.1186/1750-1172-3-11. 
41. Brannath W, Koenig F, Bauer P. Multiplicity and flexibility in clinical trials. 
Pharmaceutical statistics. 2007; 6(3):205-16. doi: 10.1002/pst.302. 
42. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review 
of barriers and opportunities. Trials. 2012; 13:145-. doi: 10.1186/1745-6215-13-145. 
43. Ananthakrishnan R, Menon S. Design of oncology clinical trials: a review. Critical 
reviews in oncology/hematology. 2013; 88(1):144-53. doi: 
10.1016/j.critrevonc.2013.03.007. 
44. Orloff JJ, Stanski D. Innovative approaches to clinical development and trial 
design. Annali dell'Istituto superiore di sanità. 2011; 47(1):8-13. doi: 
10.4415/ANN_11_01_03. 
45. Dragalin V. An introduction to adaptive designs and adaptation in CNS trials. 
European neuropsychopharmacology: the journal of the European College of 
Neuropsychopharmacology. 2011; 21(2):153-8. doi: 10.1016/j.euroneuro.2010.09.004. 
46. Coffey CS, Kairalla JA. Adaptive clinical trials: progress and challenges. Drugs in 
R&D. 2008; 9(4):229-42. 
47. Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. 
Pharmacogenomics. 2010; 11(12):1679-82. doi: 10.2217/pgs.10.153. 
48. Heckman-Stoddard BM, Smith JJ. Precision medicine clinical trials: defining new 
treatment strategies. Seminars in oncology nursing. 2014; 30(2):109-16. doi: 
10.1016/j.soncn.2014.03.004. 
49. Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, et al. Incorporation 
of biomarker assessment in novel clinical trial designs: personalizing brain tumor 
 52 
 
treatments. Current oncology reports. 2011; 13(1):42-9. doi: 10.1007/s11912-010-0144-
x. 
50. An M-W, Mandrekar SJ, Sargent DJ. A 2-stage phase II design with direct 
assignment option in stage II for initial marker validation. Clinical cancer research: 
an official journal of the American Association for Cancer Research. 2012; 18(16):4225-
33. doi: 10.1158/1078-0432.CCR-12-0686. 
51. Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing 
prognostic and predictive biomarkers in CRC clinical trials. Nature reviews Clinical 
oncology. 2011; 8(4):222-32. doi: 10.1038/nrclinonc.2011.15. 
52. Ang M-K, Tan S-B, Lim W-T. Phase II clinical trials in oncology: are we hitting the 
target? Expert review of anticancer therapy. 2010; 10(3):427-38. doi: 
10.1586/era.09.178. 
53. Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design with 
biomarkers for targeted therapies. Clinical trials (London, England). 2010; 7(5):546-
56. doi: 10.1177/1740774510372657. 
54. Berry DA. Adaptive clinical trials in oncology. Nature reviews Clinical oncology. 
2012; 9(4):199-207. doi: 10.1038/nrclinonc.2011.165. 
55. Lee JJ, Chu CT. Bayesian clinical trials in action. Statistics in medicine. 2012; 
31(25):2955-72. doi: 10.1002/sim.5404. 
56. Berry DA. Bayesian clinical trials. Nature reviews Drug discovery. 2006; 5(1):27-
36. doi: 10.1038/nrd1927. 
57. Simon R. Clinical trials for predictive medicine. Statistics in medicine. 2012; 
31(25):3031-40. doi: 10.1002/sim.5401. 
 53 
 
58. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to 
biomarker credentials. Nature reviews Clinical oncology. 2014; 11(2):81-90. doi: 
10.1038/nrclinonc.2013.218. 
59. Scher HI, Nasso SF, Rubin EH, Simon R. Adaptive clinical trial designs for 
simultaneous testing of matched diagnostics and therapeutics. Clinical cancer 
research: an official journal of the American Association for Cancer Research. 2011; 
17(21):6634-40. doi: 10.1158/1078-0432.CCR-11-1105. 
60. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. 
Clinical cancer research: an official journal of the American Association for Cancer 
Research. 2010; 16(2):691-8. doi: 10.1158/1078-0432.CCR-09-1357. 
61. Coyle VM, Johnston PG. Genomic markers for decision making: what is 
preventing us from using markers? Nature reviews Clinical oncology. 2010; 7(2):90-
7. doi: 10.1038/nrclinonc.2009.214. 
62. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational 
Cancer Research Think Tank meeting: design strategies for personalized therapy 
trials. Clinical cancer research: an official journal of the American Association for 
Cancer Research. 2012; 18(3):638-44. doi: 10.1158/1078-0432.CCR-11-2018. 
63. Tajik P, Zwinderman AH, Mol BW, Bossuyt PM. Trial designs for personalizing 
cancer care: a systematic review and classification. Clinical cancer research: an official 
journal of the American Association for Cancer Research. 2013; 19(17):4578-88. doi: 
10.1158/1078-0432.CCR-12-3722. 
64. Baker SG, Kramer BS, Sargent DJ, Bonetti M. Biomarkers, subgroup evaluation, 
and clinical trial design. Discovery medicine. 2012; 13(70):187-92. 
65. Di Maio M, Gallo C, De Maio E, Morabito A, Piccirillo MC, Gridelli C, et al. 
Methodological aspects of lung cancer clinical trials in the era of targeted agents. 
 54 
 
Lung cancer (Amsterdam, Netherlands). 2010; 67(2):127-35. doi: 
10.1016/j.lungcan.2009.10.001. 
66. Simon R. The use of genomics in clinical trial design. Clinical cancer research: an 
official journal of the American Association for Cancer Research. 2008; 14(19):5984-
93. doi: 10.1158/1078-0432.CCR-07-4531. 
67. Simon R. Development and validation of biomarker classifiers for treatment 
selection. Journal of Statistical Planning and Inference. 2008; 138:308-20. doi: 
10.1016/j.jspi.2007.06.010. PubMed PMID: S037837580700242X. 
68. Simon R. Biomarker based clinical trial design. Chinese clinical oncology. 2014; 
3(3):39. doi: 10.3978/j.issn.2304-3865.2014.02.03. 
69. Wason JMS, Trippa L. A comparison of Bayesian adaptive randomization and 
multi-stage designs for multi-arm clinical trials. Statistics in medicine. 2014; 
33(13):2206-21. doi: 10.1002/sim.6086. 
70. Sato Y, Laird NM, Yoshida T. Biostatistic tools in pharmacogenomics - advances, 
challenges, potential. Current pharmaceutical design. 2010; 16(20):2232-40. 
71. Korn EL, Freidlin B. Outcome - adaptive randomization: is it useful? Journal of 
clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 
(6):771-6. doi: 10.1200/JCO.2010.31.1423. 
72. Lai TL, Lavori PW, Shih M-CI, Sikic BI. Clinical trial designs for testing biomarker-
based personalized therapies. Clinical trials (London, England). 2012; 9(2):141-54. doi: 
10.1177/1740774512437252. 
73. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to 
personalize lung cancer prevention through reverse migration. Cancer prevention 
research (Philadelphia, Pa). 2011; 4(7):962-72. doi: 10.1158/1940-6207.CAPR-11-0232. 
 55 
 
74. Lai TL, Liao OY-W, Kim DW. Group sequential designs for developing and testing 
biomarker-guided personalized therapies in comparative effectiveness research. 
Contemporary clinical trials. 2013; 36(2):651-63. doi: 10.1016/j.cct.2013.08.007. 
75. Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in 
lymphoma. Nature reviews Clinical oncology. 2012; 9(11):643-53. doi: 
10.1038/nrclinonc.2012.156. 
76. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. 
Integrating biomarkers in clinical trials. Expert review of molecular diagnostics. 2011; 
11(2):171-82. doi: 10.1586/erm.10.120. 
77. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted 
therapy development in lung cancer--a step toward personalized medicine. Clinical 
trials (London, England). 2008; 5(3):181-93. doi: 10.1177/1740774508091815. 
78. European Medicines Agency. Reflection paper on methodological issues 
associated with pharmacogenomic biomarkers in relation to clinical development 
and patient selection London; 2011 [updated [cited 2012 Jul 3]; cited 2015 10 Oct]. 
Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011
/07/WC500108672.pdf. 
79. Liu A, Liu C, Li Q, Yu KF, Yuan VW. A threshold sample-enrichment approach 
in a clinical trial with heterogeneous subpopulations. Clinical trials (London, 
England). 2010; 7(5):537-45. doi: 10.1177/1740774510378695. 
80. Wang S-J, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in 
randomized clinical trials with genomic subset. Pharmaceutical statistics. 2007; 
6(3):227-44. doi: 10.1002/pst.300. 
 56 
 
81. Wang S-J. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute 
to 30th anniversary of PSI. Pharmaceutical statistics. 2007; 6(4):283-96. doi: 
10.1002/pst.316. 
82. Emerson SS, Fleming TR. Adaptive methods: telling "the rest of the story". Journal 
of biopharmaceutical statistics. 2010; 20(6):1150-65. doi: 
10.1080/10543406.2010.514457. 
83. Wang S-J, Hung HMJ, O'Neill RT. Adaptive patient enrichment designs in 
therapeutic trials. Biometrical journal Biometrische Zeitschrift. 2009; 51(2):358-74. doi: 
10.1002/bimj.200900003. 
84. Simon R. Designs and adaptive analysis plans for pivotal clinical trials of 
therapeutics and companion diagnostics. Expert opinion on medical diagnostics. 
2008; 2(6):721-9. doi: 10.1517/17530059.2.6.721. 
85. Jones CL, Holmgren E. An adaptive Simon Two-Stage Design for Phase 2 studies 
of targeted therapies. Contemporary clinical trials. 2007; 28(5):654-61. doi: 
10.1016/j.cct.2007.02.008. 
86. Wang S-J. Adaptive strategy versus adaptive design in pharmacogenomics or 
pharmacogenetics clinical trials. Journal of the Formosan Medical Association. 2008; 
107(S18–S26). 
87. Ho TW, Pearlman E, Lewis D, Hämäläinen M, Connor K, Michelson D, et al. 
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a 
randomized, double-blind, placebo-controlled trial using a novel adaptive 
enrichment design. Cephalalgia: an international journal of headache. 2012; 
32(10):750-65. doi: 10.1177/0333102412451358. 
88. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled clinical 
trials. 1989; 10(1):1-10. 
 57 
 
89. Tournoux-Facon C, De Rycke Y, Tubert-Bitter P. Targeting population entering 
phase III trials: a new stratified adaptive phase II design. Statistics in medicine. 2011; 
30(8):801-11. doi: 10.1002/sim.4148. 
90. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into 
phase II trials. Clinical cancer research: an official journal of the American Association 
for Cancer Research. 2009; 15(6):1898-905. doi: 10.1158/1078-0432.CCR-08-2033. 
91. Simon R, Polley E. Clinical trials for precision oncology using next-generation 
sequencing. Personalized Medicine. 2013; 10:485-95. doi: 10.2217/pme.13.36. 
92. Andre F. Study CTKI258A2202: A multicenter, open-label phase II trial of 
dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic 
breast cancer: ASCO; 2010 [cited 2015 10 Oct]. Available online: 
http://meetinglibrary.asco.org/content/52807-74. 
93. Sydes MR, Parmar MKB, James ND, Clarke NW, Dearnaley DP, Mason MD, et al. 
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate 
cancer: the MRC STAMPEDE trial. Trials. 2009; 10:39. doi: 10.1186/1745-6215-10-39. 
94. Wason JMS, Jaki T. Optimal design of multi-arm multi-stage trials. Statistics in 
medicine. 2012; 31(30):4269-79. doi: 10.1002/sim.5513. 
95. Ferraldeschi R, Attard G, de Bono JS. Novel strategies to test biological hypotheses 
in early drug development for advanced prostate cancer. Clinical chemistry. 2013; 
59(1):75-84. doi: 10.1373/clinchem.2012.185157. 
96. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons 
from real trials. Clinical Trials. 2010; 7(5):567-73. 
97. Parmar MKB, Barthel FMS, Sydes M, Langley R, Kaplan R, Eisenhauer E, et al. 
Speeding up the evaluation of new agents in cancer. Journal of the National Cancer 
Institute. 2008; 100(17):1204-14. doi: 10.1093/jnci/djn267. 
 58 
 
98. Barthel FMS, Parmar MKB, Royston P. How do multi-stage, multi-arm trials 
compare to the traditional two-arm parallel group design--a reanalysis of 4 trials. 
Trials. 2009; 10:21-. doi: 10.1186/1745-6215-10-21. 
99. Royston P, Parmar MKB, Qian W. Novel designs for multi-arm clinical trials with 
survival outcomes with an application in ovarian cancer. Statistics in medicine. 2003; 
22(14):2239-56. doi: 10.1002/sim.1430. 
100. Chow S-C, Chang M. Adaptive Design Methods in Clinical Trials, Second Edition 
Boca Raton, FL: Chapman & Hall/CRC Press Biostatistics Series; 2011. 
101. Barthel FMS, Royston P, Parmar MKB. A menu-driven facility for sample-size 
calculation in novel multiarm, multistage randomized controlled trials with a time-
to-event outcome. Stata Journal. 2009; 9(4):505–23. 
102. Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for 
treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 
182-ICON5. Gynecologic oncology. 2003; 90(2 Pt 2):S1-7. 
103. Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, et al. Evaluating 
many treatments and biomarkers in oncology: a new design. Journal of clinical 
oncology: official journal of the American Society of Clinical Oncology. 2013; 
31(36):4562-8. doi: 10.1200/JCO.2013.50.7905. 
104. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase 
II clinical trials for breast cancer. Clinical cancer research: an official journal of the 
American Association for Cancer Research. 2007; 13(20):6080-6. doi: 10.1158/1078-
0432.CCR-07-0809. 
105. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design 
for generating and prospectively testing a gene expression signature for sensitive 
patients. Clinical cancer research: an official journal of the American Association for 
Cancer Research. 2005; 11(21):7872-8. doi: 10.1158/1078-0432.CCR-05-0605. 
 59 
 
106. Moyé LA, Deswal A. Trials within Trials. Controlled Clinical Trials. 2001; 
22(6):605. 
107. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. 
Biometrika. 1988; 75(4):800. 
108. Novartis Pharmaceuticals. A Multi-center, Open Label Phase II Trial of TKI258 
in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative 
Breast Cancer: ClinicalTrials.gov; 2009 [cited 2015 10 Oct]. Available online: 
https://clinicaltrials.gov/ct2/show/NCT00958971?term=NCT00958971&rank=1. 
109. Medical Research Council. A Randomised, Placebo-controlled, Trial of 
Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and 
Concurrent and Maintenance Cediranib in Women With Platinum-sensitive 
Relapsed Ovarian Cancer: ClinicalTrials.gov; 2007 [cited 2015 10 Oct]. Available 
online: https://clinicaltrials.gov/ct2/show/study/NCT00544973?term=icon6&rank=1. 
110. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm multi-
stage clinical studies with treatment selection. Biometrika. 2012; 99(2):494-501. doi: 
10.1093/biomet/ass002. 
111. Wason JMS, Abraham JE, Baird RD, Gournaris I, Vallier A-L, Brenton JD, et al. A 
Bayesian adaptive design for biomarker trials with linked treatments. British Journal 
of Cancer. 2015. 
112. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. 
Biometrics. 1982; 38(1):143-51. 
113. London WB, Chang MN. One- and two-stage designs for stratified phase II 
clinical trials. Statistics in Medicine. 2005; 24(17):2597-611. 
114. Nallapareddy S., Arcaroli J., Touban B., Tan A., Foster N. R., Erlichman C., et al. 
A Phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated 
 60 
 
metastatic pancreatic cancer.: ASCO; 2010 [cited 2015 10 Oct]. Available from: 
http://meetinglibrary.asco.org/content/1452-72. 
115. National Cancer Institute. A Phase II Trial of AZD0530 in Previously Treated 
Metastatic Pancreas Cancer: ClinicalTrials.gov; 2008 [cited 2015 10 Oct]. Available 
online: 
https://clinicaltrials.gov/ct2/show/NCT00735917?term=NCT00735917&rank=1. 
116. Simon R. Cancer. Principles & practice of oncology (6th edition). Philadelphia: 
Lippincott Williams and Wilkins; 2001. 521-38 p. 
117. Thall PF, Simon R. A Bayesian approach to establishing sample size and 
monitoring criteria for phase II clinical trials. Controlled Clinical Trials. 1994; 
15(6):463-81. 
118. Hung HMJ, Wang S-J, O'Neill R. Statistical considerations for testing multiple 
endpoints in group sequential or adaptive clinical trials. Journal of biopharmaceutical 
statistics. 2007; 17(6):1201-10. doi: 10.1080/10543400701645405. 
119. Jennison C, Turnbull BW. Adaptive seamless designs: selection and prospective 
testing of hypotheses. Journal of biopharmaceutical statistics. 2007; 17(6):1135-61. doi: 
10.1080/10543400701645215. 
120. Wason J, Marshall A, Dunn J, Stein RC, Stallard N. Adaptive designs for clinical 
trials assessing biomarker-guided treatment strategies. British journal of cancer. 2014; 
110(8):1950-7. doi: 10.1038/bjc.2014.156. 
121. Mahajan R, Gupta K, Mahajan R, Gupta K. Adaptive design clinical trials: 
Methodology, challenges and prospect. Indian Journal of Pharmacology. 2010; 
42(4):201. 
122. DeMets DL. Current development in clinical trials: issues old and new. Statistics 
in medicine. 2012; 31(25):2944-54. doi: 10.1002/sim.5405. 
 61 
 
123. Emerson SC, Rudser KD, Emerson SS. Exploring the benefits of adaptive 
sequential designs in time-to-event endpoint settings. Statistics in Medicine. 2011; 
30(11):1199-217. 
124. Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: 
a qualitative study of the perspectives of key stakeholders on the use of adaptive 
designs in confirmatory trials. Trials. 2015; 16(1):430. 
125. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure 
for evaluating treatment with possible biomarker-defined subset effect. Journal of the 
National Cancer Institute. 2007; 99(13):1036-43. doi: 10.1093/jnci/djm022. 
126. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: 
an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. 
Clinical pharmacology and therapeutics. 2009; 86(1):97-100. doi: 10.1038/clpt.2009.68. 
127. QuantumLeap Healthcare Collaborative. I-SPY 2 Trial (Investigation of Serial 
Studies to Predict Your Therapeutic Response With Imaging And moLecular 
Analysis 2): ClinicalTrials.gov; 2009 [cited 2015 10 Oct]. Available online: 
https://clinicaltrials.gov/ct2/show/NCT01042379. 
128. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. 
Biometrika. 1986; 73(3):751-754. doi: 10.1093/biomet/73.3.751. 
129. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for 
oncology trials with subpopulation selection using correlated survival endpoints. 
Pharmaceutical statistics. 2011; 10(4):347-56. doi: 10.1002/pst.472. 
130. Mehta C, Schäfer H, Daniel H, Irle S. Biomarker driven population enrichment 
for adaptive oncology trials with time to event endpoints. Statistics in Medicine. 2014; 
33(26):4515-31. doi: 10.1002/sim.6272. 
131. Ellenberg SS, Eisenberger MA. An efficient design for phase III studies of 
combination chemotherapies. Cancer treatment reports. 1985; 69(10):1147-54. 
 62 
 
132. Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II 
trial to phase III. Biometrics. 2002; 58(4):823-31. 
133. Lin J-A, He P. Reinventing clinical trials: a review of innovative biomarker trial 
designs in cancer therapies. British medical bulletin. 2015; 114(1):17-27. doi: 
10.1093/bmb/ldv011. 
134. Simon N, Simon R. Adaptive enrichment designs for clinical trials. Biostatistics 
(Oxford, England). 2013; 14(4):613-25. doi: 10.1093/biostatistics/kxt010. 
135. Alexander BM, Wen PY, Trippa L, Reardon DA, Yung W-KA, Parmigiani G, et 
al. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-
SPY 2. Neuro-oncology. 2013; 15(8):972-8. doi: 10.1093/neuonc/not088. 
136. Freidlin B, Korn EL, Gray R. Marker Sequential Test (MaST) design. Clinical trials 
(London, England). 2014; 11(1):19-27. doi: 10.1177/1740774513503739. 
137. Freidlin B, McShane LM, Polley M-YC, Korn EL. Randomized phase II trial 
designs with biomarkers. Journal of clinical oncology: official journal of the American 
Society of Clinical Oncology. 2012; 30(26):3304-9. doi: 10.1200/JCO.2012.43.3946. 
138. Wang S-J. Utility of adaptive strategy and adaptive design for biomarker-
facilitated patient selection in pharmacogenomic or pharmacogenetic clinical 
development program. Journal of the Formosan Medical Association = Taiwan yi zhi. 
2008; 107(12 Suppl):19-27. 
139. Wang S-J, Hung HMJ, O'Neill R. Adaptive design clinical trials and trial logistics 
models in CNS drug development. European neuropsychopharmacology: the journal 
of the European College of Neuropsychopharmacology. 2011; 21(2):159-66. doi: 
10.1016/j.euroneuro.2010.09.003. 
140. Tudur Smith C, Williamson PR, Beresford MW. Methodology of clinical trials for 
rare diseases. Best practice & research Clinical rheumatology. 2014; 28(2):247-62. doi: 
10.1016/j.berh.2014.03.004. 
 63 
 
141. Chow S-C, Lu Q, Tse S-K. Statistical analysis for two-stage adaptive design with 
different study points. Journal of biopharmaceutical statistics. 2007; 17(6):1163-76. 
doi: 10.1080/10543400701645249. 
142. U. S. Food and Drug Administration. Draft Guidance for Industry—Adaptive 
Design Clinical Trials for Drugs and Biologics. : U.S. Food Drug Admin, Rockville, 
MD; 2010 [cited 2015 10 Oct].  Available  online: 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm201790.pdf. 
 
 64 
 
Chapter 3. Biomarker-Guided Non-Adaptive Trial 
Designs in Phase II and Phase III: A Methodological 
Review 
3.1. Introduction 
To complement the previous chapter (Chapter 2) which gives detailed 
information regarding the biomarker-guided adaptive designs, here we report on the 
second broad category, the so-called non-adaptive designs, in order to provide 
researchers with much needed information to an extent that has not been previously 
available. The current chapter is based on our published paper by Antoniou et al. 
(2017) (see list of Publications). 
The rapidly developing field of ‘personalized medicine’ [1], also known as 
‘individualized medicine’, ‘stratified medicine’, or ‘precision medicine’ is allowing 
scientists to treat patients by providing them with a specific regimen according to 
their individual demographic, genomic or biological characteristics. The latter two 
aforementioned characteristics are collectively known as biomarkers [2]. The terms 
‘personalized medicine’ and ‘individualized medicine’ often create confusion in 
literature, as in reality, the objective of this approach is to identify demographic- or 
biomarker-defined subgroups. Thus, as it still remains a population and not an 
individualized approach, the terms ‘stratified’ or ‘precision’ medicine are often 
considered to be more accurate. The National Institutes of Health Biomarkers 
Definitions Working Group [3] defined a biomarker to be “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” [1, 
4-7]. Biomarkers related to clinical outcome which are measured before treatment 
commences can be classified as either prognostic or predictive biomarkers. 
Prognostic biomarkers provide information regarding the likely progression of a 
disease without taking into account any specific treatment, whilst predictive 
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biomarkers provide information about the patient’s outcome given a certain 
treatment, i.e. their likely response to the treatment [4, 7-34]. Prior to utilizing a 
patient’s biomarker information in clinical practice, it is necessary that they have been 
robustly tested in terms of analytical validity (the results of testing a specific 
biomarker or biomarkers can be trusted), clinical validity (the results obtained from 
the test correlates with important clinical information) and clinical utility (the test will 
be useful in ameliorating patients’ health) [9, 13, 19, 25].  
A number of phase II and phase III trial designs have been proposed for testing 
the clinical utility of prognostic biomarkers. Due to the large amount of literature in 
this field, we have split our review into two broad categories, i.e. the biomarker-
guided non-adaptive trial designs which are presented in the current study and the 
biomarker-guided adaptive trial designs. The latter are extensively discussed in 
Chapter 2 [35].  
In this review we aim to communicate the different non-adaptive biomarker-
guided trial designs, which can be either randomized or non-randomized designs 
(e.g., single-arm designs), proposed in the literature so far and to report on the 
potential advantages and weaknesses of each. Some of them include an adaptive 
element (see section 3.2.3), although non-adaptive in the traditional sense. Therefore, 
they were included in the current chapter instead of Chapter 2 [35] which describes 
and discusses adaptive designs., 
3.2. Methods and Findings 
We undertook a search of the MEDLINE (Ovid) database, restricted to 
published papers in the English language within the previous ten years aiming to 
identify articles which describe and discuss biomarker-guided trial designs. 
Traditional trial designs, i.e. designs which do not incorporate biomarkers aiming to 
aid in making treatment decisions (we will refer to as ‘traditional’ trial designs) are 
part of our literature review search strategy in order to help us identify and 
distinguish any potential reference to biomarker-guided designs, as the finding of the 
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appropriate keywords in Medline database for biomarker-guided designs was 
challenging. Furthermore, the restriction of published papers within the past decade 
was made not only because of the large amount of literature in this field, but also for 
the identification of the most recent trial designs. Two separate strategies as 
illustrated in Figure 3.1 were used to identify relevant articles, and the keywords 
utilized in the search are presented in Appendix A.2. Our initial search resulted in 
9412 and 5024 relevant titles for biomarker-guided clinical trial designs and 
traditional trial designs, respectively. From the 9412 papers, 104 articles were 
included based on their title and abstract. From the 5024 papers, 40 articles were 
included based on their title and abstract and after removing inaccessible articles or 
those already identified in the search for biomarker-guided trial designs. An 
additional 67 eligible papers were identified from searching both the reference list of 
included articles and the internet (the internet searches were performed using the 
same keywords as those for the Ovid strategy), making a total of 211 included papers. 
Of these 211 included papers, biomarker-guided non-adaptive trial designs were 
referred to in 100 papers; 107 papers for biomarker-guided adaptive trial designs 
were reviewed in our published paper Antoniou et al., 2016 [35]. In the total number 
of 211 papers, some papers are referred to both adaptive and non-adaptive designs. 
Articles from references and internet searches which did not provide further 
information on each broad category of biomarker-guided designs were not included. 
Cited books, web pages for actual trials and papers published before 2005 are also 
not included in these numbers. For each included paper, the following details were 
extracted: definition of the trial design(s) referred to in the paper, how patients were 
screened and/or randomized based on their biomarker status, treatment groups 
randomized to, as well as other key information relating to the trial design and 
methodology, including advantages and limitations. Where reference was made in 
the included papers to an actual trial which had adopted a particular biomarker-
guided non-adaptive trial design, the clinical field with which the trial was associated 
was also recorded. However, a review of all implementations of the different trial 
designs in practice is beyond the scope of this chapter, and is an area for potential 
future work. Therefore, it is important to highlight that even where no evidence of 
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the implementation of a particular design was found in the papers included in our 
review, the design may well be currently in use in ongoing trials. 
 
Figure 3.1. Flow diagram of the review process. From our search strategy a total number of 211 papers 
have been identified giving information regarding not only the biomarker-guided designs but also 
general information about personalized medicine and biomarkers. Before arriving at 211 papers, books, 
web pages for actual trials and papers published before 2005 were excluded. The 211 papers are split 
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into two overlapping sets of 100 and 107 papers. The total of 207 is less than 211 due to overlap of papers, 
and also due to the fact that some articles referring to general information about personalized medicine 
and biomarkers and articles which do not provide further information on each broad of biomarker-
guided designs were excluded. The 107 papers for biomarker-guided adaptive trial designs were 
reviewed in our published paper Antoniou et al. (2016) [35]. 
In our review, we identified five main biomarker-guided non-adaptive trial 
designs namely: (i) single-arm designs; (ii) enrichment designs; (iii) randomize-all 
designs; (iv) biomarker-strategy designs and (v) other designs. Within each main 
design several subtypes and extensions were also identified. Graphical 
representations of the main designs and subtypes are given in Figures 3.2-3.16. 
Graphical representations of the extensions are given in Figures B.1-B.4 included in 
Appendix B. The characteristics and methodology of the main design types and 
subtypes are discussed below and are summarized in Table 3.1, whilst information 
on the extensions are discussed in Appendix B. Furthermore, sample size formulae 
for each biomarker-guided design are provided in Table 3.2. 
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Table 3.1. Types of Biomarker guided non-adaptive designs proposed within the last ten years. 
Types of Biomarker-Guided 
Non-Adaptive Trial Designs 
Utility Advantages Limitations 
Single arm designs (7 papers) [30, 
36-41] (see Figure 3.2) 
Also called: Nonrandomized 
clinical trial design, Uncontrolled 
Cohort Pharmacogenetic Study 
design 
Examples of actual trials: None 
identified a 
Useful for initial identification 
and/or validation of a biomarker. 
(A1) Considered as a simple statistical design 
as there is no need for randomization of 
patients. 
(A2) Simple logistics. 
(A3) Not complex statistical design 
(A4) In some cases, these designs may be 
viewed as ethical as all patients are given the 
opportunity to experience the experimental 
treatment. However, they may be viewed as 
unethical if the novel treatment does not 
benefit a subgroup of patients or causes 
adverse events. 
(L1) There is no distinction between 
prognostic and predictive biomarker 
as patients are not randomized to 
experimental and control treatment 
arms. 
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Enrichment designs (71 papers) 
[1, 4, 7-9, 11, 13, 15, 16, 18, 19, 21, 
23, 25-33, 36, 42-86] (see Figure 
3.3) 
Also called: Targeted design, 
Selection design, Efficient 
Targeted design, Biomarker-
Enrichment design, Marker-
enrichment design, Gene 
enrichment design, Enriched 
design, Clinically enriched Phase 
III study design, Clinically 
Enriched Trial design, Biomarker-
Enriched design, Biomarker 
Enriched design, Biomarker 
Selected trial design, Screening 
enrichment design, Randomized 
Controlled Trial (RCT) of test 
positive design, Population 
enrichment design 
Useful when we aim to test the 
treatment effect only in 
biomarker-positive subset for 
which there is prior evidence that 
the novel treatment is beneficial, 
but the candidate biomarker 
requires prospective validation. 
Useful when it is not ethical to 
assign biomarker-negative 
patients to the novel treatment 
for which there is prior evidence 
that it will not be beneficial for 
this subpopulation, or that it will 
harm them. 
Recommended when both the 
cut-off point for determination of 
biomarker-status of patients and 
the analytical validity of a 
biomarker are well established. 
(A5) Evaluates the effect of the experimental 
treatment in the biomarker-positive subgroup 
in a simple and efficient way. 
(A6) Provides clear information about 
whether the novel treatment is effective for 
the biomarker-positive subgroup, thus these 
designs can identify the best treatment for 
these patients and confirm the usefulness of 
the biomarker. 
(A7) Reduced sample size as the assessment 
of treatment effect is restricted only to 
biomarker-positive subgroup. Therefore, if the 
selected biomarker is “biologically correct” 
and reliably measured, the used enrichment 
strategy could result in a large saving of 
randomized patients. 
(A8) Enables rapid accumulation of efficacy 
data. 
(L2) Do not assess whether the 
experimental treatment benefits the 
biomarker-negative patients, thus we 
cannot obtain information about this 
subgroup. Also unable to 
demonstrate whether the targeted 
treatment is beneficial in the entire 
study population. 
(L3) Do not inform us directly about 
whether the biomarker is itself 
predictive because the relative 
treatment efficacy may be the same in 
the unevaluated biomarker-negative 
patients. Since these designs only 
enrol a subgroup of patients, they do 
not allow for full validation of the 
marker’s predictive ability. For full 
validation, a trial would need to 
randomize all patients in order to test 
 71 
 
Examples of actual trials: 
CRYSTAL [49], BRIM 3 [49-51], 
EURTAC [49], CLEOPATRA [49], 
PROFILE 1007 [49, 50], LUX-Lung 
[49], NSABP B-31 and NCCTG 
N9831 [4, 15, 16, 18, 19, 28-31, 36, 
44, 46, 52-60], CALGB-10603 [61], 
CATNON [62], CODEL [62], 
Evaluation of epidermal growth 
factor receptor variant III 
(EGFRvIII) peptide vaccination 
[62], N0923 [7, 21] , Flex study 
[64], TOGA trial [47], IPASS [33, 
43], N0147 [29], PetaCC-8 [29, 47], 
C80405 [29], ECOG E5202 [29] 
(A9) Allow us to avoid potential dilution of 
the results due to the absence of biomarker-
negative patients. For example, if the design 
had included the biomarker-negative 
population and the biomarker positivity rate 
was low as compared to the biomarker 
negative rate, then the estimation of the 
overall treatment effectiveness could be 
diluted as it would be driven by the 
biomarker-negative subset.  
(A10) Can be attractive in terms of speed and 
cost, meaning that patients are provided with 
tailored treatment sooner. 
for a treatment–biomarker 
interaction. 
(L4) Researchers should carefully 
decide whether or not to follow this 
strategy as it may be of limited value 
due to the exclusion of biomarker-
negative patients. It may be that the 
entire population could benefit from 
the experimental treatment equally 
irrespective of biomarker status, in 
which case enrolling only the 
biomarker-positive patients will 
result in slow trial accrual, increase of 
expenses and unnecessary limitation 
of the size of the indicated patient 
population. 
(L5) Concern over an ethical problem 
as we cannot include individuals in a 
clinical trial if it is believed that the 
treatment is not effective for them, as 
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raised by the US Food and Drug 
Administration (FDA) [50]. It was 
based on the facts that the 
experimental treatment can only be 
approved for a particular biomarker-
defined subpopulation (i.e. 
biomarker-positive patients) if a 
companion diagnostic test is also 
approved, and how the test can be 
approved if the Phase III trial does 
not show that the novel treatment 
does not benefit the biomarker-
negative patients. 
(L6) The accuracy of diagnostic 
devices used to identify the 
biomarkers, e.g., biomarker assays, is 
not always correct [45]. This can 
result in incorrect selection of 
biomarker-positive patients and 
therefore these patients will 
erroneously be enrolled in a trial 
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yielding biased treatment effect 
estimates. For example, even when 
the experimental treatment works 
well for a specific subgroup, if the 
biomarker assay is not able to identify 
this subgroup robustly then a 
promising treatment may be 
abandoned. 
Marker Stratified designs (45 
papers) [4, 10, 12, 13, 15-19, 21, 25-
27, 30, 31, 33, 44-46, 49-51, 53, 58, 
61, 62, 66, 68, 71-74, 79-81, 84-93] 
(see Figure 3.4) 
Also called: Marker-stratified 
design, Biomarker-stratified 
design, Stratified-Randomized 
design, Stratification design, 
Stratified design, Stratified 
Analysis design, Marker by 
treatment – interaction design, 
Useful when there is evidence 
that the novel treatment is more 
effective in the positive 
biomarker-defined subgroup 
than in the negative biomarker-
defined subgroup but there is 
insufficient compelling data 
indicating that the experimental 
treatment does not benefit the 
biomarker-negative patients. 
(A11) Ability to assess the treatment effect not 
only in the entire population but also in each 
biomarker-defined subgroup. Thus, this 
design can find the optimal treatment in the 
entire population and in each biomarker-
defined subgroup. 
(A12) An ethical design even in situations 
where the biomarker is not useful as no 
treatment decisions are made based on 
biomarker status; all decisions are made 
randomly. Consequently, if the biomarker’s 
(L7) In situations where there are 
several biomarkers and treatments 
this design may not be feasible as it 
involves randomization of patients 
between all possible treatment 
options and may require a large 
sample size. 
(L8) May not be feasible when the 
prevalence of the biomarker is low. 
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Marker-by-treatment interaction 
design, Treatment by marker 
interaction design, Treatment-by-
marker interaction design, Marker 
× treatment interaction design, 
Treatment-marker interaction 
design, Biomarker-by-treatment 
interaction design, Non-targeted 
RCT (stratified by marker) design, 
Genomic Signature stratified 
designs, Signature-Stratified 
design, Randomization or analysis 
stratified by biomarker status 
design, marker-interaction design. 
Examples of actual trials: 
MARVEL (N023) [4, 16, 30, 31, 33, 
44, 61, 89], GALGB-30506 [15, 61], 
RTOG0825 [45], EORTC 10994 p53 
[12, 66], IBCSG trial IX [18], 
MINDACT [18]  
value is in doubt, this design may be 
preferred. 
(L9) Might be expensive to test the 
entire population for its biomarker 
status. 
(L10) Measuring the biomarker up 
front may be logistically difficult. 
(L11) There is no guarantee of 
balanced groups for analysis. 
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Sequential Subgroup-Specific 
design (11 papers) [13, 14, 19, 22, 
53, 57, 58, 60, 69, 91, 94] (see 
Figure 3.5) 
Also called: sequential design, 
Fixed-sequence 2 design, 
hierarchical fixed sequence testing 
procedure 
Examples of actual trials: PRIME 
[49], MARVEL [49] 
Recommended when prior 
evidence indicates that the 
biomarker-positive 
subpopulation benefits more 
from the novel treatment as 
compared to the biomarker-
negative subpopulation.  
(A13) Allows for the estimation of treatment 
effect in biomarker-positive and biomarker-
negative subgroups. 
(A14) Preserves the overall type I error rates 
and allows for a smaller sample size than the 
parallel version mentioned below. 
(A15) Considered as the best direct evidence 
for clinical decision making as it tests the 
treatment effectiveness in both the biomarker-
positive and biomarker-negative subset in a 
sequential way. 
(A16) Do not require larger sample size than 
the overall/biomarker-positive designs when 
the prevalence of the biomarker-positive 
patients is small. 
(L12) Has less power when there is 
homogeneity of treatment across the 
different biomarker defined 
subgroups as compared to the 
overall/biomarker-positive designs. 
(L13) Need a much larger sample size 
than the overall/biomarker positive 
designs if we assume that the 
treatment effect is relatively 
homogeneous across the biomarker-
defined subsets. 
Parallel Subgroup-Specific 
design (3 papers) [14, 49, 69] (see 
Figure 3.6) 
Appropriate when the aim of the 
study is to give treatment 
recommendations for each 
(A17) Same as (A13), (A16) (L14) Same as (L12) 
(L15) Allocates the overall level 𝑎 
between the two biomarker-defined 
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Also called: Phase III Biomarker-
Stratified design 
Examples of actual trials: None 
identified a 
biomarker-defined subgroup 
separately at the same time. 
subgroup tests which means that it 
will be more difficult to achieve 
statistical significance in the 
biomarker-positive subgroup. 
Biomarker-positive and overall 
strategies with parallel 
assessment (8 papers) [1, 14, 36, 
47, 49, 69, 95, 96] (see Figure 3.7) 
Also called: Overall/biomarker-
positive design with parallel 
assessment, prospective subset 
design, hybrid design 
Examples of actual trials: S0819 
[14, 49], SATURN [14, 36, 47, 49, 
95, 96], MONET1 [14, 49], 
ARCHER [14, 49], ZODIAC [49], 
MERiDiAN [49] 
Recommended when the aim of 
the study is to assess the 
treatment effect in both the entire 
population and in the biomarker-
positive subset but not in the 
biomarker-negative population. 
(A18) Can control the overall type I error 𝑎. 
(A19) Can require smaller sample size as 
compared to the subgroup-specific designs, 
especially when we assume that the novel 
treatment equally benefits both biomarker-
defined subgroups. 
(L16) Can be overly conservative as in 
the SATURN trial because of the 
correlation between the test of 
treatment effect in the overall study 
population and in the biomarker 
subgroups. 
(L17) Cannot control the probability 
of rejecting the null hypothesis of no 
treatment effect in the biomarker-
negative subset when the treatment 
benefit is restricted to biomarker-
positive patients. Consequently, there 
is a high risk of inappropriately 
recommending the novel treatment 
for biomarker-negative patients due 
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to the large treatment effect in 
biomarker-positive subset. 
Biomarker-positive and overall 
strategies with sequential 
assessment (11 papers) [13, 14, 30, 
44, 49, 69, 80, 84, 85, 88, 94] (see 
Figure 3.8) 
Also called: Overall/biomarker-
positive design with sequential 
assessment, sequential design, 
Fixed-sequence 2 design, 
hierarchical fixed sequence testing 
procedure 
Examples of actual trials: Trial of 
letrozole plus lapatinib versus 
letrozole plus placebo in breast 
cancer, with the biomarker 
defined by human epidermal 
Might be useful in cases where 
the experimental treatment is 
expected to be effective in the 
overall population. 
(A20) Same as (A18), (A19) (L18) Can be problematic for 
determining whether the treatment is 
beneficial in the biomarker-negative 
subgroup. 
(L19) Same as (L17) 
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growth factor receptor 2 (HER2) 
[14], N0147 [30, 49] 
Biomarker-positive and overall 
strategies with fall-back analysis 
(15 papers) [10, 30, 36, 44, 47, 49, 
53, 57, 60, 69, 84, 88, 94, 96, 97] (see 
Figure 3.9) 
Also called: Biomarker-stratified 
design with fall-back analysis, fall-
back design, prospective subset 
design, sequential design, other 
analysis plan design, Fallback 
design 
Examples of actual trials: None 
identified a 
Recommended when there is 
insufficient confidence in the 
predictive value of the biomarker 
and the novel treatment is 
assumed to probably benefit all 
patients. 
(A21) Can assess the treatment effect in the 
biomarker-positive patients, if no benefit is 
detected in the overall population. 
(A22) Same as (A18), (A19) 
(L20) Same as (L17), (L18) 
Marker Sequential test design (4 
papers) [14, 49, 69, 94] (see Figure 
3.10) 
Recommended when biomarkers 
with strong credentials are 
available and we have 
(A23) Can provide clear evidence of treatment 
benefit in the biomarker-positive subgroup 
and in the biomarker-negative subgroup. 
(L21) In situations where biomarker 
status is not available for some of the 
patients included in the study, this 
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Also called: MaST design, hybrid 
design 
Examples of actual trials: ECOG 
E1910 [14, 49] 
convincing evidence that the 
novel treatment is more effective 
in biomarker-positive than in 
biomarker-negative patients. 
Appropriate when we can 
assume that the treatment will 
not be beneficial in the 
biomarker-negative 
subpopulation unless it is 
effective for the biomarker-
positive subpopulation. 
(A24) Enables sequential testing of the 
treatment effect in the entire study population 
and in the biomarker-defined subgroups to 
restrict testing of the treatment effect in the 
entire population when there is no significant 
result in the biomarker-positive subset, while 
controlling the appropriate type I error rates. 
(A25) Results in higher power as compared to 
the sequential subgroup-specific design in 
cases where the treatment effect is 
homogeneous across the biomarker-defined 
subgroups. 
(A26) Preserves the power in situations where 
the treatment effect is restricted only to the 
biomarker-positive patients and at the same 
time it controls the relevant type I error rates. 
(A27) Control the type I error rate for the 
biomarker-negative subgroup over all 
possible prevalence values. 
design can either exclude these 
patients or include them in the global 
test, however, further statistical 
adjustments might be required in that 
case. 
(L22) Does not decrease the sample 
size of the study as it was developed 
in order to increase the power 
compared to the sequential subgroup-
specific design in situations where the 
novel treatment benefits equally both 
biomarker-negative and biomarker-
positive patients. 
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(A28) The probability of erroneously 
concluding that the novel treatment is 
beneficial for the entire population when the 
global effect is driven by the biomarker-
positive patients is minimized since the 
design only tests the treatment effect in the 
entire population when no significant effect is 
detected in the biomarker-positive subgroup. 
Hybrid designs (14 papers) [1, 13, 
15, 29-31, 36, 46, 48, 55, 66, 84, 88, 
98] (see Figure 3.11) 
Also called: Mixture design, 
Combination of trial designs, 
hybrid biomarker design 
Examples of actual trials: 
TAILORx [15, 48, 55, 58, 63, 66], 
EORTC MINDACT [15, 48, 55, 66], 
ECOG 5202 study [30, 46] 
Can be used when there is prior 
evidence indicating that only a 
particular treatment is beneficial 
to a biomarker-defined subgroup 
which makes it unethical to 
randomize patients with that 
specific biomarker status to other 
treatment options. 
(A29) The feasibility of a prognostic 
biomarker can be tested. 
(A30) Allows for better risk assessment and 
improved individualized treatment since it 
assigns patients to treatments based on risk 
assessment scores instead of their biomarker 
status (biomarker-positive and biomarker-
negative patients). 
None found. 
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Biomarker-strategy designs with 
biomarker assessment in the 
control arm (21 papers) [15, 25, 26, 
32, 33, 36, 45, 61, 62, 64, 79, 82, 85, 
86, 92, 93, 99-103] (see Figure 3.12) 
Also called: Marker strategy 
design, Biomarker-strategy 
design, Strategy design, Marker-
based strategy design, Marker-
based design, Random disclosure 
design, Customized strategy 
design, Parallel controlled 
pharmacogenetic study design, 
Marker-based strategy design I, 
Biomarker-guided design, 
Biomarker-based assignment of 
specific drug therapy design, 
Marker-based strategy I design, 
Biomarker-strategy design with a 
Useful when we want to test the 
hypothesis that the treatment 
effect based on the personalized 
approach is superior to that of 
the standard of care. 
(A31) Biomarker can be validated without 
including all possible biomarker–treatment 
combinations [26] as in the non-biomarker-
based arm all patients receive only the control 
treatment. 
(A32) Have the option of testing the 
biomarker status of patients in the non-
biomarker-strategy arm which can aid 
secondary analyses [26]. 
(A33) Able to inform us whether the 
biomarker is prognostic. 
(A34) Can be expanded to investigate several 
biomarkers and treatments [103]. 
Additionally, these designs can be attractive 
when evaluating multiple biomarkers or the 
predictive value of molecular profiling 
between several treatment options is to be 
assessed [45]. 
(L23) Unable to inform us whether 
the biomarker is predictive as these 
designs are able to answer the 
question about whether the 
biomarker-based strategy is more 
effective than standard treatment, 
irrespective of the biomarker status of 
the study population. 
(L24) The evaluation of the true 
biomarker by treatment effect is not 
possible as the biomarker-positive 
patients receive only the experimental 
treatment and not the alternative 
treatment (control treatment). 
Consequently, this design cannot 
detect the case in which the control 
treatment might be more beneficial 
for the entire population. 
(L25) In case that the number of 
biomarker-positive patients is very 
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standard control, Marker strategy 
design for prognostic biomarkers 
Examples of actual trials: GILT 
docetaxel [15], Randomized phase 
III trial conducted in Spain, 
dedicated to patients with 
advanced Non-Small Cell Lung 
Cancer (NSCLC) candidates for 
first-line chemotherapy [32, 64, 
100], Study the effect of Magnetic 
Resonance Imaging (MRI) in 
patients with low back pain on 
patient outcome and to evaluate 
Doppler US of the umbilical artery 
in the management of women 
with intrauterine growth 
retardation (IUGR), Randomized 
controlled trial in recurrent 
platinum-resistant ovarian 
carcinoma [101] 
(A35) Might be used more frequently in the 
future due to the wide variety of molecular 
biomarkers, complexity of gene expression 
arrays, and several treatments directed at 
similar targets [103]. 
small, then the treatment received 
will be similar in biomarker-strategy 
arm and non-biomarker strategy arm. 
Consequently, the trial might give 
little information regarding the 
efficacy of the experimental treatment 
or it might not be able to detect it. As 
a result, this type of design should be 
used when there is an adequate 
number of biomarker-positive and 
biomarker-negative patients.  
(L26) Unable to compare directly 
experimental treatment to control 
treatment as the aim is to compare 
not the treatments but the biomarker-
strategies.  
(L27) Less efficient designs than 
biomarker-stratified designs [4, 73] 
and a poor substitute for clinical trials 
which aim to compare the 
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experimental treatment to control 
treatment, since it is possible for some 
patients in both the biomarker-based 
strategy arm and non-biomarker-
based strategy arm to be assigned to 
the same treatment (due to the 
existence of biomarker-negative 
patients in both strategy arms the 
treatment effect can be diluted) [51]. 
Consequently, as a large overlap of 
patients receiving the same treatment 
might have occurred, the comparison 
of the two biomarker-strategy arms 
results in a hazard ratio which is 
forced towards unity, i.e. no 
treatment effect exists as the effect of 
experimental versus control treatment 
is diluted by the biomarker-based 
treatment selection. For this reason, a 
large sample size is needed to detect 
at least a small overall difference in 
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outcomes between the two 
biomarker-strategy arms. 
(L28) Should be used only if you want 
to evaluate a complex biomarker-
guided strategy with a variety of 
treatment options or biomarker 
categories [73]. 
Biomarker-strategy design 
without biomarker assessment in 
the control arm (14 papers) [9, 13, 
17, 18, 20, 25, 36, 38, 61, 74, 101, 
104-106] (see Figure 3.13) 
Also called: Biomarker-strategy 
design with standard control, 
Direct-predictive biomarker-
based, RCT of testing, Test-
treatment, Parallel controlled 
pharmacogenetic diagnostic 
study, Marker strategy, Marker-
In situations where it is not 
feasible or unethical to test the 
biomarker in the entire 
population. 
(A36) Galanis et al., 2011 [45] stated that these 
designs can be attractive when evaluating 
multiple biomarkers or the predictive value of 
molecular profiling between several treatment 
options is to be assessed. Also, Freidlin and 
Korn, 2010 [73] claimed that these biomarker-
strategy designs should be used only if 
researchers want to evaluate a complex 
biomarker-guided strategy with a variety of 
treatment options or biomarker categories. 
(A37) Same as (A31), (A32), (A33) 
(L29) Criticized for their potential cost 
increase due to the fact that patients 
without predicted responsive 
biomarker are double enrolled in the 
trial (biomarker-negative patients 
receive control treatment in both 
strategy arms). 
(L30) Biomarker-positive and 
biomarker-negative subpopulations 
might be more imbalanced as 
compared with the first type of 
biomarker-strategy design due to the 
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based with no randomization in 
the non-marker-based arm, 
Classical, Marker-based strategy, 
Marker strategy design for 
prognostic biomarkers 
Examples of actual trials: A 
study, which evaluated the use of 
immediate computed tomography 
in patients with acute mild head 
injury [101, 104]. 
fact that the randomization to 
different treatment strategies is 
performed before the evaluation of 
the biomarker status (balancing the 
randomization is useful to ensure that 
all randomized patients have tissue 
available). This can happen especially 
when the number of patients is very 
small. 
(L31) Same as (L23), (L24), (L25), 
(L26), (L27) 
Biomarker-strategy design with 
treatment randomization in the 
control arm (17 papers) [15, 17, 26, 
27, 32, 36, 45, 62, 64, 66, 74, 86, 92, 
93, 106-108] (see Figure 3.14) 
Also called: Biomarker-strategy 
design with a randomized control, 
Modified marker-based strategy 
In cases where we want to know 
whether the biomarker is not 
only prognostic but also 
predictive, these designs are 
preferable as compared to the 
two previously mentioned 
biomarker-strategy designs. 
(A38) These designs have the ability to inform 
researchers about the potential superiority of 
the control treatment in the whole population 
or among a particular biomarker-defined 
subpopulation. 
(A39) Able to inform us whether the 
biomarker is prognostic or predictive.  
(L32) Generally require a larger 
sample size as compared to the 
marker-stratified designs. 
(L33) Same as (L27) 
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design (for predictive biomarkers), 
Biomarker-strategy design with 
randomized control, Marker-
based design with randomization 
in the non-marker-based arm, 
Marker-based strategy design II, 
Marker-strategy design, 
Augmented strategy design, Trial 
design allowing the evaluation of 
both the treatment and the marker 
effect 
Examples of actual trials: None 
identified a 
(A40) Allow clarification of whether the 
results which indicate efficacy of the 
biomarker-directed approach to treatment are 
caused due to a true effect of the biomarker 
status or to an improved treatment 
irrespective of the biomarker status. 
(A41) Same as (A36) 
Reverse marker-based strategy (4 
papers) [86, 92, 93, 109] (see 
Figure 3.15) 
Also called: None found 
Enables testing the interaction 
hypothesis of treatment and 
biomarker in a more efficient 
way as compared to the first (i.e. 
Biomarker-strategy design with 
biomarker assessment in the 
control arm) and third 
(A42) Can estimate directly the marker-
strategy response rate. 
(A43) Allows the estimation of the effect size 
of the experimental treatment compared to 
the control treatment for each biomarker-
defined subset separately. 
(L34) It has been claimed by Baker, 
2014 [93] that other designs than the 
reverse marker-based strategy are 
more appropriate in order to 
investigate questions which include 
both treatment effect of biomarker-
defined subgroups and the biomarker 
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Examples of actual trials: None 
identified a 
biomarker-strategy subtype 
design (i.e. Biomarker-strategy 
design with randomization in the 
control arm and the marker 
stratified design) 
(A44) There is no chance that the same 
treatment will be tailored to biomarker-
positive patients who are randomized either 
to the biomarker-based strategy arm or the 
reverse marker strategy. Also, there is no 
possibility of the same treatment assignment 
to biomarker-negative patients who are 
randomly assigned to the two biomarker-
based strategy arms. 
(A45) It has been demonstrated by Eng, 2014 
[92] that this new type of design is more than 
four times more efficient for testing the 
interaction between treatment and biomarker 
compared to Biomarker-strategy design with 
biomarker assessment in the control arm, 
Biomarker-strategy design with 
randomization in the control arm and the 
marker stratified design. 
strategy treatment effect. These 
designs should allow the estimation 
of treatment effects within biomarker-
defined subgroups as well as the 
estimation of the global treatment 
effect. 
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A specific randomized phase II 
trial design that can be used to 
guide decision making for 
further development of an 
experimental therapy. (1 paper) 
[71] (see Figure 3.16) 
Recommended when we want to 
conduct a Phase II randomized 
trial which allows decisions to be 
made about which type of Phase 
III biomarker-guided trial should 
be used.  
(A46) Works well in providing 
recommendations for phase III trial design. 
None found 
 
Table 3.2. Sample size formulae for biomarker-guided clinical trial designs. 
Types of Biomarker-
Guided Non-Adaptive 
Trial Designs 
Sample Size Formula Definition 
Single arm designs 
Standard sample size formula can be used, more information can be found in the ‘methodology’ 
part of the ‘Single arm designs’ section in the main text. 
 
Enrichment designs [55, 
61, 65, 110-112] 
Online tool for sample size calculation when using either binary or time-to-event endpoints is 
available on the following website: http://brb.nci.nih.gov/brb/samplesize/td.html [113]. 
 
 89 
 
 𝐸(𝐷𝑖,𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) =
𝑛𝑇𝜆𝑖
2(𝜆𝑖 + 𝜑𝑖)
{1 −
𝑒−(𝜆𝑖+𝜑𝑖)𝜏
(𝜆𝑖 + 𝜑𝑖)𝑇
[1 − 𝑒−(𝜆𝑖+𝜑𝑖)𝑇]} 
𝐸(𝐷𝑖,𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) refers to the 
expected number of events per 
treatment arm (time-to-event 
outcome), 𝑖 corresponds to either 
the experimental or the control 
treatment group, 1: 1 ratio between 
the two treatment arms 
(experimental: control) is assumed, 
𝜆 corresponds to the event hazard 
rate, 𝜑 is the loss to follow-up rate, 
𝑇 denotes the accrual time, patients 
enter the trial according to a 
Poisson process with rate 𝑛 per 
year over the accrual period of 𝑇 
years, τ corresponds to the follow-
up period. 
 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 = 4 [
(𝑧𝑎/2 + 𝑧𝛽)
logθ1
]
2
 
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 refers to the required 
total number of events (time-to-
event outcome), 1: 1 ratio between 
the two treatment arms 
(experimental:control) is assumed, 
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𝑧𝑎/2, 𝑧𝛽  denote the upper 𝑎/2- and 
upper 𝛽-points respectively of a 
standard normal distribution, 𝑎 
and 𝛽 denote the assumed type I 
error and type II error respectively, 
θ1 denotes the assumed hazard 
ratio between the two treatment 
groups (control vs experimental) in 
the biomarker-positive subset. 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2?̅?𝑄(1 − ?̅?𝑄) [
(𝑧𝑎/2 + 𝑧𝛽)
(𝑝𝐴
𝑄 − 𝑝𝐵)
]
2
 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚  refers to the 
required number of patients per 
treatment arm (binary outcome), 
1: 1 ratio between the two 
treatment arms (experimental: 
control) is assumed, 𝑝𝐴
𝑄 and 𝑝𝐵 are 
the response probabilities in the 
experimental and control groups 
respectively, ?̅?𝑄 = (𝑝𝐴
𝑄 + 𝑝𝐵) 2⁄ . 
𝑝𝐴
𝑄 = 𝑝𝐵 + 𝛿+, where 𝛿+ denotes the 
improvement in response 
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probability for biomarker-positive 
patients. 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 =
2𝜎2(𝑧𝑎/2 + 𝑧𝛽)
2
(𝜇𝐴+ − 𝜇𝐵+)2
 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 refers to the 
required total number of patients 
per treatment arm (continuous 
response endpoints), 1: 1 ratio 
between the two treatment arms 
(experimental: control) is assumed, 
𝜎2 denotes the anticipated common 
variance, 𝜇𝐴+ and 𝜇𝐵+ the mean 
responses for biomarker-positive 
patients in the experimental and 
control treatment arm respectively. 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2𝜎
2(𝑧𝑎/2 + 𝑧𝛽)
2
{𝜆1[(1 − 𝜔) 𝜁 + 𝜔]}
−2 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 refers to the 
required total number of patients 
per treatment arm (continuous 
response endpoints when 
accounting for error in the assaying 
of the study population), 1: 1 ratio 
between the two treatment arms 
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(experimental:control) is assumed, 
𝜔 measures the accuracy of the 
assay and corresponds to the PPV 
(positive predictive value of the 
assay, i.e. the proportion of patients 
who are assigned biomarker 
positive status according to the 
assay who are truly biomarker 
positive), 𝜆1 is the treatment effect 
in the biomarker-positive patients 
and 𝜁 = 𝜆0 𝜆1⁄  (where 𝜆0 is the 
treatment effect in the biomarker-
negative patients). 
Marker Stratified designs 
[31, 53, 60, 92, 111, 112, 
114] 
Online tool for sample size calculation when using either binary or time-to-event endpoints is 
available on the following website: http://brb.nci.nih.gov/brb/samplesize/sdpap.html [115]. 
 
 𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 = 4
(𝑧𝑎1 + 𝑧𝛽)
2
[log (𝜃1)]2
+ 4
(𝑧𝑎2 + 𝑧𝛽)
2
[log (𝜃2)]2
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑  refers to the required 
total number of events for the 
achievement of sufficient power in 
each biomarker-defined subgroup 
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separately (time-to-event 
endpoint), 1: 1 ratio between the 
two treatment arms (experimental: 
control) is assumed, 𝜃2 corresponds 
to the hazard ratio of biomarker-
negative subgroup, 𝑎1 = 𝑎2 = 𝑎 2⁄ . 
 𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 refers to the required 
total number of events for the 
achievement of sufficient power in 
the overall population (time-to-
event endpoint), 𝑘 is the proportion 
biomarker-positive patients, 1: 1 
ratio between the two treatment 
arms (experimental: control) is 
assumed. 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
=
4(𝑧𝑎/2 + 𝑧𝛽)
2
{[𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡)log(𝜃1) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)log(𝜃2)] √𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)⁄ }
2 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 refers to the required 
total number of patients for the 
achievement of sufficient power in 
the overall population (time-to-
event endpoint), 1: 1 ratio between 
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the two treatment arms 
(experimental: control) is assumed, 
𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡), 𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡) are the 
probabilities of an event in 
biomarker-positive subset and 
biomarker-negative subset 
respectively. 
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
=
[log(𝜃1)]
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
=
1
[𝑘 + (1 − 𝑘)
log(𝜃2)
log(𝜃1)
]
2 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
 refers to the ratio of the 
required number of events between 
marker stratified and enrichment 
design (time-to-event endpoint). 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
1
[𝑘 + (1 − 𝑘)
𝛿−
𝛿+
]
2 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
 refers to the ratio of the 
required number of patients 
between marker stratified and 
enrichment design (binary 
outcome), 𝛿−, 𝛿+, correspond to the 
treatment effectiveness in 
biomarker-negative and 
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biomarker-positive subgroup 
respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 = 2(𝑧𝑎 + 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝛽𝐴 + 𝛽𝐼)2
+
𝑟𝐴−(1 − 𝑟𝐴−) + 𝑟𝐵−(1 − 𝑟𝐵−)
(𝛽𝐴)2
} 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 refers to the required 
total number of patients (binary 
outcome), 𝛽0 denotes a baseline 
effect, 𝛽𝐴 denotes the added effect 
of the experimental treatment, 𝛽+ 
denotes the biomarker-positive 
effect and 𝛽𝐼  denotes the 
nonadditive effect, 𝑎 corresponds 
to the target level, 1 − 𝛽 
corresponds to the power, 𝑟𝐴+, 𝑟𝐵+ 
are the assumed response rates of 
biomarker-positive patients 
receiving the experimental and the 
control treatment respectively, 
𝑟𝐴−, 𝑟𝐵− are the assumed response 
rates of biomarker-negative 
patients receiving the experimental 
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and the control treatment 
respectively. 
Sequential Subgroup-
Specific design [57] 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+  refers to 
the required number of biomarker-
positive patients (binary outcome), 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required number 
of biomarker-positive patients 
(binary outcome) in the enrichment 
design. 
 𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐  refers to 
the required total number of 
patients (binary outcome), 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required number 
of biomarker-positive patients 
(binary outcome) in the enrichment 
design. 
 𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− =
(1 − 𝑘)𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
 
𝑁𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
−  refers to 
the required number of biomarker-
negative patients (binary outcome), 
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𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required number 
of biomarker-positive patients 
(binary outcome) in the enrichment 
design. 
 𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 
𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+  refers to 
the required number of events for 
biomarker-positive patients (time-
to-event outcome), 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is 
the required number of events for 
biomarker-positive patients (time-
to-event outcome). 
 𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 (
𝜆−
𝜆+
) (
1 − 𝑘
𝑘
) 
𝐷𝑠𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
−  refers to 
the required number of events for 
biomarker-negative patients (time-
to-event outcome), 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is 
the required number of events for 
biomarker-positive patients (time-
to-event outcome), 𝜆−, 𝜆+, are the 
event rates in biomarker-negative 
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and biomarker-positive control 
subgroups. 
Parallel Subgroup-
Specific design 
Same formula proposed for marker stratified designs could be considered to achieve sufficient 
power in each biomarker-defined subgroup simultaneously. However, in order to control the 
overall type I error rate of the design at the overall level of significance 𝛼 it is required to allocate 
this overall 𝑎 between the test for the biomarker-positive subgroup and the test for the 
biomarker-negative. Consequently, for biomarker-positive subgroup the reduced significance 
level 𝑎1 = 𝑎 − 𝑎2 can be used whereas the reduced significance level 𝑎2 = 𝑎 − 𝑎1 can be used for 
biomarker-negative subgroup. 
 
Biomarker-positive and 
overall strategies with 
parallel assessment 
If there is significant confidence that the biomarker is predictive, the sample size estimation is 
aimed at having a sufficient number of biomarker-positive individuals to enable the treatment 
effect in the biomarker positive subgroup to be detected. Standard formula for sample size 
calculation of biomarker-positive subgroup proposed for the enrichment designs could be 
considered by using the reduced significance level 𝑎1 = 𝑎 − 𝑎2. On the other hand, if there is no 
confidence in the predictive value of the biomarker, the sample size estimation is aimed at 
having a sufficient number of patients to detect a treatment effect in the overall study 
population; consequently, for the sample size calculation, the same formula proposed for marker 
stratified designs aiming to achieve sufficient power in the overall population could be applied 
by using the reduced significance level 𝑎2 = 𝑎 − 𝑎1. 
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Biomarker-positive and 
overall strategies with 
sequential assessment 
At the first stage, the standard formula for a traditional randomized trial which is the same with 
the formula proposed for enrichment designs can be applied for the biomarker-positive 
subgroup. At the second stage, the sample size formula proposed for marker stratified designs 
aiming to yield appropriate power for the entire population could be considered. 
 
Biomarker-positive and 
overall strategies with 
fall-back analysis 
At the first stage, the sample size formula proposed for marker stratified designs aiming to yield 
appropriate power for the entire population could be considered by using the reduced 
significance level 𝑎1 = 𝑎 − 𝑎2. At the second stage, the formula proposed for enrichment designs 
could be applied for the biomarker-positive subgroup by using the reduced significance level 
𝑎2 = 𝑎 − 𝑎1. 
 
Marker Sequential test 
design (MaST)  
A standard sample size calculation (i.e. the same sample size calculation as for the enrichment 
designs) can be applied for the biomarker-positive subpopulation. However, in order to have 
sufficient number of biomarker-positive patients to detect treatment effectiveness in that 
particular biomarker-defined subset and consequently to reach the desired power, the sample 
size should be calculated by using the reduced significance level 𝑎1 [0, 𝑎] instead of the global 
significance level 𝑎 which is used in the sample size formulae of the enrichment designs. The 
same formula could be considered for the sample size calculation of the biomarker-negative 
subgroup; however, the corresponding hazard ratio of that subgroup and the global significance 
level 𝑎 should be used. For the sample size calculation of the entire population, the same 
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formula proposed for marker stratified designs aiming to achieve sufficient power in the overall 
population could be considered by using the reduced significance level 𝑎2 = 𝑎 − 𝑎1. 
Biomarker-strategy, 
design with biomarker 
assessment in the control 
arm [26, 61, 92] 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 = 4 [
(𝑧𝑎/2 + 𝑧𝛽)
𝑘logθ1
]
𝟐
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 refers to the required 
total number of events (time-to-
event outcome), 1: 1 ratio between 
the two treatment arms 
(experimental: control) is assumed.  
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 =
2(𝑧1−𝑎/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛
2)
(𝑣𝑚 − 𝑣𝑛)2
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 refers to the required 
total sample size (continuous 
clinical endpoints), 1: 1 ratio 
between the two treatment arms 
(experimental:control) is assumed, 
𝑧1−𝑎/2, 𝑧1−𝛽 denote the lower 1 −
𝑎/2- and lower 1 − 𝛽-points 
respectively of a standard normal 
distribution, 𝑣𝑚 and 𝑣𝑛 denote the 
mean response from the 
biomarker-based strategy arm and 
the non-biomarker-based strategy 
arm respectively, and 𝜏𝑚
2 ,  𝜏𝑛
2 
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denote the variance of response for 
the biomarker-based strategy arm 
and non-biomarker-based strategy 
arm respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔2(1 − 𝑔2)]
Δ2
2  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼/𝑎𝑟𝑚 refers to the required 
total number of patients per arm 
(binary outcome), 𝑔1 is the 
expected response rate in the 
biomarker-based strategy arm, 𝑔2 
is the expected response rate in the 
non biomarker-based strategy arm, 
Δ2= 𝑔1 − 𝑔2, 𝑔1, 𝑔2 can be found by 
calculating the formulae 𝑘𝑟𝐴+ +
(1 − 𝑘)𝑟𝐵− and 𝑟𝐵 respectively, 𝑟𝐵 
denotes the marginal effect of 
treatment B (control treatment). 
Biomarker-strategy design 
without biomarker 
Same formulae as for the ‘Biomarker-strategy design with biomarker assessment in the control 
arm’ can be considered. 
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assessment in the control 
arm 
Biomarker-strategy design 
with treatment 
randomization in the 
control arm [26, 31, 92] 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
{log [
2𝑘𝑚𝐵+ + 2(1 − 𝑘)𝑚𝐴−
𝑘(𝑚𝐴++𝑚𝐵+) + (1 − 𝑘)(𝑚𝐴−+𝑚𝐵−)
]}
2 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 refers to the required 
total number of events (time-to-
event outcome), 1: 1 ratio between 
the two treatment arms 
(experimental: control) is assumed, 
𝑚𝐴+, 𝑚𝐴−, 𝑚𝐵+, 𝑚𝐵−, denote the 
median survival for biomarker-
positive and biomarker-negative 
patients receiving control and 
experimental treatments 
respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
2(𝑧1−𝑎/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛𝑟
2 )
(𝑣𝑚 − 𝑣𝑛𝑟)2
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 refers to the required 
total sample size (continuous 
clinical endpoints), 1: 1 ratio 
between the two treatment arms 
(experimental: control) is assumed, 
𝑣𝑛𝑟 denotes the mean response 
from the non-biomarker-based 
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strategy arm, 𝜏𝑛𝑟
2  denotes the 
variance of response for the non-
biomarker-based strategy arm 
respectively. 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔3(1 − 𝑔3)]
Δ3
2  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼/𝑎𝑟𝑚 refers to the 
required total number of patients 
per arm (binary outcome), 𝑔3 is the 
expected response rate in the non 
biomarker-based strategy arm and 
Δ3= 𝑔1 − 𝑔3, the expected response 
rate 𝑔3 can be found by calculating 
the formula 𝑟𝐴 2⁄ + 𝑟𝐵 2⁄ , 𝑟𝐴 denotes 
the marginal effect of treatment A 
(experimental treatment).  
Reverse marker-based 
strategy [92] 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝑉/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔4(1 − 𝑔4)]
Δ4
2  
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝑉/𝑎𝑟𝑚 refers to the 
required total number of patients 
per arm (binary outcome), 𝑔4 is the 
expected response rate in the 
reverse biomarker-based strategy 
arm and Δ4 = 𝑔1 − 𝑔4, the expected 
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response rate 𝑔4 can be found by 
calculating the formula 𝑘𝑟𝐵+ +
(1 − 𝑘)𝑟𝐴−, 𝑟𝐵+, 𝑟𝐴− are the assumed 
response rates of biomarker-
positive patients receiving the 
control treatment and biomarker-
negative patients receiving the 
experimental treatment.  
Randomized Phase II trial 
design with biomarkers 
[71] 
Online tool for sample size calculation is available on the following website: 
http://brb.nci.nih.gov/Data/FreidlinB/RP2BM [115]. 
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3.2.1. Single Arm Designs 
Single arm designs were referred to in seven papers (7%). In the context of 
biomarkers, these designs (Phase II designs) include the whole study population to 
which the same experimental treatment is prescribed, without taking into 
consideration biomarker status.  
Design: In this design all patients are prescribed the experimental treatment 
and there is no comparison with a control treatment. These trial designs aid in the 
identification of association between biomarker status and the efficacy or safety of 
the experimental treatment. An illustration of this approach is shown in Figure 3.2. 
 
Figure 3.2. Single arm designs 
Utility: These designs can be useful for the initial identification and/or 
validation of a biomarker and their aim is not to estimate the treatment effect in a 
definitive way but to identify whether the biomarker is sufficiently promising to 
proceed to a definitive Phase III biomarker-guided randomized controlled trial. 
Methodology: In single arm designs first, we assess the biomarker status of 
patients and then as all patients will be treated the same way we could compare the 
outcome of the biomarker-positive subgroup with the outcome of biomarker-
negative subgroup. According to Tajik et al., 2012 [116], in terms of the required 
sample size, a standard formula can be used, however one should take into 
consideration the multiple testing issue that arise due to the exploration of several 
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prognostic biomarkers (e.g., Bonferroni adjustment or normal exact method to 
protect against type I error 𝑎 for multiple tests are often considered [117]). Further 
information can be found in the paper of Zaslavasky and Scott, 2012 [117] who 
studied the sample size estimation in single arm clinical trials with multiple testing 
under frequentist and Bayesian framework. 
Statistical considerations: The single arm approach can be considered as a 
simple statistical design as there is no need for randomization. However, one 
limitation of this strategy is that there is no distinction between prognostic and 
predictive biomarkers i.e. as patients are not randomized to experimental and control 
treatment groups, it is not possible to determine whether an observed effect is 
attributable to the natural disease progression or to the treatment. Consequently, this 
study designs are unable to show the benefit of a biomarker with regard to the best 
choice of treatment. 
3.2.2. Enrichment Designs 
Enrichment designs are described in 71 papers (71%), either in Phase II or Phase 
III clinical trials, and involve randomizing only the biomarker-positive patients and 
comparing the experimental treatment versus the standard treatment only in this 
particular biomarker-defined subgroup. 
Design: Figure 3.3 graphically represents the trial design. First, the entire 
population is screened in order to identify the biomarker status of each patient. Next, 
the random assignment of individuals to different treatment arms is restricted only 
to the biomarker-positive subgroup. More precisely, biomarker-negative patients are 
excluded from the study and consequently, the assessment of the effectiveness of the 
experimental treatment is limited to the biomarker-positive subgroup. Thus, other 
patients apart from the biomarker-positive subpopulation can receive only the 
standard treatment (i.e. control treatment), but they are not included in the 
investigation during the trial design. The biomarker in this design is referred to as 
either the ‘selection’ or ‘enrichment’ biomarker. 
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Figure 3.3. Enrichment designs. “R” refers to randomization of patients. 
Utility: Enrichment designs are useful for clinical trials aiming to test the 
treatment effect in a specific biomarker-defined subpopulation where there is 
evidence to suggest that effectiveness is limited to those within that subgroup, but 
the candidate biomarker still requires prospective validation. This design is 
recommended when both the cut-off point for determination of biomarker status of 
patients and the analytical validity of the biomarker have been well established. A 
rapid turnaround time for assessing the biomarker status of a patient is also needed 
to avoid any delay in treatment initiation. This strategy is particularly useful where 
it is unethical to randomize the biomarker-negative population into different 
treatment arms, for example where there is prior evidence that the experimental 
treatment is not beneficial for biomarker-negative individuals, or is likely to cause 
them harm. However, when it remains unclear whether or not biomarker-negative 
individuals will benefit from the novel treatment, the enrichment design is not 
appropriate and alternative designs, which also assess effectiveness in the biomarker-
negative individuals, should be considered (e.g., randomize-all designs).  
Methodology: An online tool has been developed by Zhao and Simon [19, 28, 
53, 57, 60] that allows sample size planning for the enrichment design both for binary 
and time-to-event (survival) outcomes, and is available at 
http://brb.nci.nih.gov/brb/samplesize/td.html [113]. For the purpose of estimating the 
sample size in the case of a survival outcome, data are simulated based on a marker 
stratified design (see next section for further information) in which both biomarker-
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positive and biomarker-negative subgroups are investigated in the study and 
formulae for the enrichment design described in the paper of Rubinstein et al., 1981 
[110] are used. Furthermore, an exponential distribution of survival for the 
experimental and control treatment groups within both the biomarker-positive and 
biomarker-negative subpopulations is assumed. More precisely, Rubinstein et al. 
provide the formula of the expected number of events per treatment group allowing 
to include exponential loss to follow-up given the following assumptions: (i) patients 
enter the trial according to a Poisson process and patient entry times will be 
independent and identically distributed uniformly over [0, 𝑇] where 𝑇 denotes the 
accrual time. Consequently, given the total number of patients 𝑁, the times from 
entry to the end of the trial will be independent and identically distributed uniformly 
over [𝜏, 𝑇 + 𝜏], where 𝜏 denotes the follow-up time and 𝑇 + 𝜏 the total duration of the 
study and (ii) 1:1 randomization between experimental and control treatment group 
is considered. The expected number of events per treatment arm according to 
Rubinstein et al. is given by 
 
𝐸(𝐷𝑖,𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) =
𝑛𝑇𝜆𝑖
2(𝜆𝑖 + 𝜑𝑖)
{1 −
𝑒−(𝜆𝑖+𝜑𝑖)𝑡
(𝜆𝑖 + 𝜑𝑖)𝑇
[1 − 𝑒−(𝜆𝑖+𝜑𝑖)𝑇]}, 
(3.1) 
where 𝑖 corresponds to either the experimental or the control treatment group, 𝜆 
corresponds to the event hazard rate, 𝜙 is the loss to follow-up rate and patients enter 
the trial according to a Poisson process with rate 𝑛 per year over the accrual period 
of 𝑇 years. However, the required total number of events in the two treatment groups 
(experimental and control treatment group) is given by 
 
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 = 4 [
(𝑧𝑎/2 + 𝑧𝛽)
logθ1
]
2
, 
(3.2) 
where 𝜃1 denotes the assumed hazard ratio between the two treatment groups 
(control vs. experimental) in the biomarker-positive subset and the constants 𝑧𝑎/2, 𝑧𝛽 
denote the upper 𝑎/2- and upper 𝛽-points respectively of a standard normal 
distribution where 𝑎 and 𝛽 denote the assumed type I error and type II error 
respectively. Freidlin et al., 2010 [61] provided the aforementioned formula assuming 
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that all random assignments use 1:1 randomization. As in a traditional randomized 
controlled trial, if the randomization is not equal, i.e. the ratio of allocation to 
treatment and control is 𝑅: 1 rather than 1:1, the aforementioned formula for the 
required total number of events 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 which assumes 1:1 randomization can be 
multiplied by (𝑅 + 1)2 4𝑅⁄  [118]. Consequently, the “4” in the formula of 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 
becomes (𝑅 + 1)2 R⁄  and the corresponding formula for the total number of events 
becomes 
 
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =
(𝑅 + 1)2
𝑅
[
(𝑧𝑎/2 + 𝑧𝛽)
logθ1
]
2
. 
(3.3) 
In a survival study, the calculation of the total sample size in terms of number 
of patients required in the two treatment groups (experimental and control treatment 
group) to be enrolled in order to yield the aforementioned total number of events 
depends on the probability of event over the duration of the study [119]. 
Consequently, the actual number of patients required in a survival study can be given 
by 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 =
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
Pr(𝑒𝑣𝑒𝑛𝑡)
, (3.4) 
where Pr(𝑒𝑣𝑒𝑛𝑡) is the probability of observing an event in the two treatment groups 
in the study and 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 is the required total number of events. Pr(𝑒𝑣𝑒𝑛𝑡) in a 
survival study can be given by 
 Pr(𝑒𝑣𝑒𝑛𝑡) = 𝜋𝐴𝑃𝑟𝐴(𝑒𝑣𝑒𝑛𝑡) + 𝜋𝐵𝑃𝑟𝐵(𝑒𝑣𝑒𝑛𝑡), (3.5) 
where 
 
𝜋𝐴 =
𝑅
𝑅 + 1
 and 𝜋𝐵 =
1
𝑅 + 1
, 
(3.6) 
are the proportions of patients who are randomized to experimental and control 
treatment group respectively and 𝑃𝑟𝐴(𝑒𝑣𝑒𝑛𝑡) and 𝑃𝑟𝐵(𝑒𝑣𝑒𝑛𝑡) are the probabilities of 
events in experimental and control arm respectively [120]. Freedman, 1982 [121] 
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provided an approximation of the probability of event for each treatment group 
assuming equal follow-up for all patients and thus simultaneous accrual for all 
patients whereas Schoenfeld, 1983 [122] provided a more exact approximation of the 
expected event rate as compared to Freedman’s approximation. More precisely, 
according to Freedman’s approximation, 
 𝑃𝑟𝑖(𝑒𝑣𝑒𝑛𝑡) ≈ 1 − 𝑆𝑖(𝜏) (3.7) 
and according to Schoenfeld’s approximation, 
 𝑃𝑟𝑖(𝑒𝑣𝑒𝑛𝑡) ≈ 1 − {𝑆𝑖(𝜏) + 4𝑆𝑖(𝑇 2⁄ + 𝜏) + 𝑆𝑖(𝑇 + 𝜏)}/6, (3.8) 
where 𝑖 denotes the corresponding treatment group (either experimental or control), 
𝜏 denotes the follow-up time and 𝑇 the accrual period, 𝑇/2 + 𝜏 denotes the median 
follow-up time and 𝑇 + 𝜏 denotes the total duration of the study. Another 
approximation of the probability of event could be 
 𝑃𝑟𝑖(𝑒𝑣𝑒𝑛𝑡) ≈ 1 − 𝑆𝑖(𝑇 2⁄ + 𝜏) (3.9) 
considering that the survival probability can be approximated as the probability that 
a patient survives past the median follow-up time (i.e. 𝑇 2⁄ + 𝜏) [120]. 
The web-based interface of Zhao and Simon is composed of two options. If the 
first option is chosen, the treatment effects for assay-negative and assay-positive 
patients must be specified in order to evaluate the relative efficiency of enrichment 
and untargeted design, i.e. marker stratified design (see next section for further 
information) in which apart from the biomarker-positive patients, biomarker-
negative patients are also included; if the second option is chosen, it is possible to 
account for error in the assaying of the study population, thus, both the treatment 
effects for target-negative and target-positive patients must be specified as well as the 
assay’s sensitivity and specificity. 
The sample size calculation using binary data is based on the formulae 
described by Simon and Maitournam [65, 111, 112] and again the two options offered 
 111 
 
when assuming a time-to-event outcome are available, i.e. options both with and 
without accounting for error in biomarker status classification. When binary outcome 
is assumed and the allocation ratio is 1:1, the sample size of randomized patients 
required in each treatment arm (experimental and control) can be given as 
 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2?̅?𝑄(1 − ?̅?𝑄) [
(𝑧𝑎/2 + 𝑧𝛽)
(𝑝𝐴
𝑄 − 𝑝𝐵)
]
2
, 
(3.10) 
where 𝑝𝐴
𝑄 and 𝑝𝐵 are the response probabilities in the experimental and control 
groups respectively, 
 
?̅?𝑄 =
𝑝𝐴
𝑄 + 𝑝𝐵
2
 
(3.11) 
and 𝑧𝑎/2, 𝑧𝛽 denote the upper 𝑎/2- and upper 𝛽-points respectively of a standard 
normal distribution where 𝑎 and 𝛽 denote the assumed type I error and type II error 
respectively. The response probability in the experimental group can be found by 
 𝑝𝐴
𝑄 = 𝑝𝐵 + 𝛿+, (3.12) 
where 𝛿+ denotes the improvement in response probability for biomarker-positive 
patients. Consequently, the total sample size of randomized patients will be 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 = 2𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 (3.13) 
For continuous response endpoints the aforementioned formula 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 
changes to 
 
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 =
2𝜎2(𝑧𝑎/2 + 𝑧𝛽)
2
(𝜇𝐴+ − 𝜇𝐵+)2
, 
(3.14) 
where 𝜎2 denotes the anticipated common variance, 𝜇𝐴+ and 𝜇𝐵+ the mean responses 
for biomarker-positive patients in the experimental and control treatment arm 
respectively. These formulae are the standard formulae used for a traditional 
randomized trial. 
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In addition, if we want to account for error in the assaying of the study 
population, the number of patients to be randomized in each arm of the enrichment 
trial when using continuous response endpoints can be given by the following 
formula 
 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑎𝑟𝑚 = 2𝜎
2(𝑧𝑎/2 + 𝑧𝛽)
2
{𝜆1[(1 − 𝜔) 𝜁 + 𝜔]}
−2 (3.15) 
where  𝜔 measures the accuracy of the assay and corresponds to the PPV (positive 
predictive value of the assay, i.e. the proportion of patients who are assigned the 
biomarker-positive status according to the assay who are truly biomarker positive), 
𝜆1 is the treatment effect in the biomarker-positive patients and 𝜁 = 𝜆0 𝜆1⁄  (where 𝜆0 
is the treatment effect in the biomarker-negative patients) [55]. 
Simon and Maitournam [65, 111, 112] considered that apart from the number 
of patients to be randomized, the number of patients needed to be screened should 
be also reported. Thus, they stated that the expected number of patients to be 
screened in the enrichment design is 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡/𝑘 where 𝑘 corresponds to the 
proportion of biomarker-positive patients. The online tool developed by Zhao and 
Simon provides both the number of patients to be screened and to be randomized. 
Statistical considerations: Simon and Maitournam [65, 111, 112] undertook a 
simulation study, assuming a binary outcome, to compare power of the enrichment 
design with an untargeted design (i.e. marker stratified design, see next section for 
further information) in which all patients are randomized without measuring the 
biomarker. They concluded that the efficiency of the enrichment design relies both 
on the prevalence of the biomarker-positive patients and on the accuracy of the assay. 
In the situation where the assay cut-off point is not well established, there is a risk of 
severely compromising the power of the trial when using an enrichment design. 
However, assuming an accurate assay, if fewer than half of the entire study 
population are biomarker-positive and there is robust evidence that the experimental 
treatment does not benefit the biomarker-negative patients, the required number of 
randomized patients to allow sufficient power to detect a significant treatment effect 
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is much smaller in the enrichment design than in the untargeted trial design.On the 
other hand, in the latter situation a greater number of individuals would need to be 
screened when using the enrichment design, and accruing the required number of 
biomarker-positive patients could take a longer period of time. More precisely, Simon 
and Maitournam showed that an approximation of the ratio of the required number 
of patients to be randomized for the untargeted trial design as compared with the 
required number of patients randomized in the enrichment design when using binary 
outcome can be given by the following equation 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
1
[𝑘 + (1 − 𝑘)
𝛿−
𝛿+
]
2 = [
𝛿+
𝑘𝛿+ + (1 − 𝑘)𝛿−
]
2
, 
(3.16) 
where 𝑘 denotes the proportion of biomarker-positive patients, 𝛿− and 𝛿+ correspond 
to the treatment effectiveness (i.e. improvement in response probability) in 
biomarker-negative and biomarker-positive subgroups respectively. Consequently, 
in the situation where it is known that the novel treatment does not benefit the 
biomarker-negative patients at all, the ratio of the number of patients needed for 
randomization in the untargeted design relative to the number of patients required 
for the enrichment design is approximately 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
1
𝑘2
, 
(3.17) 
as 𝛿− = 0. For example, if half of patients are biomarker-positive (𝑘 = 0.5) then a 
quarter of those needed to be randomized to the untargeted design trial would need 
to be randomized to the enrichment design trial. In cases where the novel treatment 
is half as effective in biomarker-negative patients as in the biomarker-positive 
patients (i.e. 𝛿− 𝛿+⁄ = 1/2), the aforementioned ratio changes to 
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 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
≈
4
(𝑘 + 1)2
. 
(3.18) 
3.2.3. Randomize-All Designs 
Randomize-all designs (also named as all-comers/untargeted/unselected/non-
targeted/simple randomization designs) allow the inclusion of the entire population 
as eligible for randomization. Consequently, the whole study population who meet 
the eligibility criteria, is randomly assigned to the different treatment groups 
(experimental and control treatment group) regardless of biomarker status. This 
design allows assessment of treatment benefit for the entire population irrespective 
of biomarker status whilst at the same time allowing for treatment benefit to be tested 
in the two biomarker-defined subgroups separately. 
Generally, they are useful when we are uncertain about the benefit of the 
experimental treatment in the overall population versus the biomarker-defined 
subgroups, and the targeted treatment may benefit both biomarker-positive and 
biomarker-negative patients. Additionally, these designs are useful when the goal is 
to test the predictive ability of a biomarker, the assay reproducibility and accuracy is 
questionable, the turnaround time for biomarker assessment is long and the 
biomarker prevalence is high. 
Randomize-all designs are composed of two main subtypes: the Marker-
stratified designs and the Hybrid designs, which are discussed separately below. 
3.2.3.1.  Marker Stratified Designs 
These designs (prospective validation Phase III trials) were identified in 45 
papers (45%) of our review. 
Design: An illustration of the design is shown in Figure 3.4. Individuals are 
stratified into biomarker-positive and biomarker-negative subgroups according to 
the results of the biomarker assessment and then they are randomized either to the 
experimental or to the control treatment group. The biomarker status in the Marker-
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Stratified design acts as a stratification factor where stratification is used to ensure 
balance across treatment groups with regard to biomarkers. Only individuals with 
valid biomarker results enter the trial. Consequently, we have four treatment groups, 
i.e. biomarker-positive patients assigned to either the experimental treatment arm or 
the control treatment arm and biomarker-negative patients assigned to either the 
experimental treatment arm or the control treatment arm. Thus, we can assess the 
relationship between treatment effect and biomarker status. 
 
Figure 3.4. Marker Stratified designs. “R” refers to randomization of patients. 
Utility: When there is enough evidence that the experimental treatment is more 
effective in the positive biomarker-defined subgroup than in the negative biomarker-
defined subgroup but there is no sufficient compelling data that the experimental 
treatment is of no benefit in biomarker-negative individuals, the marker stratified 
design can be used. 
Methodology: Biomarker status is used to stratify the randomization, rather 
than to restrict eligibility. Marker-stratified designs can be conducted using two 
different testing plans; the so-called marker-by-treatment interaction with separate 
tests and marker-by-treatment interaction with interaction test. Both of these 
approaches involve conducting a single clinical trial, but treated as two independent 
ones for analysis purpose. 
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Marker-by-treatment interaction using separate test was referred to in 15 
papers (15%) of our review [4, 11, 12, 15, 29, 42, 45, 53, 57, 60, 80, 82, 84, 87, 88] and is 
also referred to as ‘separate randomization design’ and ‘separate by treatment 
interaction design’. This analysis plan is based on separate superiority tests in each 
biomarker-defined subgroup in order to detect the treatment efficacy in each subset. 
Two examples of actual trials which use this testing plan are the following: National 
Cancer Institute (NCI)-sponsored North Central Cancer Treatment Group Study 
N0975 [29] and the MARVEL trial [29]. 
The ‘marker-by-treatment interaction design using separate tests’ is a testing 
plan which determines whether the novel treatment is superior to the control 
treatment separately within each biomarker-defined subgroup. Consequently, the 
hypothesis to be tested, the calculation of the number of patients required for the trial, 
the estimation of the statistical power of the design and the randomization procedure 
of patients to different treatments are independent among the different subgroups 
[12]. The sample size of the trial should be calculated in such a way so as to yield 
adequate statistical power when testing whether the experimental treatment is 
superior to the control treatment separately in the two biomarker-defined subgroups. 
Hence, this approach is not widely used due to the required large sample size as 
essentially two separate trials are being conducted, and in addition interaction tests 
increase sample size requirements even further. Another limitation of this approach 
is that when multiple biomarker-defined subsets and treatments are to be 
investigated, it is difficult to implement in practice. 
The ‘marker-by-treatment interaction using interaction test’ uses a test for 
interaction between the biomarker status and treatment assignment and was 
identified in 12 papers (12%) of our review [4, 12, 15, 42, 53, 57, 60, 82, 84, 87, 88, 94]. 
A marker stratified design which uses this testing plan is also referred to in the 
literature as an ‘interaction design’ or ‘genomic signature stratified design’. First, a 
formal statistical test for interaction between biomarker status and treatment 
assignment is undertaken. If this interaction is not significant, then the study is 
continued by testing the different treatments overall at a two-sided significance level 
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of 0.05, otherwise, the treatments are compared within each biomarker-defined 
subpopulation at a two-sided 0.05 significance level (i.e. the same as in the marker-
by-treatment interaction design using separate tests). The sample size for this second 
testing plan is calculated with reference to the treatment effect in the entire study 
population. Therefore, it might not provide sufficient power for detecting the 
treatment effect in each biomarker defined-subset individually. More precisely, if the 
sample size is calculated for the overall analysis and the proportion of the biomarker-
defined subpopulation which responds to the novel treatment is very small, the 
statistical power for the subgroup analysis may be inadequate. In addition, when 
several biomarker-defined subpopulations and treatments are to be investigated, this 
strategy is not easy to be implemented. 
For the case of binary outcomes, Eng, 2014 [92] provided the formula for the 
required sample size to power the biomarker-positive and biomarker-negative 
patients separately. It is assumed that 𝑌 is a binary variable which corresponds to a 
patient’s response to their randomly tailored treatment and 𝑃(𝑌|𝑇𝑟𝑡 = 𝑖, 𝑀 = 𝑗) = 𝑟𝑖𝑗 
where 𝑖 corresponds to either the experimental or control treatment and 𝑗 
corresponds to either the biomarker-positive patients or the biomarker-negative 
patients. Hence, 
 𝑟𝑖𝑗 = 𝛽0 + 𝛽𝐴𝐼(𝑇𝑟𝑡 = 𝐴) + 𝛽+𝐼(𝑀 = 𝑀
+) + 𝛽𝐼𝐼(𝑇𝑟𝑡 = 𝐴, 𝑀 = 𝑀
+), (3.19) 
where 𝛽0 denotes a baseline effect, 𝛽𝐴 denotes the added effect of the experimental 
treatment, 𝛽+ denotes the biomarker-positive effect and 𝛽𝐼 denotes the nonadditive 
effect. Consequently, the proposed formula for the required sample size can be given 
by 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 = 2(𝑧𝑎 + 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝛽𝐴 + 𝛽𝐼)2
+
𝑟𝐴−(1 − 𝑟𝐴−) + 𝑟𝐵−(1 − 𝑟𝐵−)
(𝛽𝐴)2
}, 
(3.20) 
where 𝑎 corresponds to the target level, 1 − 𝛽 corresponds to the power. Also, 𝑟𝐴+, 𝑟𝐵+ 
are the assumed response rates of biomarker-positive patients receiving the 
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experimental and the control treatment respectively. Additionally, 𝑟𝐴−, 𝑟𝐵− are the 
assumed response rates of biomarker-negative patients receiving the experimental 
and the control treatment respectively. 
Mandrekar and Sargent, 2009 [31] provide a formula to calculate the required 
number of events when the trial has a survival outcome with 1:1 randomization to 
treatment arms, i.e. 
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
[log (
𝑚𝐴+
𝑚𝐵+
)]
2 +
4(𝑧𝑎/2 + 𝑧𝛽)
2
[log (
𝑚𝐴−
𝑚𝐵−
)]
2 , 
(3.21) 
where 𝑚𝐴+, 𝑚𝐴−, 𝑚𝐵+, 𝑚𝐵−, indicate the median overall survival for biomarker-
positive and biomarker-negative patients receiving control and experimental 
treatment, respectively and 
 𝜃1 =
𝑚𝐴+
𝑚𝐵+
= 𝐻𝑅𝑏𝑖𝑜𝑚+ , 
(3.22) 
 𝜃2 =
𝑚𝐴−
𝑚𝐵−
= 𝐻𝑅𝑏𝑖𝑜𝑚− , 
(3.23) 
correspond to the hazard ratios of biomarker-positive and biomarker-negative 
subgroups and 𝑧𝑎/2, 𝑧𝛽 denote the upper 𝑎/2- and upper 𝛽-points respectively of a 
standard normal distribution where 𝑎 and 𝛽 denote the assumed type I error and 
type II error respectively. More precisely, the total number of events is the sum of the 
required number of events for the biomarker-negative and biomarker-positive 
subpopulation. Freidlin et al., 2010 [61] stated that the required number of events in 
order to compare the experimental to the control treatment among the biomarker-
positive patients for detecting a given effect size in this biomarker-positive 
subpopulation is identical to the number of events needed by an enrichment design 
(i.e. 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡). 
Another potential formula for the required total number of events when 1:1 
randomization to treatment arms is assumed is given by 
 119 
 
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
. 
(3.24) 
Although the formula proposed by Mandrekar and Sargent, 2009 [31] achieves 
a specific power (1 − 𝛽) for each biomarker-defined subgroup separately, the 
aforementioned formula proposed in the book of Harrington, 2012 [114] aims to reach 
a power (1 − 𝛽) for the overall population to test the null hypothesis of no treatment 
effect in the entire population. According to Harrington, 2012 the required total 
number of patients to be entered to a stratified trial can be given by 
 𝑁𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
=
4(𝑧𝑎/2 + 𝑧𝛽)
2
{
[𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡)log(𝜃1) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)log(𝜃2)]
√𝑘𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡) + (1 − 𝑘)𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡)
}
, 
(3.25) 
where 𝑃𝑟(+)(𝑒𝑣𝑒𝑛𝑡), 𝑃𝑟(−)(𝑒𝑣𝑒𝑛𝑡) are the probabilities of an event in biomarker-
positive subset and biomarker-negative subset respectively. If we divide the required 
total number of events for the enrichment design by the aforementioned formula for 
the required total number of events for the stratified design, we can get the following 
approximation of the ratio 
 𝐷𝑠𝑡𝑟𝑎𝑡𝑖𝑓𝑖𝑒𝑑
𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
=
[log(𝜃1)]
2
[𝑘log(𝜃1) + (1 − 𝑘)log(𝜃2)]2
=
1
[𝑘 + (1 − 𝑘)
log(𝜃2)
log(𝜃1)
]
2. 
(3.26) 
Further, Zhao and Simon [19, 28, 53, 57, 60] have developed an online tool for 
the calculation of sample size for biomarker stratified randomized designs with 
binary or time-to-event endpoints which is available online at the following web site 
http://brb.nci.nih.gov/brb/samplesize/sdpap.html [115]. More precisely, the sample 
size for both binary and time-to-event endpoints can be performed with three 
different analysis plans; A, B and C. Before choosing one of these analysis plans in 
the web site, for binary endpoints we need to specify the probability of treatment 
response in the control arm as well as the proportion of biomarker-positive patients. 
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For survival endpoints, the hazard ratio of biomarker-positive patients versus the 
biomarker-negative control patients which corresponds to the hazard ratio of 
prognostic effect as well as the proportion of biomarker-positive patients must be 
specified. 
Analysis plan A is performed when there is confidence that an overall 
treatment effect exists. It determines the sample size on the basis of first of all 
comparing the experimental treatment to the control treatment in the entire 
randomized population at a reduced two-sided significance level 𝑎 < 0.05. If the 
overall test is not significant, then the experimental treatment is compared to the 
control treatment in the biomarker-positive patients using the significance level 
0.05 − 𝑎. Analysis Plan A is similar to the ‘Biomarker-positive and overall strategies 
design’ with fall-back analysis described later in this chapter; the difference lies in 
this in terms of the significance levels they have used. In order for the sample size to 
be estimated, the anticipated overall effect estimate, reduced two-sided significance 
level and power for the overall test need to be specified. 
Analysis plan B is performed when there is confidence that there is a treatment 
effect in the biomarker-positive subpopulation. It determines the sample size on the 
basis of first of all comparing the experimental treatment to the control treatment in 
the biomarker-positive subgroup at a two-sided significance level of 𝑎 = 0.05 level. If 
the treatment effect is found to be significant at this 0.05 level, then treatment effect 
is evaluated in the biomarker-negative subgroup again at a two-sided significance 
level of 0.05 level. This analysis plan is identical to the ‘Sequential subgroup-specific 
design’ described later in this chapter. In order for the sample size to be estimated, 
apart from the fixed significance level set to 0.05, the anticipated effect estimate in the 
biomarker-positive subpopulation and power need to be specified. 
Analysis plan C first tests whether there is a statistically significant interaction 
between treatment and biomarker [60]. If the interaction is not significant, then the 
treatments are compared in the overall study population at a two-sided significance 
level 0.05. Otherwise, the treatments are compared within the two biomarker 
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subgroups separately at a two-sided 0.05 significance level for each subgroup. 
Analysis Plan C follows either the ‘marker-by-treatment interaction process with 
interaction or the separate test process’ described above. In order for the sample size 
to be estimated, the anticipated treatment effect in the overall study population, the 
one-sided significance level for interaction test and the power for testing the 
treatment effect in the overall population need to be specified. 
In marker stratified designs, three designs can be included which differ in terms 
of their statistical testing strategies, i.e. (i) Subgroup-specific designs (i.e. sequential 
subgroup-specific design, parallel subgroup-specific design); (ii) Biomarker-positive 
and overall strategies (i.e. biomarker-positive and overall strategies with parallel 
assessment, biomarker-positive and overall strategies with sequential assessment, 
biomarker-positive and overall strategies with fall-back analysis); (iii) Marker 
sequential test design (MaST) and they are discussed in the following sections. 
Statistical considerations: Despite the fact that the marker stratified designs 
allow testing the treatment effect not only in the entire population but also in each 
biomarker-defined subpopulation, they might not be feasible when the prevalence of 
biomarker is low. Another limitation of such designs is that they might require a large 
sample size where several treatments and biomarkers are investigated in the study. 
Subgroup-Specific designs: This strategy is an approach to analyze a 
biomarker-stratified trial. It is composed of two types; ‘Sequential Subgroup-Specific 
design’ and ‘Parallel Subgroup Specific design’. Both biomarker-positive and 
biomarker-negative subgroups can be tested in a sequential or in a parallel way. With 
the parallel way, we can assess simultaneously both biomarker-positive and 
biomarker-negative patients, whereas, with the sequential way we perform first the 
assessment of biomarker-positive patients and if the result is positive then we 
continue with the biomarker-negative patients. 
Sequential Subgroup-Specific design: This approach was referred to in 11 
papers (11%) of our review. Figure 3.5 graphically represents this approach. 
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Figure 3.5. Sequential Subgroup-Specific design. “R” refers to randomization of patients. Uncolored 
boxes are referred to the first stage of the trial and colored boxes are referred to the second stage of the 
trial. Different stages refer to the analysis and not to the trial design. 
Design: The sequential testing procedure uses the assumption that it is unlikely 
that the new treatment will be effective in the biomarker-negative patients unless it 
is effective in the biomarker-positive patients. First, the treatment effect is tested in 
the biomarker-positive subpopulation using the overall two-sided significance level 
𝑎 = 0.05 (Type I error); if this test is significant then the treatment effect is tested in 
the biomarker-negative subgroup using the same level of significance 𝑎. 
Utility: Its use is recommended when there is compelling evidence that 
biomarker-positive individuals benefit more from the experimental treatment than 
the biomarker-negative patients. More precisely, it is appropriate when it is not 
expected for the novel treatment to be effective in biomarker-negative patients unless 
it is beneficial for the biomarker-positive patients. 
Methodology: As this subgroup-specific design follows a sequential 
assessment and thus the design is composed of two stages, the sample size calculation 
 123 
 
is also staged. For binary outcome the required number of biomarker-positive 
patients is the same as for the enrichment design, i.e. 
 𝑁𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 (3.27) 
As Simon, 2008 [60] stated, the total number of patients will be approximately  
 𝑁𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
 (3.28) 
where 𝑘 is the proportion of biomarker-positive patients and the number of 
biomarker-negative patients will be approximately 
 
𝑁𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− =
(1 − 𝑘)𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡
𝑘
. 
(3.29) 
For the conduct of this design, it is important to ensure that there is also an 
adequate number of biomarker-negative patients for analysis purposes. For time-to-
event outcomes, the required number of events for biomarker-positive patients is the 
same with the required number of events in the enrichment design, i.e.  
 𝐷𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
+ = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡. (3.30) 
At the time that there are 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 patients, the required number of events 
among biomarker-negative patients in terms of that among biomarker-positive 
patients (𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡) is given by 
 
𝐷𝑆𝑒𝑞𝑢𝑒𝑛𝑡𝑖𝑎𝑙 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝−𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐
− = 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 (
𝜆−
𝜆+
) (
1 − 𝑘
𝑘
), 
(3.31) 
where 𝜆−, 𝜆+ are the event rates in biomarker-negative and biomarker-positive 
control subsets at the time when there are 𝐷𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 events in the biomarker-
positive subgroup [60]. 
The significance levels 𝑎 can also be considered as one-sided significance levels 
in situations where our alternative hypothesis is not that there is just a treatment 
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effect but that the treatment benefit in the experimental group is greater than that of 
the control group. 
Statistical considerations: This strategy preserves the overall type I error rate 
𝑎 but requires a smaller number of positive patients as compared to the second type 
of subgroup-specific design, the so-called parallel subgroup-specific design (see 
below). Furthermore, it enables the identification of treatment efficacy in the 
biomarker-positive and biomarker-negative subpopulations separately. However, it 
yields low power when there is homogeneity of treatment effect across the different 
biomarker-defined subpopulations. Furthermore, in case that test for treatment effect 
among biomarker-negative patients is not statistically significant, an “exploratory” 
analysis on the biomarker-negative subgroup might be considered. 
Parallel Subgroup-Specific design: This design was identified in three papers 
(3%) of our review. 
Design: Parallel subgroup-specific design (Phase III), also referred to as a Phase 
III Biomarker-Stratified design evaluates treatment effects separately in the positive 
biomarker-defined subgroup and in the negative biomarker-defined subgroup 
simultaneously. A graphical illustration of this strategy is given in Figure 3.6. 
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Figure 3.6. Parallel Subgroup-Specific design. “R” refers to randomization of patients. 
Utility: It is appropriate when the aim of the study is to give treatment 
recommendations for each biomarker-defined subgroup separately at the same time. 
Methodology: In order to control the overall type I error rate of the design at 
the overall level of significance 𝑎 (Type I error) it is required to allocate this overall 𝑎 
between the test for the biomarker-positive subgroup and the test for the biomarker-
negative subgroup using the Bonferroni correction method [123] for multiple testing; 
e.g., if we choose the value of 0.025 for the global significance level 𝑎, then we could 
choose the values of 𝑎1 = 0.010 and 𝑎2 = 0.015 for testing the biomarker-negative 
and biomarker-positive subgroups respectively. This trial design is powered in such 
a way so as to detect the treatment effect in each biomarker-defined subgroup 
separately. A higher portion of the type I error rate can be given for the test within 
the biomarker-positive subgroup in order to maximize the power of the trial to 
identify the treatment effect in this subpopulation.  
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As in the sequential subgroup-specific design, the probability of rejecting either 
the null hypothesis of no treatment effect in the biomarker-positive subset or in the 
biomarker-negative effect under the global null hypothesis is less than or equal to the 
overall type I error rate 𝑎. Additionally, the probability of rejecting the null 
hypothesis of no treatment effect in the biomarker-negative subpopulation when the 
treatment benefit is only restricted to biomarker-positive patients is less than or equal 
to 𝑎. The significance levels 𝑎 can be considered as one-sided or two-sided 
significance levels.  
Statistical considerations: With this approach, in case that the overall level of 
significance 𝑎 is equal in both subgroup-specific designs, it is more difficult to achieve 
statistical significance in the biomarker-positive subgroup as compared to the 
sequential subgroup-specific design due to the allocation of the overall significance 
level between the two biomarker-defined subgroup tests. 
Biomarker-positive and overall strategies: This design provides an alternative 
strategy to analyzing a biomarker-stratified design. It is an indirect way of evaluating 
both biomarker and treatment by testing the treatment effect in the entire study 
population and in the biomarker-positive subgroup separately. Three approaches are 
included in the biomarker-positive and overall strategies; the parallel assessment, the 
sequential assessment and the fall-back design (see below). 
Despite the fact that the biomarker-positive subgroup and overall strategy 
design allows the treatment effect to be tested in the biomarker-positive 
subpopulation and provides good statistical power when the treatment effect is 
homogeneous across subgroups, this design is usually considered problematic and 
its use is not often recommended. More precisely, a major concern is that when the 
benefit of the novel treatment is limited to the biomarker-positive patients, it is 
possible that the design might lead to a wrong recommendation of treatment for the 
biomarker-negative patients. This might happen because when there is no treatment 
effect in the biomarker-negative subgroup, there might be an observed effect in the 
entire population due to the potentially large effect in the biomarker-positive 
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patients. This concern is particularly pronounced in the sequential version of the 
design, which first tests the biomarker-positive subgroup and then, if it is positive, it 
tests the overall population. 
Biomarker-positive and overall strategies with parallel assessment: This 
approach was identified in eight papers (8%) of our review. Figure 3.7 graphically 
represents this strategy. In the parallel version, we test both the overall population 
and biomarker-positive subgroup simultaneously. 
 
Figure 3.7. Biomarker-positive and overall strategies with parallel assessment. “R” refers to 
randomization of patients. 
Design: In this approach the treatment effect is tested in both the entire study 
population and in the biomarker-positive patients while controlling the type I error 
by allocating the overall significance level 𝑎 between the two tests. The significance 
level 𝑎 can be considered as one-sided or two-sided. 
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Utility: The parallel version is recommended when the aim of the study is to 
assess the treatment effect in both the overall study population and in the biomarker-
positive subgroup but not in the biomarker-negative subgroup. 
Methodology: If there is significant confidence that the biomarker is predictive, 
the sample size estimation is aimed at having a sufficient number of biomarker-
positive individuals to enable the treatment effect in the biomarker positive subgroup 
to be detected. On the other hand, if there is no confidence in the predictive value of 
the biomarker, the sample size estimation is aimed at having a sufficient number of 
patients to detect a treatment effect in the overall study population [14]. 
Statistical considerations: This design has the ability to control the probability 
of rejecting the null hypothesis of no treatment effect either in the biomarker-positive 
population or in the biomarker-negative population under the global null hypothesis 
of no treatment effect in the entire population at the overall significance level 𝑎. 
However, it cannot control the probability of rejecting the null hypothesis of no 
treatment effect in the biomarker-negative subset when the treatment benefit is 
restricted to biomarker-positive patients. Consequently, there is high risk of 
inappropriately recommending the experimental treatment for biomarker-negative 
patients. 
When the experimental treatment is compared to the control treatment within 
the overall population and the overall treatment effect is significant, then the test has 
high statistical power. If we are testing only the biomarker-positive subgroup and the 
treatment effect in this subgroup is significant, the statistical power is again high. This 
prospective subset analysis plan is based on testing both the overall study population 
and the biomarker-positive subgroup using significance levels, which are chosen in 
such a way that the overall significance level is equal or less than 𝑎 (type I error). An 
easy way is to split 𝑎 in such a way that the significance level for the entire population 
and the significance level for the biomarker-positive subset equals to overall 
significance level 𝑎 (typically 𝑎 = 0.05). For example, the SATURN trial 
(NCT00556712) [96] which employs a prospective subset strategy used the value of 
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0.03 as level of significance to test the treatment effect in the entire population and 
the value of 0.02 to test the treatment effect in the biomarker-positive subset; 
therefore, the overall level of significance was preserved at 0.05. The approach can be 
overly conservative as in the SATURN trial because of the correlation between the 
global and subgroup test. Other approaches [98, 124-127] have been proposed for 
adjusting the level of significance of both tests in a more accurate and less 
conservative way. 
Biomarker-positive and overall strategies with sequential assessment: This 
approach was referred to in 11 papers (11%) of our review. A graphical illustration of 
this approach is shown in Figure 3.8. 
 
Figure 3.8. Biomarker-positive and overall strategies with sequential assessment. “R” refers to 
randomization of patients. Uncolored boxes are referred to the first stage of the trial and colored boxes 
are referred to the second stage of the trial. Different stages refer to the analysis and not to the trial 
design. 
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Design: In this sequential version of the biomarker-positive and overall 
strategies, we first test the biomarker-positive subgroup using the significance level 
𝑎; if the test is significant, then we test the treatment effect in the overall population 
using the same 𝑎 level. The significance levels 𝑎 can be considered as one-sided or 
two-sided significance levels. 
Utility: The sequential version might be useful in cases where the experimental 
treatment is expected to be effective in the overall study population.  
Methodology: As this design comprises two sequential stages, it follows that 
the sample size calculation should also be staged. At the first stage, the standard 
formula for a traditional randomized trial can be used for the biomarker-positive 
subgroup using the significance level 𝑎 to estimate the treatment effect in that subset. 
More precisely, the formula used in the enrichment design for the required total 
number of events or the required number of patients can be used at the first stage of 
this design. At the second stage, the sample size must be adjusted in order to yield 
appropriate power for the entire population. 
Statistical considerations: As in the parallel version of this designs, this 
strategy does not allow for identification of treatment efficacy in the biomarker-
negative subgroup and despite the fact that it can control the overall type I error 𝑎 it 
cannot control the probability of rejecting the null hypothesis of no treatment effect 
in the biomarker-negative subset when the treatment benefit is restricted to 
biomarker-positive patients. Consequently, for this design also there is high risk of 
inappropriately recommending the novel treatment for biomarker-negative patients. 
Biomarker-positive and overall strategies with fall-back analysis: This 
strategy was identified in 15 papers (15%) of our review. It evaluates both the 
treatment effect in the overall study population and in the biomarker-positive 
subgroup sequentially. Figure 3.9 graphically represents this strategy. 
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Figure 3.9. Biomarker-positive and overall strategies with fall-back analysis. “R” refers to randomization 
of patients. Uncolored boxes are referred to the first stage of the trial and colored boxes are referred to 
the second stage of the trial. Different stages refer to the analysis and not to the trial design. 
Design: In the fall-back design, we first test the overall population using the 
reduced significance level 𝑎1 and if the test is significant, we consider that the novel 
treatment is effective in the overall population; however, if the result is not significant 
then we test the treatment effect in the biomarker-positive subgroup using the level 
of significance 𝑎2 = 𝑎 − 𝑎1, where 𝑎 is the overall significance level (Type I error rate). 
The significance levels 𝑎 can be considered as one-sided or two-sided significance 
levels. Utility: This approach is recommended when there is insufficient confidence 
in the predictive value of the biomarker and that the novel treatment is believed to 
be effective in all individuals (i.e. the rationale for the biomarker is weak). This design 
can be used in order to avoid the possibility of missing an important treatment effect 
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in the biomarker-positive patients (with insufficient benefit in the biomarker-
negative subgroup).  
Methodology: The sample size should be set in such a way so as to yield 
adequate power for the overall test at the reduced significance level 𝑎1 and for the 
potential biomarker positive subgroup analysis at significance level 𝑎 − 𝑎1 [60]. The 
fall-back version is identical to the parallel version of biomarker-positive and overall 
strategies in terms of sample sizes and study outcomes, however the difference 
between these approaches is that the fall-back strategy is useful in settings where a 
biomarker will be assessed only if the overall population benefit is not promising [14]. 
This strategy can test the treatment effectiveness in biomarker-positive patients even 
if there is no detected benefit of the novel treatment in the overall population. 
However, it does not evaluate clearly the treatment benefit in the biomarker-negative 
subpopulation. 
Statistical considerations: As the two aforementioned biomarker-positive and 
overall designs, this strategy can again control the overall type I error 𝑎 but it cannot 
control the probability of rejecting the null hypothesis of no treatment effect in the 
biomarker-negative subgroup when the treatment benefit is restricted to biomarker-
positive patients. Consequently, there is high risk of inappropriately recommending 
the novel treatment for biomarker-negative patients. Song et al., 2007 [128] and 
George, 2008 [1] have discussed refinement of the significance levels associated with 
this design, which takes into account the correlation between the test for overall 
treatment effect and the test for the biomarker-positive treatment effect [60]. 
Additionally, a recent paper by Choai et al., 2015 [97] proposes a bias-corrected 
estimation method for treatment effects for the all-comers randomized clinical trials 
with a predictive biomarker which incorporate the fall-back analysis. For Choai et al., 
2015 [97] the terminology “all-comers randomized clinical trials” is referred to the 
“Biomarker-positive and overall strategies with fall-back analysis”. More precisely, 
as this study design has an adaptive nature and is composed of two stages, a bias is 
possible to arise in the treatment effect estimation in the biomarker-positive subset 
when the first stage of the trial yields an overall result which is not significant and 
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thus fails to demonstrate a treatment efficacy in the entire population. For this reason, 
Choai et al. ,2015 [97], formulate a bias function using polynomials in order to take 
into account the possibility of failing to demonstrate overall treatment efficacy during 
the first stage of the trial. 
Marker Sequential test design (MaST): This design was identified in four 
papers (4%) of our review and while controlling the appropriate type I error rates, it 
evaluates not only the biomarker-positive and biomarker-negative subgroups but 
also the entire population sequentially to limit the assessment of treatment effect in 
the overall population when it seems that the biomarker-positive subgroup does not 
benefit from the novel treatment. A graphical illustration of this approach is given in 
Figure 3.10. 
 
Figure 3.10. Marker Sequential test design (MaST). “R” refers to randomization of patients. Uncolored 
boxes are referred to the first stage of the trial and colored boxes are referred to the second stage of the 
trial. 
Design: In this design which owns an adaptive nature, first, the biomarker-
positive subgroup is tested at a reduced level 𝑎 in [0, 𝑎] and if the result is significant, 
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then the biomarker-negative subgroup is tested at the global significance level 𝑎. 
Otherwise, if the result is not significant, then the overall population is tested at level 
𝑎2 = 𝑎 − 𝑎1  in order to make a treatment recommendation for the biomarker-
negative patients. 
Utility: It is generally recommended when robust evidence is available 
regarding a biomarker and there is prior evidence showing that the novel treatment 
is more beneficial for the biomarker-positive patients as compared to the biomarker-
negative patients. Additionally, it is appropriate when we can assume that the 
treatment will not be beneficial for the biomarker-negative subgroup unless it is 
effective for the biomarker-positive subgroup. Additionally, the marker sequential 
test design is considered as an alternative to the sequential subgroup-specific design 
when the aim is to consider the treatment effect not only in biomarker-positive but 
also in the biomarker-negative patients. 
Methodology: Freidlin et al., 2014 [69] recommended using the value of 0.022 
for the reduced significance level 𝑎1 in order to control the type I error rate for 
biomarker-negative patients at the global significance level 𝑎 = 0.025 and the value 
of 0.04 for the reduced significance level 𝑎1 in order to control the type I error rate for 
biomarker-negative patients at the global significance level 𝑎 = 0.05. 
Regarding the sample size for such a design where there is prior evidence 
indicating strong predictive ability of the biomarker, a standard sample size 
calculation (i.e. the same sample size calculation as for the enrichment designs) can 
be used for biomarker-positive subpopulation or alternatively, researchers can use 
the sample size calculation used for the sequential subgroup-specific design. 
However, in order to have sufficient number of biomarker-positive patients to detect 
treatment effectiveness in that particular biomarker-defined subset and consequently 
to reach the desired power, the sample size should be calculated using the reduced 
level 𝑎1 [0, 𝑎] instead of the global significance level 𝑎 which is used in the sample 
size formulae of the enrichment and sequential subgroup-specific designs. This will 
result in a small increase in the number of patients as compared to the enrichment 
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and sequential subgroup-specific designs. Otherwise, if the reduced significance level 
𝑎1 is not used, this would yield minor loss of power. 
Statistical consideration: Freidlin et al., 2014 [69] performed a comparison 
between the MaST and the sequential subgroup-specific design through a simulation 
study and concluded that the marker sequential design yields higher power in cases 
where the treatment effect is homogeneous across biomarker-defined subgroups. 
Additionally, with this approach, the power is preserved in situations where the 
experimental treatment is effective only for the biomarker-positive patients. 
Furthermore, in situations where biomarker status is not available for a portion of 
patients included in the trial, the marker sequential test design can either exclude 
these patients or include them in the global test, whereas, the proposed subgroup-
specific designs do not consider inclusion of these patients in the analyses. If 
researchers decide to exclude patients with unavailable biomarker status from the 
study when using a MaST design, no statistical adjustment is required. On the other 
hand, if the inclusion of this study population is chosen, then this can result in 
inflation of the type I error rate for the biomarker-negative subpopulation above the 
global significance level 𝑎 due to the modification of correlation structure between 
the biomarker-defined subgroup tests and global test. In addition, while both MaST 
and subgroup-specific designs have the ability to control the probability of 
incorrectly rejecting the null hypothesis of no treatment effect in the biomarker-
negative patients at the significance level 𝑎 when the experimental treatment does 
not work in either biomarker-defined subgroup, the sequential subgroup-specific 
approach typically has a smaller probability of incorrectly rejecting the null 
hypothesis of no treatment effect in the biomarker-negative subset (when the null 
hypothesis is true) as compared to the MaST design, especially under the global null 
hypothesis of no treatment effect in the entire population; the probability of 
incorrectly rejecting the null hypothesis of no treatment effect in the biomarker-
negative patients depends on the choice of 𝑎1. This conservativeness of sequential 
subgroup-specific design, which is due to its sequential nature, makes the MaST 
design advantageous [69]. 
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3.2.3.2. Hybrid Designs 
Hybrid designs (Phase III) were identified in 14 papers (14%) of our review and 
they can be included in the all-comers designs, where the entire population is firstly 
screened for biomarker status and all individuals enter the trial. A graphical 
illustration of this design is given in Figure 3.11. 
 
Figure 3.11. Hybrid design. “R” refers to randomization of patients. 
Design: In this approach, only the biomarker-positive patients are randomly 
assigned to either the experimental treatment group or to the control treatment group 
whereas the biomarker-negative patients receive the control treatment. These designs 
were first defined by Mandrekar and Sargent [30, 31]. The difference compared with 
the enrichment designs is that the biomarker-negative patients are not excluded from 
the study.  
Utility: Hybrid designs can be used when there is compelling prior evidence 
which shows detrimental effect of the experimental treatment for a specific 
biomarker-defined subgroup (i.e. biomarker-negative subgroup) or some indication 
of its possible excessive toxicity in that subgroup, thus making it unethical to 
randomize the patients within this population to the experimental treatment. 
Methodology: Similar to the enrichment design, hybrid designs are powered 
to identify the treatment effect only in the biomarker-defined subgroup which is 
randomly assigned to the experimental or control treatment groups. Consequently, 
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the same formula used for the required number of patients or events for the 
enrichment designs can be used for hybrid designs. This design is a combination of 
an enrichment design where we randomize patients to either the experimental or the 
control treatment group and a single-arm design in biomarker-negative patients. 
Statistical considerations: The strength of the hybrid design is that apart from 
the evaluation of the predictive ability of a biomarker, the feasibility of a prognostic 
biomarker can also be tested. It can be considered as an advantageous design of the 
enrichment designs when there is prior evidence showing not only that the control 
treatment works well for the biomarker-negative population but also a detrimental 
effect of the experimental treatment for that subgroup or possible excessive toxicity 
as we do not exclude these patients from the trial as it happens in the enrichment 
designs. 
3.2.4. Biomarker-Strategy Designs 
Generally, with biomarker-strategy designs, the study population is 
randomized to treatment strategies as opposed to treatments per se. More precisely, 
patients are randomized to either a biomarker-based treatment strategy arm where 
the biomarker is used in deciding on approach to treatment, or to an arm that does 
not use the biomarker to guide treatment. Consequently, biomarker-strategy designs 
make a comparison between two strategies—one which uses biomarker information 
to inform treatment approach and the other that does not. 
These designs are also known as biomarker-based strategy designs or 
signature-based strategy designs and they are composed of four subtypes; (i) 
biomarker-strategy designs with biomarker assessment in the control arm; (ii) 
biomarker-strategy designs without biomarker assessment in the control arm; (iii) 
biomarker-strategy designs with treatment randomization in the control arm and (iv) 
reverse marker-based strategy designs. Whilst patients randomized to the non-
biomarker based strategy arm in the first two design subtypes are allocated the 
control treatment, in the third design subtype those patients undergo secondary 
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randomization to either the control or experimental treatment. The fourth design 
subtype differs from the three aforementioned subtype designs as the non-biomarker 
based strategy arm is replaced by the reverse marker-strategy arm. The first and 
second types are similar with the difference being only in terms of ethical/feasibility 
issues regarding the acquisition of biomarker status at the beginning of the trial. 
This approach is preferred when the study is planned for a confirmatory phase 
of a certain biomarker-based strategy allowing for comparison between the 
biomarker-based strategy and non-biomarker-based strategy. 
3.2.4.1.  Biomarker-Strategy Design with Biomarker Assessment in the Control Arm 
This approach is described in 21 (21%) papers of our review.  
Design: First, the study population enrolled in the trial is tested for its marker 
status. Next, patients irrespective of their biomarker status are randomized either to 
the biomarker-based strategy arm (also referred to as personalized arm) or to the non-
biomarker-based strategy arm. In the biomarker-based strategy arm, biomarker-
positive patients receive the experimental treatment, whereas, biomarker-negative 
patients receive the control treatment. Patients who are randomized to the non-
biomarker-based strategy arm receive the control treatment irrespective of their 
biomarker status. A graphical illustration of this design is given in Figure 3.12. This 
biomarker-strategy design can be extended to more than one experimental treatment. 
More precisely, this extension is referred to as Individual profile design in literature 
and was identified in two papers [36, 72] (2%) of our review. This design includes 
different individual status, e.g., instead of biomarker-positive and biomarker-
negative subgroups we can have patients who are positive for biomarker 1, 
biomarker 2, biomarker n, leading to the selection of personalized treatments, 
(patients who are positive for biomarker 1 are treated with the corresponding 
experimental treatment 1, etc.). 
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Figure 3.12. Biomarker-strategy design with biomarker assessment in the control arm. “R” refers to 
randomization of patients. 
Utility: This approach is useful when we want to test the hypothesis that the 
treatment effect based on the biomarker-based strategy approach is superior to that 
of the standard of care. 
Methodology: The clinical utility of a biomarker can be evaluated by 
comparing the two strategy groups. The predictive utility of the marker-based 
treatment strategy could be assessed by comparing the outcome of all patients in the 
biomarker-based strategy arm to all patients in the non-biomarker-based strategy 
arm. Patients in the marker-based strategy arm do not need to be limited to two 
treatments; in principle, a marker-based strategy involving many biomarkers and 
many possible treatments could be compared to standard of care treatment. 
According to Freidlin et al., 2010 [61], assuming a survival outcome, the 
required sample size in terms of number of events for this type of biomarker-strategy 
design in order to reach power (1 − 𝛽) at significance level 𝑎 (type I error) can be 
given by 
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𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 = 4 [
(z𝑎/2 + z𝛽)
𝑘 logθ1
]
2
, 
(3.32) 
where 𝑘 denotes the prevalence of biomarker-positive patients, θ < 1 denotes the 
assumed hazard ratio in the biomarker-positive subpopulation and 𝑧𝑎/2,  𝑧𝛽 denote 
the upper 𝑎/2- and upper 𝛽-points respectively of a standard normal distribution 
where 𝑎 and 𝛽 denote the assumed type I error and type II error respectively. 
According to Freidlin et al. 2010 [61], it is assumed that there is no treatment effect in 
the biomarker-negative subpopulation (corresponding to a hazard ratio of 
experimental treatment versus control treatment of 1) and that there is no prognostic 
effect of the biomarker under the control treatment. Consequently, the overall hazard 
ratio between experimental and control arms in biomarker-positive patients and 
biomarker-negative patients can be approximated by exp[𝑘 logθ + (1 − 𝑘) log1] = θ𝑘 
[61] and this is the reason why the formula which gives the required total number of 
events (𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦) contains only the hazard ratio of biomarker-positive patients. 
Freidlin et al., 2010 [61] provided the aforementioned formula assuming that all 
random assignments use 1:1 randomization. 
Additionally, Young et al., 2010 [26] determined the total sample size needed 
for this type of biomarker-strategy designs when using continuous clinical endpoints 
by  
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼 =
2(𝑧1−𝑎/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛
2)
(𝑣𝑚 − 𝑣𝑛)2
, 
(3.33) 
where 𝑧1−𝑎/2, 𝑧1−𝛽 denote the lower 1 − 𝑎/2- and lower 1 − 𝛽-points respectively of 
a standard normal distribution, 𝑎 and 𝛽 denote the assumed type I error and type II 
error respectively, 𝑣𝑚 and 𝑣𝑛 denote the mean response from the biomarker-based 
strategy arm and the non-biomarker-based strategy arm respectively, and 𝜏𝑚
2 ,  𝜏𝑛
2 
denote the variance of response for the biomarker-based strategy arm and non-
biomarker-based strategy arm respectively. Young et al., 2010 [26] also provided 
formulae for the aforementioned variances which depend on sensitivity and 
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specificity of the assay, such that any error in the evaluation of biomarker in the 
biomarker-based strategy can be accounted for. 
For the case of binary outcomes, Eng, 2014 [92] provided the formula for the 
required sample size for each arm in a test of proportions between the two 
randomization arms (biomarker-based strategy arm and non-biomarker-based 
strategy arm). This formula can be given by 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔2(1 − 𝑔2)]
Δ2
2  
(3.34) 
where 𝑎 corresponds to the target level, 1 − 𝛽 corresponds to the power, 𝑔1 is the 
expected response rate in the biomarker-based strategy arm, 𝑔2 is the expected 
response rate in the non-biomarker-based strategy arm and Δ2= 𝑔1 − 𝑔2. The 
expected response rates  𝑔1, 𝑔2 can be found by calculating the formulae 𝑘𝑟𝐴+ +
(1 − 𝑘)𝑟𝐵− and 𝑟𝐵 respectively, the prevalence of biomarker-positive patients 
corresponds to 𝑘 and 𝑟𝐴+, 𝑟𝐵− are the assumed response rates of biomarker-positive 
patients receiving the experimental treatment and biomarker-negative patients 
receiving the control treatment, 𝑟𝐵 denotes the marginal effect of treatment B (control 
treatment). 
Statistical considerations: This type of design is able to inform researchers 
whether the biomarker is prognostic, since both biomarker positive and negative 
patients are exposed to the control treatment, but it cannot answer the question of 
whether the biomarker is predictive since only biomarker positive patients are 
exposed to the experimental treatment. Additionally, these designs have been 
criticized by many authors as less efficient than the marker-stratified designs since it 
is possible for some patients in both the biomarker-based strategy arm and non-
biomarker-based strategy arm to be assigned to the same treatment (due to the 
existence of biomarker-negative patients in both strategy arms the treatment effect 
can be diluted) and they require a large sample size to detect an overall difference in 
outcomes between arms. Furthermore, these designs cannot compare experimental 
treatment to control treatment directly as they are designed to compare not the 
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treatments but the biomarker-strategies. Another limitation of these designs is the 
uncertainty about whether the results which indicate efficacy of the biomarker-
directed approach to treatment are caused due to a true effect of the biomarker or due 
to a treatment effect irrespective of the biomarker status. 
3.2.4.2.  Biomarker-Strategy Design without Biomarker Assessment in the Control Arm 
This strategy was identified in 14 papers (14%) of our review. 
Design: In this approach, patients are again randomized between testing 
strategies (i.e. biomarker-based strategy and non-biomarker-based strategy) but it 
differs in terms of the timing of biomarker evaluation. More precisely, first, patients 
are randomized to either the biomarker-based strategy or to the non-biomarker-based 
strategy. Next, this design evaluates the biomarkers only in patients who are assigned 
to the biomarker-based strategy. Patients who are found to be biomarker-positive will 
receive the experimental treatment and patients who are biomarker-negative will 
receive the control treatment. On the other hand, the population which is randomized 
to the non-biomarker-based strategy will receive the control treatment. A graphical 
illustration of this design is given in Figure 3.13. 
 
Figure 3.13. Biomarker-strategy design without biomarker assessment in the control arm. “R” refers to 
randomization of patients. 
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Utility: This design is useful in situations where it is either not feasible or ethical 
to test the biomarker in the entire population due to several logistical (e.g., specimens 
not submitted), technical (e.g., assay failure) or clinical reasons (e.g., tumor 
inaccessible); thus the biomarker status is obtained only in patients who are tailored 
to the biomarker-based strategy arm. 
Methodology: The same mathematical formula for sample size calculation 
assuming a continuous clinical outcome proposed by Young et al. (2010) [26] and the 
formula assuming binary outcome proposed by Eng, 2014 [92] for the biomarker-
strategy design with biomarker assessment in the control arm could be applied. 
Further, in terms of survival outcome, the same formula provided for the required 
number of events in the first version of biomarker-strategy designs (i.e. biomarker-
strategy design with biomarker assessment in the control arm) could be considered. 
Statistical considerations: These designs have the same advantages and 
limitations as the previously discussed biomarker-strategy design with biomarker 
assessment in the control arm, e.g., they have been criticized for their lack of efficiency 
due to the fact that biomarker negative patients are exposed to the control treatment 
in both arms of the trial. An additional limitation is that the biomarker-positive and 
biomarker-negative subpopulations might be more imbalanced as compared with the 
first type of biomarker-strategy design due to the fact that the randomization is 
performed before the evaluation of biomarker (balancing the randomization is useful 
to ensure that all randomized patients have tissue available). 
3.2.4.3.  Biomarker-Strategy Design with Treatment Randomization in the Control Arm 
Sargent and Allegra [108] proposed another version of Biomarker-strategy 
designs where there is a second randomization between experimental and control 
treatment in the non-biomarker guided strategy arm. This strategy is referred to in 17 
papers (17%) of our review. 
Design: A graphical illustration of this approach is given in Figure 3.14. The 
two previously described biomarker-strategy designs can answer the question about 
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whether the biomarker-based strategy is more effective than standard treatment, 
irrespective of the biomarker status of the study population, whereas the biomarker-
strategy design with treatment randomization in the control treatment is able to 
inform us about whether the biomarker-based strategy is better than not only the 
standard treatment but also better than the experimental treatment in the overall 
population. This is achieved by using a second randomization the ratio of which 
should be informed by the prevalence of the biomarker in question in the population 
as a whole to ensure balance between the study arms. Patients are first randomly 
assigned to either the biomarker-based strategy arm or to the non-biomarker-based 
strategy arm. Next, patients who are allocated to the non-biomarker-based strategy 
are again randomized either to the experimental treatment arm or to the standard 
treatment arm irrespective of their biomarker status. Patients who are allocated to the 
biomarker-based strategy and who are biomarker-positive are given the 
experimental treatment and patients who are biomarker-negative are given the 
control treatment. The clinical utility of the biomarker is evaluated by comparing 
treatment effect between the biomarker-based strategy arm and non-biomarker-
based strategy arm. Such an approach can also identify whether a novel treatment is 
more effective in the entire population or in a biomarker-defined subgroup only, 
since both biomarker subgroups are exposed to both treatments. 
 
 145 
 
Figure 3.14. Biomarker-strategy design with treatment randomization in the control arm. “R” refers to 
randomization of patients. 
Utility: These designs are preferable as compared to the two previously 
discussed biomarker-strategy designs in cases where there is interest in whether the 
biomarker is not only prognostic but also predictive. 
Methodology: Mandrekar and Sargent, 2009 [31] calculated the total required 
sample size in terms of number of events for the comparison of a survival outcome 
in the biomarker-based strategy versus the non-biomarker-based strategy. According 
to them, the required total number of events when using 1:1 randomization to 
treatment arms is given by 
 
𝐷𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
4(𝑧𝑎/2 + 𝑧𝛽)
2
{log [
2𝑘𝑚𝐵+ + 2(1 − 𝑘)𝑚𝐴−
𝑘(𝑚𝐴++𝑚𝐵+) + (1 − 𝑘)(𝑚𝐴−+𝑚𝐵−)
]}
2,    
(3.35) 
where 𝜅 denotes the prevalence of the biomarker-positive patients, 
𝑚𝐴+, 𝑚𝐴−, 𝑚𝐵+, 𝑚𝐵−, denote the median survival for biomarker-positive and 
biomarker-negative patients receiving control and experimental treatments 
respectively. Also, the constants 𝑧𝑎/2,  𝑧𝛽 denote the upper 𝑎/2- and upper 𝛽-points 
respectively of a standard normal distribution where 𝑎 and 𝛽 denote the assumed 
type I error and type II error respectively. 
Additionally, Young et al., 2010 [26], considering continuous clinical outcomes, 
calculated the total sample size by 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼 =
2(𝑧1−𝑎/2 + 𝑧1−𝛽)
2
(𝜏𝑚
2 + 𝜏𝑛𝑟
2 )
(𝑣𝑚 − 𝑣𝑛𝑟)2
, 
(3.36) 
where 𝑧1−𝑎/2, 𝑧1−𝛽 denote the lower 1 − 𝑎/2- and lower 1 − 𝛽-points respectively of 
a standard normal distribution, 𝑎 and 𝛽 denote the assumed type I error and type II 
error respectively, 𝑣𝑚 and 𝑣𝑛𝑟 denote the mean response from the biomarker-based 
strategy arm and the non-biomarker-based strategy arm,) and 𝜏𝑚
2 ,  𝜏𝑛𝑟
2  denote the 
variance of response for the biomarker-based strategy arm and non-biomarker-based 
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strategy arm respectively. The only differences in the mathematical formula for the 
total sample size between this type of biomarker-strategy design and the first and 
second types mentioned above are the values of 𝑣𝑛𝑟 and  𝜏𝑛𝑟
2  , to reflect the fact that 
in the non-biomarker-based strategy arm patients are randomly assigned to either the 
experimental or control treatment. Again, the formulae can be adjusted to account for 
uncertainty in biomarker assessment. 
For the case of binary outcomes, Eng, 2014 [92] provided the formula for the 
required sample size for each arm in a test of proportions between the two 
randomization arms (biomarker-based strategy arm and non-biomarker-based 
strategy arm). This formula can be given by 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝐼𝐼/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔3(1 − 𝑔3)]
Δ3
2  
(3.37) 
where 𝑎 correspond to the target level, 1 − 𝛽 corresponds to the power, 𝑔1 is the 
expected response rate in the biomarker-based strategy arm, 𝑔3 is the expected 
response rate in the non biomarker-based strategy arm and Δ3= 𝑔1 − 𝑔3. The 
expected response rates  𝑔1, 𝑔3  can be found by calculating the formulae 𝑘𝑟𝐴+ +
(1 − 𝑘)𝑟𝐵− and 𝑟𝐴 2⁄ + 𝑟𝐵 2⁄  respectively, 𝑟𝐴 and 𝑟𝐵 denote the marginal effect of 
treatment A (experimental treatment) and treatment B (control treatment) 
respectively. 𝑟𝐴+, 𝑟𝐵− are the assumed response rates of biomarker-positive patients 
receiving the experimental treatment and biomarker-negative patients receiving the 
control treatment. The prevalence of biomarker-positive patients corresponds to 𝑘. 
Statistical considerations: Similar to both aforementioned biomarker-strategy 
designs, the biomarker-strategy design with treatment randomization in the control 
arm will need larger sample size as compared to the marker-stratified designs. 
However, one strength is that they allow clarification of whether the results which 
indicate efficacy of the biomarker-directed approach to treatment are caused due to 
a true effect of the biomarker or due to a treatment effect irrespective of the biomarker 
status which does not happen in the first two types of biomarker-strategy designs. 
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3.2.4.4. Reverse Marker-Based Strategy Design 
Eng, 2014 [92] proposed another version of biomarker-strategy designs where 
the non-biomarker-based strategy arm which is included in the three aforementioned 
subtypes of biomarker-strategy designs is replaced by the reverse marker-strategy 
arm. This strategy is referred to in four papers (4%) of our review. 
Design: A graphical illustration of this approach is given in Figure 3.15. In this 
design patients are randomized either to the biomarker-based strategy arm or the 
reverse biomarker-based strategy arm. As in the previous three biomarker-strategy 
subtype designs, patients who are allocated to the biomarker-strategy arm receive the 
experimental treatment if they are biomarker-positive whereas biomarker-negative 
patients receive the control treatment. By contrast, patients who are randomly 
assigned to the reverse biomarker-based strategy arm receive control treatment if 
they are biomarker-positive, whereas biomarker-negative patients receive 
experimental treatment. 
 
Figure 3.15. Reverse Marker-Based strategy design. “R” refers to randomization of patients. 
Utility: Reverse marker-based strategy is a more efficient strategy as compared 
to the first and third biomarker-strategy subtype design for testing the interaction 
hypothesis of treatment and biomarker. This design should be used in cases where 
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prior evidence indicates that both experimental and control treatment are effective in 
treating patients but the optimal strategy has not yet been identified. 
Methodology: This subtype design is balanced (i.e. the randomization 
frequencies for each treatment are equal independent of the prevalence of the 
biomarker) and it is powered to evaluate the interaction between treatment and 
biomarker. For the case of binary outcomes, Eng, 2014 [92] provided the formula for 
the required sample size for each arm in a test of proportions between the two 
randomization arms (biomarker-based strategy arm and reverse biomarker-based 
strategy arm). This formula can be given by 
 
𝑁𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝐼𝑉/𝑎𝑟𝑚 =
(𝑧𝑎 + 𝑧1−𝛽)
2
[𝑔1(1 − 𝑔1) + 𝑔4(1 − 𝑔4)]
Δ4
2  
(3.38) 
where 𝑎 correspond to the target level, 1 − 𝛽 corresponds to the power, 𝑔1 is the 
expected response rate in the biomarker-based strategy arm, 𝑔4 is the expected 
response rate in the reverse biomarker-based strategy arm and Δ4 = 𝑔1 − 𝑔4. The 
expected response rates 𝑔1, 𝑔4 can be found by calculating the formulae 𝑘𝑟𝐴+ +
(1 − 𝑘)𝑟𝐵− and 𝑘𝑟𝐵+ + (1 − 𝑘)𝑟𝐴− respectively, 𝑟𝐴+, 𝑟𝐵− are the assumed response rates 
of biomarker-positive patients receiving the experimental treatment and biomarker-
negative patients receiving the control treatment and 𝑟𝐴−, 𝑟𝐵+ are the assumed 
response rates of biomarker-negative patients receiving the experimental treatment 
and biomarker-positive patients receiving the control treatment The prevalence of 
biomarker-positive patients corresponds to 𝑘. 
Statistical considerations: This design enables the evaluation of the interaction 
between the biomarker and different treatments and can estimate directly the 
marker-strategy response rate. Additionally, this subtype design allows the 
estimation of the effect size of the experimental treatment compared to the control 
treatment for each biomarker-defined subgroup separately. Also, there is no chance 
that the same treatment will be tailored to biomarker-positive patients who are 
randomized either to the biomarker-based strategy arm or the reverse marker 
strategy (i.e. biomarker-positive patients in the biomarker-based strategy will be 
 149 
 
given only the experimental treatment and biomarker-positive patients in the reverse 
marker strategy arm will be given only the control treatment). Also, there is no 
possibility of the same treatment assignment to biomarker-negative patients who are 
randomly assigned to the two biomarker-based strategy arms (i.e. biomarker-
negative patients in the marker-based strategy arm will be treated with the control 
treatment, whereas biomarker-negative patients in the reverse marker strategy arm 
will be treated with the experimental treatment). According to Eng, 2014 [92] who 
compared the reverse marker-based strategy design with the first (i.e. biomarker-
strategy design with biomarker assessment in the control arm) and third (i.e. 
biomarker-strategy design with treatment randomization in the control arm) subtype 
of biomarker-strategy designs in the case of binary outcomes, the effect size in order 
to make a comparison of the different treatment strategy arms would be larger than 
in the first and third subtype designs. Furthermore, it has been shown by Eng, 2014 
that in situations where a randomly chosen treatment has a better than 7% response 
rate, the reverse marker-based strategy design works better as compared to the third 
biomarker-strategy subtype (i.e. Biomarker-strategy design with treatment 
randomization in the control arm). It has also been demonstrated that this novel 
design is more than four times more efficient in order to test the interaction between 
treatment and biomarker compared to Biomarker-strategy design with biomarker 
assessment in the control arm, Biomarker-strategy design with randomization in the 
control arm and the marker stratified design. Eng, 2014 demonstrated the benefits of 
the Reverse Marker-Based strategy design with the aim to assess the interaction 
between treatment and biomarker. However, Baker, 2014 [93] stated that other 
designs than the Reverse Marker-Based strategy design would be more appropriate 
in order to investigate questions which include treatment effect of biomarker-defined 
subgroups and biomarker-based strategy arms. 
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3.2.5. Other Designs 
3.2.5.1. A Randomized Phase II Trial Design with Biomarker Proposed by Freidlin et al., 
2012 
Freidlin et al., 2012 [71] proposed a biomarker-guided Phase II clinical trial 
design in which it, when completed, recommends which type of Phase III trial should 
be used. These recommendations for a Phase III trial are the following: (i) enrichment 
design; (ii) marker-stratified design; (iii) a traditional trial design without a 
biomarker; or (iv) drop consideration of the experimental treatment. A graphical 
illustration of this design is given in Figure 3.16. 
 
Figure 3.16. Randomized Phase II trial design with biomarkers. “R” refers to randomization of patients. 
CI refers to the confidence interval. Uncolored boxes are referred to the first stage of the trial and colored 
boxes are referred to the second stage of the trial. Different stages refer to the analysis and not to the trial 
design. 
Design: For this type of randomized Phase II trial, it is assumed that the 
experimental treatment will be more beneficial among biomarker-positive patients 
than biomarker-negative patients without ruling out the efficacy of the novel 
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treatment in biomarker-negative patients. The intermediate endpoint of progression-
free survival (PFS) is used which is able not only to give the results earlier but also to 
target larger treatment effects as compared to overall survival (OS) endpoint.  
The design starts by comparing the experimental treatment with the control 
treatment in the biomarker-positive subgroup using a one-sided level of significance 
𝑎1 = 0.10. The null hypothesis is that the progression-free survival for biomarker-
positive patients is the same for both experimental and control treatment arm 
(𝐻𝑅0,𝑏𝑖𝑜𝑚+ ≤ 1 vs. 𝐻𝑅1,𝑏𝑖𝑜𝑚+ > 1). Next, if the null hypothesis is rejected, which 
means that the experimental treatment is better than the control treatment in the 
biomarker-positive subgroup we continue with the calculation of an 80% two-sided 
confidence interval (CI) for the hazard ratio (control vs experimental) in the 
biomarker-negative subpopulation. Three decisions are made according to the values 
of the CI: (i) if the entire CI is less than 1.3 then we can continue with a Phase III 
enrichment design; (ii) if the CI includes the values 1.3 or 1.5 then we can continue 
with a Phase III marker-stratified design and (iii) if the entire CI is greater than 1.5 
then it seems that the biomarker is not useful as the novel treatment benefits both the 
biomarker-negative and biomarker-positive patients, thus, the biomarker should be 
dropped and a traditional randomized Phase III design should be conducted. 
Otherwise, if the null hypothesis is not rejected at the one-sided significance 𝑎1 =
0.10 (meaning that that the experimental treatment is not better than the experimental 
treatment in the biomarker-positive subgroup), then we continue with the 
comparison of treatments in the overall study population at one-sided level of 
significance 𝑎 = 0.05. If the null hypothesis of no treatment effect in the entire 
population is rejected, then the authors recommend to drop the biomarker and to 
continue with a traditional randomized Phase III trial due to the fact that the 
biomarker seems to be useless. On the other hand, if the null hypothesis is not 
rejected, the experimental treatment should not be tested further as it does not seem 
to be effective.  
Utility: This design should be used when we want to conduct a Phase II 
randomized trial which allows decisions to be made about which type of Phase III 
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biomarker-guided trial to proceed with. It is appropriate when there is prior evidence 
that the novel treatment benefits mostly the biomarker-positive patients without 
ruling out treatment effect in biomarker-negative patients.  
Methodology: Freidlin et al., 2012 [71] have provided an online tool for 
calculating the sample size which can be found on the following website 
http://brb.nci.nih.gov/Data/FreidlinB/RP2BM [115]. In order for a sample size to be 
estimated, the following information is required: (i) the significance levels for testing 
the treatment effect in the biomarker-positive subgroup and in the entire population; 
(ii) cut-offs and confidence intervals for the hazard ratio in the biomarker-negative 
subgroup; (iii) the prevalence of biomarker-positive patients; (iv) the median 
progression-free survival in each treatment arm in each biomarker-defined subgroup 
and (v) the accrual parameters. Regarding the accrual parameters, the author 
specifies the minimum sample size for biomarker-positive patients for which the 
accrual continues until this number is reached, the maximum number of over-accrual 
in biomarker-positive subgroup for which the accrual to the entire population stops 
after this number is reached and the maximum accrual number in biomarker-
negative patients for which the accrual to this biomarker-defined subgroup stops 
when this number is reached. 
Statistical considerations: In real life, it might not be possible to obtain the 
biomarker status for the entire population. If the biomarker status is unknown for 
some patients, then these individuals could be included in the analysis of the overall 
population. More precisely, in case that the proportions of patients with unknown 
biomarker status is low, the randomization of them to either the experimental or the 
control treatment could be considered in the second stage of this Phase II trial where 
we test the treatment effectiveness in the entire population. Another statistical 
consideration is that researchers should take into account the adjustment for inflation 
in Phase III type I error as the chosen Phase III trial design depends on the 
performance of the aforementioned randomized Phase II trial. Additionally, the 
authors suggest generally that in cases where it seems that the control treatment has 
been shown more beneficial, an aggressive interim inefficacy/futility should be used, 
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i.e. when the estimated hazard ratio of control treatment versus the experimental 
treatment is equal or less than one when half of the required number of events have 
been observed, then the accrual should stop to that biomarker-defined subgroup. 
3.3. Discussion 
A number of biomarker-guided trial designs have been proposed in the past 
decade, including both biomarker-guided adaptive and non-adaptive trial designs. 
We have undertaken a comprehensive review of the literature using an in-depth 
search strategy to report on the biomarker-guided designs proposed to date, with a 
view to providing the research community with clarity in definition, methodology 
and terminology of the various trial designs. The review is split in two parts due to 
its size; the first part of the review is focused on adaptive designs which are 
extensively discussed in Chapter 2 [35], whereas, herein we focus on non-adaptive 
designs which incorporate biomarkers.  
The review has demonstrated ambiguity and confusion regarding the 
biomarker-guided non-adaptive designs proposed by different authors. For example, 
different authors described the same trial design but with different names (see Table 
3.1). In this review, we focus on 5 main types of such designs including their subtypes 
and variations. Knowledge on how to implement and analyse these designs are 
essential in testing the effectiveness of a biomarker-guided approach to treatment; 
hence, a comprehensive review giving this knowledge is essential for the research 
community. In our in-depth study, we provide researchers with analytical 
information of these study designs not only in terms of their utility, advantages and 
limitations but also in terms of their methodology. In addition, a graphical illustration 
for each biomarker-guided design is given. A guidance document by Tajik et al., 2012 
[116] regarding the evaluation of putative biomarkers in randomized clinical trials 
came to our knowledge by personal communication as we were not able to identify 
it during our literature search. 
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The non-adaptive designs do not allow modifications of important aspects of 
the trial such as refinement of the existing study population, treatment assignment, 
study endpoints, study duration, etc. In non-adaptive designs, all these factors are 
defined before the initiation of the study and they are kept fixed during the course of 
the clinical trial. However, there is a great potential of failure when implementing 
such conventional designs due to potential wrong design assumptions of the key 
aspects of the study that might be made before the conduct of the trial. Hence, an 
adaptive design clinical study which allows on-going adaptations based on 
accumulating study data from interim analysis might hold advantageous position as 
compared to the non-adaptive trial design due to its flexibility. However, before 
implementing an adaptive design a lot of issues should be taken into careful 
consideration by research teams in order to prove that there are good reasons for 
conducting such designs. Regulatory and logistical issues, requirement of additional 
efforts for the achievement of the design, potential difficulties, possible increased cost 
and time, statistical challenges including the potential increase of the chance of a false 
conclusion that the treatment is effective (inflation of Type I error) and whether the 
adaptation process has led to positive study results that are difficult to interpret 
irrespective of having control of Type I error should be considered [129]. A recent 
paper by Dimairo et al., 2015 [130] refers to a number of obstacles and barriers when 
implementing adaptive designs in practice. Several key stakeholders in clinical trials 
research have been interviewed (i.e. UK Clinical Trials Units directors, funding board 
and panel members, statisticians, regulators, chief investigators, data monitoring 
committee members and health economists) expressing difficulties of adaptive 
designs. Lack of appropriate knowledge and familiarity of these designs in the 
scientific community, insufficient time and funding structure, additional work 
required due to the complexity of such designs and the needed statistical expertise 
and appropriate software are some of the highlighted difficulties mentioned in the 
paper of Dimairo et al., 2015 [130]. In addition, this study includes the 
characterisation of potential benefits of an adaptive design to patients, clinical trials 
as well as funders. 
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The different designs proposed so far for biomarker-guided designs, both non-
adaptive designs which remain an appealing approach to a great extent mainly due 
to their simplicity and adaptive designs which are more flexible, need to be further 
explored by the research community, as the proper choice and use of such designs 
can result in a great increase in the efficiency of a trial and expedite the development 
of novel treatments. 
The characteristics and methodology of the five main designs and their 
subtypes are discussed in the current chapter, whilst information on their variations 
are summarized in Appendix B. Additional references for these variations and the 
literature review search strategy are provided in [131, 132]. 
In this chapter we presented and discussed in detail the different types of non-
adaptive trial designs. To ensure that the guidance and graphical representations of 
Chapter 2 and 3 are easily accessible to stakeholders, an interactive web resource to 
host this information was also developed and is presented in Chapter 4. 
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Chapter 4. Online tool to help develop personalized 
medicine (BiGTeD) 
4.1. Introduction 
In this chapter we present an online tool to provide guidance on designing 
biomarker-guided clinical trials. The literature review work presented in Chapter 2 
and 3 of this thesis identified large variability between authors in terms of the 
terminology used and descriptions of the different biomarker-guided trial designs, 
which has resulted in significant ambiguity and confusion amongst those trying to 
interpret and implement the designs. The review also revealed that navigating the 
literature to gain an understanding of which trial design to implement in a given 
situation, and the practical implications of doing so, are difficult. Hence our online 
tool ‘Biomarker-Guided Trial Designs’ (BiGTeD), which is openly and freely available 
mirrors the findings of the literature review, but in a much more accessible format. 
To our best knowledge there is no web resource aimed at giving easy access to key 
information related to each different biomarker-guided clinical trial designs and 
providing a truly interactive tool allowing for the optimal design in a given setting to 
be identified. 
The decision to develop the tool stemmed from feedback by attendees of 
conferences and meetings where the literature review work was presented, which 
suggested that there was a real need for information on the different trial designs to 
be available in an easily accessible and user-friendly format. The work was also 
presented at a local North West Hub for Trials Methodology Research meeting at 
which several members of the Hub’s Stratified Medicine Working Group were 
present, and it was agreed that having the information identified in the literature 
review available via a user-friendly web resource would be extremely useful and 
would increase accessibility to stakeholders. We hope that BiGTeD will improve the 
understanding of biomarker-guided trial designs and provide much-needed 
guidance on their implementation. 
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4.2. Key features 
BiGTeD is accessible via the following link, www.BiGTeD.org, and was 
developed using Microsoft Expression Web 4. Expression Web is a full-featured 
professional tool for designing, developing, and publishing compelling, feature-rich 
websites that conform with web standards. 
Since we wished to make the tool as user-friendly as possible, a key feature of 
the tool is the inclusion of an interactive graphical representation of each trial design, 
which allows the design and flow of patients through the trial to be easily visualized. 
Graphical representations have been standardised in such a way that helps to 
highlight both the similarities and differences across different trial designs. Different 
colours are used to identify different stages of each design and components of the 
graphic where additional information is available have been highlighted using a red 
colour to be easily identifiable. To display this additional information, the user must 
simply hover the cursor over the relevant component, and key information relating 
to that component will appear as a ‘pop-up’ box, e.g. see Figure 4.1. 
 
Figure 4.1. ‘Pop-up’ box illustration. 
‘Pop-up’ box 
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To supplement each graphical representation, key details about the design e.g. 
the methodology and statistical and practical considerations are provided in more 
extensive text. Links to references relevant to each trial design identified in our 
comprehensive and in-depth literature review are also provided so that users can 
refer to them for further information as required. 
4.3. User interface 
4.3.1. Homepage 
The online tool’s homepage includes a brief background to the field of 
personalized medicine and the utility of biomarker-guided clinical trials. 
Additionally, a clickable box is provided for each individual trial design, eight for 
adaptive and five for non-adaptive designs. A snapshot of the homepage is given in 
Figure 4.2. On clicking on a clickable box, a new webpage is opened which includes 
the aforementioned graphical representation and key details. For example, if the user 
clicks on the ‘Adaptive Signature design’ button, the webpage as illustrated in Figure 
4.3 opens. It is possible to return to the homepage by simply clicking on the 
breadcrumb ‘Home’ at the top of the page. 
 
Figure 4.2. Online tool’s homepage 
Brief 
background 
Clickable 
box 
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4.3.2. Design-specific webpages: Adaptive Designs 
An example of a design-specific webpage for an adaptive trial is provided in 
Figure 4.3 which corresponds to the webpage of the Adaptive Signature design. In 
this figure we can see a shrunken version of the graphic as well as key information 
about the design, and variations of the design identified in the literature. 
 
Figure 4.3. Example of the webpage of a distinct adaptive design 
On each page a shrunken version of the graphical representation is displayed, 
which the user can click on to see an expanded version as illustrated in Figure 4.4. 
The green coloured components of the graphic represent the first stage of the design, 
whilst, the orange coloured components correspond to the second stage. For each 
component which is highlighted with a red box, further information about that 
component of the trial can be displayed if the user hovers over it with the cursor, as 
illustrated in Figure 4.5. The expanded version can be closed by clicking anywhere 
on the blackened background. 
Key 
information 
Shrunken version 
of the graphic 
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Figure 4.4. Example of an expanded version of an adaptive trial graphic  
 
Figure 4.5. Example of an expanded version of an adaptive design graphic with the ‘pop-up’ box 
showing further information 
Each design-specific webpage also includes a section entitled ‘Details’, which 
includes three clickable boxes. Clicking on the first two clickable boxes will reveal 
key information relating to the methodology (Figure 4.6) or statistical and practical 
information respectively (Figure 4.7), whilst clicking on the third clickable box will 
Highlighted 
component 
with a red box 
Further 
information 
appears when 
we hover over a 
red highlighted 
component 
with the cursor. 
 176 
 
reveal key references about the trial as identified in our comprehensive literature 
review given in Chapter 2 (Figure 4.8).  
 
Figure 4.6. Methodology information in the ‘Details’ section of an adaptive design graphic. 
 
Figure 4.7. Statistical and practical information in the ‘Details’ section of an adaptive design graphic. 
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Figure 4.8. Key references in the ‘Details’ section of an adaptive design graphic. 
Each design-specific webpage also includes a section entitled ‘Variations’ 
which includes several clickable boxes, each representing variations of the trial 
design under consideration, again as identified in our comprehensive literature 
review given in Chapter 2. Clicking on a clickable box reveals detailed information 
and key references for the variation (please see Figure 4.9 as an example). 
 
Figure 4.9. ‘Variations’ section of an adaptive design graphic 
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4.3.3. Design-specific webpages: Non-Adaptive Designs 
In a similar way to the adaptive designs, the main page of each individual non-
adaptive design is composed of a shrunken version of a graphical representation of 
the design, key information and variations to the design. A snapshot of the main page 
of one of the five distinct non-adaptive designs (the Enrichment design) is given in 
Figure 4.10. Similarly to the adaptive designs, the user can see an expanded version 
of the shrunken graphical representation by clicking on the graphic (see Figure 4.11). 
For each component which is highlighted with a red box, further information about 
that component of the trial can be displayed if the user hovers over it with the cursor, 
as illustrated in Figure 4.12. The expanded version can be closed by clicking 
anywhere on the blackened background. 
 
Figure 4.10. Example of the webpage of a distinct non-adaptive design 
 
Shrunken 
version of 
the 
graphic 
Key 
information 
Variations 
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Figure 4.11. Example of an expanded version of a shrunken non-adaptive design graphic  
 
Figure 4.12. Example of an expanded non-adaptive design graphic with a ‘pop-up’ box showing further 
information 
For the non-adaptive designs, the ‘Details’ section includes five clickable boxes. 
The first four can be clicked on to find out further details about the utility (Figure 
4.13), methodology (Figure 4.14), sample size calculation (Figure 4.15), and 
statistical/practical considerations (Figure 4.16) for the design respectively, whilst 
clicking on the fifth will reveal key references (Figure 4.17) for the design as identified 
in our literature review presented in Chapter 3. As for the adaptive designs, each non-
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adaptive design-specific webpage also includes a section entitled ‘Variations’ which 
includes several clickable boxes, each representing a variation of the trial design 
under consideration, again as identified in our comprehensive literature review given 
in Chapter 3.  
 
Figure 4.13. Utility information in the ‘Details’ section of a non-adaptive graphic 
 
Figure 4.14. Methodology information in the ‘Details’ section of a non-adaptive graphic 
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Figure 4.15. Sample size formulae in the ‘Details’ section of a non-adaptive graphic 
 
Figure 4.16. Statistical and practical information in the ‘Details’ section of a non-adaptive graphic 
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Figure 4.17. Key references in the ‘Details’ section of a non-adaptive graphic 
Some non-adaptive designs are divided into sub-categories which share the 
same characteristics, e.g. for the Randomize-all Designs’, there are two sub-
categories, the so-called ‘Marker Stratified Designs’ and the ‘Hybrid Designs’. In 
these cases, the design-specific webpage has a different layout as illustrated in Figure 
4.18. More precisely, first we present the characteristics which are relevant to both the 
main design and the sub-categories (i.e. Randomize-all Designs) and all the 
alternative names found in the literature (see Chapter 3). Next, the different sub-
categories included in the main category are given (see grey clickable boxes in Figure 
4.18). When we click on those boxes then key information and graphical 
representations relating to the sub-category specifically are presented. Apart from the 
sub-categories, variations of the main design are also provided. 
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Figure 4.18. Design-specific webpage of a non-adaptive design divided in different sub-categories. 
The sub-categories of each main design follow similar structure used in the 
distinct designs. Hence, a ‘Details’ section is provided. A snapshot of one sub-
category of the ‘Randomize All Designs’, the so-called ‘Hybrid Designs’ can be seen 
in Figure 4.19. 
 
Figure 4.19. Design-specific webpage of a sub-category of a non-adaptive design 
4.4. Discussion 
To conclude, in the current chapter we presented BiGTeD which provides a 
unique resource where details of all biomarker-guided trial designs can be easily 
explored, and will be a valuable tool for those involved in planning and 
Details section 
Characteristics 
of the main 
design and sub-
categories 
Sub-categories of the 
main design 
Variations of the main 
design 
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implementing trials in personalized medicine. A key feature is the inclusion of the 
interactive graphical representations of the trial designs. These clear graphics allow 
the design and flow of patients through the trials to be visualized, whilst having them 
standardized in terms of structure and colour coding allows the different designs to 
be easily compared. On presenting BiGTeD at conferences and meetings, we have 
received very positive feedback from academics, industry and research councils on 
its potential utility in guiding and encouraging the adoption of the most effective and 
appropriate design. It is anticipated that users could use and cite the graphical 
representations of BiGTeD in trial protocols and funding applications to aid in 
describing the trial design. We aim to continue to raise awareness of the website via 
presentations at conferences and meetings. 
Although initially BiGTeD reflects the information identified in the reviews 
reported in chapters 2 and 3, future plans include extending the tool to introduce an 
interactive element whereby certain aspects of a trial’s setting can be input with 
suggested optimal trial designs for that setting being output, as well as the 
introduction of sample size/power calculators to support each design. To inform such 
plans a workshop will be arranged, attended by experts in the field, with the aim of 
gaining consensus in terms of developing BiGTeD into a truly interactive website for 
the purpose of choosing and designing a biomarker-guided trial, what might be 
deliverable on such an interactive website, and what further methodological work 
may be required prior to making the tool truly interactive in terms of suggesting an 
appropriate trial design. Potential participants for the workshop will include 
members of the Hub Network’s Stratified Medicine Working Group and the 
Adaptive Trials Working Group. Additional participants, including clinical trial unit 
representatives, will also be invited to ensure that the needs of the end-user are 
addressed when deciding on how to extend the tool. 
In the next chapter (Chapter 5) we will explore the characteristics of one of the 
popular non-adaptive trial design and an adaptive approach of it with the aim to 
assess the efficiency of the study related to the cost and time of the trial in general. 
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We will showcase the way that simulation techniques can be performed for the 
calculation of the total study power.  
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Chapter 5. Fixed and adaptive Parallel Subgroup-
Specific design for survival outcomes: power and 
sample size 
5.1. Introduction 
In Chapter 1, we introduced the growing field of personalized medicine [1]. 
Following on from Chapters 2 and 3, we presented a number of biomarker-guided 
clinical trial designs [2-3] and showed BiGTeD in Chapter 4 which is informed by the 
literature review discussed in previous chapters. 
Whilst such designs have been given significant attention in the literature, there 
are many challenges associated with their design, analysis and practical application, 
which need to be explored further and better understood. Key challenges include 
powering the study adequately, controlling the false-positive rate, and applying 
appropriate stopping probabilities. 
In the current chapter we focus on the “Parallel Subgroup-Specific” design [4-
6] which can be explored to discuss the above challenges. The parallel subgroup-
specific design is used to test the clinical hypothesis of treatment effect, evaluating 
the effect of the experimental treatment relative to a control treatment in both a 
biomarker-negative and a biomarker-positive subgroup separately. We also consider 
an adaptive version of the design, splitting the trial into two-stages with the aim of 
stopping the study early for either a positive or negative outcome. In this adaptive 
version, the first stage involves an interim analysis after the pre-specified percentage 
of events are achieved and a decision is made whether to stop the trial early for 
efficacy or futility, or to continue to the second stage of the study. Futility and efficacy 
are assessed by comparing the p-value of the observed test statistics produced at each 
stage of the design with pre-specified stopping boundaries. The role of an interim 
analysis in a clinical trial design is important as it might allow the experimental 
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treatment to be made available earlier in case of positive results. We have conducted 
several simulation studies to evaluate a variety of scenarios. 
Our aim was to explore one of the most popular designs in personalized 
medicine as it came out from our in depth literature reviews in Chapter 2, 3, to the 
adaptive version of it in terms of their statistical characteristics (e.g. study power, 
expected sample size) and showcase the way that simulations can be performed. 
Hence, in the current chapter, we explore a fixed versus an adaptive approach in a 
popular biomarker-guided clinical trial setting. This to our best knowledge has not 
been investigated yet. 
5.2. Methods and Findings 
5.2.1. Parallel Subgroup-Specific design 
The parallel subgroup-specific design, a modified version of the marker 
stratified design, allows for the evaluation of treatment effects separately in the 
biomarker-positive subgroup and biomarker-negative subgroup at the same time [3]. 
Whilst the marker-stratified design uses the overall significance level 𝑎 for each 
biomarker-defined subgroup separately, the parallel subgroup-specific design 
controls the overall type I error rate by splitting the overall significance level 𝑎 
between the two biomarker subgroup tests such that 𝑎 = 𝑎− + 𝑎+ [3]. A graphical 
illustration of this strategy is given in Figure 5.1. 
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Figure 5.1. Parallel Subgroup-Specific design. “R” refers to randomization of patients. 𝒂 refers to the 
overall significance level between the two biomarker subgroup tests such that 𝒂 = 𝒂− + 𝒂+. 
 
All patients are screened for biomarker status (biomarker positive or biomarker 
negative) and then randomized to the experimental or control treatments in the two 
biomarker subgroups. Therefore, biomarker status acts as a stratification factor. 
Consequently, the trial is made up of four arms, i.e. biomarker-positive patients 
receiving either the experimental or the control treatment and biomarker-negative 
patients receiving either the experimental or the control treatment. A test for 
treatment effectiveness (Experimental treatment vs Control treatment) can therefore 
be performed in each biomarker-defined subgroup separately. 
Where a trial’s primary outcome is time to some specified event (e.g. time to 
death), the hypotheses being tested in the two biomarker subgroups if one assumes 
exponentially distributed times can be defined as follows: 
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i) Hypothesis being tested (case of two-sided test) in the biomarker negative 
subgroup: 𝐻0,𝑏𝑖𝑜𝑚−: log(𝜃−) = 0, where 
   𝜃− = 𝐻𝑅𝑏𝑖𝑜𝑚− =
𝜆𝐸−
𝜆𝐶−
    
denotes the hazard ratio, and 𝜆𝐸− and 𝜆𝐶− are the rate parameters of an exponential 
distribution for biomarker-negative patients receiving experimental treatment and 
control treatment respectively and 
ii) Hypothesis being tested (case of two-sided test) in the biomarker positive 
subgroup: 𝐻0,𝑏𝑖𝑜𝑚+: log(𝜃+) = 0, where 
𝜃+ = 𝐻𝑅𝑏𝑖𝑜𝑚+ =
𝜆𝐸+
𝜆𝐶+
  
refers to the hazard ratio, and 𝜆𝐸+ and 𝜆𝐶+ are the rate parameters of an exponential 
distribution for biomarker-positive patients receiving experimental treatment and 
control treatment respectively. 
5.2.1.1. Sample size calculation for time-to-event-outcomes 
For the purpose of undertaking power calculations for this design, we assume 
that the treatment effect will be tested using the log-rank test. The total number of 
events required for the parallel subgroup-specific design can be calculated by adding 
up the number of events required in each biomarker-defined subgroup. Following 
Mandrekar and Sargent (2009) [7], we assume 1:1 randomization, and therefore the 
required number of events for each biomarker-defined subgroup can be calculated 
by 
 
𝐷𝑗 = 4
(𝑧𝑎𝑗 + 𝑧𝛽)
2
[log(𝜃𝑗)]
2  
(5.1) 
where 𝑗 denotes either the biomarker positive subgroup (𝑗 = +) or the biomarker 
negative subgroup (𝑗 = −), 𝑧𝑎𝑗, 𝑧𝛽 denote the upper 𝑎𝑗- and upper 𝛽-points 
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respectively of a standard normal distribution and the required total number of 
events can be calculated by 
 
𝐷 = 𝐷− + 𝐷+ = 4
(𝑧𝑎− + 𝑧𝛽)
2
[log(𝜃−)]2
+ 4
(𝑧𝑎+ + 𝑧𝛽)
2
 
[log(𝜃+)]2
     
(5.2) 
where 𝑎− and 𝑎+, denote the type I error rates for biomarker-negative and biomarker-
positive subgroup respectively such that 𝑎− + 𝑎+ = 𝑎, and 𝑎 is the nominal 
significance level (if one-sided e.g., 𝑎 = 0.025 in our case) and 𝛽 corresponds to the 
type II error rate (it is common across the two subgroups). One-sided significance 
levels are used in situations where an alternative hypothesis specifies that the 
treatment benefit in the experimental group is greater than that of the control group. 
In case that a two-sided 𝑎 is used (e.g, 𝑎 = 0.05), then the required total number of 
events can be calculated by 
𝐷 = 𝐷− + 𝐷+ = 4
(𝑧𝑎−/2 + 𝑧𝛽)
2
[log(𝜃−)]2
+ 4
(𝑧𝑎+/2 + 𝑧𝛽)
2
[log(𝜃+)]2
. 
When more than one hypothesis for the assessment of experimental treatment 
efficacy is being tested, it is important to control the familywise error rate (FWER) by 
adjusting for multiplicity of testing to ensure that the probability to commit at least 
one Type I error does not exceed the nominal significance level. To achieve this, a 
conservative Bonferroni correction method is often used where 𝑎 is allocated between 
the test for the biomarker-negative subgroup and the test for the biomarker-positive 
subgroup either equally (i.e. 𝑎/2) or unequally, meaning that the significance levels 
assigned to each biomarker defined-subgroup then add up to the total significance 
level 𝑎.  
The calculation of the total sample size needed for this study is based on the 
total number of events and the probability that a subject will get an event prior to the 
end of the study [8]. Therefore, the sample size required for subgroup 𝑗 is, 
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𝑁𝑗 =
𝐷𝑗
𝑃𝑟𝑗(𝑒𝑣𝑒𝑛𝑡)
    
(5.3) 
where 𝑗 refers to the biomarker-defined subgroup, 𝑃𝑟𝑗(𝑒𝑣𝑒𝑛𝑡) corresponds to the 
probability of observing an event in biomarker subgroup 𝑗 which can be calculated 
by  
𝑃𝑟𝑗(𝑒𝑣𝑒𝑛𝑡) = 𝜋𝐸𝑃𝑟𝐸𝑗(𝑒𝑣𝑒𝑛𝑡) + 𝜋𝐶𝑃𝑟𝐶𝑗(𝑒𝑣𝑒𝑛𝑡), 
with   
 𝜋𝐸 =
𝑅
𝑅 + 1
 and 𝜋𝐶 =
1
𝑅 + 1
. 
𝜋𝐸 and 𝜋𝐶  are the proportions of patients who are randomized to the experimental 
and control treatment arm respectively. 𝑅 is the allocation ratio which is given by the 
sample size in experimental arm divided by the sample size in control arm. Here we 
assume equal allocation between treatment arms for each biomarker-defined 
subgroup [9]; hence 𝑅 = 1 and 𝜋𝐸 = 𝜋𝐶 = 0.5. 𝑃𝑟𝐸𝑗(𝑒𝑣𝑒𝑛𝑡) and 𝑃𝑟𝐶𝑗(𝑒𝑣𝑒𝑛𝑡) are the 
probabilities of event in the experimental and control treatment arm respectively in 
subgroup 𝑗 . If 𝑖 now denotes treatment group (either experimental (𝐸) or control (𝐶)) 
and if one assumes exponentially distributed times as described in detail in [9], the 
probability of an event in treatment arm 𝑖 of subgroup 𝑗 can be calculated by  
 
𝑃𝑟𝑖𝑗(𝑒𝑣𝑒𝑛𝑡) = 1 −
1
(
log(2)
𝑚𝑖𝑗
) × 𝑇𝑗
× [𝑒
−(
log(2)
𝑚𝑖𝑗
)×𝜏𝑗
− 𝑒
−(
log(2)
𝑚𝑖𝑗
)×(𝑇𝑗+𝜏𝑗)
] 
(5.4) 
where 𝑇𝑗 corresponds to the length in months of the accrual period, during which a 
homogeneous Poisson entry process is assumed, of the biomarker-defined subgroup 
𝑗 and 𝜏𝑗 corresponds to the follow-up period of the biomarker-defined subgroup 𝑗. 
𝑚𝑖𝑗 denotes the median survival time of treatment arm 𝑖 in biomarker-defined 
subgroup 𝑗 where  
 𝑚𝐸− =
𝑚𝐶−
𝜃−
      (5.5) 
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and 
 𝑚𝐸+ =
𝑚𝐶+
𝜃+
. (5.6) 
Formula (5.4) could be generalized to arbitrary, continuous survival functions.  
Using the sample size of each biomarker-defined subgroup, the corresponding 
accrual rate (number of patients recruited per month) for subgroup 𝑗 is 𝑎𝑟𝑗 which can 
be calculated by 
 
 𝑎𝑟𝑗 =
𝑁𝑗
𝑇𝑗
. 
(5.7) 
5.2.1.2. Simulation Study 1 
The scope of this simulation study is to confirm that we can achieve the 
desirable power in each biomarker-defined subgroups under different simulation 
settings for a time-to-event outcome. We calculate the required number of events and 
patients for each biomarker-defined subgroup (𝐷𝑗, 𝑁𝑗) from (5.1) and (5.3). Different 
scenarios are considered by varying hazard ratios (𝜃−, 𝜃+) and significance levels 
(𝑎−, 𝑎+). In our simulation study, we assume that the biomarker-negative patients 
have a worse treatment outcome as compared to the biomarker-positive subgroup. 
We assume outcome to be an adverse effect such as time to death and so the assumed 
hazard ratio values < 1 reflects the fact that the experimental treatment is superior to 
the control treatment in both biomarker subgroups. Further, the lower hazard ratio 
value assumed for a specific biomarker-defined subgroup reflects a greater treatment 
effect in that subgroup. Hence, in all scenarios of hazard ratios, we consider higher 
𝜃− than 𝜃+. More specifically, four scenarios of hazard ratios, i.e. (i) 𝜃− = 0.6 and 𝜃+ =
0.4, (ii) 𝜃− = 0.7 and 𝜃+ = 0.5, (iii) 𝜃− = 0.8 and 𝜃+ = 0.6 and (iv) 𝜃− = 0.9 and 𝜃+ =
0.7 and three scenarios of significance levels (i) 𝑎− = 𝑎+ = 0.0125, (ii) 𝑎− = 0.015 and 
𝑎+ = 0.010 and (iii) 𝑎− = 0.010 and 𝑎+ = 0.015 are considered. We set the median 
survival time of biomarker-negative subgroup in Control group (𝑚𝐶−) in (5.5) at 5 
months and we calculate the corresponding median survival time for the 
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Experimental group in that subgroup. We set the median survival time of biomarker-
positive subgroup in Control group (𝑚𝐶+) in (6.6) at 10 months and we calculate the 
corresponding median survival time for the Experimental group in that subgroup. 
Additionally, we set the type II error rate at 20%, i.e.  𝛽 = 0.2 in (5.1) which 
corresponds to 80% power (i. e. 1 − 𝛽 = 0.8), length of accrual period (𝑇𝑗) in (5.4) at 
18 months and length of follow-up period (𝜏𝑗) in (5.4) at 12 months for each 
biomarker-defined subgroup. Study entry times and event times for each biomarker-
defined subgroup are generated as described below. 
The time of study entry for participants in each biomarker-defined subgroup is 
modelled with a Uniform distribution for entry times. More precisely, the entry times 
of patients recruited into the biomarker negative subgroup in the first month are 
assumed by randomly generating 𝑎𝑟− (the accrual rate) numbers from 𝑈~𝑈𝑛𝑖𝑓[0,1] 
(i.e. randomly splitting the accrual period by the number of recruited patients). 
Similarly, 𝑎𝑟+ numbers are generated from 𝑈~𝑈𝑛𝑖𝑓[0,1] to obtain study entry times 
of patients recruited into the biomarker positive subgroup during the first month. To 
obtain study entry times for those in the biomarker negative and biomarker positive 
subgroups during the second month, a further 𝑎𝑟− and 𝑎𝑟+ numbers respectively are 
randomly generated from 𝑈~𝑈𝑛𝑖𝑓[1,2]. The accrual continues until the assumed 
accrual period 𝑇𝑗. Thus, in the 𝑇𝑗
𝑡ℎ month, study entry times are generated from 
𝑈~𝑈𝑛𝑖𝑓[𝑇𝑗 − 1, 𝑇𝑗]. At the end of the accrual period 𝑁+and 𝑁− participants in total 
have been recruited. 
Event times are generated from an exponential distribution assuming hazard 
rate 𝜆𝑖𝑗 for 𝑗th biomarker-defined subgroup receiving treatment 𝑖. The values of 𝜆𝑖𝑗 
can be determined by  
𝑆𝑖𝑗(𝑚𝑖𝑗) = exp(−𝜆𝑖𝑗 × 𝑚𝑖𝑗) = 0.5, 
where 𝑚𝑖𝑗 are corresponding median survival times, and 𝑆𝑖𝑗(𝑚𝑖𝑗) is the exponential 
median survival probability for subgroup 𝑗 and treatment 𝑖. By solving 𝑆𝑖𝑗(𝑚𝑖𝑗) for 
𝜆𝑖𝑗 gives  
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𝜆𝑖𝑗 =
ln2
𝑚𝑖𝑗
. 
We assume patients are not lost to follow-up during the study, and hence any 
censoring in both biomarker-defined subgroups is due to the event occurring after a 
‘cutoff’ time. The cutoff time refers to the time after study start at which a pre 
specified number of events 𝐷𝑗 for each biomarker-defined subgroup has been 
reached. A time 𝑡𝑖𝑗 (i.e. sum of accrual time and follow-up time) is generated for each 
patient, and if 𝑡𝑖𝑗 is less than the cutoff time then it is assumed that the event was 
observed at 𝑡𝑖𝑗, otherwise the patient’s event time is censored at 𝑡𝑖𝑗. 
One-sided p-value for treatment effect in each biomarker-defined subgroup are 
computed using the log-rank test. One-sided p-value are considered because we 
assume that the treatment benefit in the experimental group is greater than that in 
the control group. 
5.2.1.3. Results from simulation study 1 
The results are drawn from 10000 iterations. The simulated power of each 
biomarker-defined subgroup is preserved approximately at 80% across all scenarios 
of hazard ratios and significance levels. The accrual rates and the number of events 
and patients to reach the nominal level of power (80%) corresponding to different 
scenarios of hazard ratios and significance levels are presented in Table C.1 provided 
in Appendix C. The power for each biomarker-defined subgroup yielded from the 
simulation study is also presented. Figure 5.2 (A-C) illustrates the required number 
of events for each biomarker-defined subgroup versus the corresponding hazard 
ratio for each of the three scenarios of significance levels. Figure 5.2 (D-F) illustrates 
the required number of patients of each biomarker-defined subgroup versus the 
corresponding hazard ratio for each of the three scenarios of significance levels. As 
expected, the number of events and therefore the sample size required for each 
biomarker-defined subgroup increases with the increase of the corresponding hazard 
ratio at the same significance level. Furthermore, at each scenario of hazard ratio, we 
can achieve a smaller sample size and necessary number of events for each 
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biomarker-defined subgroup with a larger significance level (for example, when 𝐻𝑅 
scenario (i) 𝜃− = 0.6 and 𝜃+ = 0.4, and when 𝑎+ = 0.015, we achieve the smallest 
necessary number of events and sample sizes). 
From Table C.1, and more clearly from Figure 5.2 (A-C) and Figure 5.2 (D-F), it 
can be seen that for each scenario of hazard ratios, the required number of events and 
patients in the biomarker-negative subgroup is greater than in biomarker-positive 
subgroup. 
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Figure 5.2. A, B, C represent the required number of events and D, E, F represent the required number of patients of each biomarker-defined subgroup which achieve 80% 
power versus the corresponding hazard ratio for each of the three scenarios of significance levels. Figure 5.2 A and D corresponds to the significance levels 𝒂− = 𝒂+ =
𝟎. 𝟎𝟏𝟐𝟓, Figure 5.2 B and E corresponds to the significance levels 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and Figure 5.2 C and F corresponds to the significance levels 𝒂− = 𝟎. 𝟎𝟏𝟎 
and 𝒂+ = 𝟎. 𝟎𝟏𝟓. 
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Figure 5.3 (A, B) represents the required number of events which achieve 80% 
power versus the hazard ratio for each of the three scenarios of significance levels in 
each biomarker-defined subgroup separately. Figure 5.3 (C, D) represents the 
required number of patients which achieve 80% power versus the hazard ratio for 
each of the three scenarios of significance levels in each biomarker-defined subgroup 
separately. The corresponding numerical results are presented in Table C.1.   
It can be seen that for all scenarios of hazard ratios, the highest value of the 
number of events and patients in the biomarker-negative subgroup and in the 
biomarker-positive subgroup is given by 𝑎− = 0.010 and 𝑎+ = 0.010 for negative and 
positive patients respectively and the lowest value is given by 𝑎− = 0.015 and 𝑎+ =
0.015 for negative and positive patients respectively. 
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Figure 5.3. A, B represent the required number of events and C, D represent the required number of patients which achieve 80% power versus the hazard ratio in each of 
the three scenarios of significance levels for each biomarker-defined subgroup separately. Figure 5.3 A and C corresponds to the biomarker-negative subgroup and the 
following significance levels: (i) 𝒂− = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎. Figure 5.3 B and D corresponds to the biomarker-positive subgroup and the following 
significance levels: (i) 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂+ = 𝟎. 𝟎𝟏𝟓. 
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5.2.2. An adaptive version of the Parallel Subgroup-Specific design 
We explore a two-stage adaptive design starting with the parallel assessment 
of treatment effect in each biomarker-defined subgroup. In the first stage an interim 
analysis is included where each biomarker-defined subgroup can stop early for 
futility or efficacy. The interim analysis is based on a fixed and pre-specified 
percentage of target events. In case that we do not stop after the first stage due to 
early efficacy or futility, the trial continues to the second stage, testing the efficacy of 
the experimental treatment in each biomarker-defined subgroup separately. A 
graphical illustration of this strategy is given in Figure 5.4. 
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Figure 5.4. Adaptive Parallel Subgroup-Specific design. “R” refers to randomization of patients. 𝑫𝟏+ and 
𝑫𝟏− correspond to the target number of events of the biomarker-positive subgroup and biomarker-
negative subgroup respectively at the first stage of the study. 𝑫+ and 𝑫− correspond to the total required 
number of events of the biomarker-positive subgroup and biomarker-negative subgroup respectively 
which are planned according to the non-adaptive approach. 𝑫𝟐+ and 𝑫𝟐− correspond to the number of 
events of the biomarker-positive subgroup and biomarker-negative subgroup respectively at the second 
stage of the study. 
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Adaptive designs differ from fixed designs in that they permit the performance 
of interim analyses during the course of the study leading to adaptations of 
hypotheses which are under investigation. Results from interim analyses are used to 
make a decision regarding the trial. Several sources of multiplicity problems can arise 
in the conduct of adaptive trial designs resulting in the inflation of the overall type I 
error rate (probability of a false positive result). One of the sources of type I error 
inflation is the adaptation of design and analysis features with combination of 
information across trial stages [10]. Hence, alpha-adjustment (i.e. adjustment of the 
alpha level at each interim analysis so that the overall type I error rate remains at the 
desired level) is needed so that the overall type I error rate remains under control. A 
variety of methods for the control of type I error rate in adaptive designs have been 
proposed which are thoroughly summarized by Chang (2014) [11]. Our study is 
based on a flexible and general approach to adaptive designs for alpha-adjustment 
proposed by Chang (2007) [12] in which the test statistic of the final analysis is defined 
as the sum of the unadjusted stagewise p-value (𝑝𝑙 ). More precisely, at the kth stage of 
an adaptive design, the test statistic which can be viewed as cumulative evidence 
against the null is given by 
𝑇′𝑘 = ∑ 𝑝𝑙
𝑘
𝑙=1
, 𝑘 = 1, … , 𝐿 =: "𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑠𝑡𝑎𝑔𝑒". 
Before conducting the two-stage design, pre-specification of stopping rules and 
stopping boundaries for efficacy and futility are needed. Stopping probabilities (i.e. 
rejection probabilities), which are calculated based on the stopping boundaries, are 
essential operating characteristics of adaptive designs and they are classified into two 
types. The first type is the so-called ‘efficacy stopping probability’ which refers to the 
unconditional probability of rejecting the null hypothesis of no treatment effect, thus 
the trial stops in order to claim efficacy. The second type is the so-called ‘futility 
stopping probability’ which refers to the unconditional probability of not rejecting 
the null hypothesis of no treatment effect, thus the trial stops in order to claim futility. 
Hence, the following stopping boundaries should be chosen: (i) the early efficacy 
stopping boundaries in stage 1, i.e. 𝜖1− and 𝜖1+ for biomarker-negative and 
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biomarker-positive patients respectively, (ii) the early futility stopping boundaries in 
stage 1, i.e. 𝑏1− and 𝑏1+ for biomarker-negative and biomarker-positive patients 
respectively and (iii) the final efficacy stopping boundaries, 𝜖2− and 𝜖2+ for 
biomarker-negative and biomarker-positive patients respectively.  
If there is prior belief that the experimental treatment is of strong benefit to 
patients, then the trial should be designed without early futility stopping (i.e. we need 
to set a larger value for 𝑏1− and/or 𝑏1+). When early efficacy stopping is allowed (e.g., 
to allow possibility of making treatment available to patients earlier or to allow 
possibility of unnecessary treatment exposure or unnecessary trial costs), then the 
trial should be designed with a large value of 𝜖1− and/or 𝜖1+. 
After the appropriate choice of 𝜖1−, 𝜖1+ and 𝑏1−, 𝑏1+, we can solve for the final 
efficacy stopping boundaries, i.e. 𝜖2−, 𝜖2+with reference to Chang et al.’s method 
based on the sum of p-value. More precisely, in a clinical trial with k interim analyses, 
the stopping boundary can be derived by calculating the rejection probability under 
the null hypothesis which takes into account the stopping rules described below. The 
rejection probability at the kth stage is defined by 𝜓𝑘(𝜖𝑘), where 
 𝜓𝑘(𝑡′) = Pr(𝜖1 < 𝑇′1 < 𝑏1, … , 𝜖𝑘−1 < 𝑇
′
𝑘−1 < 𝑏𝑘−1, 𝑇
′
𝑘 < 𝑡′)
= ∫ … ∫ ∫ 𝑓𝑇′1…𝑇′𝑘(𝑡′1, … 𝑡′𝑘)
𝑡′
−∞
𝑏𝑘−1
𝜖𝑘−1
𝑏1
𝜖1
d𝑡′𝑘d𝑡′𝑘−1 … d𝑡′1 
(5.8) 
where 𝑡′ ≥ 0, 𝑡′𝑙(𝑙 = 1, … , 𝑘) is the test statistic at the 𝑙th stage, and 𝑓𝑇′1…𝑇′𝑘 is the joint 
probability density function of 𝑇′1, … 𝑇′𝑘. The stopping rules for futility can be either 
binding or non-binding. In the non-binding rule the possibility of stopping early for 
futility will not be considered in the decision of the efficacy stopping boundary 
whereas in the binding category the futility rule is taken into account when making 
inference. As it is stated by Chang (2014) [11], the regulatory bodies currently adopt 
the non-binding futility rule in order to ensure that the familywise Type I error rate 
is controlled regardless of whether a decision is made to continue the trial despite a 
futility boundary being crossed. According to Chang (2007) [12], it is better to set 
 203 
 
𝑏1− = 𝜖2− and 𝑏1+ = 𝜖2+. Based on (5.8), according to [12] the final efficacy stopping 
boundaries can be found by  
𝜖2 = √(𝑎 − 𝜖1) + 𝜖1, 
where 𝜖1 < 𝑎 and 𝑎 refers to the level of significance. In our case, the final efficacy 
stopping boundaries for each biomarker-defined subgroup with non-binding futility 
rule can be found by the following formulations,  
𝜖2− = √(𝑎− − 𝜖1−) + 𝜖1−, 
𝜖2+ = √(𝑎+ − 𝜖1+) + 𝜖1+, 
where 𝜖1− < 𝑎− and 𝜖1+ < 𝑎+. 
For the biomarker-negative subgroup of the two-stage adaptive design which tests 
the efficacy of the experimental treatment, the stopping rules are the following, 
Stage 1: {
Reject the null hypothesis (stop for efficacy)                                 if 𝑇′1− ≤ 𝜖1−
Do not reject the null hypothesis (stop for futility)                         if 𝑇′1− > 𝑏1−
Continue to the second stage                                                   if 𝜖1− < 𝑇′1− ≤ 𝑏1−
 
where 0 < 𝜖1− < 𝑏1− ≤ 1 and 𝑇′1− refers to the test statistic as defined previously in 
this section in the biomarker-negative subgroup at the first stage of the study , 
Stage 2: {
Reject the null hypothesis (stop for efficacy)            if 𝑇′2− ≤ 𝜖2−
Do not reject the null hypothesis (stop for futility)  if 𝑇′2− > 𝜖2−
 
where 𝑇′2− refers to the test statistic in the biomarker-negative subgroup at the 
second stage of the study.  
For the biomarker-positive subgroup of the two-stage adaptive design which tests 
the efficacy of the experimental treatment, the stopping rules are the following, 
Stage 1: {
Reject the null hypothesis (stop for efficacy)                                                 if 𝑇′1+ ≤ 𝜖1+
Do not reject the null hypothesis (stop for futility)                                         if 𝑇′1+ > 𝑏1+
Continue to the second stage                                                                   if 𝜖1+ < 𝑇′1+ ≤ 𝑏1+
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where 0 < 𝑎1+ < 𝑏1+ ≤ 1 and 𝑇′1+ refers to the test statistic in the biomarker-positive 
subgroup at the first stage of the study, 
Stage 2: {
Reject the null hypothesis (stop for efficacy)             if 𝑇′2+ ≤ 𝜖2+
Do not reject the null hypothesis (stop for futility)  if 𝑇′2+ > 𝜖2+
 
where 𝑇′2+ refers to the test statistic in the biomarker-positive subgroup at the second 
stage of the study.  
We now assume the interim fraction for the biomarker-negative subgroup to be 
𝑓− which refers to a specific proportion of the required total number of events in the 
biomarker-negative subgroup, and the interim fraction for the biomarker-positive 
subgroup be 𝑓+ which refers to a specific proportion of the required total number of 
events in the biomarker-positive subgroup. Using these interim fractions, we 
calculate the target number of events for each subgroup at the interim stage (stage 1), 
to be:  
𝐷1− = 𝐷− × 𝑓−, 
𝐷1+ = 𝐷+ × 𝑓+, 
for negative and positive patients respectively. The log-rank test statistics of each 
biomarker-defined subgroup at the first stage (interim analysis) are based on 𝐷1−, 𝐷1+ 
and given by 
𝑇′𝐿1− = √
?̂?1−
4
× [log(𝜃−)]~𝑁 (√
𝐷1−
4
× [log(𝜃−)], 1), 
𝑇′𝐿1+ = √
?̂?1+
4
× [log(𝜃+)]~𝑁 (√
𝐷1+
4
× [log(𝜃+)], 1), 
for the biomarker-negative subgroup and biomarker-positive subgroups 
respectively. One sided p-value corresponding to the observed values 𝑡′𝐿1− and 𝑡′𝐿1+ 
of the test statistics of each biomarker-defined subgroup in stage 1 are given by  
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𝑝1− = 𝑃𝑟(𝑇′𝐿1− ≥ 𝑡′𝐿1−|𝐻0,𝑏𝑖𝑜𝑚−), 
𝑝1+ = 𝑃𝑟(𝑇′𝐿1+ ≥ 𝑡′𝐿1+|𝐻0,𝑏𝑖𝑜𝑚+), 
for the biomarker-negative subgroup and biomarker-positive subgroups 
respectively.  
In the first interim analysis, the test statistic is equal to the p-value at stage 1; 
hence in our simulation study we proceed with the following rules: If 𝑝1− > 𝑏1− 
or/and 𝑝1+ > 𝑏1+ then the study which is testing the efficacy of the experimental 
treatment in biomarker-negative subgroup and/or biomarker-positive subgroup is 
stopped for futility at stage 1. If 𝑝1− ≤ 𝜖1− and/or 𝑝1+ ≤ 𝜖1+ then the study which is 
testing the efficacy of the experimental treatment in biomarker-negative subgroup 
and/or biomarker-positive subgroup is stopped for efficacy at stage 1. Otherwise, if 
𝜖1− < 𝑝1− ≤ 𝑏1− and/or if 𝜖1+ < 𝑝1+ ≤ 𝑏1+, the study which is testing the treatment 
effect in each biomarker-defined subgroup continues to the second stage.  
The log-rank test statistics of each biomarker-defined subgroup at the second 
stage of the study are given by 
𝑇′′𝐿2− = √
(?̂?− − ?̂?1−)
4
× [log(𝜃−)]~𝑁 (√
(𝐷− − 𝐷1−)
4
× [log(𝜃−)], 1), 
𝑇′′𝐿2+ = √
(?̂?+ − ?̂?1+)
4
× [log(𝜃+)]~𝑁 (√
(𝐷+ − 𝐷1+)
4
× [log(𝜃+)], 1), 
for the biomarker-negative subgroup and biomarker-positive subgroups 
respectively. One-sided p-values corresponding to the observed values 𝑡′′𝐿2− and 
𝑡′′𝐿2+ of the test statistics of each biomarker-defined subgroup in stage 2 are given by 
𝑝2− = 𝑃𝑟(𝑇′′𝐿2− ≥ 𝑡′′𝐿2−|𝐻0,𝑏𝑖𝑜𝑚−), 
𝑝2+ = 𝑃𝑟(𝑇′′𝐿2+ ≥ 𝑡′′𝐿2+|𝐻0,𝑏𝑖𝑜𝑚+), 
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for the biomarker-negative subgroup and biomarker-positive subgroup respectively. 
The test statistic of the final analysis for each biomarker-defined subgroup is based 
on the sum of stagewise p-value and can be given by 
𝑇′− = 𝑝1− + 𝑝2−, 
𝑇′+ = 𝑝1+ + 𝑝2+, 
for the biomarker-negative subgroup and biomarker-positive subgroup respectively. 
5.2.2.1. Simulation Study 2 
To investigate the effect of introducing an adaptive element to our study 
design, we have conducted a second simulation study which is performed by using 
the R statistical software. To do this we assume the same total number of events and 
patients as we did for Simulation Study 1 where our design was not adaptive, 
therefore making the same assumptions regarding significance levels for biomarker-
negative and biomarker-positive subgroups (𝑎−, 𝑎+), hazard ratios (𝜃−, 𝜃+), median 
survival time in Control group (𝑚𝐶−, 𝑚𝐶+), accrual period (𝑇−, 𝑇+) and follow-up 
period (𝜏−, 𝜏+) as we did previously. Therefore we assume accrual time (𝑇𝑗) to be 18 
months for both subgroups, follow-up time (𝜏𝑗) to be 12 months for both subgroups 
and  consider the following four different scenarios for the hazard ratios, (i) 𝜃− = 0.6 
and 𝜃+ = 0.4, (ii) 𝜃− = 0.7 and 𝜃+ = 0.5, (iii) 𝜃− = 0.8 and 𝜃+ = 0.6 and (iv) 𝜃− = 0.9 
and 𝜃+ = 0.7. For each scenario of hazard ratios we again assume three different 
scenarios for significance levels for the biomarker-negative and biomarker-positive 
subgroups, i.e. (i) 𝑎− = 𝑎+ = 0.0125, (ii) 𝑎− = 0.015 and 𝑎+ = 0.010 and (iii) 𝑎− =
0.010 and 𝑎+ = 0.015. For each hazard ratios and significance level combination 
explored previously, we test the implication of different percentages of the 
information fraction. The different information fractions considered are as follows: 
(i) 𝑓− = 𝑓+ = 25%, (ii) 𝑓− = 𝑓+ = 50% and (iii) 𝑓− = 𝑓+ = 75% . Our aim is to explore 
the impact of these different information fractions on study power as well as on the 
stopping probabilities for futility (𝐹𝑆𝑃𝑗) and efficacy (𝐸𝑆𝑃𝑗). 
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In our simulation study for all the scenarios of hazard ratios for each biomarker-
defined subgroup we used a high value of early efficacy stopping boundaries, i.e. 
𝜖1+, 𝜖1− and thus a high value of early futility stopping boundaries, i.e. 𝑏1+, 𝑏1− as it 
is believed that the experimental treatment is promising. Thus, for the three cases of 
significance levels for each biomarker-defined subgroup we have set the following 
stopping boundaries: 
(i) when 𝑎− = 𝑎+ = 0.0125, 
for 𝜖1+ = 0.0080 we get 𝑏1+ = 𝜖2+ = √(𝑎+ − 𝜖1+) + 𝜖1+ = 0.1029, 
for 𝜖1− = 0.0070 we get 𝑏1− = 𝜖2− = √(𝑎− − 𝜖1−) + 𝜖1− = 0.1129, 
(ii) when 𝑎− = 0.015 and 𝑎+ = 0.010, 
for 𝜖1+ = 0.0080 we get 𝑏1+ = 𝜖2+ = √(𝑎+ − 𝜖1+) + 𝜖1+ = 0.0527, 
for 𝜖1− = 0.0070 we get 𝑏1− = 𝜖2− = √(𝑎− − 𝜖1−) + 𝜖1− = 0.0964, 
(iii) when 𝑎− = 0.010 and 𝑎+ = 0.015, 
for 𝜖1+ = 0.0080 we get 𝑏1+ = 𝜖2+ = √(𝑎+ − 𝜖1+) + 𝜖1+ = 0.0917, 
for 𝜖1− = 0.0070 we get 𝑏1− = 𝜖2− = √(𝑎− − 𝜖1−) + 𝜖1− = 0.0618. 
In all cases we have used a slightly lower value for 𝜖1− (i.e. 0.007) assuming that 
it is believed that the experimental treatment is less promising in biomarker-negative 
subgroup as compared to the biomarker-positive subgroup. 
Different values of stopping boundaries could be used for each assumed 
scenario of hazard ratios and significance levels based on how promising the 
experimental treatment seems to be in each subgroup. However, for simplicity, in our 
study we set only one value of 𝜖1+ for biomarker-positive subgroup and only one 
value of 𝜖1− for biomarker-negative subgroup in all cases of hazard ratios. 
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The general efficiency related to the cost and time of the trial can be seen from 
the expected number of events and expected sample size of the trial which are 
calculated by using the futility and efficacy stopping probabilities. The expected 
sample size is defined by Chang (2014) [11] as a function of the effect size and its 
uncertainty, which are unknown. Hence, apart from the stopping probabilities and 
power, this simulation study also provides the average expected number of events 
for each biomarker-defined subgroup (𝐷−
𝑒𝑥𝑝, 𝐷+
𝑒𝑥𝑝
). Based on the futility (𝐹𝑆𝑃𝑗) and 
efficacy stopping probabilities (𝐸𝑆𝑃𝑗), we also calculate the average expected sample 
size for each biomarker-defined subgroup, i.e. 
𝑁−
𝑒𝑥𝑝 = [(𝐸𝑆𝑃− + 𝐹𝑆𝑃−) × 𝑁1−] + {[1 − (𝐸𝑆𝑃− + 𝐹𝑆𝑃−)] × 𝑁−}, 
𝑁+
𝑒𝑥𝑝 = [(𝐸𝑆𝑃+ + 𝐹𝑆𝑃+) × 𝑁1+] + {[1 − (𝐸𝑆𝑃+ + 𝐹𝑆𝑃+)] × 𝑁+}, 
for negative and positive patients respectively. Assuming that we have constant 
accrual, we can calculate the expected duration of the trial for testing the treatment 
effect in each biomarker-defined subgroup, i.e. 
𝑇−
𝑒𝑥𝑝 = [(𝐸𝑆𝑃− + 𝐹𝑆𝑃−) × (𝑇− + 𝜏−) × 𝑓−] + {[1 − (𝐸𝑆𝑃− + 𝐹𝑆𝑃−)] × (𝑇− + 𝜏−)}, 
𝑇+
𝑒𝑥𝑝 = [(𝐸𝑆𝑃+ + 𝐹𝑆𝑃+) × (𝑇+ + 𝜏+) × 𝑓+] + {[1 − (𝐸𝑆𝑃+ + 𝐹𝑆𝑃+)] × (𝑇+ + 𝜏+)}, 
for negative and positive patients respectively. 
5.2.2.2. Results from simulation study 2 
Table 5.1 in this section and Tables C.2-C.4 in Appendix C provide the 
simulation results drawn from 10000 iterations for each scenario of hazard ratios and 
significance levels, for each different assumed percentage of information fraction, i.e. 
(i) 𝑓− = 𝑓+ = 25%, (ii) 𝑓− = 𝑓+ = 50% and (iii) 𝑓− = 𝑓+ = 75%. We report the expected 
number of events and patients, expected total study duration, futility stopping 
probability, efficacy stopping probability and total power of the study in additional 
to the required number of patients and events (as presented in Table C.1 for the fixed 
Parallel Subgroup-Specific design). 
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Table 5.1. Results for expected number of events and patients, expected total study period, futility stopping probability, efficacy stopping probability and power of a two-
stage design in scenario 1 of hazard ratios for different percentages of information fraction. Number of events and patients from Table C.1 (calculated from (5.1) and (5.3) 
respectively) which achieve 80% power for the first scenario of hazard ratios and significance levels are also presented. 
  Simulation setting Number Simulated Power 
 Group of patients Significance 
level 
Hazard ratio Required 
Number of 
events 
Required 
  Number of 
patients 
Expected Total 
study period 
(months)  
Expected 
Number 
of events 
Expected 
Number of 
patients 
FSP ESP Power 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.6 
0.4 
- 
146 
45 
191 
168 
76 
244 
17.6 
16.9 
- 
86 
25 
111 
99 
43 
142 
0.3694 
0.3947 
- 
0.1810 
0.1894 
-  
0.5659 
0.5371 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.6 
0.4 
- 
139 
48 
187 
160 
81 
241 
16.8 
14.0 
- 
78 
22 
100 
90 
38 
128 
0.4172 
0.5071 
- 
0.1692 
0.2059 
- 
0.4999 
0.4257 
- 
Biomarker-negative 0.010 0.6 154 177 14.9 77 88 0.4821 0.1886 0.4454 
25
%
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Biomarker-positive 
Entire population 
0.015 
0.025 
0.4 
- 
43 
197 
72 
249 
16.1 
- 
23 
100 
39 
127 
0.4300 
- 
0.1885 
- 
0.4990 
- 
 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.6 
0.4 
- 
146 
45 
191 
168 
76 
244 
21.4 
21.4 
- 
106 
32 
138 
120 
54 
138 
0.1650 
0.1865 
- 
0.4114 
0.3859 
- 
0.7259 
0.6982 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.6 
0.4 
- 
139 
48 
187 
160 
81 
241 
21.3 
19.6 
- 
99 
31 
130 
114 
53 
167 
0.2044 
0.2670 
- 
0.3730 
0.4279 
- 
0.6697 
0.6146 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.6 
0.4 
- 
154 
43 
197 
177 
72 
249 
20.2 
21.0 
- 
103 
30 
133 
119 
50 
169 
0.2435 
0.2159 
- 
0.4126 
0.3873 
- 
0.6400 
0.6555 
- 
50
%
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.6 
0.4 
- 
146 
45 
191 
168 
76 
244 
25.0 
24.9 
- 
122 
37 
159 
140 
63 
203 
0.0704 
0.0830 
- 
0.5915 
0.6036 
- 
0.7743 
0.7558 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.6 
0.4 
- 
139 
48 
187 
160 
81 
241 
25.0 
24.2 
- 
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39 
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134 
65 
199 
0.0943 
0.1330 
- 
0.5674 
0.6356 
- 
0.7266 
0.7185 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.6 
0.4 
- 
154 
43 
197 
177 
72 
249 
24.5 
24.9 
- 
126 
36 
162 
145 
60 
205 
0.1148 
0.1030 
- 
0.6204 
0.5708 
- 
0.7273 
0.7214 
- 
 
75
%
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From Table 5.1 and Tables C.2-C.4, it can be seen that the futility stopping 
probability of each biomarker-defined subgroup at each significance level decreases 
when the percentage of information fraction increases. In contrast, the efficacy 
stopping probability, the total power of the study, the sample size and the number of 
events increase with the increase of the information fraction. 
When the interim fraction is set to 25% of the required total number of events, 
the simulation results indicate that the trial is underpowered. When the interim 
fraction is based on 50% of the required total number of events we still do not have a 
gain in power compared to the nominal level 80%, however, it achieves 
approximately 73% and 70% power in biomarker-negative and biomarker-positive 
subgroup respectively in all scenarios of hazard ratios when 𝑎− = 𝑎+ = 0.0125. 
Compared to the 30 months overall duration of the fixed design, in the above scenario 
the expected overall duration is reduced approximately by one third. When the 
interim fraction is based on 75% of the required total number of events, we can 
achieve higher level of power, i.e. approximately 77% and 76% power in biomarker-
negative and biomarker-positive subgroup respectively in all scenarios of hazard 
ratios when 𝑎− = 𝑎+ = 0.0125. Compared to the 30 months overall duration of the 
fixed design, in the above scenario the expected overall duration does not exceed 25 
months. These results for the first scenario of hazard ratios are graphically 
represented in Figure 5.5. The results for the remaining scenarios of hazard ratios are 
graphically represented in Figures C.1-C.3 in Appendix C. 
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Figure 5.5. Efficacy stopping probability, futility stopping probability and power of a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 1 of hazard ratios. Each row of graphs represents the different probabilities versus the interim fraction of each biomarker-defined subgroup 
when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. 
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Figure 5.6 shows the expected number of events and patients of the adaptive 
Parallel Subgroup-Specific design and the required number of events and patients of 
the fixed Parallel Subgroup-Specific design for each biomarker-defined subgroup 
versus the corresponding hazard ratios for the first level of information fraction (i.e. 
25%). Figures C.4-C.5 provided in Appendix C show the expected number of events 
and patients of the adaptive Parallel Subgroup-Specific design and the required 
number of events and patients of the fixed Parallel Subgroup-Specific design for each 
biomarker-defined subgroup versus the corresponding hazard ratios for the second 
and third level of information fraction (i.e. 50%, 75%). Figure 5.6 and Figures C.4-C.5 
show that the expected number of events for both biomarker-defined subgroups in 
all cases of hazard ratios is lower than the required number of events. Additionally, 
in all cases of interim fraction and significance levels, both the required and the 
expected number of events are greater in biomarker-negative subgroup as compared 
to the biomarker-positive subgroup. Furthermore, they show that the expected 
number of patients for both biomarker-defined subgroups in all cases of hazard ratios 
is lower than the required number of patients. In addition, in all cases of interim 
fraction and significance levels, both the required and the expected number of 
patients are greater in biomarker-negative subgroup as compared to the biomarker-
positive subgroup. 
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Figure 5.6. Expected number of events and patients in two-stage design and required number of events and patients in one-stage design for each biomarker-defined 
subgroup versus the hazard ratios of each biomarker-defined subgroup when the interim fraction is 25%. The first two graphical representations in each row of graphs 
represent the number of events versus the hazard ratio of each biomarker-defined subgroup when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− =
𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. The remaining graphical representations in each row of graphs represent the number of patients versus the hazard ratio of each 
biomarker-defined subgroup when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. 
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5.3. Discussion 
To conclude, in the current chapter we have considered a fixed design which 
evaluates the efficacy of treatment in each biomarker-defined subgroup and an 
adaptive approach which involves early stopping of the trial due to efficacy or 
futility. The scope of the simulation study of the fixed design is to investigate the 
power under different scenarios in a given simulation setting which takes into 
account accrual and follow-up of patients. Next, we extend the fixed design into a 
two-stage design with interim analysis used for decision making. The aim of the two-
stage version was to investigate the general efficiency of the study by calculating the 
expected number of events and patients as well as stopping probabilities, overall 
power and expected duration of the study under different scenarios of the 
information fraction (i.e. specific proportion of the required total number of events 
applied in interim analysis). The tests between the two biomarker-defined subgroups 
are independent and one could present the results for only one of them. However, 
this could have added confusion regarding how control of the overall alpha is 
handled. Additionally, presenting results for both subgroups adds completeness to 
our study. It would be worth mentioning that early stopping in one biomarker 
defined-subgroup and not the other will still require screening patients from the 
entire population. Hence, this should be taken into account when conducting a real 
clinical trial. 
We programmed the simulation studies in R statistical software. Our results 
indicate that when the information fraction used in interim analysis is low (25%) the 
study will not achieve adequate power. However, for equally allocated significance 
levels we can achieve sufficient power (between 70% and 80%) if the specific 
proportion of the required total number of events is equal or greater than 50%. 
One significant challenge encountered when conducting such flexible trial 
designs is the multiplicity issues which should be carefully considered, e.g., in our 
simulation study we took into account the control of type I error not only because we 
had to combine information from both stages of the design but because we tested 
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more than one subgroup of interest at the same time. Several methods have been 
proposed recently for multiplicity adjustment and suggestions of appropriate 
stopping boundaries when an interim analysis is introduced in the study design. 
Thus, the implications of the operating characteristics to the decision-making when 
these methods are applied should be explored to get the optimal results. Our 
simulation studies are limited to particular methods, however, they give us a general 
insight into the implications of an event driven design for which the decision making 
is based on the results of an interim analysis. We explore a fixed versus an adaptive 
approach in a popular biomarker-guided clinical trial setting which to our best 
knowledge has not been investigated yet. 
The adaptive version of the parallel subgroup-specific design could be 
extended by using a blinded sample size re-estimation approach [11] that reestimated 
based on the event rate. More precisely, the idea behind this method is that at the 
interim analysis -which in our case will be based on a fixed percentage of target 
events- we can allow for re-evaluation of the sample size when there is uncertainty 
about the event rate.. 
Knowledge on how to design, implement and analyse biomarker-guided 
clinical trials is essential for testing the effectiveness of a biomarker-guided approach 
to treatment. The proper choice and use of such designs can increase the probability 
of success of clinical trials resulting in the development of novel treatments. Adaptive 
designs might be more complex and need more time during the planning process due 
to several simulations of possible scenarios that should be conducted aiming to 
investigate the statistical properties of the design under specific situations. However, 
they will continue to be an attractive approach of clinical development as they can 
lead to potential reduction in cost and time compared to a non-adaptive approach. 
In the next chapter (Chapter 6) we will show how a researcher could choose the 
most appropriate design among several non-adaptive trials. A series of strategies 
have been developed that could be used in future for the decision making. 
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Chapter 6. Deciding on the best biomarker-guided trial 
design: a case study 
6.1. Introduction 
In the previous chapter we explored statistical properties of a fixed and 
adaptive design through a particular simulation setting. In the current chapter we  
reconsider the most appropriate design for a clinical trial previously proposed for 
testing whether a genotype-guided treatment strategy results in reduced rate of 
relapse in alcohol-dependent patients. The design originally proposed was not 
feasible due to low prevalence of the genetic marker. Here, we explore the various 
biomarker-guided non-adaptive trial designs and apply a strategy to choose the most 
appropriate for the trial in question. To our best knowledge, there is no suggested 
strategy in literature to help in decision making. We also apply statistical techniques 
to calculate the necessary sample size, considering both binary and time-to-event 
outcomes. For time-to-event outcomes we propose an approximation for the 
calculation of the required number of events. In addition, an adaptive version of the 
proposed design is explored in Chapter 7, to address a degree of uncertainty that 
surrounds the assumed effect size. 
6.2. Background to the proposed trial (STRONG trial) 
Existing research: Alcohol misuse accounts for almost 10% of the total UK 
disease burden [1], with an estimated 22,000 deaths each year [2]. Over 12% of 
Accident and Emergency attendances are attributed to alcohol, increasing to 70% at 
peak times [3]. The annual cost of alcohol-related harm (e.g. violent incidents, anti-
social behaviour, working days lost, hospital admissions, domestic violence, impact 
on the family expenditure on specialist alcohol treatment, premature deaths) to the 
NHS has been estimated to be £2 billion [2]. An assessment of alcohol-related harm 
showed that 38% of men and 16% of women (aged 16-64 years) have an alcohol use 
disorder, equating to approximately to 8.2 million people in England. Of most 
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concern is that an estimated 3-5% of the population of England (1.1 million people) 
are alcohol dependent. 
Pharmacotherapy of alcohol dependence: Clinical trials have shown both 
acamprosate and naltrexone to be superior to placebo in reducing the rate of relapse 
to drinking following detoxification [4, 5]. Importantly, both naltrexone and 
acamprosate given to patients in the presence of supportive interventions are 
effective in treating patients who might otherwise not receive treatment [6]. NICE 
guidance (CG115) [6] recommends therapy with either acamprosate or naltrexone in 
conjunction with psychological support. However, while acamprosate is licensed in 
the UK, naltrexone is not. Even though a US Randomized Controlled Trial [7] 
(COMBINE: Combined Pharmacotherapies and Behavioural Interventions for 
Alcohol Dependence Study) reported naltrexone either alone or combined with 
behavioural intervention to be superior to acamprosate and placebo (Naltrexone 
reduced hazard of time until a heavy drinking day(hazard ratio, 0.72; 97.5% CI, 0.53 
- 0.98; p-value=0.02), most evident in those receiving medical management but not 
combined behavioural intervention (CBI) but that acamprosate had no significant 
effect on drinking vs placebo (either by itself or with any combination of naltrexone, 
CBI, or both), recent meta-analyses [4, 5] have shown  both naltrexone and 
acamprosate to be effective and safe strategies in alcoholism treatment. More 
precisely, the first meta-analysis [5] which was based on a total of 50 RCTs with 7793 
participants has shown that naltrexone reduced the risk of heavy drinking compared 
to placebo (relative risk, 0.83; 95% CI, 0.76 -0.90). The second meta-analysis [4] which 
was based on a total of 24 RCTs with 6915 participants has shown that acamprosate 
reduced the risk of any drinking compared to placebo (relative risk, 0.86; 95% CI, 
0.81-0.91). However, adjunct therapy is rarely offered in hospital settings as indicated 
by NICE (CG115). Given the potential benefits of the use of pharmacotherapy in 
conjunction with psychosocial support in treating alcohol dependence, this 
represents an important area where better evidence would improve management of 
the condition in acute hospitals. 
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Variability in treatment response to pharmacotherapy of alcohol 
dependence: Some studies have highlighted that the effect size for response to 
naltrexone and acamprosate over placebo is in the small-to-moderate range [8, 9]. 
More specifically, in in the systematic review by Bouza et al. (2004) in which 33 
studies were included, “Acamprosate was associated with a significant improvement 
in abstinence rate (odds ratio, 1.88; 95% CI, 1.57 to 2.25; p-value<0.001). Short-term 
administration of naltrexone reduced the relapse rate significantly (odds ratio, 0.62; 
95% CI, 0.52 to 0.75; p-value<0.001), but was not associated with a significant 
modification in the abstinence rate (odds ratio, 1.26; 95% CI, 0.97 to 1.64; 
p-value=0.08). There were insufficient data to ascertain naltrexone's efficacy over 
more prolonged periods. Acamprosate had a good safety pattern and was associated 
with a significant improvement in treatment compliance (odds ratio, 1.29; 95% CI, 
1.13 to 1.47; p-value<0.001). Naltrexone's side effects were more numerous, yet the 
drug was nevertheless tolerated acceptably without being associated with a lower 
adherence to treatment (odds ratio, 0.94; 95% CI, 0.80 to 1.1; p-value=0.5). However, 
overall compliance was relatively low with both medications” [8]. In Srisurapanont 
et al. [9] in which a total of 2861 patients in 24 RCTs presented in 32 papers were 
included, it is stated that “For short-term treatment, naltrexone significantly 
decreased relapses (relative risk, 0.64; 95% CI, 0.51–0.82), but not return to drinking 
(relative risk, 0.91; 95% CI, 0.81–1.02). Short-term treatment of naltrexone 
significantly increased nausea, dizziness, and fatigue in comparison to placebo 
(relative risks, 95% CI: 2.14, 1.61 to 2.83; 2.09, 1.28 to 3.39; 1.35, 1.04 to 1.75). 
Naltrexone administration did not significantly diminish short-term discontinuation 
of treatment (relative risk, 0.85; 95% CI, 0.70–1.01)”. Studies have also shown that 
certain subpopulations respond better to pharmacotherapy than others [10]. Indeed, 
these findings point to the need for better strategies to stratify patients so that those 
most likely to respond to alcohol pharmacotherapy can be identified.  
Predictors of naltrexone response: It is clear that not all individuals with 
alcohol dependence respond to naltrexone in a similar manner. Various factors have 
been suggested to be important predictors of naltrexone response; these include 
clinical factors such as family history of alcoholism (odds ratio, 2.084; 95% CI, 1.189 
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to 3.653; p-value= 0.010) [10], early age at onset of drinking problems (odds ratio, 
2.004; 95% CI, 1.150 to 3.491; 𝑝 − 𝑣𝑎𝑙𝑢𝑒 =0.014) [10], comorbid use of other drugs of 
abuse (odds ratio, 6.348; 95% CI, 2.159 to 18.668; p-value<0.001) [10], and importantly, 
genetic factors such as mu-opioid receptor polymorphisms (odds ratio, 5.75; 95% CI, 
1.88 to 17.54 [11], odds ratio, 6.28; 95% CI, 1.94 to 20.34 [12], odds ratio, 0.77; 95% CI, 
0.28 to 2.15 [13]). 
One of the most consistent predictors of naltrexone response is a missense 
single nucleotide polymorphism (SNP) in the OPRM1 gene, which encodes the mu-
opioid receptor type 1, the site of action of naltrexone [13]. This SNP results in the 
substitution of asparagine to aspartate at position 40 (Asn40Asp; rs1799971; A to G) 
resulting in structural variation in the receptor’s extracellular domain. Asn40Asp is 
defined as a functional polymorphism of the mu-opioid receptor gene (OPRM1) and 
Asp40 refers to the mutant allele. Alcohol is known to increase the release of 
endogenous opioids such as β-endorphin and encephalin in humans; blockade of 
opioid receptors with naltrexone leads to less alcohol-induced pleasure and 
intoxication, and ultimately, less craving and relapse [14].  
Ray and Hutchison [15, 16] in two separate lab-based placebo-controlled 
experiments in humans reported that the effect of naltrexone on blunting alcohol 
induced highs was stronger in those who carried the Asp40 allele. A similar though 
distinct SNP which similarly affects the ability of the receptor to bind the endogenous 
ligand β-endorphin has also been reported to reduce alcohol-induced stimulation 
and alcohol consumption in rhesus monkeys [17]. In 2003, Oslin et al. [13], as part of 
a sub-study to a clinical trial reported that treatment-seeking alcohol-dependent 
individuals (African Americans and European Americans) with at least one copy of 
the Asp40 allele responded to naltrexone better than those without the allele [13]. 
More precisely, subjects who did not relapse compared to those who were 
homozygous for the Asn40 allele (odds ratio, 3.52; 95% CI interval, 1.03–11.96), and 
time to first relapse in the naltrexone-treated subjects was significantly longer in those 
with the Asp40 variant (hazard ratio, 2.79; 95% CI, 1.05-7.41). However, a subset 
analysis of the Veterans Affairs Naltrexone Cooperative Study [18], which included 
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215 alcohol-dependent male subjects, did not find any association between the 
carriage of Asp40 allele and rate of return to heavy drinking following naltrexone 
treatment (SNP x treatment effect p-value≥0.05). Although the available patient 
sample was larger than that in the study by Oslin et al. [13], the authors highlighted 
limited statistical power for detecting a SNP x treatment interaction effect. Apart from 
the limited statistical power, the authors reported also differences in clinical makeup 
of the sample between their study and that by Oslin et al., in particular a higher 
proportion of participants with severe alcohol dependency, as possible reasons for 
the failure to find an association. Anton et al. performed a retrospective 
pharmacogenetic analysis [11] of the COMBINE cohort (n=604; Caucasians only), one 
of the largest trials addressing the effectiveness of naltrexone against acamprosate 
and behavioural intervention [7]. This study found that individuals who carried at 
least one Asp40 mutant allele showed the best clinical outcome in the naltrexone 
treated arm (87.1% good outcome in Asp40 mutant allele carriers vs 54.8% good 
outcome in non-carriers; odds ratio, 5.75; 95% CI, 1.88-17.54). In the study, “good 
outcome” was defined as “abstinent or moderate drinking without problems, a 
maximum of 11 (women) or 14 (men) drinks per week, with no more than 2 days on 
which more than 3 drinks (women) or 4 drinks (men) were consumed, and 3 or fewer 
alcohol-related problems endorsed on the Drinker Inventory of Consequences scale 
during the last 8 weeks of treatment”. The subset of individuals with at least one copy 
of the Asp40 allele who were treated with naltrexone also had a reduced number of 
heavy drinking days and an increased number of abstinent days over time than did 
Asp40 carriers who were treated with placebo and Asp40 non-carriers (Asn40 
homozygotes) who were treated with either naltrexone or placebo. A further 
haplotype-based sub-study reported similar results but also observed that the 
Asn40Asp SNP contributed most to the haplotype function [12]. The Asn40Asp SNP 
is also important in predicting treatment response in other ethnicities. A Korean 
study reported significantly lower rates of relapse (odds ratio of Asn40 patients 
versus Asp40 variant patients, 10.608; p-value=0.072) to drinking in individuals who 
carry the Asp40 mutant allele [19], whilst a recent double blind, randomized, placebo-
controlled laboratory trial of naltrexone in non-treatment-seeking Asian American 
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heavy drinkers found Asp40 mutant allele carriers to experience lower alcohol 
craving on naltrexone than non-carriers which was indicated by the statistically 
significant medication × genotype interaction (p-value<0.05) [20]. 
With 3 out of 4 retrospective clinical sub-studies [11, 13, 18, 19] and several 
laboratory based studies [15, 16, 20] supporting a role for Asn40Asp SNP in 
naltrexone response, there is accumulating evidence, and biological plausibility, of 
the importance of this polymorphism in predicting naltrexone response in alcohol 
dependent patients. However, in order to demonstrate its clinical utility in guiding 
treatment, there is a need for an appropriately powered RCT designed to evaluate 
stratification of patients. To our knowledge, there is only one prospective RCT 
currently ongoing in the US (Clinical Trials.Gov Identifier: NCT00831272) where 
genotype-based stratification of naltrexone treatment in alcohol dependent patients 
is being compared to placebo in 340 patients. Given the 20% frequency of Asp40 allele 
in European Caucasians, it is thought that a prospective RCT with adequate power 
to detect clinically meaningful differences in the outcomes is required.  
Predictors of acamprosate response: Factors suggested to be important in 
acamprosate response include a typological differentiation of chronic alcoholism [21, 
22] (those with a more severe dependence and greater withdrawal syndrome [type 
I]; and those with anxiety [type II], and lesser prevalence of baseline somatic distress 
[21]. In an analysis by Kiefer et al. [21], out of a total of 143 participants, 101 subjects 
were typologized as type I and 42 subjects as type II based on Cloninger’s criteria for 
alcoholism typology [21]. In the placebo treatment group a significant association was 
found between type and time to relapse as well as time to first drink. The same 
association was not found, however, for patients in the naltrexone, acamprosate and 
naltrexone plus acamprosate treatment groups. In addition, for type II participants, 
naltrexone, acamprosate and naltrexone plus acamprosate treatments were more 
effective in terms of time to first drink and time to relapse as compared to the placebo 
treatment group. Genetic predictors of acamprosate response are not well reported; 
however, evidence for the role of genetic factors is emerging. A 2011 study reported 
an intronic SNP in the GATA binding protein 4 gene (GATA4) to be associated with 
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relapse in acamprosate treated alcohol dependent patients (odds ratio, 2.255; 95% CI, 
1.385–3.670) [23]. In the aforementioned study, 374 patients were included in the 
investigation and they were all participants of the PREDICT (patients with renal 
impairment and diabetes undergoing computed tomography) study for whom 
genotype information was available. The PREDICT study (Identifier: NCT00289614) 
was conducted at 23 sites in North America and China. GATA4 is a transcription 
factor regulating the transcription of atrial natriuretic peptide which is known to be 
involved in the pathophysiology of alcohol dependence. In addition, variation in 
genes involved in glutamatergic and GABAergic pathways through which 
acamprosate moderates neurochemical changes may also contribute to variability in 
its response, according to a Dutch study [24]. However, it is important to note that (a) 
studies undertaken so far have been relatively small; and (b) there has been no 
independent replication. There is thus a need for further evidence to support the role 
of genetic factors in predicting response to acamprosate. 
Furthermore, given that both naltrexone and acamprosate appear similar in 
terms of therapeutic efficacy in unstratified patients with alcohol dependency, a 
design has been chosen that allows a comparison with acamprosate to gauge the 
benefit of stratification, maintain equipoise, and lay the foundations for future work 
which will involve other markers (clinical and laboratory) to further stratify, and 
hence optimize, treatment in this difficult-to-treat patient group. 
6.2.1. Previously proposed randomized controlled trial of a stratified 
approach to Naltrexone treatment 
A number of studies, as described above, suggest a strong effect of the 
Asn40Asp SNP on naltrexone response in alcohol-dependent individuals. However, 
given the observed heterogeneity in effect sizes, and the fact that all studies 
conducted so far have explored the contribution of this SNP in a retrospective 
manner, and usually with small sample sizes, there is a need to ascertain the clinical 
efficacy conferred by genotype guided prescribing of naltrexone in alcohol 
dependent individuals in a prospective manner.  
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Recognizing this need, a randomized controlled trial was previously proposed 
to test the clinical utility of a stratified approach to naltrexone treatment. The 
proposed trial utilized a stratification design (which is called Biomarker Strategy 
Design [25]) proposed by the Institute of Medicine on their report on genomic 
biomarkers [26]. It was proposed that the design would allow the evaluation of 
whether genotype-guided prescribing of naltrexone based on the presence or absence 
of Asn40Asp SNP presented any clear benefit in terms of outcomes in alcohol-
dependent patients.  
The primary objective of the trial was to determine whether a genotype-guided 
treatment strategy would result in reduced rate of relapse to any drinking at 12 
months in the treatment of alcohol dependence when compared to clinical care as 
recommended by NICE guidelines (non-genotype guided treatment strategy). 
A two-armed, randomized controlled trial was proposed. In one arm (the non-
genotype-guided arm) patients were to be randomized to either naltrexone or 
acamprosate (1:1 ratio). In the other arm (the genotype-guided arm), the treatment of 
patients was to be dependent on the carriage of the OPRM1 Asp40 allele. Patients 
with at least one copy of the Asp40 allele (patients homozygous or heterozygous for 
the Asp40 allele) would receive naltrexone whilst patients with no copy of the Asp40 
allele (patients homozygous for the Asn40 allele) would receive acamprosate. The 
graphical illustration of the proposed design is given at Figure 6.1. Prescribing 
acamprosate in both randomisation arms in this way ensured that all patients 
received a pharmacotherapeutic intervention in accordance with NICE guidelines, to 
ensure that there was equipoise between both arms. In addition, despite the open 
label design of the trial, it ensured blinding to clinicians, nurses and patients in terms 
of the underlying genotype and reasons for choice of therapy. 
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Figure 6.1. Biomarker-strategy design with treatment randomization in the control arm adopted in 
STRONG trial. “R” refers to randomization of patients. Naltrexone corresponds to the experimental 
treatment (A) and Acamprosate corresponds to the control treatment (B). Asp40 + (Asp40 present) 
corresponds to biomarker-positive patients and Asp40 - (Asp40 absent) corresponds to biomarker-
negative patients. 
Return to any drinking at 12 months was selected as the primary outcome 
which was also considered as the primary endpoint for most of the previous RCTs [7, 
27]. It is a binary variable containing the information whether a patient returned to 
drinking after detoxification, or whether a patient remained fully abstinent.  
The primary outcome would be measured utilizing a prospective drink diary. 
If at any stage during the 12 month follow-up period the patient recorded having a 
drink, they would be classified as having returned to drinking. ‘Event rate’ refers to 
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returning to drinking which is a negative outcome and ‘response rate’ refers to not 
returning to drinking which is a positive outcome. 
6.2.2. Sample size calculation of the previously proposed design 
Sample size formula: For the case of binary outcomes, Eng (2014) [28] provided 
formula (3.37) (see Subsection 3.2.4) for the required sample size for each arm in a 
Biomarker Strategy Design trial. 
The expected response rates 𝑔1 in the genotype-guided arm and 𝑔3 in the non-
genotype-guided arm can be found by calculating the formulae 
 𝑔1 = 𝑘𝑟𝐴+ + (1 − 𝑘)𝑟𝐵−   (6.1) 
and 
 𝑔3 = 𝑟𝐴 2⁄ + 𝑟𝐵 2⁄      (6.2) 
respectively; 𝑟𝐴 and 𝑟𝐵 denote the marginal effect of treatment A (naltrexone: 
experimental treatment) and treatment B (acamprosate: control treatment) 
respectively. 𝑟𝐴+ and  𝑟𝐵− are the assumed response rates of biomarker-positive 
patients (i.e. patients with Asp40 present) receiving the experimental treatment and 
biomarker-negative patients (i.e. patients with Asp40 absent) receiving the control 
treatment respectively. 𝑘 is the prevalence of biomarker-positive patients.  
When designing the trial, the response rate in the non-genotype-guided arm 
(𝑔3) is given, whereas, the response rate in the alternative arm (𝑔1) is unknown. 
However, based on 𝑔3 and the decision made by a panel of clinicians regarding the 
minimally clinically meaningful effect size (Δ3), we can calculate 𝑔1 by 𝑔1 = Δ3 + 𝑔3. 
Estimating expected response rate in non-genotype-guided arm, 𝒈𝟑: Return 
to any drinking for acamprosate, without assuming dropouts returned to drinking, 
has an estimated event rate of 0.27 (95% CI: 0.23-0.32). This event rate was estimated 
from data on rate of return to any drinking and rate of dropouts from two meta-
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analyses (analysis 1.1. and 1.16 respectively) of the Cochrane acamprosate review [5]. 
Results are illustrated in Figure 6.2. 
 
Figure 6.2. Rate of return to any drinking for acamprosate 
The COMBINE study [7] has reported a difference of 3% (95% CI: - 4%, 9%) 
between acamprosate and naltrexone event rates of those having returned to drinking 
at 1 year. Taking the upper limit of the 95% CI for the estimated acamprosate event 
rate (0.32) i.e. assuming the worst case scenario, and the 3% difference estimated in 
the COMBINE study, return to any drinking for naltrexone has an estimated event 
rate of 0.29. The overall event rate in the non-genotype-guided arm (𝑔3) can therefore 
be expected to be 0.31 as calculated by 0.5 × 0.32 (acamprosate) + 0.5 × 0.29 
(naltrexone) based on (6.2). Consequently, the response rate in the baseline arm (i.e. 
non-genotype-guided arm) can be estimated as 𝑔3 = 1 − 0.31 = 0.69.  
Estimating expected response rate in genotype-guided arm, 𝒈𝟏: In this arm, 
as patients who are positive for the Asp40 genotype receive only naltrexone and 
patients who are negative for the Asp40 genotype receive only acamprosate, the 
anticipated event rate is a weighted event rate of Asp40 genotype positive patients 
receiving naltrexone and Asp40 genotype negative patients receiving acamprosate. 
Therefore, based on data on rate of return to any drinking in patients on naltrexone 
carrying at least one copy of the Asp40 allele (12.9%) from the COMBINE genetics 
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sub-study [11], and given a 20% prevalence of the Asp40 allele, combining this with 
the upper limit of the event rate estimate from the Cochrane acamprosate review, the 
best estimate for the event rate in the genotype arm can be calculated using (6.1) by 
0.2 (i.e. biomarker positive prevalence) × 0.129 (i.e. biomarker positive naltrexone 
event rate) + 0.8 (i.e. biomarker negative prevalence) × 0.32 (i.e. acamprosate event 
rate) = 0.282. 
Consequently, the response rate in the genotype-guided arm would be 1 - 0.282 
= 0.72. The 0.72 response rate in the genotype arm leads to a difference in response 
rates between non-genotype and genotype-guided arms (Δ3) of 0.72 - 0.69 = 0.03 (3% 
difference), and this estimate provides us with an estimate of what a realistic effect 
size might be. Even in the extreme situation where the 20% with the Asp40 allele have 
no relapse, the event rate in the genotype arm can be calculated using (6.1) by 0.2 × 0 
+ 0.8 × 0.32 = 0.256. Hence, the response rate in the genotype-guided arm would be 1 
– 0.256= 0.74. The 0.74 response rate in the genotype arm leads to a difference in 
response rates between non-genotype and genotype-guided arms (Δ3) of 0.74 – 0.69 
= 0.05 (5% difference). For this reason, realistically the difference in outcomes between 
the two arms based on data from the literature is known to be around 5% or less. 
Consequently, we will consider in our case study three scenarios of target effect sizes 
(Δ3), 3%, 5% and 10% for the sample size calculation. After having set the values of 
Δ3, the response rate in the genotype-guided arm (𝑔1) can be found by 𝑔1 = Δ3 + 𝑔3.  
In reality, the assumed effect sizes should be discussed with a panel of expert 
clinicians who will decide which effect size can be considered as a minimally 
clinically significant difference.  
Based on the aforementioned effect sizes and the response rate in the non-
genotype-guided arm we calculate the corresponding sample size and the results are 
presented in Table 6.1.  
Table 6.1. Sample size of the Biomarker-strategy design with treatment randomisation in the control 
arm in each effect size scenario. 
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 Scenario 1 Scenario 2 Scenario 3 
Non-genotype guided arm response rate (𝒈𝟑) 0.69 0.69 0.69 
Difference in response rates between strategy 
arms (Δ𝟑) 
0.03 (3%) 0.05 (5%) 0.1 (10%) 
Genotype-guided arm response rate (𝒈𝟏 =
Δ𝟑 + 𝒈𝟑) 
0.72 0.74 0.79 
Two-sided significance level (𝒂) 0.05 0.05 0.05 
Power (𝟏 − 𝜷) 0.8 0.8 0.8 
Sample size per arm calculated by (3.37) 3624 1276 298 
Sample size per arm allowing for a 30% 
dropout rate calculated by 
[(𝟑. 𝟑𝟕) (𝟏 − 𝐝𝐫𝐨𝐩𝐨𝐮𝐭 𝐫𝐚𝐭𝐞)⁄ ] 
5178 1824 426 
Total sample size 10356 3648 852 
 
To demonstrate a 3% improvement in the response rate for the genotype-
guided arm over the non-genotype guided arm with 80% power and at a two-sided 
5% significance level, 3624 patients will be required per arm. Allowing for a 30% 
dropout rate, 5178 patients will be required per arm, therefore a total of 10356 patients 
will need to be recruited. To demonstrate a 5% improvement in the response rate for 
the genotype-guided arm over the non-genotype guided arm with 80% power and a 
two-sided significance level, 1276 patients will be required per arm. Allowing for a 
30% dropout rate, 1824 patients will be required per arm, therefore a total of 3648 
patients will be recruited. To demonstrate a 10% improvement in the response rate 
for the genotype-guided arm over the non-genotype guided arm with 80% power and 
at a two-sided 5% significance level, 298 patients will be required per arm. Allowing 
for a 30% dropout rate, 426 patients will be required per arm, therefore a total of 852 
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patients will be recruited. However, according to data identified within the literature 
review, the 10% difference in response rates between the strategy arms is unlikely. 
6.3. Reasons for inefficiency of the previously proposed design 
This Biomarker-strategy design with treatment randomization in the control 
arm is inefficient in our case as a very large sample size is required. This design is 
generally a poor substitute for clinical trials which aim to compare the experimental 
treatment to control treatment, since we have biomarker-positive and biomarker-
negative patients in both the biomarker-guided arm and non-biomarker-guided arm 
being assigned to the same treatment, therefore diluting the treatment effect [29, 30]. 
Consequently, as a large overlap of patients receiving the same treatment might 
occur, the comparison of the two biomarker-strategy arms results in an odds ratio 
which is forced towards unity, i.e. no treatment effect [29]. For this reason, a large 
sample size is needed especially in cases where the prevalence of biomarker is low 
and the assumed overall difference between the two biomarker-strategy arms is small 
[29]. 
Generally, the Biomarker-Strategy Design with treatment randomization in the 
control arm needs a larger sample size as compared to so-called ‘marker-stratified’ 
designs and for this reason it is considered a less efficient design [29]. However, a 
strength of this design is that it allows clarification of whether the results which 
indicate efficacy of the biomarker-guided approach to treatment are caused due to a 
true effect of the biomarker or due to a treatment effect irrespective of biomarker 
status. 
As this design has been proven inefficient for our study we reconsider in the 
next section what might be the most appropriate design among the various non-
adaptive biomarker-guided clinical trial designs outlined in Chapter 3. 
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6.4. Reconsideration of the most appropriate design 
By taking into consideration the information regarding the utility of each 
design given in Chapter 3 [29], we extracted the following questions which we 
believed were key when deciding which non-adaptive design to use for the STRONG 
trial: 
1. Is our goal to test a treatment effect in a biomarker-positive subgroup only? 
This aim would be appropriate where there was prior evidence indicating that 
effectiveness was limited to those within that particular subgroup, but the candidate 
biomarker still required prospective validation [29], and is the aim being addressed 
in the ‘Enrichment’ trial design. The design is recommended when the analytical 
validity of the biomarker has been well established and is particularly appropriate 
where it is unethical to randomize the biomarker-negative population into different 
treatment arms, for example where there is prior evidence that the experimental 
treatment is not beneficial for biomarker-negative individuals, or is likely to cause 
them harm. However, when it remains unclear whether or not biomarker-negative 
individuals will benefit from the novel treatment, the enrichment design is not 
appropriate and alternative designs, which also assess effectiveness in the biomarker-
negative individuals, should be considered [29]. 
STRONG trial: Our aim is to test treatment effectiveness both in biomarker-
positive and biomarker-negative patients. Current NICE guidelines (CG115) [6] 
recommends therapy with either acamprosate (control treatment in STRONG) or 
naltrexone (experimental treatment in STRONG) to alcohol dependent patients 
(regardless of genotype), hence, both genotype groups should be investigated in our 
study and the Enrichment design is therefore not appropriate. 
2. Is our biomarker extremely rare? 
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If the biomarker is rare (<20%), then the Enrichment design should again be 
considered. An all-comers strategy is not recommended in this case as the treatment 
effect in the overall population would be diluted [29]. 
STRONG trial: In our study the prevalence of Asn40Asp SNP is 20%. This 
proportion is low; however, it is not extremely rare. 
3. Is our goal to test treatment effectiveness both in biomarker-positive and 
biomarker-negative patients as well as to assess the interaction between treatment 
and biomarker in all patients? 
A design which allows all these values to be estimated is appropriate when 
there is enough evidence that the experimental treatment is more effective in the 
biomarker-positive subgroup than in the biomarker-negative subgroup, but when 
there is insufficient evidence that the experimental treatment is of no benefit in 
biomarker-negative individuals [29]. Such designs are referred to as ‘Marker-
stratified’ designs, of which there are several variations including ‘Subgroup-specific’ 
designs, ‘Biomarker-positive and overall strategies’ design, and ‘Marker sequential 
test’ design (‘MAST’) (see Chapter 3, Subsection 3.2.3.1.) [29]. Marker-stratified 
designs can be conducted using two different analysis plans; the so-called ‘marker-
by-treatment interaction with separate tests’ and ‘marker-by-treatment interaction 
with interaction test’ (see Chapter 3, Subsection 3.2.3.1.) [29]. 
STRONG trial: The aim of the STRONG trial is to test effectiveness within both 
biomarker-defined subgroups as well as to investigate the interaction term which will 
indicate whether the biomarker is predictive or not. Hence, the Marker-stratified 
design could be a potential design for our trial. 
4. Is our goal to test a treatment effect in a biomarker-positive subgroup only but 
there is compelling prior evidence which shows efficacy of the control treatment for 
the biomarker-negative subgroup?  
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Where this is the case, Hybrid designs are recommended. Hybrid designs are 
particularly recommended when there is compelling prior evidence showing a 
detrimental effect of the experimental treatment for the biomarker-negative 
subgroup, or some indication of its possible excessive toxicity, as well as evidence 
showing that the control treatment works well in that subgroup [29].  
STRONG trial: There is no evidence of our experimental treatment, naltrexone, 
having a detrimental effect in Asp40- patients, so this design is inappropriate for our 
trial. 
5. Is our goal to test a clinical strategy in all patients? 
Designs aimed at testing the clinical strategy of offering a biomarker-guided 
approach to treatment take into consideration the prevalence of the biomarker as well 
as its interaction with treatment to characterize the potential impact of the biomarker 
strategy in clinical practice care. Such designs are called ‘Biomarker-strategy’ designs 
and test the joint deployment of the biomarker and active treatment as a strategy. 
They include the following designs: (i) biomarker-strategy with biomarker 
assessment in the control arm, (ii) biomarker-strategy without biomarker assessment 
in the control arm, (iii) biomarker-strategy with treatment randomization in the 
control arm and (iv) reverse marker-based strategy designs [29]. 
STRONG trial: Since the aim of our trial is to test the effectiveness of a 
genotype-guided approach to treatment of alcohol-dependent patients, a Biomarker-
strategy design may be appropriate.  
So far, we have therefore determined that either a Marker-stratified design or a 
Biomarker-strategy design may be appropriate for the STRONG trial. The following 
questions help us further to choose among the different biomarker-strategy designs. 
6. Is our goal to test the hypothesis that the treatment effect based on the biomarker-
guided strategy approach is superior to that of the standard of care where all patients 
receive only the control treatment? 
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If this is the case, either the Biomarker-strategy design with biomarker 
assessment in the control arm or the Biomarker-strategy design without biomarker 
assessment in the control arm could be used. The latter would be preferred in 
situations where it is either not feasible or unethical to test the biomarker in the entire 
population (e.g., specimens not submitted, assay failure, tumour inaccessible) [29]. 
STRONG trial: Since NICE guidance (CG115) [6] recommends therapy with 
either acamprosate (experimental treatment) or naltrexone (control treatment), 
neither treatment can be considered the ‘standard of care’ approach and therefore 
these two designs cannot be considered for the STRONG trial. 
7. Is our goal to test a clinical strategy in all patients as well as to test whether the 
biomarker is not only prognostic but also predictive (interaction between treatment 
and biomarker)? 
The Biomarker-strategy design with treatment randomization in the control 
arm is appropriate when this is the goal. Patients are first randomly assigned to either 
the genotype-guided strategy arm or to the non-genotype-guided strategy arm. Next, 
patients who are allocated to the non-genotype-guided strategy are again 
randomized either to the experimental treatment arm or to the standard treatment 
arm irrespective of their biomarker status. Patients who are allocated to the genotype-
guided strategy and who are biomarker-positive receive the experimental treatment 
and patients who are biomarker-negative receive the control treatment [29]. 
STRONG trial: In our trial, we are aiming to test the effectiveness of a 
genotype-guided treatment strategy, and are wishing to test whether the SNP of 
interest if predictive and so this is a potential design for our study. However, this is 
the design which we previously considered and found that it was not plausible due 
to the relatively low prevalence of the genetic marker.  
8. Is our aim to test the clinical strategy of a biomarker-guided approach in all 
patients and the predictive ability of the biomarker, whilst ensuring that the 
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probability of a patient being assigned the same treatment regardless of which arm 
they are randomized to is zero? 
The Reverse Marker-Based strategy design is appropriate where this is the case. 
Patients are randomized either to the genotype-guided strategy arm or to a reverse 
genotype-guided strategy arm. Patients who are allocated to the genotype-guided 
arm receive the experimental treatment if they are biomarker-positive whereas 
biomarker-negative patients receive the control treatment. By contrast, patients who 
are randomly assigned to the reverse genotype-guided arm receive control treatment 
if they are biomarker-positive, whereas biomarker-negative patients receive the 
experimental treatment. 
STRONG trial: Since we are interested in testing the effectiveness of our 
genotype-guided approach to treatment and whether our SNP is predictive, and at 
the same time have prior evidence that both naltrexone and acamprosate are effective 
in treating alcohol dependence (hence current NICE guidance), it is ethical to adopt 
this design in our trial. 
6.5. Sample size calculations for the STRONG trial assuming different 
study designs 
Based on our conclusions above, in the following sections we investigate the 
use of two biomarker-guided trial designs in the STRONG trial i.e. the Marker 
Stratified design (two variations of that design are also included) and the Reverse 
Marker-Based strategy design. The primary outcome, upon which our sample size 
calculation is based, is return to any drinking at 12 months. 
6.5.1. Using the Marker Stratified design in the STRONG trial 
The graphical representation of this design is given in Figure 6.3. 
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Figure 6.3. Marker Stratified design adopted in STRONG trial. “R” refers to randomization of patients. 
Naltrexone corresponds to the experimental treatment (A) and acamprosate corresponds to the control 
treatment (B). Asp40 + (Asp40 present) corresponds to biomarker-positive patients and Asp40 - (Asp40 
absent) corresponds to biomarker-negative patients. 
Sample size formula: Eng (2014) [28] provided formula (3.20) for the required 
total sample size for a trial with this design, assuming a binary outcome (see 
Subsection 3.2.3.1.).  
𝑟𝐵+,  𝑟𝐴− are the assumed response rates of biomarker-positive patients (i.e. 
patients who carry the Asp40 ) receiving the control treatment and biomarker-
negative patients i.e. patients who do not carry the Asp40 allele) receiving the 
experimental treatment. The sample size for the Marker Stratified design does not 
depend on the biomarker prevalence, therefore the trial arm can be closed once the 
required number of patients has accrued, without the need to re-estimate the sample 
size. Of course, the lower the prevalence the longer the accrual period for the 
biomarker positive arm. For an actual clinical study which uses this design, the 
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sample size calculation is based on the response rate in the control arm of each 
biomarker-defined subgroup (i.e. 𝑟𝐵+, 𝑟𝐵−) and on the minimally clinically 
meaningful effect size of each biomarker-defined subgroup (i.e. 𝑟𝐴+ − 𝑟𝐵+ and 𝑟𝐴− −
𝑟𝐵−) which is decided by a panel of clinicians. Based on these parameters, the 
response rate in the experimental arm of each biomarker-defined subgroup can be 
found and thus the sample size of each subgroup can be calculated. 
As mentioned in the previous section regarding the biomarker-strategy design, 
the event rate for return to any drinking for acamprosate can be estimated as from 
the Cochrane acamprosate review [5] to be 0.32. Consequently, the estimated 
response rate for those on acamprosate is estimated as 1 - 0.32 = 0.68. If we consider 
the impact of genetics, based on data on rates of return to any drinking in patients on 
naltrexone carrying at least one copy of the Asp40 allele (12.9%) and those not 
carrying the Asp40 allele (45.2%) from the COMBINE genetics sub-study [11], the 
estimated naltrexone response rate in the biomarker-positive subgroup is 1 - 0.129 = 
0.871 and in the biomarker-negative subgroup is 1 - 0.452 = 0.548. We have identified 
no studies investigating association between acamprosate response and the 
Asp40Asn SNP. Hence, we will assume that the acamprosate response rate is 
independent of genotype at the SNP and is therefore 0.68. Based on this data, the 
difference in response rates between the naltrexone and acamprosate treatment arms 
in the biomarker-positive subgroup can be estimated as 0.871 - 0.68 = 0.191 and the 
difference in the biomarker-negative subgroup can be estimated as 0.548 - 0.68 = -
0.132 which indicates that the acamprosate treatment performs better compared to 
the naltrexone treatment. 
These estimated differences provide us with an idea of what the true differences 
may be in each of the biomarker subgroups. In reality, the differences would be 
discussed with a panel of clinicians in order to decide which effect size can be 
considered as a minimally clinically significant difference for each subgroup. 
However, in our sample size calculation we assume three scenarios of differences 
with a range from small difference to high difference, and the results are presented 
in Table 6.2; scenarios 4 to 9 give some combinations of the first three scenarios. The 
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first scenario corresponds to differences of 5% and -20% in biomarker-positive 
subgroup and biomarker-negative subgroup respectively. The second scenario 
corresponds to differences of 10% and -15% in biomarker-positive subgroup and 
biomarker-negative subgroup respectively. The third scenario corresponds to 
differences of 19.1% and -13.2% in biomarker-positive and biomarker-negative 
subpopulation respectively, in line with our estimates based on published data. 
Sample sizes, based on these assumptions, are provided in Table 6.2. 
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Table 6.2. Sample size of the Marker Stratified design based on the target effect size and acamprosate response rate in each biomarker-defined subgroup. 
 Scenarios 
 1 2 3 4 5 6 7 8 9 
Acamprosate response rate in biomarker-positive subgroup (𝒓𝑩+) 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 
Acamprosate response rate in biomarker-negative subgroup (𝒓𝑩−) 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 
Difference in response rates between naltrexone and acamprosate treatment 
arm in biomarker-positive subgroup (effect size in positive subgroup) 
0.05 0.10 0.191 0.05 0.05 0.10 0.10 0.191 0.191 
Difference in response rates between naltrexone and acamprosate treatment 
arm in biomarker-negative subgroup (effect size in negative subgroup) 
-0.20 -0.15 -0.132 -0.15 -0.132 -0.20 -0.132 -0.20 -0.15 
Naltrexone response rate in biomarker-positive subgroup 
 (𝒓𝑨+ = 𝐞𝐟𝐟𝐞𝐜𝐭 𝐬𝐢𝐳𝐞 𝐢𝐧 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐬𝐮𝐛𝐠𝐫𝐨𝐮𝐩 + 𝒓𝑩+) 
0.73 0.78 0.871 0.73 0.73 0.78 0.78 0.871 0.871 
Naltrexone response rate in biomarker-negative subgroup 
 (𝒓𝑨− = 𝐞𝐟𝐟𝐞𝐜𝐭 𝐬𝐢𝐳𝐞 𝐢𝐧 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝐬𝐮𝐛𝐠𝐫𝐨𝐮𝐩 + 𝒓𝑩−) 
0.48 0.53 0.548 0.53 0.548 0.48 
 
0.548 0.48 0.53 
Two-sided significance level (𝒂) 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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Power (𝟏 − 𝜷) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
Total sample size (N) calculated by (3.20) 2787 937 561 2930 3023 794 1030 325 468 
Total sample size allowing for a 30% dropout rate calculated by 
[(𝟑. 𝟐𝟎) (𝟏 − 𝐝𝐫𝐨𝐩𝐨𝐮𝐭 𝐫𝐚𝐭𝐞)⁄ ] 
3982 1339 801 4186 4319 1134 1472 465 669 
 
In the first scenario of differences, with 80% power and at a 5% significance level, 2787 patients will be required. Allowing for a 30% 
dropout rate, 3982 patients will need to be recruited if this study design is assumed. In the second scenario of differences, with 80% power 
and at a 5% significance level, 937 patients will be required. Allowing for a 30% dropout rate, 1339 patients will need to be recruited if this 
study design is assumed. In the third scenario of differences, with 80% power and at a 5% significance level, 561 patients will be required. 
Allowing for a 30% dropout rate, 801 patients will need to be recruited if this study design is assumed. In the fourth scenario of differences, 
with 80% power and at a 5% significance level, 2930 patients will be required. Allowing for a 30% dropout rate, 4186 patients will need to 
be recruited if this study design is assumed. In scenario 5 of differences, with 80% power and at a 5% significance level, 3023 patients will 
be required. Allowing for a 30% dropout rate, 4319 patients will need to be recruited if this study design is assumed. In scenario 6 of 
differences, with 80% power and at a 5% significance level, 794 patients will be required. Allowing for a 30% dropout rate, 1134 patients 
will need to be recruited if this study design is assumed. In scenario 7 of differences, with 80% power and at a 5% significance level, 1030 
patients will be required. Allowing for a 30% dropout rate, 1472 patients will need to be recruited if this study design is assumed. In scenario 
8 of differences, with 80% power and at a 5% significance level, 325 patients will be required. Allowing for a 30% dropout rate, 465 patients 
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will need to be recruited if this study design is assumed. In scenario 9 of differences, with 80% power and at a 5% significance level, 468 
patients will be required. Allowing for a 30% dropout rate, 669 patients will need to be recruited if this study design is assumed. 
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6.5.1.1. Using a variation of the Marker Stratified design – the Sequential Subgroup-
Specific design 
In this section we investigate a version of Marker Stratified design, the so-called 
Sequential Subgroup-Specific design (see Chapter 3, Subsection 3.2.3.1), which 
consists of the analysis of biomarker-negative patients contingent on statistical 
significance in biomarker-positive patients. A graphical illustration of this design is 
given in Figure 6.4. 
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Figure 6.4. Sequential Subgroup Specific design adopted in STRONG trial. “R” refers to randomization of patients. Naltrexone corresponds to the experimental treatment 
(A) and acamprosate corresponds to the control treatment (B). Asp40 + (Asp40 present) corresponds to biomarker-positive patients and Asp40 - (Asp40 absent) corresponds 
to biomarker-negative patients. 
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Sample size formula: Simon (2008) [31] provided formula (3.28) for the total 
sample size for this trial design, again assuming a binary outcome (see Subsection 
3.2.3.1.). This formula is composed of the sum of the formula (3.27) which 
corresponds to the biomarker-positive patients and (3.29) which corresponds to the 
biomarker-negative patients. These formulae depend on 𝑁𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 which denotes 
the required total sample size for a trial assuming an enrichment design [29]. By using 
the part of formula (3.20) (see Subsection 3.2.3.1.) proposed in Eng (2014) [28] which 
refers to the biomarker-positive subgroup, formula (3.28) can be written as: 
 
𝑁 = 2(𝑧𝑎 + 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝑟𝐴+ − 𝑟𝐵+)𝟐
}
+ 2
(1 − 𝑘)
𝑘
(𝑧𝑎
+ 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝑟𝐴+ − 𝑟𝐵+)𝟐
}     
(6.3) 
For the purpose of our sample size calculation, we make the same assumptions 
regarding the response rate in the biomarker-positive subgroup and the effect size as 
we did when considering the Marker Stratified design. The sample size calculation is 
given in Table 6.3. The same scenarios of difference in response rates between 
naltrexone and acamprosate treatment arm in biomarker-positive subgroup used in 
the Marker Stratified design are considered. 
Table 6.3. Sample size of the Sequential Subgroup-Specific design based on the target effect size and 
acamprosate response rate in biomarker-positive subgroup. 
 Scenario 1 Scenario 2 Scenario 3 
Acamprosate response rate in biomarker-positive 
subgroup (𝒓𝑩+) 
0.68 0.68 0.68 
Difference in response rates between naltrexone and 
acamprosate treatment arm in biomarker-positive 
subgroup (effect size in positive subgroup) 
0.05 0.10 0.191 
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Naltrexone response rate in biomarker-positive 
subgroup (𝒓𝑨+ = 𝐞𝐟𝐟𝐞𝐜𝐭 𝐬𝐢𝐳𝐞 𝐢𝐧 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐬𝐮𝐛𝐠𝐫𝐨𝐮𝐩 +
𝒓𝑩+) 
0.73 0.78 0.871 
Two-sided significance level (𝒂) 0.05 0.05 0.05 
Power (𝟏 − 𝜷) 0.8 0.8 0.8 
Total sample size (N) calculated by (6.3) 13019 3055 710 
Total sample size allowing for a 30% dropout rate 
calculated by [(𝟔. 𝟑) (𝟏 − 𝐝𝐫𝐨𝐩𝐨𝐮𝐭 𝐫𝐚𝐭𝐞)⁄ ] 
18598 4364 1014 
In scenario 1, with 80% power and at a 5% significance level, 13019 patients 
will be required. Allowing for a 30% dropout rate, 18598 patients will need to be 
recruited if this study design is adopted. In scenario 2, with 80% power and at a 5% 
significance level, 3055 patients will be required. Allowing for a 30% dropout rate, 
4363 patients will need to be recruited if this study design is adopted. In scenario 3, 
with 80% power and at a 5% significance level, 710 patients will be required. 
Allowing for a 30% dropout rate, 1014 patients will need to be recruited if this study 
design is adopted. 
6.5.1.2. Using a variation of the Marker Stratified design: the Parallel Subgroup-Specific 
design 
In this section another version of the Marker Stratified design is explored, the 
so-called Parallel Subgroup-Specific design which tests both biomarker-defined 
subgroups, however it controls for the type I error (see Chapter 3, Subsection 3.2.3.1.). 
The graphical illustration of this design is given in Figure 6.5. 
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Figure 6.5. Parallel Subgroup-Specific design adopted in STRONG trial. “R” refers to randomisation of 
patients. Naltrexone corresponds to the experimental treatment (A) and acamprosate corresponds to the 
control treatment (B). Asp40 + (Asp40 present) corresponds to biomarker-positive patients and Asp40 - 
(Asp40 absent) corresponds to biomarker-negative patients. 
Sample size formula: When more than one hypothesis for treatment efficacy is 
being tested, it is important to control the familywise error rate (FWER) to ensure that 
the probability of committing at least one Type I error does not exceed the nominal 
significance level. To achieve this within the current study design, a conservative 
Bonferroni correction method is often used where the nominal significance level 𝑎 is 
allocated between the test for the biomarker-negative subgroup and the test for the 
biomarker-positive subgroup either equally (i.e. 𝑎/2) or unequally, meaning that the 
total significance level is 𝑎. The following sample size formula assuming 𝑎+ and 𝑎− 
significance levels for biomarker-positive and biomarker-negative subgroups 
respectively was proposed in Eng (2014) [28] for this design,  
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𝑁 = 2(𝑧𝑎+ + 𝑧1−𝛽)
2
{
𝑟𝐴+(1 − 𝑟𝐴+) + 𝑟𝐵+(1 − 𝑟𝐵+)
(𝑟𝐴+ − 𝑟𝐵+)𝟐
}
+ 2(𝑧𝑎− + 𝑧1−𝛽)
2
{
𝑟𝐴−(1 − 𝑟𝐴−) + 𝑟𝐵−(1 − 𝑟𝐵−)
(𝑟𝐴− − 𝑟𝐵−)𝟐
}.   
(6.4) 
For the purpose of our sample size calculation, we again make the same 
assumptions regarding the response rate in the biomarker-positive subgroup and the 
effect size as we did when considering the Marker Stratified design. The sample size 
calculation is given in Table 6.4; scenarios 4 to 9 give some combinations of the first 
three scenarios. The same scenarios of difference in response rates between 
naltrexone and acamprosate treatment arm in biomarker-positive subgroup and 
biomarker-negative subgroup used in the Marker Stratified design are considered.
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Table 6.4. Sample size of the Parallel Subgroup-Specific design based on the target effect size and acamprosate response rate in each biomarker-defined subgroup. 
 Scenarios 
 1 2 3 4 5  6  7 8 9 
Acamprosate response rate in biomarker-positive subgroup 
(𝒓𝑩+) 
0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 
Acamprosate response rate in biomarker-negative 
subgroup (𝒓𝑩−) 
0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.68 
Difference in response rates between naltrexone and 
acamprosate treatment arm in biomarker-positive 
subgroup (effect size in positive subgroup) 
0.05 0.10 0.191 0.05 0.05 0.10 0.10 0.191 0.191 
Difference in response rates between naltrexone and 
acamprosate treatment arm in biomarker-negative 
subgroup (effect size in negative subgroup) 
-0.20 -0.15 -0.132 -0.15 -0.132 -0.20 -0.132 -0.20 -0.15 
Naltrexone response rate in biomarker-positive subgroup 
(𝒓𝑨+ = 𝐞𝐟𝐟𝐞𝐜𝐭 𝐬𝐢𝐳𝐞 𝐢𝐧 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐬𝐮𝐛𝐠𝐫𝐨𝐮𝐩 + 𝒓𝑩+) 
0.73 0.78 0.871 0.73 0.73 0.78 0.78 0.871 0.871 
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Naltrexone response rate in biomarker-negative subgroup 
(𝒓𝑨− = 𝐞𝐟𝐟𝐞𝐜𝐭 𝐬𝐢𝐳𝐞 𝐢𝐧 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝐬𝐮𝐛𝐠𝐫𝐨𝐮𝐩 + 𝒓𝑩−) 
0.48 0.53 0.548 0.53 0.548 0.48 0.548 0.48 0.53 
Two-sided significance level (𝒂+, 𝒂−) 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.025 
Power (𝟏 − 𝜷) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
Total sample size (N) calculated by (6.4) 3375 1134 680 3547 3661 962 1248 394 566 
Total sample size allowing for a 30% dropout rate 
calculated by [(𝟔. 𝟒) (𝟏 − 𝐝𝐫𝐨𝐩𝐨𝐮𝐭 𝐫𝐚𝐭𝐞)⁄ ] 
4821 1620 
 
971 5067 5230 1374 1782 563 809 
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In scenario 1, with 80% power and at a 5% significance level, 3375 patients will 
be required. Allowing for a 30% dropout rate, 4821 patients will need to be recruited 
if this study design is chosen. In scenario 2, with 80% power and at a 5% significance 
level, 1134 patients will be required. Allowing for a 30% dropout rate, 1620 patients 
will need to be recruited if this study design is chosen. In scenario 3, with 80% power 
and at a 5% significance level, 680 patients will be required. Allowing for a 30% 
dropout rate, 971 patients will need to be recruited if this study design is chosen. In 
scenario 4, with 80% power and at a 5% significance level, 3547 patients will be 
required. Allowing for a 30% dropout rate, 5067 patients will need to be recruited if 
this study design is chosen. In scenario 5, with 80% power and at a 5% significance 
level, 3661 patients will be required. Allowing for a 30% dropout rate, 5230 patients 
will need to be recruited if this study design is chosen. In scenario 6, with 80% power 
and at a 5% significance level, 962 patients will be required. Allowing for a 30% 
dropout rate, 1374 patients will need to be recruited if this study design is chosen. In 
scenario 7, with 80% power and at a 5% significance level, 1248 patients will be 
required. Allowing for a 30% dropout rate, 1782 patients will need to be recruited if 
this study design is chosen. In scenario 8, with 80% power and at a 5% significance 
level, 394 patients will be required. Allowing for a 30% dropout rate, 563 patients will 
need to be recruited if this study design is chosen. In scenario 9, with 80% power and 
at a 5% significance level, 566 patients will be required. Allowing for a 30% dropout 
rate, 809 patients will need to be recruited if this study design is chosen.  
6.5.2. Using the Reverse Marker-Based strategy design in the STRONG trial 
A graphical illustration of this approach is given in Figure 6.6. Patients 
randomized to the reverse genotype-guided arm will receive only acamprosate 
(control treatment) if they carry the Asp40 allele and those who do not carry the 
Asp40 allele will receive only naltrexone (experimental treatment). For the genotype 
guided arm, patients who carry the Asp40 allele will receive naltrexone (experimental 
 254 
 
treatment) while patients who do not carry the Asp40 allele will receive acamprosate 
(control treatment). 
 
Figure 6.6. Reverse Marker-Based strategy design adopted in STRONG trial. “R” refers to randomization 
of patients. Naltrexone corresponds to the experimental treatment and acamprosate corresponds to the 
control treatment. Asp40 + (Asp40 present) corresponds to biomarker-positive patients and Asp40 - 
(Asp40 absent) corresponds to biomarker-negative patients. 
Sample size formula: For the case of binary outcomes, Eng (2014) [28] provided 
formula (3.38) for the required sample size for each arm in a trial with this design (see 
Subsection 3.2.4.4.). 
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The expected response rates 𝑔1, 𝑔4 in the genotype-guided arm and in the 
reverse-genotype-guided arm respectively can be found by calculating the formulae 
 𝑘𝑟𝐴+ + (1 − 𝑘)𝑟𝐵− (6.5) 
and 
 𝑘𝑟𝐵+ + (1 − 𝑘)𝑟𝐴−   (6.6) 
For an actual clinical study which uses this design, the sample size calculation 
should be based on the response rate in the control arm, i.e. the response rate in the 
reverse-genotype-guided arm (𝑔4) and on the decision made by a panel of clinicians 
regarding the minimally clinically meaningful effect size, i.e. Δ4. Hence, the response 
rate in the alternative arm can be found by 𝑔1 = Δ4 + 𝑔4. 
Based on the data obtained from the literature search that has been undertaken 
we can estimate the response rate in the genotype-guided arm and in the reverse-
genotype-guided arm and thus what may be a realistic effect size that we can expect 
to observe. As discussed in the Biomarker-strategy design, the response rate on 
acamprosate can be assumed as 0.32, based on the Cochrane acamprosate review [5]. 
If we consider the impact of genetics, we can estimate rates of return to any drinking 
in patients on naltrexone carrying at least one copy of the Asp40 allele (12.9%) and 
those not carrying the Asp40 allele (45.2%) from the COMBINE genetics sub-study 
[11]. We have not identified any studies investigating association between the 
Asp40Asn SNP and response to acamprosate hence we assume that the acamprosate 
response rate in both the biomarker-positive and biomarker-negative subgroups is 
0.32. Assuming a 20% prevalence of the Asp40 allele and using formula (6.6) above, 
the event rate in the reverse-genotype arm is calculated to be 0.43 [0.2 × 0.32 (i.e. 
acamprosate) + 0.8 × 0.452 (i.e. naltrexone in negative subgroup)]. Consequently, the 
response rate in the reverse-genotype-guided arm is estimated as  𝑔4 = 1 – 0.43 =0.57. 
Further, using formula (6.5) above, the overall event rate in the genotype-guided arm 
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is expected to be 0.28 [0.2 × 0.129 (i.e. naltrexone in positive subgroup) + 0.8 × 0.32 (i.e. 
acamprosate)]. Hence, the response rate in the genotype-guided arm is estimated as 
𝑔1 = 1 – 0.28=0.72.  
Based on published data, the difference in response rates between the reverse-
genotype-guided arm and the genotype-guided arm can therefore be estimated as 
0.72 - 0.57 = 0.15 (15%). Even if the 20% with the Asp40 genotype have no relapse the 
difference in response rates would be [0.2 × (1 – 0) + 0.8 × (1 – 0.32)] – 0.57=0.17 (17%). 
For this reason, realistically the difference in outcomes between the two arms of the 
trial based on data from the literature is known to be around 17% or less. In our case 
study we consider three scenarios of target effect sizes (Δ4) with a range from small 
effect size to higher effect size, 15%, 17%, 20% for the sample size calculation. After 
having set the aforementioned values of Δ4, the response rate in the genotype-guided 
arm (𝑔1) can be found by 𝑔1 = Δ4 + 𝑔4. In reality, these scenarios of effect sizes 
should be discussed with a panel of expert clinicians who will decide which effect 
size can be considered as a minimally clinically significant difference. Results of 
estimating the sample size under these scenarios are presented in Table 6.5. 
Table 6.5. Sample size of the Reverse Marker-Based strategy design with treatment randomization in 
the control arm in each effect size scenario. 
 Scenario 1 Scenario 2 Scenario 3 
Reverse-genotype guided arm 
response rate (𝒈𝟒) 
0.57 0.57 0.57 
Difference in response rates between 
strategy arms (Δ𝟒) 
0.15 (15%) 0.17 (17%) 0.20 (20%) 
Genotype-guided arm response rate 
(𝒈𝟏 = Δ𝟒 + 𝒈𝟒) 
0.72 0.74 0.77 
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Two-sided significance level (𝒂) 0.05 0.05 0.05 
Power (𝟏 − 𝜷) 0.8 0.8 0.8 
Sample size per arm calculated by 
(3.38) 
156 120 83 
Sample size per arm allowing for a 
30% dropout rate calculated by 
[(𝟑. 𝟑𝟖) (𝟏 − 𝐝𝐫𝐨𝐩𝐨𝐮𝐭 𝐫𝐚𝐭𝐞)⁄ ] 
224 172 119 
Total sample size 448 344 238 
To demonstrate a 15% improvement in the response rate for the genotype-
guided arm over the non-genotype guided arm with 80% power and at a two-sided 
5% significance level, 156 patients will be required per arm. Allowing for a 30% 
dropout rate, 224 patients will be required per arm, therefore a total of 448 patients 
will be recruited. To demonstrate a 17% improvement in the response rate for the 
genotype-guided arm over the non-genotype guided arm with 80% power and a two-
sided significance level, 120 patients will be required per arm. Allowing for a 30% 
dropout rate, 172 patients will be required per arm, therefore a total of 344 patients 
will be recruited. To demonstrate a 20% improvement in the response rate for the 
genotype-guided arm over the non-genotype guided arm with 80% power and a two-
sided significance level, 83 patients will be required per arm. Allowing for a 30% 
dropout rate, 119 patients will be required per arm, therefore a total of 238 patients 
will be recruited. 
6.6. Discussion 
For the primary outcome of the STRONG trial which refers to return to any 
drinking at 12 months (binary outcome), we have calculated the total sample size 
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required for four potential designs. The estimated total sample size for each design 
is given in Table 6.6. 
Table 6.6. Required total number of patients for four potential designs applied to STRONG trial. 
Design Total sample 
size for both 
arms with 30% 
dropout rate 
Total sample 
size per arm 
without 
dropout rate 
Difference in response 
rates 
Biomarker-strategy 10356 
 
3624 
 
3% (between genotype-guided arm 
and non-genotype-guided arm)  
3648 
 
1276 5% (between genotype-guided arm 
and non-genotype-guided arm) 
852 298 10% (between genotype-guided arm 
and non-genotype-guided arm) 
Marker Stratified 3982 
 
2787 
 
5% (between naltrexone and 
acamprosate in positive subgroup) 
and -20% (between naltrexone and 
acamprosate in negative subgroup) 
1339 
 
937 
 
10% (between naltrexone and 
acamprosate in positive subgroup) 
and -15% (between naltrexone and 
acamprosate in negative subgroup) 
801 
 
561 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
and -13.2% (between naltrexone and 
acamprosate in negative subgroup) 
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4186 
 
2930 
 
5% (between naltrexone and 
acamprosate in positive subgroup) 
and -15% (between naltrexone and 
acamprosate in negative subgroup) 
4319 
 
3023 
 
5% (between naltrexone and 
acamprosate in positive subgroup) 
and -13.2% (between naltrexone and 
acamprosate in negative subgroup) 
1134 
 
794 10% (between naltrexone and 
acamprosate in positive subgroup) 
and -20% (between naltrexone and 
acamprosate in negative subgroup) 
1472 
 
1030 10% (between naltrexone and 
acamprosate in positive subgroup) 
and -13.2% (between naltrexone and 
acamprosate in negative subgroup) 
465 325 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
and -20% (between naltrexone and 
acamprosate in negative subgroup) 
669 468 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
and -15% (between naltrexone and 
acamprosate in negative subgroup) 
Sequential 
Subgroup-Specific 
18598 
 
13019 
 
5% (between naltrexone and 
acamprosate in positive subgroup) 
4364 3055 10% (between naltrexone and 
acamprosate in positive subgroup) 
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1014 
 
710 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
Parallel Subgroup-
Specific 
4821 
 
3375 5% (between naltrexone and 
acamprosate in positive subgroup) 
and -20% (between naltrexone and 
acamprosate in negative subgroup) 
1620 1134 10% (between naltrexone and 
acamprosate in positive subgroup) 
and -15% (between naltrexone and 
acamprosate in negative subgroup) 
971 680 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
and -13.2% (between naltrexone and 
acamprosate in negative subgroup) 
5067 3547 5% (between naltrexone and 
acamprosate in positive subgroup) 
and -15% (between naltrexone and 
acamprosate in negative subgroup) 
5230 3661 5% (between naltrexone and 
acamprosate in positive subgroup) 
and -13.2% (between naltrexone and 
acamprosate in negative subgroup) 
1374 962 10% (between naltrexone and 
acamprosate in positive subgroup) 
and -20% (between naltrexone and 
acamprosate in negative subgroup) 
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1782 1248 10% (between naltrexone and 
acamprosate in positive subgroup) 
and -13.2% (between naltrexone and 
acamprosate in negative subgroup) 
563 394 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
and -0.20% (between naltrexone and 
acamprosate in negative subgroup) 
809 566 19.1% (between naltrexone and 
acamprosate in positive subgroup) 
and -0.15% (between naltrexone and 
acamprosate in negative subgroup) 
Reverse Marker-
Based strategy 
448 156 15% (between genotype-guided arm 
and reverse-genotype-guided arm) 
334 172 17% (between genotype-guided arm 
and reverse-genotype-guided arm) 
238 119 20% (between genotype-guided arm 
and reverse-genotype-guided arm) 
In this chapter, we sought to demonstrate a potential procedure for researchers 
to follow in order to identify the most appropriate type of trial for their particular 
case. After answering a list of questions that we developed to assist in making this 
decision and calculating the required sample size, we demonstrate that Reverse 
Marker-Based strategy design is the optimal design for the STRONG trial when the 
endpoint is binary. It requires fewer patients than the other three non-adaptive trial 
designs that have been proposed for the STRONG trial andit is ethically acceptable 
since both treatments (i.e. naltrexone and acamprosate) are recommended. This work 
could be extended to time-to-event outome as can be seen in section 6.6.1. To 
complement this chapter, in Chapter 7, we will demonstrate the sample size re-
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estimation method by incorporating unblinded interim estimates of the effect size 
into our selected design, due to uncertainty about the true effect size in both the 
strategy arms.  
6.6.1. Non-adaptive design with time-to-event outcome 
As some participants may be lost to follow-up prior to the 12 month time point 
at which the primary outcomes is assessed, we propose that trialists consider a time 
to event outcome ‘time to first drink’ as the primary outcome. This outcome was used 
either as a primary or secondary outcome in previous trials, e.g. [5, 32]. 
Assume a time to event outcome will allow observations for the participants to 
be censored at the time of dropout. In a survival study (see Chapter 3), the sample 
size in terms of number of events required in the two treatment groups (experimental 
and control treatment group) assuming 1:1 randomization is given by 
 
𝐷 =
4(𝑧𝑎 + 𝑧1−𝛽)
2
[log(𝐻𝑅)]2
 
(6.7) 
where 𝐻𝑅 corresponds to the hazard ratio of the two treatment groups and it is equal 
to the median survival in the experimental group divided by the median survival in 
the control group [29]. In the Reverse Marker-Based strategy design, instead of 
having two treatment arms we have two strategy arms (genotype-guided arm and 
reverse-genotype-guided arm). Thus, based on (6.7) for time-to-event outcomes, 
assuming 1:1 randomization between genotype-guided arm and reverse-genotype-
guided arm, we propose the following equation as an approximation for the required 
number of events of the Reverse Marker-Based strategy design, i.e.  
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𝐷 =
4(𝑧𝑎 + 𝑧1−𝛽)
2
[log(𝐻𝑅)]2
=
4(𝑧𝑎 + 𝑧1−𝛽)
2
[log (
𝑚𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝑎𝑟𝑚
𝑚𝑟𝑒𝑣𝑒𝑟𝑠𝑒 𝑎𝑟𝑚
)]
2
=
4(𝑧𝑎 + 𝑧1−𝛽)
2
[log (
𝑘𝑚𝐴+ + (1 − 𝑘)𝑚𝐵−
𝑘𝑚𝐵+ + (1 − 𝑘)𝑚𝐴−
)]
2, 
(6.8) 
where 𝑚𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝑎𝑟𝑚, 𝑚𝑟𝑒𝑣𝑒𝑟𝑠𝑒 𝑎𝑟𝑚 are the median times to first drink in the genotype-
guided arm and reverse genotype-guided arm respectively and the 𝑚𝐴+, 𝑚𝐵−, 𝑚𝐵+, 
𝑚𝐴− are the median times to first drink of biomarker-positive patients receiving 
naltrexone, biomarker-negative patients receiving acamprosate, biomarker-positive 
patients acamprosate and biomarker-negative patients receiving naltrexone 
respectively. The median of the strategy arm and reverse arm can follow 
approximately a weighted sum formula similar to [33]. 
In 2003 a double-blind, placebo-controlled study comparing and combining 
naltrexone and acamprosate in relapse prevention of alcoholism was published by 
Kiefer et al. [32]. In this randomized trial, the 160 participants with alcoholism 
received naltrexone, acamprosate, combination of both treatments, or placebo for 12 
weeks. Survival analyses were performed on the lapse events (first alcohol intake). 
From the curves of the survival probabilities toward the event “first alcohol intake” 
for each of the treatment groups in Kiefer et al. [32] we can derive the median time to 
first drink for patients receiving acamprosate, i.e. 𝑚𝐵 ≈ 4.3 weeks and the median 
time to first drink for patients receiving the naltrexone, i.e. 𝑚𝐴 ≈ 6.7 weeks. For 
acamprosate, we assume the same median time to first drink for both biomarker-
positive and biomarker-negative patients (i.e. 𝑚𝐵 ≈ 𝑚𝐵+ ≈ 𝑚𝐵− ≈ 4.3) as in the case 
when assuming a binary outcome. For our optimal design (i.e. Reverse Marker-Based 
Strategy design), when the outcome is binary, the difference in response rates 
between the reverse-genotype-guided arm and the genotype-guided arm is estimated 
approximately 15%. Hence, for the time-to-event outcome, we will vary the effect size 
(i.e. hazard ratio between the two strategy arms) between 0.75 and 0.85 which 
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correspond to a moderate hazard ratio in order to calculate the required sample size 
in terms of number of events. These scenarios of effect sizes should be tested from a 
panel of expert clinicians who will decide which of these effect sizes can be 
considered as a minimally clinically significant difference. Based on formula (6.8), 380 
events are needed at a two-sided 5% significance level to achieve 80% power when 
the hazard ratio is 0.75. When the hazard ratio is 0.77, 0.81 and 0.84, we need 460, 708 
and 1034 events respectively to achieve 80% power (Table 6.7). 
 
 
Table 6.7. Required total number of events and corresponding hazard ratio of the Reverse Marker-Based 
strategy design applied to STRONG trial.  
 Scenario 1 Scenario 2 Scenario 3 Scenario 4 
Hazard ratio 0.75 0.77 0.81 0.84 
Two-sided significance level (𝒂) 0.05 0.05 0.05 0.05 
Power (𝟏 − 𝜷) 0.8 0.8 0.8 0.8 
Total number of events (𝑫) 
calculated by (7.8) 
380 460 708 1034 
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Chapter 7. Case study - An adaptive approach 
7.1. Introduction 
In the case study of the STRONG trial (Chapter 6) we identified the optimal 
design, the so-called Reverse Marker-Based strategy design. In the current chapter 
we consider incorporating sample size re-estimation into our chosen design.. 
Specifically, we consider an adaptive trial design and sample size re-estimation due 
to uncertainty about the true effect size in both the genotype-guided arm and the 
reverse-genotype-guided arm. In this adaptive version of the design, we allow early 
stopping of the trial at the end of the interim analysis due to efficacy of the study in 
the case where we have obtained a significant p-value showing that the genotype-
guided arm is better than the reverse-genotype-guided arm. This ensures reduction 
in cost and time of the study as there is no need to enrol further patients to prove 
efficacy. We also allow the study to stop for futility because of non-promising results 
at the interim stage. 
7.2. Choosing the type of Sample size re-estimation method 
When designing a clinical trial, there is often lack of knowledge regarding the 
design parameters fed into initial sample size calculations, such that there is 
uncertainty regarding the validity of sample size estimates for a clinical trial design 
with fixed sample size. In such cases, an adaptive design which enables adjustment 
(either increase or decrease) of the number of patients to provide desired study power 
can be adopted, i.e. the so-called sample size re-estimation design [1]. Here, the initial 
sample size estimate can be adjusted according to the results of an interim analysis 
where the accumulating data are examined to check whether they provide 
information that is consistent with the assumptions made in the initial sample size 
calculations. 
For sample size re-estimation several methods have been recommended in the 
literature, including blinded, unblinded and mixed methods [1]. More precisely, in 
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the blinded sample size re-estimation approach the results from interim analysis are 
used without unblinding treatment assignment to provide an updated estimate of the 
nuisance parameter (e.g. variance of the outcome) based on which the sample size of 
the trial will be recalculated. Hence, with this approach only the variance will be 
estimated at the interim analysis stage and the sample size will be reassessed based 
on that and the initial assumption of treatment difference. In contrast, the unblinded 
method uses the knowledge of treatment assignment. Hence, at the interim analysis 
stage, both the treatment effect and variability estimates will be calculated and they 
will inform the updated sample size. Similar to the blinded method, the treatment 
difference is not revealed when using the mixed approach and the sample size 
adjustment will be a combination of a blinded estimate and a futility boundary which 
will be based on unblinded data (i.e. blinded approach with a futility analysis added). 
In cases where there is considerable lack of knowledge about the treatment effect and 
nuisance parameter, the unblinded sample size re-estimation method might be 
preferred. For this reason, in the STRONG trial we adopt the unblinded method. Two 
types of the unblinded sample size recalculation are considered: (i) adjustment based 
on effect-size ratio and (ii) adjustment based on conditional power. Additionally, as 
we are assuming a two-stage (i.e. one interim analysis is included) adaptive design, 
we need to allow for the results from each stage to be combined. To do this, we adopt 
a common method which is based on the inverse-normal stagewise p-value proposed 
by Lehmacher and Wassmer [2]. More precisely, when this method is used, the 
inverse standard normal distribution is applied to the p-values at each stage (i.e. the 
second stage p-value is not using the stage 1 + stage 2 data), with the aim of obtaining 
a standardized normal statistic. After that, we obtain the combined standardized 
normal statistic by combining the normal statistics initially obtained through a 
weighted sum.  
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7.3. Simulation study 1: With the option of early stopping of the trial 
for efficacy 
To illustrate the proposed design, a simulation study is performed for both 
binary and time-to-event outcomes. In this simulation study, we allow the trial to 
stop only for efficacy. 
7.3.1. Calculation of required sample size 
First, we calculate the required fixed sample size per arm of the Reverse 
Marker-Based strategy design.   
For a binary outcome, equation (3.38) given in Subsection 3.2.4.4. is used for the 
calculation of the number of patients per arm, while for an event-time outcome, we 
calculate the required number of events based on the formula in equation (6.8) in 
Subsection 6.6.1, and then the required number of patients following formulations in 
Subsection 3.2.2. of Chapter 3 [3]. More precisely, the total number of patients is 
calculated by 
𝑁 =
𝐷
𝑃𝑟(𝑒𝑣𝑒𝑛𝑡)
, 
where D refers to the required number of events. 𝑃𝑟(𝑒𝑣𝑒𝑛𝑡) corresponds to the 
probability of observing an event and can be defined as 
𝑃𝑟(𝑒𝑣𝑒𝑛𝑡) = 𝜋𝑔𝑒𝑃𝑟𝑔𝑒(𝑒𝑣𝑒𝑛𝑡) + 𝜋𝑟𝑒𝑃𝑟𝑟𝑒(𝑒𝑣𝑒𝑛𝑡), 
where subscripts 𝑔𝑒 and 𝑟𝑒 refer to genotype-guided strategy arm and reverse-
genotype-guided strategy arm respectively and 𝜋𝑔𝑒 and 𝜋𝑟𝑒 are the proportions of 
patients who are randomized to genotype-guided strategy arm and reverse-
genotype-guided strategy arm respectively. 
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Let 𝑃𝑟𝑠(𝑒𝑣𝑒𝑛𝑡) where 𝑠 (𝑠 = 𝑔𝑒 or 𝑠 = 𝑟𝑒) be the probability of event in each 
strategy arm and can be calculated by using the formula given in Kleinbaum and 
Klein (2012) [4], i.e. 
𝑃𝑟𝑠(𝑒𝑣𝑒𝑛𝑡) = 1 −
1
(
log(2)
𝑚𝑠
) × 𝑇
× [𝑒
−(
log(2)
𝑚𝑠
)×𝜏
− 𝑒
−(
log(2)
𝑚𝑠
)×(𝑇+𝜏)
], 
where 𝑇 corresponds to the accrual period and 𝜏 corresponds to the follow-up period. 
𝑚𝑠 denotes the median time-to-event of the corresponding treatment strategy arm, 
and is given by 
𝑚𝑠 = 𝑘𝑚𝑠+ + (1 − 𝑘)𝑚𝑠−, 
where 𝑘 denotes the biomarker prevalence and 𝑚𝑠+ and  𝑚𝑠− are the median time-to-
event in the corresponding treatment strategy arm of biomarker-positive and 
biomarker-negative subgroups respectively. 
7.3.2. Target number of patients at the interim stage 
Next, we calculate the target number of patients to be included in the interim 
analysis per arm based on a fixed interim fraction 𝑓 by  
𝑁1 = 𝑁/𝑎𝑟𝑚 × 𝑓. 
7.3.3. Variance of outcome 
The variance for the two treatment strategy arms, under large sample size 
assumptions, can be defined for a binary outcome by 
𝜎 = √?̅?(1 − ?̅?), 
[1] where ?̅? is the average of the response rates across both trial arms. For an event-
time outcome, with uniform patient entry (i.e. time of patient entry for participants is 
modeled with a Uniform distribution for entry times. The accrual continues until the 
 274 
 
assumed accrual period 𝑇. Thus, study entry times are generated from 𝑈~𝑈𝑛𝑖𝑓[𝑇 −
1, 𝑇]), the variance can be defined by  
𝜎 = ?̅?(1 + 𝑢)(−1/2), 
where 
𝑢 =
exp[−?̅? × (𝑇 + 𝜏)] × [1 − exp(?̅? × 𝑇)]
(𝑇 × ?̅?)
, 
and ?̅? in case of time-to-event outcome refers to the average of the hazard rates across 
both trial arms [1]. 
7.3.4. Test statistic of the first stage 
For each simulated iteration, we generate one random number for the 
genotype-guided arm (𝑔1
′) from a normal distribution with mean 𝑔1 and standard 
deviation 𝜎/√𝑁1 and one random number for the reverse-genotype-guided arm (𝑔4
′) 
with mean 𝑔4 and standard deviation 𝜎/√𝑁1 , independently. When the outcome is 
binary, 𝑔1 and 𝑔4 refers to the response rate of genotype-guided arm and reverse-
genotype-guided arm respectively (see Chapter 3, Subsection 3.2.4.4.). If the outcome 
is time-to-event, 𝑔1 and 𝑔4 correspond to the hazard rates of genotype-guided arm 
and reverse-genotype-guided arm respectively. Since 
𝑔1
′~𝑁 (𝑔1,
𝜎2
𝑁1
) 
and 
𝑔4
′~𝑁 (𝑔4,
𝜎2
𝑁1
), 
then 
𝑔1
′ − 𝑔4
′~𝑁 (𝑔1 − 𝑔4,
2𝜎2
𝑁1
). 
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Hence, the test statistic under the null hypothesis 𝐻0: 𝑔1 − 𝑔4 = 0 can be given by 
𝑇1 =
(𝑔1
′ − 𝑔4
′) × √
𝑁1
2
𝜎
. 
The corresponding p-value of the observed test statistic 𝑇1 is given by 
𝑝1 = 𝑃𝑟(𝑇1 ≥ 𝑡1|𝐻0), 
where 𝐻0 is the null hypothesis of no treatment effect. 
7.3.5. Stopping boundaries 
Before conducting a two-stage design, pre-specification of stopping rules and 
boundaries for efficacy and/or futility are needed. Stopping probabilities (i.e. 
rejection probabilities), which are calculated based on the stopping boundaries, are 
essential operating characteristics of adaptive designs. Two types of stopping 
probabilities exist, the so-called ‘efficacy stopping probability’ which refers to the 
unconditional probability of rejecting the null hypothesis of no treatment effect, thus 
the trial stops in order to claim efficacy and the ‘futility stopping probability’ which 
refers to the unconditional probability of not rejecting the null hypothesis of no 
treatment effect, thus the trial stops in order to claim futility. In our simulation study, 
we have considered the two most common types of stopping boundaries which allow 
early stopping of the trial only for efficacy: (i) O’Brien and Fleming’s boundaries; and 
(ii) Pocock’s boundaries. Generally, O’Brien-Fleming efficacy boundaries are 
preferred when the aim is to keep the trial going instead of stopping the trial early 
due to promising results. On the contrary, with the Pocock efficacy boundaries there 
is greater chance of stopping the trial early as they sum up the type I error rate earlier. 
Stopping boundaries for efficacy can be determined by the formula of O’Brien-
Fleming and Pocock alpha or 𝑎-spending function which has been defined by Demets 
and Lan (1994) as “A way of describing the rate at which the total level of significance 
(𝑎) is spent as a continuous function of information fraction and thus induces a 
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corresponding boundary” [5]. The 𝑎-spending function that approximates the 
O’Brien-Fleming boundary is [5]: 
𝑎O’Brien−Fleming(𝑡
∗) = 2 − 2Φ(𝑍𝑎 2⁄ √𝑡∗⁄ ), 
and the 𝑎-spending function that approximates Pocock’s boundary is [5]: 
𝑎Pocock(𝑡
∗) = 𝑎 ln[1 + (𝑒 − 1)𝑡∗], 
where Φ denotes the standard normal cumulative distribution function, 𝑎 is the 
nominal type I error rate (for a one-sided test, 𝑎 = 𝑎 2⁄ ) and 𝑡∗ denotes the 
information fraction, e.g., for a two-stage design, an equally spaced 𝑡∗ is equal to 1 2⁄  
in the first stage and 2 2⁄  in the second stage. Additionally, 𝑎O’Brien−Fleming(𝑡
∗) and 
𝑎Pocock(𝑡
∗) are the 𝑎-spending functions at interim time 𝑡∗ for a one-sided test. These 
𝑎-spending functions present the cumulative type I error rate of O’Brien-Fleming and 
Pocock boundaries spent up to the information time 𝑡∗. Consequently, the type I error 
to spend at the 𝑜th stage with information time 𝑡𝑜
∗ can be found by  
𝑎O’Brien−Fleming(𝑡𝑜
∗) − 𝑎O’Brien−Fleming(𝑡𝑜−1
∗ ) and 𝑎Pocock(𝑡𝑜
∗) − 𝑎(𝑡𝑜−1
∗ ), 
for O’Brien-Fleming type and Pocock type boundaries respectively.  
Based on the aforementioned stopping boundaries, decisions are made during 
the interim analysis about whether to stop the trial early for efficacy. More precisely, 
if 𝑝1 ≤ 𝑎1, where 𝑎1 refers either to the type I error at stage 1 calculated by using the 
O’Brien-Fleming or Pocock method and 𝑝1 is the p-value of the observed value 𝑡1 of 
the test statistic at stage 1, the trial is stopped for efficacy at stage 1, meaning that the 
null hypothesis of no treatment effect is rejected. Otherwise, the trial continues to the 
second stage.  
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7.3.6. Sample size adjustment 
If the trial has been stopped for efficacy at the first stage of the study, the sample 
size equals 𝑁1, however, if the trial continues to the second stage, we recalculate the 
sample size.  
i) If the adjustment is chosen based on effect-size ratio [1], then the formation 
of the sample size adjustment can be given by 
𝑁𝑓𝑖𝑛𝑎𝑙 = 𝑚𝑖𝑛 {𝑁𝑚𝑎𝑥, 𝑚𝑎𝑥 [𝑁/𝑎𝑟𝑚, (
𝑔1 − 𝑔4
|𝑔1′ − 𝑔4′| + 0.0000001
)
𝑡𝑢
× 𝑁/𝑎𝑟𝑚] }, 
where 𝑁𝑓𝑖𝑛𝑎𝑙 is the newly estimated number of patients per group, 𝑁/𝑎𝑟𝑚 is the 
estimated sample size per group of a non-adaptive design, 𝑁𝑚𝑎𝑥 is a 
prespecified parameter in our simulations which refers to the chosen upper 
limit of total sample size per group and 𝑡𝑢 is a tuning parameter that is often 
chosen to be 2 [6]. The small number 0.0000001 is added to avoid numerical 
overflow if 𝑔1
′ − 𝑔4
′ = 0. In real practice, the allowed maximum sample size 
𝑁𝑚𝑎𝑥 will be determined by the sponsors of the trial who will decide a suitable 
sample size extension.  
ii) If an adjustment based on conditional power with the limit of the maximum 
number of patients (𝑁𝑚𝑎𝑥) allowed due to cost and time considerations is 
selected [1], then the formation of the sample size can be given by  
𝑁2 = 𝑚𝑖𝑛 [𝑁𝑚𝑎𝑥 − 𝑁1,
2𝜎2
(𝑔1 − 𝑔4)2
(
𝑧1−𝑎2 − 𝑤1𝑧1−𝑝1
√1 − 𝑤1
2
− 𝑧1−𝑐𝑃)
2
], 
where 𝑎2 is the final efficacy stopping boundary, 𝑐𝑃 is the target conditional 
power (pre-specified parameter in our simulations which refers to an approach 
that quantifies the probability of rejecting the null hypothesis of no effect once 
some data are available) which might be determined by funding bodies in real 
practice, 𝑝1 is the p-value of the observed test statistic 𝑡1 at stage 1 and 𝑧1−𝑎2 =
Φ−1(1 − 𝑎2), 𝑧1−𝑐𝑃 = Φ
−1(1 − 𝑐𝑃), 𝑧1−𝑝1 = Φ
−1(1 − 𝑝1), where Φ denotes the 
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standard normal cumulative distribution function. Information from both 
stages is combined using the inverse normal combination test where 𝑤1 and 𝑤2 
are pre-specified weights satisfying 𝑤1
2 + 𝑤2
2 = 1 [2]. In our simulation, we fix 
𝑤1 = 𝑤2 = 1/√2. 
7.3.7. Test statistic of the second stage 
A similar process used for the determination of the first stage test statistic is 
followed for the determination of the second stage test statistic (see Section 7.3.4.). 
The difference is that test statistic of the second stage will be based on the adjustment 
of the sample size. More precisely, after the recalculation of the sample size,  
i) when the adjustment is based on effect-size ratio method, we generate one 
random number for the genotype-guided arm (𝑔1
′′) from normal 
distribution with mean 𝑔1 and the new standard deviation 𝜎/√𝑁𝑓𝑖𝑛𝑎𝑙 − 𝑁1 
and one random number for the reverse-genotype-guided arm (𝑔4
′′) with 
mean 𝑔4 and the new standard deviation 𝜎/√𝑁𝑓𝑖𝑛𝑎𝑙−𝑁1. Therefore, the test 
statistic of the second stage is given by 
𝑇2 =
(𝑔1
′′ − 𝑔4
′′) × √
𝑁𝑓𝑖𝑛𝑎𝑙 − 𝑁1
2
𝜎
. 
ii) when the sample size adjustment is based on the conditional power method, 
we generate one random number for the genotype-guided arm (𝑔1
′′) from 
normal distribution with mean 𝑔1 and the new standard deviation 𝜎/√𝑁2 
and one random number for the reverse-genotype-guided arm (𝑔4
′) with 
mean 𝑔4 and the new standard deviation 𝜎/√𝑁2. The test statistic of the 
second stage is given by 
𝑇2 =
(𝑔1
′′ − 𝑔4
′′) × √
𝑁2
2
𝜎
. 
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7.3.8. Final test statistic 
The test statistic of the final analysis (inverse normal combination test) is based 
on the weighted sum of test statistics of each stage and can be given by 
𝑍2 = 𝑤1𝑡1 + 𝑤2𝑡2 =
𝑡1 + 𝑡2
√2
, 
according to Lehmacher and Wassmer (1999) who suggested the use of equal 
weights, i.e. 1 √𝑠⁄ , where 𝑠 denotes the number of stages of the design [2]. The 
corresponding 𝑝-value to the final test statistic 𝑍2 is given by 
𝑝2 = 𝑃𝑟(𝑍2 ≥ 𝑧2|𝐻0), 
where 𝐻0 is the null hypothesis of no treatment effect. If 𝑝2 ≤ 𝑎2, where 𝑎2 refers to 
the type I error at stage 2 calculated by using either the O’Brien-Fleming or Pocock 
method, we get the total study power. 
7.3.9. Simulation parameters 
In our simulation study we consider both types of boundaries to preserve the 
overall type I error rate for effectiveness at the one-sided 0.025 level. More precisely, 
we have used the O’Brien-Fleming’s efficacy stopping boundaries 0.001525323 and 
0.02347468 for stage 1 and stage 2 respectively and the Pocock efficacy stopping 
boundaries 0.01550286 and 0.009497137 for stage 1 and stage 2 respectively calculated 
by the package GroupSeq in R statistical software. The weights for combining both 
stages are also pre-specified as  𝑤1 = 𝑤2 = 1/√2 according to Lehmacher and 
Wassmer (1999) to ensure control of the type I error rate [2]. In addition, we assume 
that a reasonable sample size extension is no more than 100 patients. Hence, we allow 
recruitment of an additional 100 patients (𝑁𝑚𝑎𝑥 = 𝑁/𝑎𝑟𝑚 + 100) as an upper limit of 
the allowed sample size. The type II error rate, 𝛽 = 0.2, was assumed for the 
calculation of the fixed number of events and patients required in a standard non-
adaptive design. Three cases of information fraction were explored, i.e. (i) 𝑓 = 0.25, 
(ii) 𝑓 = 0.50, (iii) 𝑓 = 0.75 in order to investigate a range from low to high percentage.  
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We performed 1000000 simulated iterations for binary and time-to-event 
outcome using both the effect size method and the conditional power method.  
In the simulation study for binary outcome, the response rate in the genotype-
guided arm is assumed to be 𝑔1 = 0.72 and in the reverse genotype-guided arm is 
𝑔4 = 0.57 based on the non-adaptive calculations of the Reverse Marker-Based 
strategy design in Chapter 6. These response rates result in 15% difference in response 
rates between the two strategy arms. 
The time-to-event outcome is based on the study by Kiefer et al. [7] in which 
participants with alcoholism were randomized between naltrexone, acamprosate, 
combination of both treatments, or placebo with 12 weeks follow-up period and the 
accrual period 2 years (i.e 104.28 weeks). In our case, the accrual time and total study 
period were fixed at 104.28 weeks and 116.28 weeks respectively which correspond 
to 12 weeks of follow-up. 
In the simulation study for time-to-event outcome, four scenarios of median 
time-to-event for biomarker-positive and biomarker-negative patients receiving the 
experimental treatment were considered as in Chapter 6, i.e. (i) 𝑚𝐴+ = 6, 𝑚𝐴− = 6.7, 
(ii) 𝑚𝐴+ = 6.7, 𝑚𝐴− = 6, (iii) 𝑚𝐴+ = 6.6, 𝑚𝐴− = 6.3 and (iv) 𝑚𝐴+ = 6.3, 𝑚𝐴− = 6.6. For 
biomarker-negative and biomarker-positive patients receiving the control treatment, 
the median time-to-event was 4.3 weeks (𝑚𝐵− = 𝑚𝐵+ = 4.3). The corresponding 
hazard ratios for the four scenarios of median survival times are 0.746, 0.845, 0.807 
and 0.765 respectively calculated by using the divisor of formula (6.8) in Chapter 6. 
The hazard rate in the genotype-guided arm is given by  
𝑔1 =
ln2
𝑚𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝑎𝑟𝑚
, 
where 
𝑚𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝑎𝑟𝑚 = 𝑘𝑚𝐴+ + (1 − 𝑘)𝑚𝐵−, 
and the hazard rate in the reverse-genotype-guided arm is given by 
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𝑔4 =
ln2
𝑚𝑟𝑒𝑣𝑒𝑟𝑠𝑒 𝑎𝑟𝑚
, 
where 
𝑚𝑟𝑒𝑣𝑒𝑟𝑠𝑒 = 𝑘𝑚𝐵+ + (1 − 𝑘)𝑚𝐴−. 
Simulation parameters for binary and time-to-event outcomes are summarized 
in Table 7.1. 
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Table 7.1. Summary of simulation parameters for both binary and time-to-event outcomes. 
 Binary outcome Time-to-event outcome Selection 
Efficacy stopping boundary-
Stage 1 (scenario 1) 
0.001525323 similar to binary outcome O’Brien-Fleming’s boundary 
Efficacy stopping boundary-
Stage 1 (scenario 2) 
0.01550286 similar to binary outcome Pocock boundary 
Efficacy stopping boundary-
Stage 2 (scenario 1) 
0.02347468 similar to binary outcome O’Brien-Fleming’s boundary 
Efficacy stopping boundary-
Stage 2 (scenario 2) 
0.009497137 similar to binary outcome Pocock boundary 
Weights for combining Stage 
1 and Stage 2 
𝑤1 = 𝑤2 = 1/√2 similar to binary outcome Equal weights for simplicity 
Upper limit of the allowed 
sample size 
𝑁𝑚𝑎𝑥 = 𝑁/𝑎𝑟𝑚 + 100 similar to binary outcome 100 patients is assumed as a 
reasonable sample size extension 
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for our trial. Hence, we allow 
recruitment of an additional 100 
patients. 
Type II error rate 𝛽 = 0.2 similar to binary outcome 80% power needed for the 
calculation of the fixed number of 
events and patients required in a 
standard non-adaptive design. 
Information fraction 
 
(i) 𝑓 = 0.25, 
(ii) 𝑓 = 0.50,  
(iii) 𝑓 = 0.75 
similar to binary outcome Three cases of information 
fraction were explored in order to 
investigate a range from low to 
high percentage. 
Median time-to-event for 
patients receiving the 
experimental treatment  
Not applicable (i) 𝑚𝐴+ = 6, 𝑚𝐴− = 6.7, 
(ii) 𝑚𝐴+ = 6.7, 𝑚𝐴− = 6, 
(iii) 𝑚𝐴+ = 6.6, 𝑚𝐴− = 6.3 
Four scenarios of median time-to-
event for biomarker-positive and 
biomarker-negative patients 
receiving the experimental were 
considered based on Chapter 6 
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(iv) 𝑚𝐴+ = 6.3, 𝑚𝐴− = 6.6 
 
Median time-to-event for 
patients receiving the control 
treatment 
Not applicable 𝑚𝐵− = 𝑚𝐵+ = 4.3 Median time-to-event for 
biomarker-positive and 
biomarker-negative patients 
receiving the control treatment 
was based on Chapter 6 
Response rate/Hazard rate in 
genotype-guided arm 
𝑔1 = 0.72 𝑔1 =
ln2
𝑚𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦
, 
where  
𝑚𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑦 𝑎𝑟𝑚 = 𝑘𝑚𝐴+ + (1 − 𝑘)𝑚𝐵− 
Calculations based on Chapter 6 
Response rate/Hazard rate in 
reverse-genotype-guided 
arm 
𝑔4 = 0.57 𝑔4 =
ln2
𝑚𝑟𝑒𝑣𝑒𝑟𝑠𝑒 𝑎𝑟𝑚
, 
where 
𝑚𝑟𝑒𝑣𝑒𝑟𝑠𝑒 𝑎𝑟𝑚 = 𝑘𝑚𝐵+ + (1 − 𝑘)𝑚𝐴− 
Calculations based on Chapter 6 
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7.4. Simulation study 2: With the option of early stopping of the trial 
for efficacy and futility 
Apart from the efficacy stopping probability, another important design change 
is the early cessation of the trial due to futility of treatment effect in case that the 
results are not promising enough at the end of the interim analysis. If the trial claims 
futility, it does not necessarily mean that the treatment of interest is ineffective, but it 
shows that even though the study was initially powered at a sufficient high 
percentage (e.g. 80%), at the interim stage, the revised accumulating information 
results in much lower power. Therefore, it can be shown that the study will not be 
plausible as a very large sample size would be required to reach the desired power.  
We extend simulation study 1 by allowing the trial to stop early for futility at 
the end of the interim stage. According to Lan and Demets (2009) [8], one suggestion 
of futility boundary could be the use of a beta (𝛽) spending function. More 
specifically, 𝑎 (type I error) can be replaced with 𝛽 (type II error) in the formula of 
Pocock type spending function 𝑎Pocock(𝑡
∗). Therefore, we can have the following 𝛽-
spending function, 
𝛽Pocock(𝑡
∗) = 𝛽 ln[1 + (𝑒 − 1)𝑡∗]. 
Decisions are made during the interim analysis about whether to stop the trial 
early for efficacy and futility or to continue to the second stage of the study. More 
precisely, if 𝑝1 > 𝛽1, where 𝛽1 refers to the futility stopping boundary, the trial is 
stopped for futility at stage 1, meaning that the null hypothesis of no treatment effect 
is accepted. If 𝑝1 ≤ 𝑎1, where 𝑎1 refers to the type I error at stage 1 calculated by using 
the O’Brien-Fleming or Pocock method, the trial is stopped for efficacy at stage 1, 
meaning that the null hypothesis of no treatment effect is rejected. Otherwise, if 𝑎1 <
𝑝1 ≤ 𝛽1, the trial continues to the second stage. In our simulation study, the nominal 
level of power was set at 80%, thus, the type II error rate (i. e. 𝛽 ) corresponds to 0.2. 
Therefore, the futility stopping boundary used for our two-stage design is equal to 
0.124. The simulation study 1, which allows the trial to stop early only due to efficacy, 
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follows the same decision process, however, 𝛽1 is equal to 1 meaning that we do not 
allow the study to stop early for futility. 
7.5. Simulation results 
Results from Simulation study 1 and Simulation study 2 for both binary and 
time-to-event outcome are described below. 
Graphical summaries are presented in Figures 7.1 to 7.70. The numerical 
summaries are presented in Appendix D, Tables D.1.1-D.1.4 and D.2.1-D.2.4 for 
binary outcome from Simulation study 1 and Simulation study 2 respectively. The 
fixed sample size, difference in response rates between the two strategy arms, 
average adaptive sample size, efficacy stopping probability and rejection probability 
are presented. The rejection probability of the null hypothesis corresponds to the type 
I error rate whereas the rejection probability of the alternative hypothesis 
corresponds to the total power of the study. Results from Simulation study 1 and 2 
for time-to-event outcome are summarized in Appendix D, in Tables D.1.5-D.1.8 and 
D.2.5-D.2.8 respectively. The fixed number of events and number of patients for the 
non-adaptive design and the corresponding hazard ratio are presented. Additionally, 
the average sample size, efficacy and futility stopping probability and rejection 
probability of the study under the null hypothesis and alternative hypothesis in each 
of the three cases of information fraction are shown.  
7.5.1. Binary Outcome 
7.5.1.1. Control of type I error rate 
In both simulation studies, the type I error rate is well controlled (<0.025) when 
either the effect-size ratio method or the conditional power method for sample size 
adjustment is used with O’Brien-Fleming and Pocock decision boundaries. More 
precisely, in Simulation study 1 (i.e. only efficacy stopping of the trial is allowed), the 
type I error rate is equal to 0.024706 (i.e. rejection probability under the null 
hypothesis in Appendix D, Tables D.1.1-D.1.2) in all scenarios of information fraction 
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for which the O’Brien-Fleming decision boundaries are applied and it is equal to 
0.021698 (i.e. rejection probability under the null hypothesis in Appendix D, Tables 
D.1.3-D.1.4) for Pocock decision boundaries (Figure 7.1). In Simulation study 2 (i.e. 
both efficacy and futility stopping of the trial are allowed), the type I error rate is 
equal to 0.018734 (i.e. rejection probability under the null hypothesis in Appendix D, 
Tables D.2.1-D.2.2) in all scenarios for which the O’Brien-Fleming efficacy boundaries 
are applied and it is equal to 0.020321 (i.e. rejection probability under the null 
hypothesis in Appendix D, Tables D.2.3-D.2.4) for Pocock efficacy boundaries (Figure 
7.2). All resulting type I error values shown in Figures 7.1 and 7.2 are under the 0.025 
level, indicating that the type I error rate is well controlled. 
 
Figure 7.1. Type I error versus the information fraction of Simulation study 1. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). 
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Figure 7.2. Type I error versus the information fraction of Simulation study 2. The horizontal line 
represents the level of significance of the non-adaptive design (i.e. 0.025). 
7.5.1.2. Power of the study 
Figure 7.3 from Simulation study 1, under the alternative hypothesis, when the 
effect-size ratio method for sample size adjustment is applied, shows that we can 
achieve greater power with the O’Brien-Fleming decision boundaries as compared to 
the Pocock’s type boundaries. The conditional power method results in greater power 
with the O’Brien-Fleming decision boundaries as compared to Pocock boundaries 
only when the information fraction is 25%. For 50% and 75% information fraction, it 
seems that Pocock boundaries yield greater power as compared to the O’Brien-
Fleming efficacy boundaries. It can also be seen that for 50% and 75% of information 
fraction, the power is improved compared to the nominal level of power in the non-
adaptive design as it exceeds 80% in both types of sample size adjustment and both 
types of stopping boundaries. At 25% information fraction, the power exceeds the 
nominal level (i.e. 80%) only when the effect-size ratio method with the O’Brien-
Fleming decision boundaries is applied. 
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Figure 7.3. Power versus the information fraction under the alternative hypothesis of Simulation study 
1. The horizontal line represents the power of the non-adaptive design (i.e. 80%). 
Figure 7.4 from Simulation study 2, under the alternative hypothesis, shows 
that the power exceeds the nominal level (i.e. 80%) only at 75% information fraction 
when all types of sample size adjustment methods and stopping boundaries are used 
apart from the combination of the conditional power method with the O’Brien-
Fleming decision boundaries. Among the different sample size adjustment methods 
and stopping boundaries, the effect-size ratio method with the O’Brien-Fleming 
decision boundaries results in the highest power and the conditional power method 
with the same type of stopping boundaries results in the lowest power. 
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Figure 7.4. Power versus the information fraction under the alternative hypothesis of Simulation study 
2. The horizontal line represents the power of the non-adaptive design (i.e. 80%). 
7.5.1.3. Sample size of the study 
Figure 7.5 from Simulation study 1, under the alternative hypothesis, shows 
gain in efficiency (i.e. smaller sample size compared to that of the non-adaptive 
design) only at 25% and 50% information fraction when the conditional power 
method with the O’Brien-Fleming boundaries is applied. In all other cases, there is 
loss of efficiency as the sample size is increased compared to the number of patients 
required for the non-adaptive design. 
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Figure 7.5. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 1. The horizontal line represents the sample size of the non-adaptive design. 
However, this is changed when introducing both efficacy and futility stopping in the 
trial. It can be seen in Figure 7.6 (Simulation study 2) that the sample size is decreased 
when using both types of sample size adjustment and stopping boundaries apart 
from 75% information fraction under effect-size ratio method and O’Brien-Fleming 
decision boundaries.  
 
Figure 7.6. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 2. The horizontal line represents the sample size of the non-adaptive design. 
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Across the different methods for the recalculation of the sample size and stopping 
boundaries, in both Figures 7.5 and 7.6, the smallest sample size is achieved when the 
conditional power method with O’Brien-Fleming boundaries is applied and the 
largest sample size is achieved with the effect-size ratio method and the same type of 
stopping boundaries. 
From Simulation study 1, under the null hypothesis, all values are above the 
horizontal line in Figure 7.7 indicating the increase of the sample size compared to 
the sample size of the non-adaptive design. The largest increase of the sample size as 
compared to the number of patients required for the non-adaptive approach 
corresponds to 75% information fraction. Specifically, with the 75% information 
fraction, 156 patients per arm required for the non-adaptive approach, and we 
achieved 250 patients per arm with the conditional power method and O’Brien-
Fleming decision boundaries, 251 patients per arm with the effect-size ratio method 
and the same type of boundaries, 253 patients per arm with the conditional power 
method and Pocock boundaries and 251 patients per arm with the effect-size ratio 
method and the same type of stopping boundaries. These numbers are very close to 
the allowed maximum sample size (𝑁𝑚𝑎𝑥). 
 
Figure 7.7. Sample size versus the information fraction under the null hypothesis of Simulation study 1. 
The horizontal line represents the sample size of the non-adaptive design. 
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However, this situation changes when introducing the futility stopping in 
Simulation study 2. As shown in Figure 7.8, all values are under the horizontal line 
indicating a decrease in sample size compared to a fixed design. Figure 7.8 shows that 
in both methods of sample size recalculation and both types of efficacy boundaries 
the number of patients increases when the information fraction increases. The largest 
increase of the sample size as compared to the number of patients required for the 
non-adaptive approach corresponds to 75% information fraction. More precisely, 
with the 75% information fraction, 156 patients per arm were required for the non-
adaptive approach, and we would require 128 patients per arm with the conditional 
power method and O’Brien-Fleming efficacy boundaries, 132 patients per arm with 
the effect-size ratio method and the same type of stopping boundaries and 131 
patients when the conditional power method and the effect-size ratio method with 
Pocock efficacy boundaries are used. 
 
Figure 7.8. Sample size versus the information fraction under the null hypothesis of Simulation study 2. 
The horizontal line represents the sample size of the non-adaptive design. 
7.5.1.4. Efficacy stopping probability 
In both simulation studies, under the alternative hypothesis, the efficacy 
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increase of information fraction. Consequently, the largest value is obtained at 75% 
information fraction. Additionally, the efficacy stopping probability is always greater 
with the Pocock decision boundaries compared to the probabilities obtained with the 
O’Brien-Fleming decision boundaries. 
 
Figure 7.9. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 1. 
 
Figure 7.10. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2. 
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Similarly to the alternative hypothesis, in both simulation studies under the 
null hypothesis, the efficacy stopping probabilities depend only on the efficacy 
stopping boundaries and not on the sample size adjustment methods. Figures 7.11, 
7.12 show that the efficacy stopping probabilities remain the same across the different 
percentages of information fraction for each type of stopping boundaries. Higher 
values are achieved when the Pocock stopping boundaries are used compared to the 
O’Brien-Fleming efficacy boundaries. 
 
Figure 7.11. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 1. 
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Figure 7.12. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2. 
7.5.1.5. Futility stopping probability 
In Simulation study 2, the futility stopping probability depends only on the 
type of stopping boundaries and not on the method of sample size recalculation. As 
shown in Figure 7.13, futility stopping probability (FSP) decreases with the increase 
of information fraction under the alternative hypothesis and it depends only on the 
type of stopping boundaries and not on the method of sample size recalculation. 
Hence, the smallest value of futility probability is obtained at 75% information 
fraction. The application of Pocock stopping boundaries results in slightly higher 
futility stopping probabilities compared to the use of the O’Brien-Fleming efficacy 
boundaries. 
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Figure 7.13. Futility stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2. 
Similarly to the alternative hypothesis, the futility stopping probabilities under 
the null hypothesis of Simulation study 2, depend only on the efficacy stopping 
boundaries and not on the sample size adjustment methods. Figure 7.14 shows that 
the futility stopping probabilities remain the same across the different percentages of 
information fraction for each type of stopping boundaries. Similar values are 
achieved with each type of stopping boundaries. 
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Figure 7.14. Futility stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2. 
7.5.2. Time-to-event Outcome 
7.5.2.1. Control of type I error rate 
Similarly to the binary outcome, it can be seen from our results that the type I 
error rate is well controlled (<0.025) also in the case of survival outcome. The type I 
error rate in each simulation study is the same with that in binary outcome and all 
the different scenarios of hazard ratio have the same type I error rate. More precisely, 
in Simulation study 1, the type I error rate is equal to 0.024706 (i.e. rejection 
probability under the null hypothesis in Appendix D, Tables D.1.5-D.1.6) in all 
scenarios of information fraction and hazard ratios for which the O’Brien-Fleming 
decision boundaries are applied and it is equal to 0.021698 (i.e. rejection probability 
under the null hypothesis in Appendix D, Tables D.1.7-D.1.8) for Pocock decision 
boundaries. In Simulation study 2, the type I error rate is equal to 0.018734 (i.e. 
rejection probability under the null hypothesis in Appendix D, Tables D.2.5-D.2.6) in 
all scenarios of information fraction and hazard ratio for which the O’Brien-Fleming 
efficacy boundaries are applied and it is equal to 0.020321 (i.e. rejection probability 
under the null hypothesis in Appendix D, Tables D.2.7-D.2.8) for Pocock efficacy 
boundaries. The results of type I error rate versus the information fraction in both 
simulation studies for each scenario of hazard ratio are shown in Figures 7.15-7.22 
below. In all cases, the type I error rate is well controlled as all resulting values are 
under 0.025 level. 
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First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.15. Type I error versus the information fraction under the null hypothesis of Simulation study 
1 for the first scenario of hazard ratio. The horizontal line represents the level of significance of the non-
adaptive design (i.e. 0.025). 
 
Figure 7.16. Type I error versus the information fraction under the null hypothesis of Simulation study 
2 for the first scenario of hazard ratio. The horizontal line represents the level of significance of the non-
adaptive design (i.e. 0.025). 
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Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.17. Type I error versus the information fraction under the null hypothesis of Simulation study 
1 for the second scenario of hazard ratio. The horizontal line represents the level of significance of the 
non-adaptive design (i.e. 0.025). 
 
Figure 7.18. Type I error versus the information fraction under the null hypothesis of Simulation study 
2 for the second scenario of hazard ratio. The horizontal line represents the level of significance of the 
non-adaptive design (i.e. 0.025). 
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Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.19. Type I error versus the information fraction under the null hypothesis of Simulation study 
1 for the third scenario of hazard ratio. The horizontal line represents the level of significance of the non-
adaptive design (i.e. 0.025). 
 
Figure 7.20. Type I error versus the information fraction under the null hypothesis of Simulation study 
2 for the third scenario of hazard ratio. The horizontal line represents the level of significance of the non-
adaptive design (i.e. 0.025). 
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Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.21. Type I error versus the information fraction under the null hypothesis of Simulation study 
1 for the fourth scenario of hazard ratio. The horizontal line represents the level of significance of the 
non-adaptive design (i.e. 0.025). 
 
Figure 7.22. Type I error versus the information fraction under the null hypothesis of Simulation study 
2 for the fourth scenario of hazard ratio. The horizontal line represents the level of significance of the 
non-adaptive design (i.e. 0.025). 
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7.5.2.2. Power of the study 
Figures 7.23 to 7.26 from Simulation study 1, under the alternative hypothesis, 
when the effect-size ratio method for sample size adjustment is applied, show that 
we can achieve greater power with the O’Brien-Fleming decision boundaries as 
compared to the Pocock’s type boundaries in all scenarios of hazard ratio. Under 
conditional power method, in the first and fourth scenario of hazard ratio (i.e. 0.746 
and 0.765 respectively) the power is higher with the O’Brien-Fleming decision 
boundaries compared to Pocock boundaries only at 25% information fraction 
(Figures 7.23, 7.26). For 50% and 75% information fraction, it seems that Pocock 
boundaries yield higher power as compared to the O’Brien-Fleming efficacy 
boundaries (Figures 7.23, 7.26). In the second scenario of hazard ratio (i.e. 0.845), 
when conditional power method is applied, the O’Brien-Fleming decision boundaries 
result in higher power compared to the Pocock boundaries in all cases of information 
fraction (Figure 7.24). In the third scenario of hazard ratio (i.e. 0.807), the conditional 
power method achieves higher power with the Pocock boundaries compared to the 
same method with the O’Brien-Fleming decision boundaries only at 75% information 
fraction (Figure 7.25). From Figure 7.23 which corresponds to the first scenario of 
hazard ratio (i.e. 0.746), we can see that at 50% and 75% information fraction, the 
power is improved compared to the nominal level of power in the non-adaptive 
design as it exceeds 80% in both types of sample size adjustment methods and both 
types of stopping boundaries. At 25% information fraction, the power exceeds the 
nominal level (i.e. 80%) only when the effect-size ratio method with the O’Brien-
Fleming decision boundaries is applied. From Figure 7.24 which corresponds to the 
second scenario of hazard ratio (i.e. 0.843), it is shown that the power is improved 
compared to the nominal level of power in the non-adaptive design at 25% and 50% 
information fraction only when the effect-size ratio method with the O’Brien-Fleming 
boundaries is applied. At 75% information fraction, the power is improved compared 
to that of the fixed design only when the O’Brien-Fleming boundaries are applied. In 
the third scenario of hazard ratio (i.e. 0.807), the power exceeds the nominal level (i.e. 
80%) in both sample size re-estimation methods and stopping boundaries at 75% 
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information fraction, whereas at 25% and 50% information fraction, only the effect-
size ratio method with the O’Brien-Fleming boundaries achieves power greater than 
80% (Figure 7.25). In the fourth scenario of hazard ratio (i.e. 0.765), we have greater 
power than 80% at 50% and 75% information fraction (Figure 7.26). At 25% 
information fraction, only the effect-size ratio method with the O’Brien-Fleming 
boundaries exceeds the 80% nominal level of power. 
First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.23. Power versus the information fraction under the alternative hypothesis of Simulation study 
1 for the first scenario of hazard ratio. The horizontal line represents the power of the non-adaptive 
design. 
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Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.24. Power versus the information fraction under the alternative hypothesis of Simulation study 
1 for the second scenario of hazard ratio. The horizontal line represents the power of the non-adaptive 
design. 
Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.25. Power versus the information fraction under the alternative hypothesis of Simulation study 
1 for the third scenario of hazard ratio. The horizontal line represents the power of the non-adaptive 
design. 
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Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.26. Power versus the information fraction under the alternative hypothesis of Simulation study 
1 for the fourth scenario of hazard ratio. The horizontal line represents the power of the non-adaptive 
design. 
Results of power versus the information fraction under the alternative 
hypothesis of Simulation study 2 in each scenario of hazard ratio are presented in 
Figures 7.27 to 7.30 below. Under the alternative hypothesis, in the first, third and 
fourth scenario of hazard ratio (i.e. 0.746, 0.807 and 0.765 respectively), the power 
exceeds the nominal level (i.e. 80%) only at 75% information fraction when all types 
of sample size adjustment methods and stopping boundaries are used apart from the 
combination of the conditional power method with the O’Brien-Fleming decision 
boundaries (Figures 7.27, 7.29, 7.30). Among the different sample size adjustment 
methods and stopping boundaries, the effect-size ratio method with the O’Brien-
Fleming decision boundaries results in the highest power and the conditional power 
method with the same type of stopping boundaries results in the smallest power 
(Figure 7.27, 7.28) in all cases of hazard ratio. In the second scenario of hazard ratio 
(i.e. 0.845), all resulting power are below the horizontal line which corresponds to the 
nominal level of power (i.e. 80%), thus, the power is not preserved (Figure 7.28).  
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First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.27. Power versus the information fraction under the alternative hypothesis of Simulation study 
2 for the first scenario of hazard ratio (i.e. 0.746). The horizontal line represents the power of the non-
adaptive design. 
Second scenario of hazard ratio (i.e. 0.845) 
Figure 7.28. Power versus the information fraction under the alternative hypothesis of Simulation study 
2 for the second scenario of hazard ratio (i.e. 0.807). The horizontal line represents the power of the non-
adaptive design. 
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Third scenario of hazard ratio (i.e. 0.807) 
Figure 7.29. Power versus the information fraction under the alternative hypothesis of Simulation study 
2 for the third scenario of hazard ratio (i.e. 0.845). The horizontal line represents the power of the non-
adaptive design. 
Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.30. Power versus the information fraction under the alternative hypothesis of Simulation study 
2 for the fourth scenario of hazard ratio (i.e. 0.765). The horizontal line represents the power of the non-
adaptive design. 
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7.5.2.3. Sample size of the study 
In Simulation study 1, under the alternative hypothesis of the first scenario of 
hazard ratio (i.e. 0.746), the horizontal line which indicates the sample size of the non-
adaptive design in Figure 7.31, shows loss of efficiency at 75% information fraction 
with all the combinations of sample size recalculation methods and stopping 
boundaries.  
 
Figure 7.31. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 1 for the first scenario of hazard ratio (i.e. 0.746). 
At 25% and 50% information fraction, there is gain in efficiency only in the case of the 
conditional power method with the O’Brien-Fleming boundaries as the 
corresponding values are below the horizontal line which indicates the sample size 
of the non-adaptive design (Figure 7.31). However, with the introduction of both 
efficacy and futility stopping in the trial (Simulation study 2), there is gain in 
efficiency in all cases apart from the effect-size ratio method with the O’Brien-
Fleming boundaries at 75% information fraction as the values in Figure 7.32 are below 
the horizontal line.  
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Figure 7.32. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 2 for the first scenario of hazard ratio (i.e. 0.746). 
Under the alternative hypothesis of the second scenario of hazard ratio (i.e. 
0.845), it can be seen in Figure 7.33 that there is gain in efficiency in all cases apart 
from the combination of effect-size ratio method with the O’Brien-Fleming 
boundaries at 25% and 75% of information fraction.  
 
Figure 7.33. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 1 for the second scenario of hazard ratio (i.e. 0.845). The horizontal line represents the sample size 
of the non-adaptive design. 
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However, with the introduction of both efficacy and futility stopping of the trial 
(Simulation study 2), the sample size is decreased with all the combinations of sample 
size recalculation methods and stopping boundaries across the different percentages 
of information fraction compared to the sample size of the non-adaptive design 
(Figure 7.34).  
 
Figure 7.34. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 2 for the second scenario of hazard ratio (i.e. 0.845). The horizontal line represents the sample size 
of the non-adaptive design. 
Under the alternative hypothesis of the third scenario of hazard ratio (i.e. 0.807), 
loss of efficiency can be observed at all levels of information fraction with the 
combination of the effect-size ratio method and the O’Brien-Fleming boundaries 
(Figure 7.35), whereas in Simulation study 2, all values in Figure 7.36 are below the 
horizontal line and thus only gain in efficiency can be observed. 
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Figure 7.35. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 1 for the third scenario of hazard ratio (i.e. 0.807). The horizontal line represents the sample size 
of the non-adaptive design. 
 
Figure 7.36. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 2 for the third scenario of hazard ratio (i.e. 0.807). The horizontal line represents the sample size 
of the non-adaptive design. 
Under the alternative hypothesis of the fourth scenario of hazard ratio (i.e. 
0.765), the sample size is increased compared to the sample size of the non-adaptive 
design at 75% information fraction (Figure 7.37). However, at 50% information 
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fraction, the only loss of efficiency is observed with the effect-size ratio method and 
the O’Brien-Fleming boundaries and at 25% information fraction, the only gain in 
efficiency is obtained with the conditional power method and the O’Brien-Fleming 
boundaries (Figure 7.37). 
 
Figure 7.37. Sample size versus the information fraction under the alternative hypothesis of Simulation 
study 1 for the fourth scenario of hazard ratio (i.e. 0.765). The horizontal line represents the sample size 
of the non-adaptive design. 
In Simulation study 2 where we allow the trial to stop either for efficacy or futility, 
the sample size is smaller than that of the non-adaptive design apart from the case of 
the effect-size ratio method with the O’Brien-Fleming boundaries at 75% information 
fraction (Figure 7.38). 
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Figure 7.38. Sample size versus the information fraction under the alternative and null hypothesis of 
Simulation study 2 for the fourth scenario of hazard ratio (i.e. 0.765). The horizontal line represents the 
sample size of the non-adaptive design. 
In Simulation study 1, under the null hypothesis of all scenarios of hazard ratio, 
all the values are above the horizontal line in Figures 7.39 to 7.42 indicating the 
increase of the sample size compared to the sample size of the non-adaptive design. 
In both methods of sample size recalculation and both types of decision boundaries, 
the number of patients increases when the information fraction also increases in each 
case of hazard ratio. In each scenario of hazard ratio, the largest increase of the sample 
size as compared to the number of patients required for the non-adaptive approach 
corresponds to the effect-size ratio method with O’Brien-Fleming decision 
boundaries and 75% information fraction. More precisely, in the first scenario of 
hazard ratio (i.e. 0.746) from 186 patients per arm which are required for the non-
adaptive approach, we have calculated 284 patients per arm which is very close to 
the upper limit of sample size for the study which we allowed (i.e. 286 patients per 
arm). For the second scenario of hazard ratio (i.e. 0.845), from 558 patients per arm 
required for the non-adaptive approach, we have calculated 559 patients per arm (the 
upper limit of 658 patients per arm was allowed). For the third scenario of hazard 
ratio, (i.e. 0.807), from 346 patients per arm required for the fixed design, we have 
calculated 362 patients per arm allowing a maximum sample size of 446 patients per 
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arm. For the fourth scenario of hazard ratio, (i.e. 0.765), from 224 patients per arm 
required for the fixed design, we reached 247 patients per arm in the adaptive 
approach allowing for a maximum sample size of 324 patients. 
First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.39. Sample size versus the information fraction under the null hypothesis of Simulation study 
1 for the first scenario of hazard ratio. The horizontal line represents the sample size of the non-adaptive 
design. 
Second scenario of hazard ratio (i.e. 0.845) 
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Figure 7.40. Sample size versus the information fraction under the null hypothesis of Simulation study 
1 for the second scenario of hazard ratio. The horizontal line represents the sample size of the non-
adaptive design. 
Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.41. Sample size versus the information fraction under the null hypothesis of Simulation study 
1 for the third scenario of hazard ratio. The horizontal line represents the sample size of the non-adaptive 
design. 
Fourth scenario of hazard ratio (i.e. 0.765) 
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Figure 7.42. Sample size versus the information fraction under the null hypothesis of Simulation study 
1 for the fourth scenario of hazard ratio. The horizontal line represents the sample size of the non-
adaptive design. 
In Simulation study 2, under the null hypothesis of all scenarios of hazard ratio, 
all the values are below the horizontal line in Figures 7.43 to 7.46 indicating the 
decrease of the sample size compared to the sample size of the non-adaptive design. 
Hence, we can observe gain in efficiency when allowing the trial to stop early either 
for efficacy or futility. In both methods of sample size recalculation and both types of 
decision boundaries for all scenarios of hazard ratios, the number of patients 
increases when the information fraction increases. In each scenario of hazard ratio, 
the largest increase of the sample size as compared to the number of patients required 
for the non-adaptive approach corresponds to the effect-size ratio method with 
O’Brien-Fleming decision boundaries and 75% information fraction. More 
specifically, in the first scenario of hazard ratio, (i.e. 0.746), from 186 patients per arm 
which are required for the non-adaptive approach, we have calculated 196 patients 
per arm allowing for the upper limit of sample size at 286 patients per arm. For the 
second scenario of hazard ratio (i.e. 0.845), from 558 patients per arm which are 
required for the non-adaptive approach, we have calculated 534 patients per arm (the 
upper limit of 658 patients per arm was allowed). For the third scenario of hazard 
ratio (i.e. 0.807), from 346 patients per arm required for the fixed design, we have 
calculated 343 patients per arm allowing a maximum sample size of 446 patients per 
arm. For the last scenario of hazard ratio (i.e. 0.765), from 224 patients per arm 
required for the fixed design, we reached 231 patients per arm in the adaptive 
approach allowing for a maximum sample size of 324 patients. 
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First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.43. Sample size versus the information fraction under the null hypothesis of Simulation study 
2 for the first scenario of hazard ratio. The horizontal line represents the sample size of the non-adaptive 
design. 
Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.44. Sample size versus the information fraction under the null hypothesis of Simulation study 
2 for the second scenario of hazard ratio. The horizontal line represents the sample size of the non-
adaptive design. 
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Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.45. Sample size versus the information fraction under the null hypothesis of Simulation study 
2 for the third scenario of hazard ratio. The horizontal line represents the sample size of the non-adaptive 
design. 
Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.46. Sample size versus the information fraction under the null hypothesis of Simulation study 
2 for the fourth scenario of hazard ratio. The horizontal line represents the sample size of the non-
adaptive design. 
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7.5.2.4. Efficacy stopping probability 
In both simulation studies, under the alternative hypothesis of all scenarios of 
hazard ratio, the efficacy stopping probability depends only on the type of stopping 
boundaries. In can be seen in Figures 7.47 to 7.54 that the efficacy stopping probability 
increases with the increase of information fraction. Consequently, the largest value is 
obtained at 75% information fraction. Additionally, the efficacy stopping probability 
is always greater with the Pocock decision boundaries compared to the probabilities 
obtained with the O’Brien-Fleming decision boundaries. 
First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.47. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the first scenario of hazard ratio. 
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Figure 7.48. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the first scenario of hazard ratio. 
Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.49. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the second scenario of hazard ratio. 
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Figure 7.50. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the second scenario of hazard ratio. 
Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.51. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the third scenario of hazard ratio. 
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Figure 7.52. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the third scenario of hazard ratio. 
Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.53. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 1 for the fourth scenario of hazard ratio. 
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Figure 7.54. Efficacy stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the fourth scenario of hazard ratio. 
Similarly to the alternative hypothesis, in both simulation studies, under the 
null hypothesis, the efficacy stopping probabilities depend only on the efficacy 
stopping boundaries and not on the sample size adjustment methods. Figures 7.55 to 
7.62 show that the efficacy stopping probabilities remain the same across the different 
percentages of information fraction for each type of stopping boundaries for all 
scenarios of hazard ratio. Higher values are achieved when the Pocock stopping 
boundaries are used compared to the O’Brien-Fleming efficacy boundaries. 
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First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.55. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 1 for the first scenario of hazard ratio. 
 
Figure 7.56. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the first scenario of hazard ratio. 
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Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.57. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 1 for the second scenario of hazard ratio. 
 
Figure 7.58. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the second scenario of hazard ratio. 
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Third scenario of hazard ratio (i.e. 0.807) 
Figure 7.59. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 1 for the third scenario of hazard ratio. 
 
Figure 7.60. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the third scenario of hazard ratio. 
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Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.61. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 1 for the fourth scenario of hazard ratio. 
 
Figure 7.62. Efficacy stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the fourth scenario of hazard ratio. 
7.5.2.5. Futility stopping probability 
In Simulation study 2, the futility stopping probability in all scenarios of hazard 
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sample size recalculation. It decreases with the increase of information fraction under 
the alternative hypothesis (Figure 7.63 to 7.66) and it depends only on the type of 
stopping boundaries and not on the method of sample size recalculation. Hence, the 
smallest value of futility probability is obtained at 75% information fraction. The 
application of Pocock stopping boundaries results in slightly higher futility stopping 
probabilities compared to the use of the O’Brien-Fleming efficacy boundaries. 
First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.63. Futility stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the first scenario of hazard ratio. 
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Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.64. Futility stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the second scenario of hazard ratio. 
Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.65. Futility stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the third scenario of hazard ratio. 
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Fourth scenario of hazard ratio (i.e. 0.765) 
Figure 7.66. Futility stopping probability versus the information fraction under the alternative 
hypothesis of Simulation study 2 for the fourth scenario of hazard ratio. 
Similarly to the alternative hypothesis, the futility stopping probabilities in all 
scenarios of hazard ratios depend only on the efficacy stopping boundaries and not 
on the sample size adjustment methods under the null hypothesis in both simulation 
studies. Figures 7.67 to 7.70 show that the futility stopping probabilities remain the 
same across the different percentages of information fraction for each type of 
stopping boundaries. Similar values are achieved with each type of stopping 
boundaries. 
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First scenario of hazard ratio (i.e. 0.746) 
 
Figure 7.67. Futility stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the first scenario of hazard ratio. 
Second scenario of hazard ratio (i.e. 0.845) 
 
Figure 7.68. Futility stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the second scenario of hazard ratio. 
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Third scenario of hazard ratio (i.e. 0.807) 
 
Figure 7.69. Futility stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the third scenario of hazard ratio. 
Fourth scenario of hazard ratio (i.e. 0.765) 
 
Figure 7.70. Futility stopping probability versus the information fraction under the null hypothesis of 
Simulation study 2 for the fourth scenario of hazard ratio. 
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7.6. Discussion 
This chapter has focused on unblinded sample size reassessement. Generally, 
this approach is more controversial compared to the blinded method and has been 
characterized by the U.S. Food and Drug Administration (FDA) as a “less well 
understood approach” as it faces challenges with regard to operational bias [9]. In 
practice, several considerations should be taken into account (e.g. regulatory 
requirements, resources, efficiency etc.) before implementing these methods [10].   
Our results show that there is a significant increase in the number of patients 
when the futility stopping boundary is not adopted, compared to the sample size 
which is needed for the non-adaptive design. The increase of the sample size is 
greater when the information fraction increases. When the futility stopping boundary 
is considered in our study, a reduced sample size can be seen from our results at all 
levels of information fraction. Furthermore, our results show that generally we can 
achieve greater power compared to the nominal level of power by using the sample 
size adjustment methods when allowing the trial to stop either for efficacy or futility.  
It is important to note that at 25% information fraction, the futility boundary is 
too permissive and the trial is stopping too often. Hence, the futility boundary should 
be adjusted for the different information fractions.  
Additionally, the current simulations assume that first stage patients are fully 
assessed before the interim analysis starts, and second stage patients are recruited 
afterwards. However, in practice, recruitment usually continues at an interim 
analysis, so this study could be extended to approach a more realistic scenario. 
In general, sample size re-estimation is more difficult when a time-to-event 
outcome is used because when an interim analysis takes place, some patients who 
were recruited in stage 1, may not have an event by the time of analysis. Different 
approaches to this issue can be found in [11-13]. 
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Different scenarios, methods for sample size recalculation and various options 
for stopping boundaries for efficacy and futility proposed to date can result in either 
satisfactory or poor statistical properties. One size does not fit all, thus, it is of utmost 
importance to study carefully though simulations the implication of each choice to 
the trial and investigate which option could be adjusted to a particular case. 
In this chapter, the sample size re-estimation approach was applied to a 
biomarker-guided clinical trial design which was chosen as the optimal for STRONG 
trial presented in Chapter 6. This approach is similar to a regular randomized 
controlled trial, however, the difference is in the calculation of the required total 
number of patients which is based on the sample size formula of Reverse Marker-
Based strategy design. In the next chapter (Chapter 8), we will describe various 
practical challenges of biomarker-guided trials, such as funding, ethical and 
regulatory issues, recruitment, monitoring samples and laboratories, biomarker 
assessment, data sharing, and resource that should be addressed when investigators 
conduct a biomarker-guided clinical trial. 
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Chapter 8. Challenges in Practice 
8.1. Introduction 
In the previous chapter (Chapter 7) we performed simulation studies to explore 
the statistical and operating characteristics of an adaptive approach applied to the 
optimal design chosen in Chapter 6. In this chapter we investigate the challenges 
faced in practice when implementing a biomarker-guided trial, including those 
related to funding, ethical and regulatory issues, recruitment, monitoring samples 
and laboratories, biomarker assessment, data sharing, and resources. To identify and 
explore the key challenges arising, the author of this thesis, together with the leaders 
of the MRC Hubs for Trials Methodology Research Network’s Stratified Medicine 
Working Group (SMWG) organized a workshop, ‘Biomarker-guided trials: 
challenges in practice’ and invited delegates with practical experience of conducting 
biomarker-guided trials from various disciplines including statisticians, trial 
managers, information systems specialists and clinicians. The workshop, held at the 
University of Liverpool in London Campus on 15th March 2017, was attended by 25 
participants and the findings from the day form the basis for the content of this 
chapter.  
In section 8.2 we describe some of the planned and ongoing trials the workshop 
delegates have been involved with, and in the remaining sections discuss practical 
challenges informed by their experiences working on these trials, together with some 
of my own reflections on those issues. Therefore, it is important to note that any 
statements made in this chapter are based on the delegates’ personal experiences. 
8.2. Examples of clinical trials 
i) The National Lung Matrix trial (ongoing trial) [1]: This is a phase II non-
randomized umbrella trial consisting of multiple single arm trials within one 
protocol. The aim of the trial is to investigate several new treatments hypothesized to 
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be of benefit to patients with advanced non-small cell lung cancer (NSCLC), and for 
whom surgery and radiotherapy are not deemed appropriate treatments.  
The Matrix trial runs alongside the Cancer Research UK Stratified Medicine 
Programme (SMP2), where a next generation sequencing 28 gene panel test is used 
to assess the genetic profile of trial participants, which then determines which single 
arm trial (strata), and hence drug, they are assigned to. The trial adopts a Bayesian 
adaptive design with an interim analysis at 15 patients for each strata and final 
analysis of a target group of 30 patients per strata. The primary outcome is tumour 
shrinkage rate of at least 30%, which is deemed desirable.  
ii) Phase II trial of olaparib in patients with advanced castration resistant 
prostate cancer (TOPARP) (ongoing trial) [2]: This is an open label, phase II, single 
arm adaptive trial for biomarker-driven selection based on response rate. It aims to 
evaluate the anti-tumour activity of the Poly (ADP-ribose) polymerase (PARP) 
inhibitor, olaparib, in metastatic castration resistant prostate cancer (mCRPC) and to 
identify molecular signatures for PARP inhibitor sensitivity with a pre-planned 
analysis to identify a biomarker-defined sensitive subgroup. First, unselected (i.e. 
without biomarker guided patient selection) mCRPC patients are all treated with 
olaparib and during the first stage of the design, if the response rate is high (i.e. >
50% responding) then further patients are recruited and a randomized placebo 
controlled clinical trial to evaluate the efficacy and safety of olaparib in these 
unselected mCRPC patients is undertaken. If the response rate is low (i.e. response 
rate < 10%), the trial is stopped. If in the intermediate range (10-50% responding), 
potential biomarkers of response are investigated and if a potential biomarker is 
identified, with those positive for the biomarker having a high response rate (>50%), 
the trial continues to the second stage with inclusion of the biomarker selected 
patients. 
iii) Adaptive multi-arm phase II trial of maintenance targeted therapy after 
chemotherapy in metastatic urothelial cancer (ATLANTIS) (ongoing) [3]: This is an 
adaptive multi-arm randomized phase II trial which aims to explore whether 
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maintenance targeted therapy after chemotherapy, with treatment selection based on 
biomarker profile, delays time to progression and increases overall survival for 
patients with advanced urothelial cancer.  
iv) PRIMUS (ongoing) [4]:  This is an adaptive phase II trial, with biomarker 
evaluation integrated into the trial, which aims to assess the efficacy of FOLFOX-A 
(FOLFOX and nab-paclitaxel) when compared to AG (nab-paclitaxel and 
gemcitabine) in patients with metastatic pancreatic cancer, both in a biomarker-
positive group and in biomarker-unselected patients).  
v) SALONICA (planned trial): This is a stratified adaptive trial in ovarian 
cancer aiming not only to detect the key genomic determinants of response and 
resistance to neoadjuvant platinum-base chemotherapy in high-grade serous ovarian 
cancer but also to identify and validate putative biomarkers as well as test several 
novel drugs and corresponding putative biomarkers in women with poor response 
to neoadjuvant platinum chemotherapy through a phase II trial platform.  
vi) TASTER (planned trial): This trial aims to identify predictors, at the point 
of diagnosis, of the efficacy of standard-of-care or some novel combination therapies 
in Chronic Myeloid Leukaemia (CML) patients who do not respond to tyrosine 
kinase inhibitor therapy. Both in vivo models of drug response and clinical data will 
be used to identify molecular signatures of stem cell resistance. 
vii) POETIC (Peri-Operative Endocrine Therapy for Individualizing Care) 
(ongoing trial) [5]: This is a randomized, multicentre Phase III trial which aims to 
investigate whether having perioperative aromatase inhibitor (AI) therapy two 
weeks before and two weeks after surgery is more effective for postmenopausal 
women with ER+/PgR+ positive invasive breast cancer than having standard care 
alone. 4,476 patients were recruited from 130 UK centres with more than 2000 clinical 
staff. Patients received either AI therapy for 4 weeks (two weeks before and two 
weeks after surgery) or no AI therapy.  
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viii) FOCUS4 trial (ongoing trial) [6]: This is an umbrella clinical trial 
consisting of parallel, molecularly stratified randomized comparisons in patients 
with metastatic colorectal cancer (mCRC). Patients with newly diagnozed mCRC are 
registered into the trial and commence their standard first line chemotherapy which 
typically lasts for approximately 16 weeks. During this time, a sample of their tumour 
is sent away to one of two dedicated FOCUS4 laboratories who perform genomic and 
molecular tests on the tumour. This enables stratification of the patients into one of a 
number of pre-specified molecular subgroups (called cohorts). Patients are then 
offered entry into a randomized trial (called comparison) testing a specific targeted 
therapy for their subtype of cancer. All these comparisons are randomized and 
controlled and wherever possible use a placebo in the control group. 
8.3. Challenges 
8.3.1. Funding issues 
Although funders appear to be enthusiastic about supporting biomarker-
guided trials, due to their complexity the resources required to deliver them are 
typically substantially higher than for trials with more simple designs. This needs to 
be factored into the decision making process when deciding on whether to fund, 
recognising that despite increased costs the trial may well be more efficient in 
demonstrating patient benefit. When considering the additional resources required, 
the increased administrative burden on staff should not be forgotten, for instance 
those arising with umbrella type designs where all the necessary paperwork has to 
be repeated for each part of the trial. Funders also often struggle with the monitoring 
of biomarker-guided trials, particularly those with an adaptive design, and are often 
uncertain and inconsistent in how they handle amendments to the design. It is typical 
for an amendment that is cost neutral to be approved quickly without additional 
approvals, but if the amendment is likely to cost money (e.g. the addition of a new 
trial arm) then it has to go through the more classic route of peer-review and funding 
approval. It is possible that research groups with experience of running such trials 
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could work together with funders to help inform and advise them on the implications 
of using such designs for their funding streams.    
To avoid the same peer review process being triggered with each addition of 
trial arms, funders may expect applicants to provide estimated details of these 
potential additions at the outset to allow them to earmark the foreseeable additional 
budget and provide approval in principle. So, a researcher submitting an application 
for an umbrella trial, for example to include initial arms A to D, would be required to 
also estimate how much it would cost to make changes E, F, and G at time points X,Y 
and Z. However, this can be difficult as it requires knowledge not only of the 
approximate size of the cohorts to be added (or indeed removed) within those 
changes, but also the time point at which they will be added and the approximated 
end date. In addition, including additional forecasted costs could easily make a trial 
very unattractive to funders due to its expense, for example projected total costs for 
a large trial could use up the entire budget for a particular funding call. Funders will 
always be limited by the pot of money available within a particular fiscal period and 
will be faced with many competing funding requests, many of which will have 
simpler and easier to understand designs with more transparent budgets.  
To convince funders, it may be that some of the currently ongoing trials need 
to be completed to understand whether they represent good value for money, 
although this could be misleading since it is widely felt that many of the trials  are 
significantly underfunded as they currently stand. Quite often, it is the Clinical Trial 
Units (CTU) costs (e.g. trial management, trial monitoring, trial statistician) that are 
compromised because they are more malleable than other costs. It is possible that 
academia and funding bodies could work together in order to co-create funding 
solutions. For example, funding bodies with a long-term research commitment in a 
particular disease area (e.g. Cancer Research UK) could provide the essential long-
term core funding for such a trial (e.g. CTU costs) by setting aside a proportion of 
their annual budget indefinitely, while other funding bodies with a shorter-term 
vision (e.g. pharmaceutical companies or smaller charities) could provide add-on 
funds associated to a particular treatment arm of their interest (i.e. additional 
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infrastructure and personnel costs). A funding structure of this type would not only 
provide sufficient funds for successful trial delivery but could also allow for more 
transparent and efficient allocation and monitoring of resources while creating cost 
saving opportunities through synergies. 
There has also been some confusion about who should fund the additional 
biomarker tests within a trial. Funders have previously suggested that this is a 
National Health Service (NHS) associated cost since it is used to direct treatment, 
however the test is often not available on the NHS, and thus they have refused to 
fund it. The situation may be slowly changing, however, since we are moving into an 
era where more biomarker tests are going to be routinely undertaken in practice.  
Finally, an additional funding issue is related to whether the trial uses 
previously untested biomarkers or more established and validated ones; the former 
may incur additional costs for the development, validation and standardization of 
appropriate tests, delays in the expected start date and recruitment problems due to 
poor quality of biomarker assessment results. 
Overall, we believe that detailed planning and clear communication between 
researchers and funders are vitally important to ensure that future trials can be fairly 
considered and appropriately funded. There is also room for education, with those 
with practical experience of such trials sharing their knowledge with funding bodies. 
Trialists and funders alike may feel overwhelmed by these trials but in fact they are 
not as complicated as is often believed. Broken down into separate arms they can be 
considered as individual trials being controlled by an overarching research team and 
with some additional biomarker analyses. If they are broken down in this way and 
communicated effectively, then they should not be feared. 
8.3.2. Ethical and Regulatory Issues 
A key issue here is the confusion that sometimes exists within regulatory bodies 
about the characteristics of a biomarker-guided trial, for example, understanding the 
difference between an umbrella and a MAMS trial and how these are different from 
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a conventional trial. For instance, there is an expectation that when adding a new 
Investigational Medicinal Product (IMP) to an umbrella trial there should also be a 
new CTA (Clinical Trial Authorization), which is clearly not the case. It is important 
for regulators to appreciate that adaptations to the design are part of the original 
regulatory approval submission. There is also often the belief that from a commercial 
perspective the trial will be testing, developing and marketing a companion 
diagnostic alongside the therapeutic which is usually not the case. 
Although there is general consensus that research ethics committees are very 
positive and receptive to these types of trials, there are many ongoing administrative 
issues that would benefit from being addressed. Whilst an ethics committee might 
give their overall ethical approval at the very start of a trial, it is often not clear how 
the addition of new arms will be approved at a later date. Depending on the local 
practice, such amendments may not be reviewed, discussed and approved by a sub-
committee or may even come through simply as a chairman’s action. Consequently, 
the trial documents are perhaps not checked as thoroughly as the original application 
and the amendments may not be scrutinised in sufficient detail. In addition, there is 
inconsistency in terms of what documentation ethics committees request to approve 
such an amendment, with some requesting a new submission and others seeking a 
major amendment. It is important that discussions are held with the HRA to ensure 
that their administrative systems, paperwork, and their version control is adapted to 
deal with these types of amendments adequately. Researchers with experience of 
running such trials would be well placed to advise in this regard. 
There are similar administrative issues that need addressing with the 
Medicines and Healthcare products Regulatory Agency (MHRA), and similar 
discussions could be had with them. For example, the name of a trial’s CTA is given 
in accordance with the initial treatment arms included in the trial; however, these 
may not be part of the trial after a while which can lead to confusion in terms of 
terminology. 
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From the perspective of patients, some challenges relating to the informed 
consent process may arise. There are examples of having to consent patients into the 
trial on the same day of diagnosis, which clearly requires a lot of sensitivity and both 
careful and appropriate communication. There is also an issue related to the fact that 
biomarker screening might fail requiring a second biopsy. Obtaining a second biopsy 
can be difficult because patients are often not well enough. Having a trial option for 
non-stratified patients (including those with failed biopsies) can be a good idea, 
particularly if biomarker screening is invasive or has a high failure rate.  
Effective communication to patients is also fundamental to ensure that there is 
a clear understanding of why these sorts of biomarker trials are undertaken, as whilst 
they are often about targeting treatments to patients who are believed to have the 
best chance of benefitting, they can also be about trying to avoid treatments in 
patients who don’t need them. This will aid acceptance by those being denied a 
treatment due to their biomarker profile. Trials would also benefit from improving 
how personalized medicine is described to the public, since this can be misleading. 
Whilst on the surface personalizing treatment may sound like the perfect solution, 
patient expectations need to be managed. It should not be communicated as an 
approach to ensure that a treatment will definitely work in a patient with given 
biomarker status, but rather is an approach that will mean it is more likely to work.  
An additional ethical challenge, this time more so from the researchers’ 
perspective is that since patients’ samples are often being genotyped, there is always 
the risk that susceptibility to certain diseases are uncovered. Whilst this issue can be 
covered in the informed consent process from the patient’s perspective, it can pose a 
moral dilemma to those involved in conducting the trial. Additionally, from the 
patients’ perspective, they can often assume that having certain mutations in their 
tumour means an increased risk of disease in relatives. Hence, careful communication 
is again needed in order to clarify the difference between mutations in a tumour and 
germline mutations (i.e. hereditary mutations passed on from parents to offspring). 
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In summary, several ethical and regulatory challenges can arise ranging from a 
lack of understanding about administrative procedures to issues relating to 
communications with patients. It is essential that accurate information about 
biomarker-guided trials are communicated to all relevant stakeholders so that they 
are educated on the characteristics and advantages of such trials. 
8.3.3. Recruitment 
Uncertainty in recruitment rates, especially in trials which include rare 
biomarker groups can be a big concern. The prediction of recruitment rate into 
umbrella trials can be difficult as several factors need to be considered: 1) the 
estimated prevalence of each biomarker, which might not be accurately known at the 
design stage and in the case of trials that evaluate multiple biomarkers might also be 
affected by overlapping groups; 2) the failure rate of lab diagnostic biopsies in the 
technology hubs; and 3) additional factors related to the consent rate. The difficulties 
are compounded by the fact that funders and sponsors regularly question whether 
the reached recruitment rate is close to the projected. If not, they may require 
recalculations and protocol amendments which can often be more complex for 
biomarker-guided trials, in particular umbrella trials, than for a traditional trial. 
Hence, new methodology for predicting the rate of recruitment may be needed for 
these trials. 
Recruitment issues can be patient related or researcher related. From the 
patients’ perspective, they may not want to join the trial for various reasons, for 
example, they may be weary after the first line treatment, their disease may have 
progressed, or they may simply not be interested in the new drug and would like to 
take a break from treatment. In addition, having complex tissue sampling 
(mandatory fresh biopsies) is always a challenge for recruitment since patients are 
generally less interested.  
From the researchers’ perspective, slow set up of comparisons may occur 
leading to sites losing their enthusiasm which can have an impact on the recruitment 
 346 
 
of patients. In turn, this may affect the motivation of commercial partners to get 
involved. Further problems can arise when it is difficult to predict recruitment 
timelines. Another barrier to timely recruitment may be a high screen failure rate, 
requiring an increase in screening activity at site with further cost implications. 
Additionally, it can take longer than the expected timeframe to deliver biomarker 
results to centres, which can have an impact on accrual. 
In addition, the dropout rate from trials can be significant, particularly where 
trials involve very ill patients with rapid deterioration. Long waiting times for the 
genetic profiling can result in patients not being well enough to participate by the 
time their biomarker status was identified. This issue is often compounded further 
due to the length of time taken to test a patient’s sample meaning that it is not 
uncommon for a patient to have died before the results are available. Even if they are 
still alive, the patients may have deteriorated and decide they no longer want to be 
involved in the trial. Risk of dropout is further increased since once someone has been 
randomized the workup for whichever treatment they are stratified to can be a very 
involved process, and the patient may decide to take the simpler option of not taking 
part in the trial. Also, receiving an extra novel drug may require travel to a further 
location and those in a terminal illness or with advanced disease may not wish to do 
so, and would rather try to enjoy their remaining months. Although it is impossible 
to predict what these patients will decide, their likelihood of dropping out can be 
reduced by ensuring rapid turnaround times for biomarker test results, and this 
should be encouraged. 
To summarize, given the multiple factors impacting how quickly patients will 
be identified, recruited and retained in a biomarker-guided trials, estimating an 
accurate rate of recruitment will always be difficult. Further, even if patient accrual 
and retention is good, research staff responsible for recruiting patients may be less 
efficient if delays occur in setting up sites. It is suggested, therefore, that well-
designed pilot and feasibility studies are undertaken prior to trial commencement to 
ensure a more accurate understanding of recruitment rate as well as a smoother and 
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more rapid process of site set-up. Laboratories should also be sufficiently equipped 
and efficient to deal with rapid biomarker analysis turnaround.   
8.3.4. Monitoring samples and labs   
Providing a lab is accredited it is expected that good internal audit trails are in 
place, however logistical problems can occur in the transfer of results from the lab to 
the CTU. Often, data are not sent on an individual patient basis, but rather in batches 
of hundreds, or thousands at a time, so it is important to agree on procedures for 
transferring these data accurately in order that mix-ups do not occur. Problems can 
arise when lab staff are not always GCP (Good Clinical Practice) trained, and there 
have been examples of data confidentiality being breached when staff have not 
appreciated that the data were clinical trial data which were therefore required to 
remain confidential until the trial had been reported. Therefore, it is recommended 
that there should be a better understanding of GCP requirements within labs. 
Monitoring patient samples requires a significant amount of work and 
coordination. For example, a first sample may be received and there might be 
insufficient tumour, meaning that another sample has to be requested. A full audit 
trail is therefore required (accurate and traceable matching of patients and tissue 
samples) to ensure that the correct value ends up in the analysis. A large amount of 
data cleaning is also typically required. 
In terms of the handling and tracking of samples, local research nurses, 
pathologists, lab staff as well as the CTU should be involved. Further difficulties arise 
if the tissue obtained has inadequate tumour tissue or is not viable and further 
requests for samples need to be made back to the original hospital pathology 
departments.  
To ensure optimal efficiency it is recommended that lots of samples are batched 
up to be sent all at once instead of using additional resources on several small runs. 
However, this can often lead to problems with lower than anticipated recruitment 
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leading to further delays whilst labs wait for enough samples to justify running a 
batch.  
Another challenge associated with biomarker analysis is that science is 
advancing so quickly, things can change dramatically after the funding application 
stage with many additional opportunities arising. It is recommended that a separate 
lab manual is used outside the protocol in order to minimize any associated protocol 
amendments. 
In terms of ensuring completeness and quality of tissue samples received, 
communication and collaboration between clinicians and laboratory staff should be 
strengthened to ensure that the samples are taken, stored and sent off in accordance 
with the protocol. In addition, the CTU’s central trial monitoring capabilities should 
be utilized to ensure efficient sample tracking. In our view, strong collaboration 
between the CTU and the laboratory staff is much needed as the success of a 
biomarker-guided trial depends heavily on the accurate and timely delivery of lab 
results.  
8.3.5. Biomarker assessment 
The setup of SMP2 is a major undertaking for biomarker trials, especially for 
these umbrella trials, and the trial’s success relies on SMP2 being successful. Lung 
biopsies from advanced cancer patients can be really challenging, and this may apply 
to other diseases too. 
One major challenge during biomarker assessment is that we are often dealing 
with small samples which can be heterogeneous and a mix of normal tissue with 
tumor tissue. This results in less confidence that a mutation, which is in fact present, 
will be detected, and therefore less confidence in the randomization procedure since 
it is directly linked to this assessment. Biomarker misclassification issues therefore 
represent a major challenge within biomarker-stratified trials, and should be 
addressed. The analytical validity of a biomarker in terms of sensitivity and 
specificity is a challenging but very important issue and understanding the accuracy 
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of an assay is a necessary consideration. If a sample fails completely, it is easy to class 
it as failed; if there is a partial fail, for example if 8 genes are tested and 6 of them pass 
completely but one of them passes 90% and another one fails 50%, this represents a 
difficult result to handle and it can be difficult to randomize a patient based upon 
such a result.  
8.3.6. Data sharing issues 
When a pharmaceutical company is involved in a trial, alongside the clinical 
study report it is expected that the company will also request the trial data to be 
shared with them at the end of the trial, within a data sharing framework. However,  
there is sometimes pressure for the data to be shared in real time or at least at periodic 
intervals (e.g., to guide business decisions) throughout the time the trial is open. 
Current consensus suggests that this is not a good idea for phase III trials but in a 
phase II trial (particularly a non-randomized one) there are varied opinions as to its 
merits (especially when considering a response rate endpoint). One argument against 
this type of data sharing during the trial is that historically, if you questioned why a 
phase II trial had failed, one reason was that the clinicians or chief investigators were 
too selective to pick their patients when they had a fixed threshold of responders to 
reach to call it a success (e.g., picking patients more likely to respond creating a 
distorted cohort of patients in the latter part of the trial). Sharing data during the trial 
could result in these types of situations arising again. An argument for data sharing 
during the trial from the companies’ perspective is that each of these patients are 
individuals and they will learn from the genomic profiles of those patients who the 
real responders are to their targeted agents. They want the ability to know this 
information effectively in real time so they can pool their data with the data from any 
other study that they are working on worldwide, so that they can learn and make a 
business case for the future development of their pharmaceutical product. 
The direct involvement of pharmaceutical companies can prove challenging in 
general since, due to their financial investment, they will likely be keen for trial data 
to be shared with them on an ongoing basis. Further, whilst decisions in terms of the 
 350 
 
closure of strata are the responsibility of the trial steering committee, pharmaceutical 
companies may wish to be heavily involved in the decision making process. 
Data sharing requests from pharmaceutical companies are likely to be common 
in biomarker guided trials as the sharing of clinical data could enhance the medical 
research. However, differing viewpoints in terms of how and when data should be 
shared can be particularly challenging for the trial management team. To ensure that 
good relations are maintained with all interested parties, it is recommended that a 
clear data sharing policy and common data standards are developed and agreed at 
the beginning of the trial. 
8.3.7. Resources 
In terms of CTU management, ensuring the availability of appropriate 
resources is a challenge. Biomarker-guided trials require a large number of personnel, 
a lot of effort, and a lot of money. Information Technology (IT) support is frequently 
underestimated and vital for many types of biomarker-guided trials. Data scientists 
serve a vital function and they need to be adequately costed into any grant 
application. For perpetual trials, databases and case report forms (CRFs) are 
important to get right as they could be used for a long time. The complexity of the 
CRF is another challenge, since the data required often vary between strata. Hence, 
there is a need to have several different CRFs and therefore the IT requirements are 
equivalent to several separate trials with an additional need for a more sophisticated 
database structure. Protocol amendments lead to additional problems due to the fact 
that for just one amendment (e.g. an additional medical assessment), all CRFs require 
modification.  
Furthermore, administrative support for things such as preparing site packs is 
often underestimated, and the need for collaboration between a CTU and biomarker 
labs put further pressure on resources. A huge amount of biomarker expertise is 
required, which is not always available within a trials unit. Other challenges 
associated with their collaboration relate to lab agreements (e.g., impact on data 
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sharing) and the processes for tracking, blinding and pseudo-anonymization of 
samples. 
More complex work is also needed when adding new comparisons. Several 
issues need to be considered at that time; a new trial needs to be set-up, including 
protocol and CRFs development, database development, setting up of contracts, 
drugs supply etc. while existing comparisons are already running, making the 
implementation of amendments at centres very challenging.  
 
To summarize, the resources required for efficient management of a biomarker-
guided trial should not be under-estimated and CTUs need to ensure that they are 
prepared in particular for the administrative burdens that come with such trials, and 
cost them into any funding applications. 
8.4. Recommendations to overcome practical challenges 
 Define the objectives of the study and consider hypotheses carefully. Clinical trial 
team should decide whether they should employ a statistical test to prove that a 
treatment is superior to another (i.e. superiority trial) or that two treatments are 
not too different in characteristics (i.e. equivalence trial) or that a treatment is not 
worse than another (i.e. non-inferiority trial). Additionally, the significance level 
of a test (i.e. type I error) as well as the type II error should be pre-specified 
according to the level of evidence being sought (Phase II exploratory or Phase III 
confirmatory trial).  
 Use BiGTeD to explore various designs according to hypothesis. 
 Construct research questions which will result in the right choice of the study 
design. These questions can be developed by using the information related to the 
utility of biomarker-guided trial designs provided in Chapter 2 and 3 of this thesis 
as well as BiGTeD. An example of research questions with their answers can be 
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found in Chapter 6. For instance, questions could be asked to check whether: the 
evaluation of treatment effect would be performed only in biomarker-positive 
subgroup or not, the required sample size would be large due to low prevalence 
of biomarker, several treatments and biomarker levels exist, testing a clinical 
strategy would be of interest, there is uncertainty regarding the magnitude of the 
treatment effect that would suggest the use of an adaptive strategy, etc. 
 Operating characteristics such as sample size, study power, trial duration of the 
clinical trial should be investigated through different simulations approaches (see 
Chapter 5, 7). 
 Consider challenges faced in real practice which are presented in the current 
chapter. Some of these challenges are listed below: 
- Funding issues due to higher resources required for these designs compared 
to non-biomarker-guided trial designs, lack of funders’ knowledge on the 
implications of using such designs, etc. 
- Ethical and regulatory issues mostly related to lack of understanding about 
administrative procedures to issues relating to communications with patients. 
- Recruitment issues regarding the estimation of an accurate rate of 
recruitment, delays in setting up sites, ill-equipped and inefficient 
laboratories. 
- Issues arise in the monitoring of samples and labs when lab staff are not GCP 
trained, communication and collaboration between clinicians and laboratory 
staff is not effective, etc. 
- Small samples which can be heterogeneous as well as the analytical validity 
of a biomarker in terms of sensitivity and specificity. 
- Challenging issues when pharmaceutical companies request sharing of 
clinical data. 
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- Underestimation of IT and administrative support, complex databases and 
CRFs. 
8.5. Discussion 
Here, informed by the workshop ‘Biomarker-guided trials: challenges in 
practice’ several practical challenges in conducting biomarker-guided trials have 
been considered. Although many of the challenges discussed relate to very large and 
complex biomarker-guided trials such as umbrella trials, similar challenges appear 
in biomarker-guided clinical trials more generally.  
Despite the aforementioned challenges, the biomarker-guided trials discussed 
within this chapter represent hugely successful research projects using novel designs 
which will hopefully inform future trials.  
To conclude, benefits of adopting biomarker-guided trial designs can arise, 
despite several teething problems resulting from using such novel methodologies. 
However, the significant investments required to successfully conduct such trials 
should not be underestimated, and it is imperative that the practical challenges they 
bring for clinicians, laboratories, regulators, academia, industry and patients as 
outlined above should be acknowledged and addressed at the outset. As the need for 
trials in stratified medicine increases, however, it is anticipated that through 
experience stakeholders will become more familiar with the designs, and the 
procedures involved in conducting and managing them will evolve and adapt 
accordingly. It is important therefore that the knowledge gained by those with 
experience of biomarker-guided trials is communicated to the wider research 
community such that all stakeholders are educated about the complex issues 
associated with biomarker-guided clinical trials and recommendations on how they 
may be overcome. 
The final chapter (Chapter 9) gives a general overview of the topics discussed 
in this thesis and gives some future directions.  
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Chapter 9. Conclusions and Future Research 
Recent advances in genomics and the heterogeneous nature of diseases and 
response to their treatment has led to an increasing interest in personalized medicine 
which aims to select the treatment approach best suited to a patient and promises to 
accelerate and improve drug development. Clinical trials are essential research tools 
for testing the safety and efficacy of treatments and can explore whether a treatment 
works well for patients and also which treatment is most effective for a particular 
subgroup of patients. Today, biomarkers are becoming an integral part of clinical 
trials as they are considered key tools in the identification of patient subgroups most 
likely to benefit or most likely to suffer adverse reactions from a given treatment [1, 
2]. Hence, so-called biomarker-guided trial designs are pivotal in advancing the field 
of personalized medicine which aims to give ‘the right treatment to the right patient, 
at the right dose at the right time’ [1]. The purpose of this thesis was to acquire a 
deeper understanding of biomarker-guided clinical trials, by exploring and 
describing the various trial designs proposed to date, providing guidance on their 
application and on choosing the most appropriate design in a given setting, as well 
as considering some of the practical issues that need to be considered when 
implementing such trials. The finding of this thesis will help guide investigators 
planning biomarker-guided trials and facilitate the process of translating biomarker-
discoveries into clinical practice. 
The thesis begins with a comprehensive review of the literature which provided 
the research community with a detailed overview of the biomarker-guided clinical 
trial designs proposed in recent years. These designs are classified into two main 
categories, the so-called adaptive and non-adaptive trials. The first broad category 
includes eight distinct biomarker-guided adaptive designs, namely: (i) Adaptive 
signature design, (ii) Outcome-based adaptive randomization design, (iii) Adaptive 
threshold sample-enrichment design, (iv) Adaptive patient enrichment design, (v) 
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Adaptive parallel Simon two-stage design, (vi) Multi-arm multi-stage designs, (vii) 
Stratified adaptive design and (viii) Tandem two-stage design and their nine 
variations which were presented in detail in Chapter 2. The second broad category is 
composed of five main biomarker-guided non-adaptive trial designs namely: (i) 
single-arm designs; (ii) enrichment designs; (iii) randomize-all designs; (iv) 
biomarker-strategy designs and (v) other designs as well as several subtypes and 
extensions which were thoroughly discussed in Chapter 3. Both chapters provided 
clear graphical representations of each trial design, which were standardized to 
facilitate comparison of key features across designs, and key aspects, such as their 
definition, methodology, utility, advantages and disadvantages were discussed. The 
two chapters will serve as guidance documents for investigators embarking on 
biomarker-guided clinical trials and will help with addressing and reducing the 
confusion and ambiguity surrounding biomarker-guided designs. Key information 
and graphical representations of each design can also be accessed through our 
interactive web-tool BiGTeD (www.BiGTeD.org). It was evident that one size did not 
fit all and each design had a variety of both advantages and disadvantages; hence, 
careful consideration is needed before their implementation. This interactive web 
resource will improve understanding of biomarker-guided clinical trials, and will 
help guide researchers embarking on trials in personalized medicine in identifying 
the most optimal design in a given setting. The key features and user interface of 
BiGTeD were described in detail in Chapter 4.  
In Chapter 5, we explored statistical aspects of a well-known non-adaptive 
design, the so-called Parallel subgroup-specific design which evaluates separately the 
treatment effect in each biomarker-defined subgroup at the same time. We proposed 
sample size calculation techniques for a time-to-event outcome. Since more than one 
hypothesis for the assessment of efficacy of experimental treatment is being tested, 
the Bonferroni correction method was applied which allocates the overall level of 
significance between the test for biomarker-negative and biomarker-positive 
patients. Additionally, a simulation study was conducted with the aim of confirming 
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that the desirable power is achieved in each biomarker-defined subgroup under 
different settings of accrual and follow-up of patients. Further, the general efficiency 
of the study related to the cost and time of the trial was explored by implementing an 
adaptive approach of the aforementioned design. An interim analysis was suggested 
after a pre-specified percentage of events have been reached, based on which 
decisions are made about whether to stop the trial early due to efficacy or futility. The 
key issues that arose with the involvement of an interim analysis, which splits the 
study design into two stages, included the control of the type I error rate, pre-
specification of stopping rules and stopping boundaries. Our work showed that if we 
use 25% of the required total number of events, the trial will be underpowered, 
whereas if the percentage is set at 50% and 75%, we can achieve power greater than 
70% when the allocation of the level of significance is equal for both biomarker-
defined subgroups. Although this chapter is based on particular settings and 
methods, our simulation studies provide a general insight into the operating 
characteristics of a design which involves an interim analysis based on a pre-specified 
number of events.  
Chapter 6 illustrated several key aspects of biomarker-guided trial settings in 
practice through application to the STRONG trial, a clinical trial previously proposed 
to a UK funder, aiming to test whether a genotype-guided treatment strategy leads 
to reduced rate of relapse in alcohol-dependent patients. The Biomarker-strategy 
design which was initially chosen for that study, proved to be inappropriate due to 
the large number of patients needed to ensure sufficient power. Hence, we addressed 
several clinical and statistical questions to identify the most suitable non-adaptive 
clinical trial design for our purpose. By carefully considering the key information of 
each non-adaptive design described in Chapter 3 and our calculations for required 
total sample size for both binary and survival outcomes, we concluded that the 
Reverse Marker-Based strategy design is the most optimal design for the STRONG 
trial. In this design patients are randomized to either the genotype-guided arm where 
biomarker-positive patients are treated with naltrexone whereas biomarker-negative 
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patients are assigned to the acamprosate or to the reverse-genotype-guided arm 
where patients are assigned to the opposite treatment order. The aforementioned 
design is ethical due to the fact that both naltrexone and acamprosate have been 
proven effective for all patients. To complement this chapter, we incorporated the 
sample size re-estimation method based on unblinded interim estimates of the effect 
size into our selected design due to uncertainty about the true effect size in both the 
strategy arms. The operating characteristics of this design were investigated in 
Chapter 7 with the performance of two simulation studies which take into account 
the option of early stopping of the trial only for efficacy as well as either for efficacy 
or futility. Chapter 7 also provided a general overview of sample size re-estimation 
methods. Our findings indicated that greater power can be achieved compared to the 
nominal level of power when we allow the trial to stop either for efficacy or futility. 
However, each clinical study is different and has its own set of characteristics, 
therefore the conduct of simulation studies plays a key role in the understanding of 
the operating characteristics of a trial which will result in the right choice of trial 
design. The simulation codes from the R statistical software are presented in 
Appendix C.2, D.3. 
In the final chapter of this thesis, we described various practical challenges of 
biomarker-guided trials, such as funding, ethical and regulatory issues, recruitment, 
monitoring samples and laboratories, biomarker assessment, data sharing, and 
resource that should be addressed when investigators conduct a biomarker-guided 
clinical trial. With the rapid growth of studies relating to personalized medicine, and 
the conduct of increasingly complex clinical trials, it is essential that these challenges 
are addressed, and by reflecting on existing ongoing biomarker-guided trials, we 
provided suggestions as a list of recommendations on how they may be resolved. 
Importantly, we found that collaboration between stakeholders of different 
backgrounds such as regulators, clinicians, statisticians etc. is essential, and could be 
achieved by workshops held aiming to share experiences and exchange ideas. 
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The current thesis enhanced the understanding of biomarker-guided clinical 
trials and provided much-needed guidance for stakeholders involved in the 
implementation of such trials. The right choice of trial design will lead to successful 
and efficient clinical trials in the era of personalized medicine as well as improving 
the drug development process which will result in safer and more effective 
treatments. 
9.1. Future directions 
In the current era of personalized medicine, biomarkers are becoming 
increasingly important in treatment decision-making to improve outcome for 
patients. Biomarkers can be binary, categorical or measured on a continuous scale. 
Binary biomarkers can define two subpopulations, thus, patients are classified into 
two biomarker-defined subgroups, the biomarker-positive and biomarker-negative 
subgroup, whereas categorical and continuous biomarkers can define several 
subpopulations. The classification of patients in the case of a continuous biomarker 
is more complicated since the optimal number of cutpoints and their values need to 
be determined. Little guidance on how to choose an optimal threshold exists in the 
literature and to the best of our knowledge, only one trial design specifically aimed 
at continuous biomarkers has been proposed in the literature, the so-called Adaptive-
threshold design. This design was suggested for settings in which a putative 
biomarker is measured on a continuous or graded scale with its threshold for 
detecting individuals who would benefit from the novel treatment unknown at the 
initial stage of a Phase III trial (see Chapter 3). It is recommended that future research 
is undertaken for the investigation of methodologies to determine appropriate 
biomarker thresholds which will lead to optimal stratification of patients [6].  
The proposed future work relating to BiGTeD include incorporating sample 
size and power calculators for each design as well as an interactive element in which 
the characteristics of a study could be inserted and suggestions about the most 
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appropriate trial design for a given setting output. Specifically, researchers could 
input details about their trial e.g. Is there already strong evidence for a stratifying 
biomarker? YES/NO; Is the biomarker threshold already known? YES/NO etc. and 
the website would then provide a suggested optimal trial design.  
More work is required in terms of sample size and power calculations in 
biomarker-guided designs. The work on Chapter 5 could be improved upon by 
incorporating a sample size re-estimation approach at the interim analysis stage with 
the aim of revising the information which is collected in case of uncertainty about the 
treatment effect size for which the study was powered. However, the choice of an 
unblinded sample size re-estimation method should be carefully evaluated as 
operational challenges, organizational and statistical issues may arise [3-5]. 
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Appendix A 
Appendix A includes supporting information related to Chapter 2 of this 
thesis. More specifically, variations of biomarker-guided adaptive trial designs are 
presented in A.1. Literature review search strategies for both biomarker-guided 
clinical trial designs and for traditional trial designs are given in A.2. 
A.1. Variations of biomarker-guided adaptive trial designs 
Variations of the main biomarker-guided adaptive designs are discussed below 
and their characteristics are summarized further in Table A.1.  
Variations of Adaptive signature design 
Adaptive threshold design  
This variation of the aforementioned Adaptive Signature design is mentioned 
in 25 papers (23.4%) of our review. The difference between the Adaptive Signature 
design and the Adaptive Threshold design is that the first one is used to develop and 
validate a biomarker, whereas this variant tries to identify and validate an optimal 
cut-off point for a pre-specified biomarker. In other words, the Adaptive Threshold 
design was suggested for settings in which a putative biomarker is measured on a 
continuous or graded scale with its threshold for detecting individuals who would 
benefit from the novel treatment not predefined at the initial stage of a Phase III trial. 
In terms of Figure 2.2, the difference between the main design (Adaptive Signature 
design) and this variant corresponds to the biomarker-positive subset. More 
precisely, in the main design, if there is no claim of treatment effectiveness in the 
entire population, then a portion of individuals is used to develop a predictive 
biomarker signature and the remaining portion is used to compare the treatment 
effect. However, in this variant if there is no claim of treatment effectiveness in the 
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entire population, the design identifies and validates a cut-off point for a 
prospectively selected biomarker. Adaptations here are referred to the subgroup and 
there are no modifications regarding the required number of patients or 
randomization ratio. In this design, human samples are collected to measure a pre-
specified biomarker from the entire population at the beginning of the study but the 
value of biomarker is not used as an eligibility criteria. 
Two analysis plans compose this approach, the so-called ‘analysis plan A’ and 
‘analysis plan B’.  The first plan is identical to the strategy proposed for the Adaptive 
Signature design. The second plan uses a more effective method to accommodate the 
multiplicity issue when combining the statistical tests for the entire population and 
the biomarker-defined subgroup by incorporating the correlation structure of the two 
test statistics. More precisely, the plans A and B are different in the way the test 
statistics and thus its distribution assuming true null hypothesis is calculated. For 
Plan A, the test statistic is calculated as the maximum, across all possible cutoff 
values, of the log-likelihood ratio statistic for treatment effect for those with 
biomarker values above the cutoff value. For plan B, the test statistic is calculated as 
the larger of the test statistic for procedure A and the log-likelihood ratio statistic for 
treatment effect in the entire population. The second plan is considered a 
generalization of the first plan because in case that a difference between experimental 
treatment and the standard of care is demonstrated, then the next stage is to find the 
biomarker threshold above which the targeted treatment is more beneficial for 
patients than the control treatment, consequently, among the cut-off points of a 
measured score of a biomarker, the maximum value is selected. This plan uses a 
larger sample size, resulting in appropriate power for establishing the statistical 
significance of treatment effect restricted to patients with biomarker values above an 
initially unknown cut-off point. 
Jiang et al. (2007) [125] proposed the use of bootstrap re-sampling method for 
the estimation of the point estimate and a confidence interval for the cut-off point and 
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described the sample size planning for this design. Also, according to Jiang et al. 
(2007) [125] if plan B does not reject the null hypothesis, the estimation of the cut-off 
point value would be inexplicable, and thus it should not be estimated. Jiang et al. 
(2007) [125] demonstrated through a simulation study that the second plan was more 
effective than the first one. A modification of the global test of the null hypothesis 
which was used by Jiang et al. (2007) [125] is illustrated in the paper of Simon (2012) 
[57]. The Adaptive Threshold design can detect efficiently a global treatment effect 
and provides statistically valid tests when the promising treatment effect is limited 
to a particular biomarker-defined subset, however, a larger sample size may be 
required and can lead also to redundant power. 
Molecular signature design  
Molecular Signature design is mentioned in 2 two articles (1.9%). It is a Phase 
III design which collects tissue samples from the entire population at the start of the 
trial and analyse them when the study is near completion. 
After the collection of tissue samples from the entire population, all patients are 
randomized to either the experimental treatment or the standard treatment. The 
methodology is similar to the Adaptive Signature design. This approach makes the 
comparison of the novel drug with the standard of care, but on a primary outcome 
measure which here is the overall survival using the significance level of 0.04. In case 
that the results show the effectiveness of an experimental treatment over the control 
arm, we claim the effectiveness of treatment in the overall population. Otherwise, an 
analysis is conducted for the identification and validation of the biomarker classifier 
(i.e. a combination of biomarkers) which gives the best primary outcome measure. A 
portion of subjects is used for the detection of a biomarker classifier and the 
remainder of patients for its validation. It is considered as a promising strategy 
without statistical considerations mentioned.  
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Cross-validated Adaptive Signature design 
Cross-validated Adaptive Signature design (CVASD) is found in 19 papers 
(17.8%) of our review. It was proposed by Freidlin et al. (2010) [60] aiming to increase 
the efficiency of the Adaptive Signature design. Similar to the Adaptive signature 
approach it is a Phase III frequentist trial design based on a fall back strategy in order 
to identify candidate biomarkers in the training set of the study and evaluate them in 
the validation set.  
The difference between Adaptive signature design and Cross-validated 
Adaptive Signature design is in terms of the methodology analysis. The former is 
composed of a split-sample approach, using approximately half of patients to 
develop the biomarker signature and the remainder of patients to validate it, 
whereas, the latter uses the K-fold cross validation procedure, i.e. there are K cross-
validated training sets which are used to classify subjects in the corresponding K 
cross-validated validation sets. After the classification of all patients, we compare the 
experimental treatment versus the control treatment in the biomarker-positive 
patients (i.e. subgroup of classifier positive patients). The Cross-validated Adaptive 
Signature design may yield larger power but it faces the same challenges with its 
main design and also includes the multiplicity problem.  
Generalized adaptive signature design  
Generalized Adaptive Signature approach is described in 2 papers (1.9%). 
Firstly, candidate biomarkers are selected and the cut-off points are optimized using 
a training set and secondly, the chosen biomarkers are assessed in the validation set. 
According to Simon (2010) [18], this approach is applicable when there are a number 
of available candidate biomarkers, but data from a Phase III setting is required for 
choosing the most appropriate biomarkers. A major drawback of this design is the 
limited power when we assess the treatment effect in the biomarker-defined subset. 
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Adaptive signature design with subgroup plots  
Adaptive Signature design with Subgroup Plots [64] is an extension of 
Adaptive Signature design which has been proposed in order to add flexibility. It 
uses tail-oriented or sliding window subgroup plots in order to identify a subset of 
patients which is most likely to respond to a particular experimental treatment after 
taking into account several cut-off points of the benefit score obtained by the 
subgroup plots. In this way it provides broader confidence intervals of the estimated 
treatment benefit. No statistical considerations have been found for this approach. 
Variation of Outcome-based adaptive randomization design 
Bayesian covariate adjusted response-adaptive randomization  
The Bayesian Covariate Adjusted Response-Adaptive Randomization 
(BCARA) is identified in two articles (1.9%) and it was proposed in 2010 by Eickhoff 
et al. (2010) [53]. This strategy which combines a Bayesian, an adaptive and biomarker 
classification approach aims to match patients with the most efficacious treatments 
by utilizing patient’s biomarker information becoming available during the conduct 
of the clinical trial. This strategy may be useful in the explanatory phase II setting of 
the drug development [53]. It is also considered as a response-adaptive 
randomization strategy as the allocation of the study population depends on the 
responses of previous outcomes. A partial least square logistic regression approach 
is conducted to determine adaptively predictive biomarker-defined subsets. 
The general procedure of this approach is composed of four steps according to 
Eickhoff et al. (2010) [53]: (i) randomly assign the first 𝑛∗ >= 𝐽∗(K + 1) patients to the 
different treatment arms where 𝐽 the number of different treatment groups and K the 
number of biomarkers. At least one response should be observed in each of the 
different treatment groups before moving to the Bayesian response adaptive 
randomization; (ii) after each new individual has been enrolled in the study, 
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predictive biomarker-defined groups are determined by utilizing a partial least 
squares logistic regression strategy (PLSLR) which can predict whether the patient 
can benefit from the treatment. The biomarker status is determined before the 
randomization; (iii) after the establishment of the biomarker status and biomarker-
defined groups of each new individual, the individual is then randomly assigned into 
one of the treatment arms using a BCARA randomization; (iv) according to the results 
of the BCARA randomization the trial either stops or continues based on decision 
rules proposed by Eickhoff et al. (2010) [53]. The Bayesian covariate adjusted 
response-adaptive trial design has the ability to identify the biomarker-defined 
groups likely to respond to a treatment but it does not control the Type I error and in 
order to ensure that the identified result is true, a Phase III study should be 
conducted.  
Variation of Adaptive patient enrichment design 
Modified Bayesian version of the two-stage design of Wang et al. (2007) [80] 
A variation of Adaptive Patient Enrichment design by Wang et al. (2007) [80] 
was found in 2 papers (1.9 %). It is a Phase III Bayesian two-stage design proposed 
by Karuri and Simon (2012) [7] for the evaluation of both treatment and biomarker. 
Karuri and Simon (2007) [7] use a Bayesian framework in order to allow further 
flexibility for expressing the degree of prior information regarding the utility of a 
biomarker. More precisely, posterior distribution of treatment effects within the 
biomarker-positive and biomarker-negative subgroups based on an interim analysis 
of first-stage is used in order to come to a decision regarding the recruitment and the 
continuation of the trial. This approach allows for early termination of the study 
during the initial stage of the trial and has a satisfactory power. No statistical 
challenges have been identified. 
Variations of Multi-arm multi-stage (MAMS) design 
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Two-stage adaptive seamless design  
Two-stage Adaptive Seamless design is a type of clinical trial design identified 
in 28 papers (26.2%) of our review. It uses the MAMS approach combining two 
separate studies into one single study and uses interim monitoring as well as multi-
arm design features. It connects the explanatory Phase II stage for treatment selection 
and confirmatory Phase III stage for the final comparison of the chosen experimental 
treatments with the standard of care. The Two-stage Adaptive Seamless design aims 
to improve the power in the Phase II stage in order to continue on the Phase III stage 
having obtained important promising information. In the definitive analysis, it uses 
data from patients registered during the Phase II and Phase III stages. A prerequisite 
of this strategy is the availability of a reliable early endpoint. An example of actual 
trial which uses the two-stage adaptive seamless design is the ISPY2 trial [54, 93, 126, 
127]. 
Brannath et al. (2009) [36] propose an approach which uses Bayesian decision 
tools and is based on the two-stage seamless design in order to confirm that the 
identified biomarker-defined subgroup from a Phase II study is sensitive to the new 
treatment in a separate explanatory phase (i.e. a study which is conducted at the same 
time with the two-stage adaptive seamless design) and afterward conduct a Phase III 
study with this selected subgroup. More precisely, the general procedure of this 
Phase II/III strategy is presented by Brannath et al. (2009) [36] as follows: When half 
of individuals are recruited in the study, an interim analysis is performed in order to 
decide whether to accept or not a biomarker-defined subpopulation identified in a 
separate exploratory study. At this interim stage, a decision is also made about 
whether to continue accruing patients from the aforementioned biomarker-defined 
subset or from the entire study population. If the first case occurs, the treatment effect 
is assessed only in this biomarker subpopulation and if the second case happens, the 
treatment effect is tested in the entire population and biomarker-defined subgroup at 
the same time. In case that there is no identified biomarker-defined subpopulation 
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from the separate exploratory study, the trial continues in the overall population 
using a classical group sequential design. The major advantage of this type of design 
is its ability to reduce the costs and also the selection of the target population in a 
reliable way. Also, appropriate methodology, such as that used by Brannath et al. 
(2009) [36] where multiple testing is adjusted by a weighted combination of p-value 
from data of the second stage and the first stage, and Simes’ step-up process [128] is 
used when combining data form both Phases in order to maintain the Type I error 
rate.  An extension of the above approach by Brannath et al. (2009) [36] is proposed 
by Jenkins et al. (2011) [129] which can result in the rapid approval of novel 
treatments to the most appropriate individuals who are likely to benefit from the new 
drug. During the Phase II trial an interim analysis is conducted using a short-term 
intermediate outcome measure (i.e. survival endpoint) in order to select the 
population (either the entire population or the biomarker-positive patients) which 
will be used in the Phase III study with a long-term endpoint. 
Mehta et al. (2014) [130] proposed an alternative seamless approach for 
subgroup selection in time-to-event-data for situations where there is no a priory 
assumption that a biomarker is predictive of treatment efficacy; consequently their 
design tests whether there is treatment effect in both biomarker-negative and 
biomarker-positive subpopulation separately instead of testing the null hypothesis of 
no treatment effect in the entire study population and in biomarker-positive subset. 
According to Scher et al. (2011) [59], formulas for sample size 
calculation/allocation are proposed in situations where the study endpoints are 
continuous, discrete, and contain time-to-event data supposing the availability of a 
well-established relationship between the study endpoints at different stages, and 
that the study objectives at different stages are the same. Ang et al. (2010) [52] have 
stated that even in case that the trial stops early, a Phase III infrastructure should be 
developed. Such strategies have been proposed by Ellenberg and Eisenberger (1985) 
[131] and Inoue et al. (2002) [132] for evaluating the possibility to stop early or to 
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continue to the confirmatory phase III repeatedly during the explanatory phase. The 
aforementioned designs are useful in situations where there is strong belief in the 
efficacy of the experimental therapy that can lead the study to the confirmatory 
phase, but confirm of this assumption is needed [52]. Despite the fact that this 
approach is considered as a more efficient strategy yielding larger power as 
compared with the conduct of separate trials, it can lead to introduction of bias and 
inflation of the type I error rate.   
Group Sequential design  
Adaptive Group Sequential design is found in 2 papers (1.9%) which can be 
incorporated into the MAMS approach for the development and validation of 
personalized therapies and is proposed by Lai et al. (2013) [74]. This strategy aims to 
find the most beneficial treatment for future patients based on their biomarker 
profiles, with a guaranteed probability of correct selection. It was proposed for the 
examination of multiple composite hypotheses not only in the entire study 
population but also in the biomarker-positive subgroups [133].The design  is based 
on approved treatments, and aims to improve patient’s health by providing them 
with the most efficacious (yet unidentified) treatment. Additionally, another crucial 
objective of this approach is that the development of a novel treatment strategy for 
the forthcoming patients and the confirmation that the treatment effect of this 
strategy is in fact more effective than the historical mean effect of the control 
treatment plus a predetermined threshold [74].  
According to Lai et al. (2013) [74], it is an approach for “jointly developing and 
testing treatment recommendations for biomarker classes, while using multi-armed 
bandit ideas to provide sequentially optimizing treatments to patients in the trial”. 
According to an interim data analysis, sequential decisions about whether to continue 
the study or not, are taken. It is considered a simple approach where selection of cut-
off points is not required before the conduct of the first interim analysis. 
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Table A.1. Characteristics of variations of Biomarker-guided adaptive trial designs 
Types of variations of 
Biomarker-guided 
adaptive trial designs 
Phase  Pros  Cons  
Adaptive threshold 
design (25 papers) [3, 6, 
8, 12, 14, 15, 18, 20, 21, 27, 
29, 30, 47, 57, 58, 63, 64, 
68, 70, 74, 78, 84, 125, 
134] 
Also called: 
Biomarker adaptive 
threshold design 
III Validation of a candidate biomarker without need for an 
established cut-off point. 
Identification of an optimal cut-off point for detecting 
sensitive patients (i.e. biomarker-positive patients). 
Detection of overall treatment effect if one exists. 
Statistically valid test if treatment benefit is restricted to a 
biomarker-defined subgroup. 
Reduces dependence on Phase II data for establishing a 
test cut-off point. 
More efficient design as compared to the traditional 
design (i.e. standard broad eligibility Phase III design 
based on assessing the global treatment effect in the 
Requirement of a pre-specified biomarker for sensitivity, but 
not an established cut-off point. 
Data from the same study to both define and validate the 
cut-off point of the biomarker may raise concerns. 
Augmented costs due to the potential sample size increase 
and/or redundant power by partitioning the overall type I 
error. 
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overall population when the proportion of sensitive 
patients is low). 
Molecular signature 
design (2 papers) [32, 63] 
No alternative names 
found for this trial 
design 
III Considered as a promising strategy for drug development 
as it takes advantage of the use of an end-point with clear 
clinical gain. 
No information found 
Cross-validated 
adaptive signature 
design (19 papers) [9, 14-
16, 18, 20, 21, 24, 27, 32, 
59, 60, 62-64, 66, 84, 104, 
135] 
No alternative names 
found for this trial 
design 
III Gain more power as it could maximize the number of 
individuals taking part in the development of the 
biomarker signature.  
Can detect the subset of patients most likely to respond to 
a specific treatment in a more reliable way. 
Same challenges as the Adaptive signature design. 
Multiplicity problem for statistical testing as the statistical 
test would be conducted twice. 
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Generalized adaptive 
signature (2 papers) [18, 
63] 
No alternative names 
found for this trial 
design 
III Optimizes the test based on randomized data for patients 
in the Phase III setting. 
Limits its power when testing the effectiveness of an 
experimental treatment in the biomarker-positive subgroup. 
Adaptive signature 
design with subgroup 
plots (1 paper) [64] 
No alternative names 
found for this trial 
design 
III No information found No information found 
Bayesian covariate 
adjusted response-
adaptive randomization 
(2 papers) [53, 63] 
II Ability to incorporate prior knowledge from biomarkers 
into the design. 
Identification of the subgroups for which a particular 
experimental treatment is more effective. 
The Type I error is not controlled in the traditional sense. 
An independent Phase III study focused on the selected 
biomarker-defined subgroups is required to show that the 
identified promising result is definitely true. 
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No alternative names 
found for this trial 
design 
Can result in reduction of the number of patients required 
when compared to alternative designs (i.e. non-adaptive 
trial designs). 
Solves the issue of the incorporation of information of 
multiple and possibly correlated biomarkers. 
Modified Bayesian 
version of the two-stage 
design of Wang et al. 
(2007) [80] (2 papers) [7, 
136] 
Also called: 
Two-Stage Bayesian 
design                          
III Can incorporate prior belief regarding the strength of 
biomarker into the Phase III setting using a Bayesian 
framework and simultaneously protecting the study 
population and minimizing the Type I error in the 
biomarker-positive and biomarker-negative subgroups 
Can terminate the study early according to whether the 
treatment is effective or not in the biomarker-positive 
subgroup at the interim stage whereas the main design by 
Wang et al. (2007) [80] does not allow for early 
termination of the trial. 
Satisfactory power for testing the biomarker-positive 
subgroup. 
No information found 
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Enables the reduction of number of biomarker-negative 
patients for whom a particular treatment tailored to them 
seems to be ineffective according to biological evidence. 
The utilized Bayesian formulation sheds light on the 
nature of inference at the end of the study. 
Can result in reduction of costs of clinical development. 
Two-stage adaptive 
seamless design (28 
papers) [20, 23, 33, 36, 37, 
40, 42, 43, 45-47, 52, 54, 
59, 68, 74, 82, 93, 119, 126, 
129-131, 137-142] 
Also called: 
Seamless Phase II/III 
designs 
Adaptive Seamless  
II/III The evaluation of each experimental therapy can be 
performed without requiring the conduct of separate 
large-scale Phase II trials. 
Flexibility and efficiency of trials can be increased. 
Individuals from both explanatory and confirmatory 
stages are used in the definitive analysis; hence, the 
design avoids ‘wasting’ individuals already registered in 
Phase II setting. 
A significant concern is that the results obtained from the 
Phase II analysis, which becomes an interim analysis of the 
Phase III study should remain in the hands of the data 
monitoring committee due to confidentiality.  
Concerns also arise regarding the efficiency and validity of 
such a trial design.  
Sometimes, the endpoints within the different phases are 
dissimilar, hence, a decision is required on how to combine 
the data obtained from both stages in order to use them in 
the definitive analysis. This challenge is further discussed in 
the paper of Chow et al. (2007) [141]. 
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Phase II/III Adaptive 
design 
Two-stage Adaptive 
Seamless design  
Adaptive Seamless Phase 
II/III design 
Diminishes the potential loss of time between the 
completion of Phase II stage and the beginning of patient 
enrollment in Phase III setting. 
The same standard of care can be used in both stages of 
the study. 
Can result in the same quality of evidence as in a 
traditional design but with a smaller number of patients. 
Can result in the speedup of drug development and also 
in a successful Phase III trial. 
More efficient due to the improved power and the ability 
to control the Type I error as compared with the conduct 
of separate studies. 
The required power of both individual studies may be 
acquired by using a smaller number of patients than that 
of a single study.  
Two separate trials (Phase II and Phase III) are conducted 
under one single trial protocol, but in reality, researchers 
According to the Draft Guidance by U.S. Food and Drug 
Administration (2010) [142], an adaptive seamless phase 
II/III design is described as a less well-understood design 
which may introduce bias and inflation of the Type I error 
rate.  
Calculation and allocation of the necessary sample size for 
the two separate studies. 
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analyze them separately using data from each stage, 
resulting in this way in savings of time and cost. 
Group Sequential 
design (2 papers) [74, 
133] 
No alternative names 
found for this trial 
design 
 Researchers do not have to choose the cut-off points 
which should be used to designate the biomarker classes 
until the performance of the first interim analysis. 
Non-promising treatments can be dropped at an early 
stage. 
No information found 
 378 
 
A.2. Literature review search strategies for both biomarker-guided 
clinical trial designs and for traditional trial designs 
MEDLINE 
Traditional clinical trial designs  
1. Clinical Trials as Topic/ 
2. Clinical Trial/ 
3. 1 or 2 
4. Research Design 
5. design*.mp.  
6. Research design*.mp. 
7. Statistical design*.mp. 
8. Study design*.mp. 
9. Traditional design*.mp. 
10. Trial design*.mp. 
11. 4 or 5 or 6 or 7 or 8 or 9 or 10 
12. 3 and 11 
13. limit 12 to (english language and “review articles”) 
14. limit 13 to last ten years 
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MEDLINE 
Biomarker-guided clinical trial designs  
1. Clinical Trials as Topic/  
2. clinical trial*. ti, ab. 
3. 1 or 2 
4. design*. ti, ab. 
5. 3 and 4 
6. limit 5 to comment 
7. limit 5 to editorial 
8. limit 5 to journal article 
9. limit 5 to guideline 
10. limit 5 to systematic reviews 
11. limit 5 to “review” 
12. limit 5 to technical report 
13. limit 5 to practice guideline 
14. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. limit 14 to English language 
16. limit 15 to last 10 years 
17. exp *marker/ or biological marker/ or clinical marker/ 
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18. (marker* or biomarker* or factor* or classifier or signature* or target* or 
endpoint). ti, ab. 
19. 17 or 18 
20. 16 and 19 
The Ovid strategy was conducted by following the guidance by BMA Library - 
MEDLINE Plus. Basic Course. Notes for OvidSP; 2012. Available from: 
http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&ve
d=0ahUKEwjS7_OmodvJAhWGVhQKHZr0AZMQFggdMAA&url=http%3A%2F%2
Fbma.org.uk%2F-
%2Fmedia%2Ffiles%2Fpdfs%2Fabout%2520the%2520bma%2Flibrary%2Fmedline%
2520plus%2520basic%2520course%2520manual%25202012.pdf&usg=AFQjCNGFxc
WiS11CJsroeeIETAWjW0neUA. 
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Appendix B 
Appendix B includes supporting information related to Chapter 3. More 
precisely, extensions of biomarker-guided non-adaptive trial designs are given in the 
current section. The literature review search strategies for both biomarker-guided 
clinical trial designs and for traditional trial designs are given are given in A.2. 
Extensions of biomarker-guided non-adaptive trial designs: 
Variations of Biomarker-Strategy Designs 
Sequential before-after pharmacogenetic diagnostic study: The design 
identified in two papers [36,38] (2%) of our review. A graphical illustration of this 
design is given in Figure B.1. 
 
Figure B.1. Sequential before–after pharmacogenetic diagnostic study 
This approach was proposed in the field of pharmacogenetics involving the 
assessment of pharmacogenetic diagnostics being performed during the study. In this 
sequential approach each patient serves as his/her own control) [38]. Treatments are 
tailored to patients before genotyping and then again after genotyping. A comparison 
of outcomes before and after the introduction of pharmacogenomics is conducted. 
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This individual crossover approach requires a smaller number of patients as 
compared to the previous designs described and is not considered complex in its 
implementation. Additionally, before–after comparisons are the basis of medical 
practice in many important therapeutic areas such as surgery [38] and they can 
inform researchers about whether a personalized treatment is more effective than the 
standard of care. However, types of systematic error (i.e. bias which yield incorrect 
estimate of a measure of disease) might be introduced, e.g., due to errors on 
classification of outcomes or on the assessment of the biomarker status of patients. 
Classifier randomization design: Another extension of biomarker-strategy 
designs is the Classifier randomization design which was identified in two papers 
[36,107] (2%) of our review. An example of an actual trial which uses this strategy is 
the NNBC-3 European trial [107]. A graphical illustration of this design is given in 
Figure B.2. 
 
Figure B.2. Classifier randomization design. “R” refers to randomization of patients. 
 
This is an approach proposed for the validation of prognostic biomarkers which 
randomly assign the study population between classifiers (i.e. a new biomarker and 
a standard biomarker) rather than treatments validating directly the new biomarker. 
With this approach, we compare the new and standard classifiers in order (i) to show 
equivalence in outcome, i.e. the outcome of patients assigned to the new biomarker 
is not too different to that obtained from patients in the standard classifier 
independently of the low/high level in each category; (ii) to show superiority in 
outcome, i.e. the outcome of patients assigned to the new classifier who are given the 
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experimental treatment is superior to that obtained from the patients given the 
control treatment. 
Modified marker strategy design: This modified version of the biomarker-
strategy design was identified in five papers [9,19,22,58,91] (5%) of our review. A 
graphical illustration of this approach is given in Figure B.3. 
 
Figure B.3. Modified marker strategy design. “R” refers to randomization of patients. 
In this design, biomarker assessment is required in the entire population before 
randomization to either the biomarker-based strategy arm or to the non-biomarker-
based strategy arm. However, only patients for whom treatment assignment would 
be influenced by biomarker result are then randomized—those whose treatment 
assignment would be the same regardless of biomarker result are off study. An 
example of an actual trial which uses this approach is the MINDACT trial. More 
precisely, in the MINDACT trial the entire population is evaluated by two analyses, 
the 70-gene profile (biomarker-based analysis) as well as clinicopathologic factors 
(non-biomarker-based analysis). Next, only patients with discordant results (i.e. 
patients predicted to be high risk based on one of the two analyses and low risk 
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patients based on the other analysis) will be randomized to either the biomarker-
based strategy or to the non-biomarker-based strategy). 
Next, as exactly in the biomarker-strategy design with biomarker assessment in 
the control arm, patients who are randomly assigned to the biomarker-based strategy 
arm are treated either with the experimental treatment if they have biomarker-
positive status or with the control treatment if they have biomarker-negative status. 
The main limitation of biomarker-strategy designs is that they can result in a 
significant number of patients in the trial who are assigned to the same treatment in 
both biomarker-based strategy arm and non-biomarker-based strategy arm (i.e. 
biomarker-negative patients in the biomarker-based strategy arm receive control 
treatment but, biomarker-negative patients might also receive control treatment in 
the non-biomarker-based strategy arm as the random assignment of the entire 
population to this strategy arm is independent of their biomarker-status). 
Consequently, a large sample size is needed to identify the diluted treatment effect. 
This modified version promises to solve this limitation of biomarker-strategy designs 
by only randomizing patients for whom treatment assignment is influenced by 
biomarker result. 
Variation of Randomize-All Designs 
Two-way stratified design: A version of the Biomarker Stratified design is the 
Two-way Stratified design which was referred to in two papers [107,132] (2%) of our 
review. Figure B.4 represents the graphical illustration of this strategy. 
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Figure B.4. Two-way Stratified design (for validation of prognostic biomarkers). “R” refers to 
randomization of patients. 
In this approach, patients are stratified according to their biomarker results. 
Standard treatment is tailored to patients with a low score, experimental treatment is 
given to patients with a high score and those with an intermediate score are 
randomized to either experimental or standard treatment. An example of an actual 
trial which uses this approach is that conducted by the “Arbeitsgemeinschaft 
Gynakologische Onkologie” (AGO) Study Group in cooperation with the EORTC 
Receptor and Biomarker Study Group for the “Chemo-N0 trial” to validate UPA and 
PAI1 as prognostic indicators in node negative breast cancer [107]. 
According to Spira et al. [132] a noninferiority design for the intermediate 
group can be used and has the statistical power to detect a 3% or greater difference 
between the randomized arms. 
Since there is no direct prospective comparison between the novel and standard 
classifier, the two-way stratified design provides further, although indirect, 
validation of the biomarker. 
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Appendix C 
Appendix C includes supporting information (table and figures) and R codes related to Chapter 5. Tables and figures can be found 
in C.1. R codes used to produce the results of the Parallel Subgroup-Specific design and its adaptive version are given in C.2.1 and C.2.2 
respectively. 
C.1. Supporting tables and figures 
Table C.1. Accrual rate and number of events and patients (calculated from (5.7), (5.1) and (5.3) respectively) which achieve approximate 80% power for different scenarios 
of hazard ratios and significance levels, and the corresponding power of each biomarker-defined subgroup yielded from the simulation. 
 Simulation setting Accrual rate and required numbers  Simulated 
power 
Group of patients Significance 
level 
Hazard 
ratio 
Accrual rate Number of 
 events 
Number of  
patients 
Power 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.6 
0.4 
- 
9 
4 
- 
146 
45 
191 
168 
76 
244 
0.798 
0.788 
- 
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.6 
0.4 
- 
9 
4 
- 
139 
48 
187 
160 
81 
241 
0.796 
0.792 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.6 
0.4 
- 
10 
4 
- 
154 
43 
197 
177 
73 
250 
0.791 
0.792 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.7 
0.5 
- 
19 
7 
- 
299 
79 
378 
335 
126 
461 
0.804 
0.786 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.7 
0.5 
- 
18 
7 
- 
285 
84 
369 
320 
133 
453 
0.798 
0.793 
- 
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.7 
0.5 
- 
20 
7 
- 
316 
76 
392 
354 
120 
474 
0.798 
0.800 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.8 
0.6 
- 
47 
12 
- 
764 
146 
910 
841 
220 
1061 
0.796 
0.796 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.8 
0.6 
- 
45 
13 
- 
729 
154 
883 
803 
232 
1035 
0.800 
0.796 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.8 
0.6 
- 
49 
12 
- 
806 
139 
945 
888 
210 
1098 
0.799 
0.793 
- 
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.9 
0.7 
- 
207 
24 
- 
3425 
299 
3724 
3720 
434 
4154 
0.806 
0.804 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.9 
0.7 
- 
197 
25 
- 
3268 
316 
3584 
3550 
458 
4008 
0.803 
0.798 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.9 
0.7 
- 
218 
23 
- 
3616 
285 
3901 
3928 
414 
4342 
0.804 
0.796 
- 
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Table C.2. Results for expected number of events and patients, expected total study period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 2 of hazard ratios for different percentages of information fraction. Number of events and patients from Table C.1 (calculated from (5.1) and 
(5.3) respectively) which achieve 80% power for the second scenario of hazard ratios and significance levels are also presented. 
  Simulation setting    Number Simulated Power 
 Group of patients Significance 
level 
Hazard ratio Required 
Number of 
events 
Required 
  Number of 
patients 
Expected Total 
study period 
(months)  
Expected 
Number 
of events 
Expected 
Number of 
patients 
FSP ESP Power 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.7 
0.5 
- 
299 
79 
378 
335 
125 
460 
17.6 
16.9 
- 
176 
44 
220 
197 
70 
267 
0.3672 
0.3931 
- 
0.1817 
0.1895 
- 
0.5678 
0.5382 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.7 
0.5 
- 
285 
84 
369 
320 
133 
453 
16.8 
14.0 
- 
160 
39 
199 
179 
62 
241 
0.4173 
0.5070 
- 
0.1696 
0.2060 
- 
0.5000 
0.4258 
- 
Biomarker-negative 0.010 0.7 316 354 14.9 157 176 0.4823 0.1879 0.4450 
25
%
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Biomarker-positive 
Entire population 
0.015 
0.025 
0.5 
- 
76 
392 
121 
475 
16.1 
- 
41 
198 
65 
241 
0.4268 
- 
0.1899 
- 
0.5028 
- 
 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.7 
0.5 
- 
299 
79 
378 
335 
125 
460 
21.7 
21 
- 
217 
55 
272 
243 
88 
331 
0.1655 
0.1846 
- 
0.3848 
0.4142 
- 
0.7246 
0.7004 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.7 
0.5 
- 
285 
84 
369 
320 
133 
453 
21.3 
19.6 
- 
203 
55 
258 
228 
87 
315 
0.2036 
0.2674 
- 
0.3736 
0.4273 
- 
0.6700 
0.6145 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.7 
0.5 
- 
316 
76 
392 
354 
121 
475 
20.2 
21.0 
- 
212 
53 
265 
238 
85 
323 
0.2425 
0.2118 
- 
0.4127 
0.3915 
- 
0.6414 
0.6593 
- 
50
%
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.7 
0.5 
- 
299 
79 
378 
335 
125 
460 
25.0 
24.8 
- 
249 
65 
314 
280 
104 
384 
0.0707 
0.0824 
- 
0.5922 
0.6046 
- 
0.7739 
0.7571 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.7 
0.5 
- 
285 
84 
369 
320 
133 
453 
25.0 
24.2 
- 
238 
68 
306 
267 
107 
374 
0.0944 
0.1322 
- 
0.5671 
0.6366 
- 
0.7264 
0.7193 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.7 
0.5 
- 
316 
76 
392 
354 
121 
475 
24.5 
24.9 
- 
258 
63 
21 
289 
100 
389 
0.1141 
0.1007 
- 
0.6187 
0.5812 
- 
0.7262 
0.7277 
- 
 
 
 
75
%
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Table C.3. Results for expected number of events and patients, expected total study period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 3 of hazard ratios for different percentages of information fraction. Number of events and patients from Table C.1 (calculated from (5.1) and 
(5.3) respectively) which achieve 80% power for the third scenario of hazard ratios and significance levels are also presented. 
  Simulation setting    Number Simulated Power 
 Group of patients Significance 
level 
Hazard ratio Required 
Number of 
events 
Required 
  Number of 
patients 
Expected Total 
study period 
(months)  
Expected 
Number 
of events 
Expected 
Number of 
patients 
FSP ESP Power 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.8 
0.6 
- 
764 
146 
912 
841 
221 
1061 
17.6 
16.9 
- 
449 
82 
531 
495 
125 
620 
0.3678 
0.3921 
- 
0.1815 
0.1903 
- 
0.5680 
0.5399 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.8 
0.6 
- 
729 
154 
883 
803 
233 
1036 
16.8 
14 
- 
409 
72 
481 
450 
109 
559 
0.4162 
0.5072 
- 
0.1694 
0.2051 
- 
0.5004 
0.4245 
- 
Biomarker-negative 0.010 0.8 806 888 14.9 400 440 0.4839 0.1881 0.4434 
25
%
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Biomarker-positive 
Entire population 
0.015 
0.025 
0.6 
- 
139 
945 
210 
1098 
16.1 
- 
75 
475 
113 
553 
0.4276 
- 
0.1893 
- 
0.5013 
- 
 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.8 
0.6 
- 
764 
146 
912 
841 
221 
1061 
21.7 
21.0 
- 
554 
102 
656 
609 
155 
764 
0.1658 
0.1827 
- 
0.3849 
0.4161 
- 
0.7244 
0.7034 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.8 
0.6 
- 
729 
154 
883 
803 
233 
1036 
21.3 
19.6 
- 
518 
101 
619 
571 
152 
723 
0.2036 
0.2687 
- 
0.3743 
0.4245 
- 
0.6711 
0.6118 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.8 
0.6 
- 
806 
139 
945 
888 
210 
1098 
20.2 
21 
- 
542 
97 
639 
597 
147 
744 
0.2438 
0.2126 
- 
0.4123 
0.3895 
- 
0.6400 
0.6576 
- 
50
%
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.8 
0.6 
- 
764 
146 
912 
841 
221 
1061 
25.1 
24.8 
- 
637 
121 
758 
702 
183 
885 
0.0706 
0.0821 
- 
0.5923 
0.6053 
- 
0.7739 
0.7580 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.8 
0.6 
- 
729 
154 
883 
803 
233 
1036 
25.0 
24.2 
- 
608 
124 
732 
670 
188 
858 
0.0944 
0.1345 
- 
0.568 
0.6336 
- 
0.7276 
0.7160 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.8 
0.6 
- 
806 
139 
945 
888 
210 
1098 
24.5 
24.9 
- 
658 
115 
773 
725 
175 
900 
0.1144 
0.1021 
- 
0.6199 
0.5755 
- 
0.7252 
0.7236 
- 
 
 
75
%
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Table C.4. Results for expected number of events and patients, expected total study period, futility stopping probability, efficacy stopping probability and power of a 
two-stage design in scenario 4 of hazard ratios for different percentages of information fraction. Number of events and patients from Table C.1 (calculated from (5.1) and 
(5.3) respectively) which achieve 80% power for the fourth scenario of hazard ratios and significance levels are also presented. 
  Simulation setting    Number Simulated Power 
 Group of patients Significance 
level 
Hazard ratio Required 
Number of 
events 
Required 
  Number of 
patients 
Expected Total 
study period 
(months)  
Expected 
Number 
of events 
Expected 
Number of 
patients 
FSP ESP Power 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.9 
0.7 
- 
3425 
299 
3724 
3720 
434 
4154 
17.6 
16.9 
- 
2014 
168 
2182 
2187 
245 
2432 
0.3678 
0.3924 
- 
0.1816 
0.1897 
- 
0.5678 
0.5392 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.9 
0.7 
- 
3268 
316 
3584 
3550 
458 
4008 
16.8 
14 
- 
1831 
147 
1978 
1989 
213 
2202 
0.4171 
0.5076 
- 
0.1691 
0.2056 
- 
0.4995 
0.4245 
- 
Biomarker-negative 0.010 0.9 3616 3928 14.9 1794 1948 0.4838 0.1882 0.4436 
25
%
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Biomarker-positive 
Entire population 
0.015 
0.025 
0.7 
- 
285 
3901 
413 
4341 
16.1 
- 
153 
1947 
222 
2170 
0.4277 
- 
0.1892 
- 
0.5010 
- 
 
 
 
 
 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.9 
0.7 
- 
3425 
299 
3724 
3720 
434 
4154 
21.7 
21 
- 
2482 
210 
2692 
2696 
304 
3000 
0.1656 
0.1835 
- 
0.3849 
0.4151 
- 
0.7248 
0.7017 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.9 
0.7 
- 
3268 
316 
3584 
3550 
458 
4008 
21.3 
19.6 
- 
2324 
206 
2530 
2524 
299 
2823 
0.2046 
0.2681 
- 
0.3732 
0.4260 
- 
0.6704 
0.6129 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.9 
0.7 
- 
3616 
285 
3901 
3928 
413 
4341 
20.2 
21.0 
- 
2430 
199 
2629 
2639 
289 
2928 
0.2437 
0.2127 
- 
0.4124 
0.3894 
- 
0.6401 
0.6575 
- 
50
%
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Biomarker-negative 
Biomarker-positive 
Entire population 
0.0125 
0.0125 
0.025 
0.9 
0.7 
- 
3425 
299 
3724 
3720 
434 
4154 
25.0 
24.8 
- 
2857 
248 
3105 
3103 
359 
3462 
0.0709 
0.0826 
- 
0.5925 
0.6051 
- 
0.7734 
0.7572 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.015 
0.010 
0.025 
0.9 
0.7 
- 
3268 
316 
3584 
3550 
458 
4008 
25.0 
24.2 
- 
2727 
255 
2982 
2962 
370 
3332 
0.0944 
0.1344 
- 
0.5679 
0.6338 
- 
0.7272 
0.7162 
- 
Biomarker-negative 
Biomarker-positive 
Entire population 
0.010 
0.015 
0.025 
0.9 
0.7 
- 
3616 
285 
3901 
3928 
413 
4341 
24.5 
24.9 
- 
2952 
237 
3189 
3206 
343 
3549 
0.1146 
0.1022 
- 
0.6199 
0.5752 
- 
0.7254 
0.7236 
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Figure C.1. Efficacy stopping probability, futility stopping probability and power of a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 2 of hazard ratios. Each row of graphs represents the different probabilities versus the interim fraction of each biomarker-defined subgroup 
when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. 
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Figure C.2. Efficacy stopping probability, futility stopping probability and power of a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 3 of hazard ratios. Each row of graphs represents the different probabilities versus the interim fraction of each biomarker-defined subgroup 
when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. 
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Figure C.3. Efficacy stopping probability, futility stopping probability and power of a two-stage design versus the interim fraction (25%, 50%, 75%) in each biomarker-
defined subgroup for scenario 4 of hazard ratios. Each row of graphs represents the different probabilities versus the interim fraction of each biomarker-defined subgroup 
when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. 
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Figure C.4. Expected number of events and patients in two-stage design and required number of events and patients in one-stage design for each biomarker-defined 
subgroup versus the hazard ratios of each biomarker-defined subgroup when the interim fraction is 50%. The first two graphical representations in each row of graphs 
represent the number of events versus the hazard ratio of each biomarker-defined subgroup when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− =
𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. The remaining graphical representations in each row of graphs represent the number of patients versus the hazard ratio of each 
biomarker-defined subgroup when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓. 
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Figure C.5. Expected number of events and patients in two-stage design and required number of events and patients in one-stage design for each biomarker-defined 
subgroup versus the hazard ratios of each biomarker-defined subgroup when the interim fraction is 75%. The first two graphical representations in each row of graphs 
represent the number of events versus the hazard ratio of each biomarker-defined subgroup when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− =
𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓 respectively. The remaining graphical representations in each row of graphs represent the number of patients versus the hazard ratio of each 
biomarker-defined subgroup when (i) 𝒂− = 𝒂+ = 𝟎. 𝟎𝟏𝟐𝟓, (ii) 𝒂− = 𝟎. 𝟎𝟏𝟓 and 𝒂+ = 𝟎. 𝟎𝟏𝟎 and (iii) 𝒂− = 𝟎. 𝟎𝟏𝟎 and 𝒂+ = 𝟎. 𝟎𝟏𝟓. 
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C.2. R codes  
R codes for the Parallel Subgroup-Specific design and its adaptive version are given 
in C.2.1 and C.2.2 respectively. The R codes in C.2.2 are created based on examples 
and codes found in Chang M. Adaptive Design Theory and Implementation Using 
SAS and R, Second Edition. 2nd ed. London: CRC Press; 2014. 
C.2.1. Parallel Subgroup-Specific design 
###The following codes correspond to case 1. Similar codes are ###used for the 
remaining cases (Please change the ###corresponding parameters) 
 
 
#### Case 1 
 
 
#### a1=0.0125, a2=0.0125 
#### hr.negative=0.7, hr.positive 0.5 
 
 
 
med.control.negative =5  
med.control.positive=10 
 
 
hr.negative = 0.7  
hr.positive=0.5  
 
 
a<-0.025  
a2<-0.0125  
a1<-a-a2  
 
number.of.events.positive<-(4*((qnorm(a2)+qnorm(0.20))^2))/(log(hr.positive))^2 
number.of.events.positive 
number.of.events.negative<-(4*((qnorm(a1)+qnorm(0.20))^2))/(log(hr.negative))^2 
number.of.events.negative 
 
 
med.tmt.negative<- med.control.negative / hr.negative 
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med.tmt.negative 
med.tmt.positive<- med.control.positive / hr.positive 
med.tmt.positive 
 
 
A.positive<-18 
T.positive<-30 
F.positive<-T.positive-A.positive 
 
n.positive<-(number.of.events.positive) 
n.positive 
cut2<-round(n.positive) 
cut2 
 
pe.positive<-1-((1/((log(2)/ med.tmt.positive)*A.positive))*((exp(-(log(2) / 
med.tmt.positive)*F.positive))-(exp(-(log(2) / 
med.tmt.positive)*(A.positive+F.positive))))) 
pc.positive<-1-((1/((log(2)/ med.control.positive)*A.positive))*((exp(-(log(2) / 
med.control.positive)*F.positive))-(exp(-(log(2) / 
med.control.positive)*(A.positive+F.positive))))) 
 
 
N.positive<-n.positive/(0.5*pe.positive+0.5*pc.positive) 
N.positive 
n2<-round(N.positive) 
n2 
n13<-round(N.positive/2) 
n13 
 
A.negative<-18 
T.negative<-30 
F.negative<-T.negative-A.negative 
 
 
n.negative<-(number.of.events.negative) 
n.negative 
cut1<-round(n.negative) 
cut1 
 
pe.negative<-1-((1/((log(2) / med.tmt.negative)*A.negative))*((exp(-(log(2) / 
med.tmt.negative)*F.negative))-(exp(-(log(2) / 
med.tmt.negative)*(A.negative+F.negative))))) 
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pc.negative<-1-((1/((log(2) / med.control.negative)*A.negative))*((exp(-(log(2) / 
med.control.negative)*F.negative))-(exp(-(log(2) / 
med.control.negative)*(A.negative+F.negative))))) 
 
 
N.negative<-n.negative/(0.5*pe.negative+0.5*pc.negative) 
N.negative 
n1<-round(N.negative) 
n1 
n11<-round(N.negative/2) 
n11 
 
kappa<-0.5 
p<-0.5 
 
permonth.negative<-round(N.negative/A.negative) 
permonth.negative 
permonth.positive<-round(N.positive/A.positive) 
permonth.positive 
 
 
#### Fix enrolment and vary study duration 
 
 
simCombTest <- function(n11=n11, n13=n13, 
med.control.negative=med.control.negative, 
med.control.positive=med.control.positive, 
hr.negative=hr.negative,hr.positive=hr.positive, 
                        permonth.negative=permonth.negative, 
permonth.positive=permonth.positive, cut1=cut1,cut2=cut2, kappa=kappa, p=p){ 
   
   
  # number of patients nij 
  # i = 1, 2 (stages) / j = control, tmt 
   
  ### negative 
  n12 <- n11 * (1 - kappa) / kappa 
  n1 <- n11 + n12 
   
  #### positive 
  n14 <- n13 * (1 - kappa) / kappa 
  n2<-n13+n14 
   
  ####total 
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  n<-n1+n2 
   
  # generate arrival times for negative 
  arrivetime.negative <- NULL 
  for (i in 1:ceiling(n1 / permonth.negative)){arrivetime.negative <- 
c(arrivetime.negative, runif(permonth.negative, min =i- 1, max =i ))}  
  arrivetime.negative <- arrivetime.negative[1:n1] 
   
   
  # generate arrival times for positive 
  arrivetime.positive <- NULL 
  for (i in 1:ceiling(n2 / permonth.positive)){arrivetime.positive <- 
c(arrivetime.positive, runif(permonth.positive, min =i- 1, max =i ))}  
  arrivetime.positive <- arrivetime.positive[1:n2] 
   
   
   
  # generate event times for negative population 
  med.tmt.negative<- med.control.negative / hr.negative 
  time11 <- rexp(n11, rate = log(2) / med.control.negative) 
  time12 <- rexp(n12, rate = log(2) / med.tmt.negative) 
   
   
  # generate event times for positive population 
  med.tmt.positive<- med.control.positive / hr.positive 
  time13 <- rexp(n13, rate = log(2) / med.control.positive) 
  time14 <- rexp(n14, rate = log(2) / med.tmt.positive) 
   
   
  # observed times for stage 1 - negative patients 
  choose1 <- sample(1:(n11 + n12)) 
  choose11 <- sort(choose1[1:n11]) 
  choose12 <- sort(choose1[(n11 + 1):(n11 + n12)]) 
   
   
  # observed times for stage 1 - positive patients 
  choose2 <- sample(1:(n13+ n14)) 
  choose13 <- sort(choose2[1:n13]) 
  choose14 <- sort(choose2[(n13 + 1):(n13 + n14)]) 
   
   
  #####total time is event time plus arrival time 
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  tottime11 <- arrivetime.negative[choose11] + time11  #### #total study period for 
those on control treatment who are #negative 
  tottime12 <- arrivetime.negative[choose12] + time12 #### #total study period for 
those on experimental treatment who #are negative 
  tottime1 <- c(tottime11, tottime12) #### negative 
   
  tottime13 <- arrivetime.positive[choose13] + time13  #### #total study period for 
those on control treatment who are #positive 
  tottime14 <- arrivetime.positive[choose14] + time14 #### #total study period for 
those on experimental treatment who #are positive 
  tottime2 <- c(tottime13, tottime14) #### positive 
   
   
   
  # find cutoff for stage 1-negative patients 
  cutoff1 <- sort(tottime1)[cut1]  ### we mean the time after #study start at which a 
prespecified  number of events has #been reached 
  event1 <- ifelse(tottime1 > cutoff1, 0, 1) 
   
  # find cutoff for stage 1-positive patients 
  cutoff2 <- sort(tottime2)[cut2]  ### we mean the time after study start at which a 
prespecified  number of events has been reached 
  event2 <- ifelse(tottime2 > cutoff2, 0, 1) 
   
   
   
  # apply censoring-negative 
  event.negative <- event1 
  time.negative <- c(time11, time12) 
   
     
   
  tmt.negative <- c(rep(0, n11), rep(1, n12)) 
  stage.negative <- c(rep(1, n11 + n12)) 
  subgroup.negative<-c(rep(0,n11 + n12)) 
   
   
  # apply censoring-positive 
  event.positive <- event2 
  time.positive <- c(time13, time14) 
   
   
   
  tmt.positive <- c(rep(0, n13), rep(1, n14)) 
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  stage.positive <- c(rep(1, n13 + n14)) 
  subgroup.positive<-c(rep(1,n13 + n14)) 
   
   
  time<-c(time.negative,time.positive) 
  event<-c(event.negative,event.positive) 
  tmt<-c(tmt.negative,tmt.positive) 
  subgroup<-c(subgroup.negative,subgroup.positive) 
   
   
  dat.overall <- data.frame(time, event, tmt,subgroup) 
  colnames(dat.overall) <- c("time", "event", "tmt","subgroup") 
   
   
  data.frame(id=1:n, 
             time=time, 
             event=event, 
             tmt=tmt, 
             subgroup=subgroup, 
             cutoff1=cutoff1, 
             cutoff2=cutoff2) 
   
} 
 
 
set.seed(09032014) 
 
nsim<-10000 
 
hazratn1<-rep(NA,nsim) 
hazratp1 <- rep(NA,nsim) 
bettern1<- rep(NA,nsim) 
betterp1<- rep(NA,nsim) 
zn1<- rep(NA,nsim) 
zp1<- rep(NA,nsim) 
 
 
pn1<- rep(NA,nsim) 
pp1<- rep(NA,nsim) 
pnp1<- rep(NA,nsim) 
 
cutoff1<-rep(NA,nsim) 
cutoff2<-rep(NA,nsim) 
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for(k in 1:nsim){ 
  dat <- simCombTest(n11=n11, n13=n13, 
med.control.negative=med.control.negative, 
med.control.positive=med.control.positive, 
hr.negative=hr.negative,hr.positive=hr.positive, 
                     permonth.negative=permonth.negative, 
permonth.positive=permonth.positive, cut1=cut1,cut2=cut2, kappa=kappa, p=p) 
   
  cutoff1[k]<-dat$cutoff1[1] 
  cutoff2[k]<-dat$cutoff2[1] 
   
   
   
  # cox model in negative: 
  ind1 <- (dat$subgroup== 0 & !is.na(dat$subgroup)) 
  if(sum(ind1) > 0){ 
    hazard1 <- coxph(Surv(time = time[ind1], event = event[ind1]) 
~tmt[ind1],data=dat) 
    test1 <- survdiff(Surv(time =time[ind1], event = event[ind1]) ~ tmt[ind1],data=dat) 
  } else { 
    warning("Subgroup analysis not possible - all subgroup on same treatment") 
    hazard2 <- NA 
    hazratn1 <- NA 
    pn1 <- NA 
    zn1 <- NA 
    test2 <- NA 
  } 
   
  # cox model in positive only: 
  ind2 <- (dat$subgroup== 1 & !is.na(dat$subgroup)) 
  if(sum(ind2) > 0){ 
    hazard2 <- coxph(Surv(time = time[ind2], event = event[ind2]) 
~tmt[ind2],data=dat) 
    test2 <- survdiff(Surv(time =time[ind2], event = event[ind2]) ~ tmt[ind2],data=dat) 
  } else { 
    warning("Subgroup analysis not possible - all subgroup on same treatment") 
    hazard2 <- NA 
    hazratp1 <- NA 
    pp1 <- NA 
    zp1 <- NA 
    test2 <- NA 
  } 
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  # save hazard ratios 
  hazratn1[k] <- exp(hazard1$coef) 
  hazratp1[k] <- exp(hazard2$coef) 
   
   
   
  zn1[k]<- sqrt(test1$chi) 
  zp1[k]<- sqrt(test2$chi) 
   
   
  #### 1-sided 
   
  pn1[k]<-(2*(1 - pnorm(zn1[k])))/2 
  pp1[k]<-(2*(1 - pnorm(zp1[k])))/2 
   
   
   
  pnp1[k]<- min(2 * min(pn1[k], pp1[k]), max(pn1[k], pp1[k]))   
   
   
   
  #write.table(dat,file=" ",sep = ",",append=TRUE,dec=".",qmethod="double") 
   
} 
 
rejection.probability.negative<-sum( pn1<a1)/nsim 
rejection.probability.positive<-sum( pp1<a2)/nsim 
 
meanhazn1 <- exp(mean(log(hazratn1), na.rm = TRUE)) 
meanhazp1 <- exp(mean(log(hazratp1), na.rm = TRUE)) 
medhazn1 <- median(hazratn1, na.rm = TRUE) 
medhazp1 <- median(hazratp1, na.rm = TRUE) 
meanpn1 <- mean(pn1, na.rm = TRUE) 
meanpp1 <- mean(pp1, na.rm = TRUE) 
meancutoff1<-mean(cutoff1) 
meancutoff2<-mean(cutoff2) 
 
 
res <-  
list("cut1"=cut1,"cut2"=cut2,"sumevents"=cut1+cut2,"n1"=n1,"n2"=n2,"sumsize"=n1+n
2,"a1"=a1,"a2"=a2,"HR negative" = meanhazn1,"HR positive" =meanhazp1, 
             "rejection.probability.negative"=rejection.probability.negative, 
             "rejection.probability.positive"=rejection.probability.positive, 
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             "meancutoff1"=meancutoff1,"meancutoff2"=meancutoff2) 
 
 
res 
 
 
results<-unlist(cbind(res)) 
results<-data.frame((c("Number of events_Negative","Number of 
events_Positive","total number of events","Sample size_Negative","Sample 
size_Positive","total sample size", 
                       "Alpha level_Negative","Alpha level_Positive","HR negative","HR 
positive", 
                       "rejection.probability.negative","rejection.probability.positive","Total 
study period_Negative", 
                       "Total study period_Positive")),round(results,3)) 
 
 
names(results)<-c("Definition","Results") 
 
results 
 
 
save(results, file = paste(path.results, "results_simulation_scenario=1", ".rdata", sep = 
"")) 
save(results, file = paste(path.code, "code_simulation_scenario=1", ".rdata", sep = "")) 
C.2.2. An adaptive version of the Parallel Subgroup-Specific design 
### The following codes correspond to Scenario 1. Similar codes are used for other 
scenarios (Please change the corresponding parameters). 
#### Scenario 1 
#### a1=0.0125, a2=0.0125 
#### hr.negative=0.6, hr.positive 0.4 
#### InfoTime.negative=0.25   (we will try also 0.50, 0.75) 
#### InfoTime.positive=0.25   (we will try also 0.50, 0.75) 
 
med.control.negative =5 
med.control.positive=10 
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hr.negative = 0.6 
hr.positive=0.4 
 
 
a<-0.025 
a2<-0.0125  
a1<-a-a2  
 
number.of.events.positive<-(4*((qnorm(a2)+qnorm(0.20))^2))/(log(hr.positive))^2 
number.of.events.positive 
number.of.events.negative<-(4*((qnorm(a1)+qnorm(0.20))^2))/(log(hr.negative))^2 
number.of.events.negative 
 
 
med.tmt.negative<- med.control.negative / hr.negative 
med.tmt.negative 
med.tmt.positive<- med.control.positive / hr.positive 
med.tmt.positive 
 
 
A.positive<-18 
T.positive<-30 
F.positive<-T.positive-A.positive 
 
n.positive<-(number.of.events.positive) 
n.positive<-round(n.positive) 
 
 
pe.positive<-1-((1/((log(2)/ med.tmt.positive)*A.positive))*((exp(-(log(2) / 
med.tmt.positive)*F.positive))-(exp(-(log(2) / 
med.tmt.positive)*(A.positive+F.positive))))) 
pc.positive<-1-((1/((log(2)/ med.control.positive)*A.positive))*((exp(-(log(2) / 
med.control.positive)*F.positive))-(exp(-(log(2) / 
med.control.positive)*(A.positive+F.positive))))) 
 
 
N.positive<-n.positive/(0.5*pe.positive+0.5*pc.positive) 
N.positive<-round(N.positive) 
 
A.negative<-18 
T.negative<-30 
F.negative<-T.negative-A.negative 
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n.negative<-(number.of.events.negative) 
n.negative<-round(n.negative) 
 
 
pe.negative<-1-((1/((log(2) / med.tmt.negative)*A.negative))*((exp(-(log(2) / 
med.tmt.negative)*F.negative))-(exp(-(log(2) / 
med.tmt.negative)*(A.negative+F.negative))))) 
pc.negative<-1-((1/((log(2) / med.control.negative)*A.negative))*((exp(-(log(2) / 
med.control.negative)*F.negative))-(exp(-(log(2) / 
med.control.negative)*(A.negative+F.negative))))) 
 
 
 
N.negative<-n.negative/(0.5*pe.negative+0.5*pc.negative) 
N.negative<-round(N.negative) 
 
 
permonth.negative<-round(N.negative/A.negative) 
permonth.negative 
 
permonth.positive<-round(N.positive/A.positive) 
permonth.positive 
 
 
 
#### alpha1=early efficacy stopping boundary 
#### beta1=early futility stopping boundary 
### alpha2=final efficacy boundary 
 
#log(hr.positive) 
 
DCSPSurv2<-function(nSims=10000, Model="sum", alpha.positive=0.0125, 
alpha.negative=0.0125, beta=0.2, tStd=30, tAcr=18, 
lnHR.positive=log(hr.positive),lnHR.negative=log(hr.negative), 
N.positive=N.positive, n.positive=n.positive, N.negative=N.negative, 
n.negative=n.negative, InfoTime.positive=0.25, 
InfoTime.negative=0.25,alpha1.positive=0.0080 , beta1.positive=0.1029, 
alpha2.positive=0.1029,alpha1.negative=0.0070, beta1.negative=0.1129, 
alpha2.negative=0.1129){ 
   
  FSP.positive<-0;ESP.positive<-0;AveDs.positive<-0; Power.positive<-0; 
  FSP.negative<-0;ESP.negative<-0;AveDs.negative<-0; Power.negative<-0; 
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  Ds.positive<-n.positive 
  Ds1.positive<-Ds.positive*InfoTime.positive 
   
  Ds.negative<-n.negative 
  Ds1.negative<-Ds.negative*InfoTime.negative 
   
   
   
  set.seed(09032014) 
   
   
  for(i in 1:nSims) { 
     
     
    nFinal.positive<-Ds1.positive 
     
    T1.positive<-rnorm(1)+sqrt(Ds1.positive/4)*(-lnHR.positive) 
     
     
     
    nFinal.negative<-Ds1.negative 
     
    T1.negative<-rnorm(1)+sqrt(Ds1.negative/4)*(-lnHR.negative) 
     
     
    p1.positive<-1-pnorm(T1.positive) 
     
    if (p1.positive>beta1.positive) {FSP.positive=FSP.positive+1/nSims} 
     
     
    if (p1.positive<=alpha1.positive) { 
       
      Power.positive=Power.positive+1/nSims; ESP.positive=ESP.positive+1/nSims 
       
    } 
 
     
    p1.negative<-1-pnorm(T1.negative) 
     
    if (p1.negative>beta1.negative) {FSP.negative=FSP.negative+1/nSims} 
     
     
    if (p1.negative<=alpha1.negative) { 
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      Power.negative=Power.negative+1/nSims; ESP.negative=ESP.negative+1/nSims 
       
    } 
      
     
    if (p1.positive>alpha1.positive&p1.positive<=beta1.positive){ 
       
      nFinal.positive<-Ds.positive 
       
      T2.positive<-rnorm(1)+sqrt((Ds.positive-Ds1.positive)/4)*(-lnHR.positive) 
       
       
      p2.positive<-1-pnorm(T2.positive) 
       
      if (Model=="sum"){TS2.positive=p1.positive+p2.positive} 
      if (Model=="ind"){TS2.positive=p2.positive} 
      if (Model=="prd"){TS2.positive=p1.positive*p2.positive} 
       
      if (TS2.positive<=alpha2.positive) {Power.positive=Power.positive+1/nSims} 
       
    } 
     
     
    if (p1.negative>alpha1.negative&p1.negative<=beta1.negative){ 
       
      nFinal.negative<-Ds.negative 
       
      T2.negative<-rnorm(1)+sqrt((Ds.negative-Ds1.negative)/4)*(-lnHR.negative) 
       
       
      p2.negative<-1-pnorm(T2.negative) 
       
      if (Model=="sum"){TS2.negative=p1.negative+p2.negative} 
      if (Model=="ind"){TS2.negative=p2.negative} 
      if (Model=="prd"){TS2.negative=p1.negative*p2.negative} 
       
      if (TS2.negative<=alpha2.negative) {Power.negative=Power.negative+1/nSims} 
       
    } 
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    AveDs.positive<-AveDs.positive+nFinal.positive/nSims 
    AveDs.negative<-AveDs.negative+nFinal.negative/nSims 
     
     
  } 
   
  
  #Padj=alpha1+Power-ESP 
   
  results=print(cbind(Model, 
FSP.positive=round(FSP.positive,4),ESP.positive=round(ESP.positive,4),Power.posit
ive=round(Power.positive,4),AveDs.positive=round(AveDs.positive),N.positive, 
                      
FSP.negative=round(FSP.negative,4),ESP.negative=round(ESP.negative,4),Power.ne
gative=round(Power.negative,4),AveDs.negative=round(AveDs.negative),N.negativ
e)) 
   
} 
 
DCSPSurv2(nSims=10000, Model="sum", alpha.positive=0.0125, 
alpha.negative=0.0125, beta=0.2, tStd=30, tAcr=18, 
lnHR.positive=log(hr.positive),lnHR.negative=log(hr.negative), 
N.positive=N.positive, n.positive=n.positive, N.negative=N.negative, 
n.negative=n.negative, InfoTime.positive=0.25, 
InfoTime.negative=0.25,alpha1.positive=0.0080 , beta1.positive=0.1029, 
alpha2.positive=0.1029,alpha1.negative=0.0070, beta1.negative=0.1129, 
alpha2.negative=0.1129) 
   
 
###expected sample size 
# calculate the following: (FSP+ESP)*N.positive 
#N.positive*(ESP.positive+FSP.positive) 
 
 
###expected duration 
#(FSP.+ESP)*time from the first patient-in to the kth interim analysis 
#(InfoTime*30)*(0.1731+0.7023)
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Appendix D 
Appendix D includes supporting information related to Chapter 7. Results of 
Simulation study 1 are presented in Appendix D.1 and results of Simulation study 2 
are given in Appendix D.2. R codes are provided in Appendix D.3.  
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D.1. Results for Simulation study 1 
Table D.1.1. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the effect-size ratio method and 
O’Brien-Fleming decision boundaries. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25%  Null 231 0.001930 0.024706    
Alternative 191 0.067743 0.870993    
50% Null 246 0.001930 0.024706    
 Alternative 182 0.179273 0.903351    
75% Null 251 0.001930 0.024706    
 Alternative 182 0.315503 0.907162    
 
 420 
 
Table D.1.2. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the conditional power method and 
O’Brien-Fleming decision boundaries. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
156 
 
 
0.15 
 
25% Null 233 0.001930 0.024706    
Alternative 150 0.067743 0.785080 
50% Null 243 0.001930 0.024706    
 Alternative 148 0.179273 0.819279    
75% Null 250 0.001930 0.024706    
 Alternative 162 0.315503 0.849604    
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Table D.1.3. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the effect-size ratio method and 
Pocock decision boundaries. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25% Null 230 0.016078 0.021698    
Alternative 172 0.224221 0.761714    
50% Null 246 0.016078 0.021698    
 Alternative 163 0.426191 0.836597    
75% Null 251 0.016078 0.021698    
 Alternative 169 0.600358 0.886253    
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Table D.1.4. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the conditional power method and 
Pocock decision boundaries. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25% Null 246 0.016078 0.021698    
Alternative 176 0.224221 0.771788    
50% Null 250 0.016078 0.021698    
 Alternative 163 0.426191 0.838188    
75% Null 253 0.016078 0.021698    
 Alternative 167 0.600358 0.880163    
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Table D.1.5. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the effect-size ratio method 
and O’Brien-Fleming decision boundaries. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
183 
 
186 
 
0.746 
25% Null 271 0.001930 0.024706    
Alternative 220 0.068805 0.863041 
50% Null  282 0.001930 0.024706    
 Alternative 211 0.182171 0.896072 
75% Null 284 0.001930 0.024706    
 Alternative 211 0.320094 0.899924 
 
 
 
 
 
 
25% Null 643 0.001930 0.024706 
 Alternative 576 0.069643 0.807397 
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550 558 0.845 50% Null 654 0.001930 0.024706    
 Alternative 553 0.184371 0.841650    
75% Null 657 0.001930 0.024706    
 Alternative 559  0.323890 0.837346    
 
341 
 
346 
 
0.807 
25% Null 431 0.001930 0.024706    
 Alternative 374 0.069385 0.827455    
50% Null 442 0.001930 0.024706    
 Alternative 359 0.183666 0.862614    
75% Null 445 0.001930 0.024706 
 Alternative 362 0.322716 0.862878    
   25% Null 308 0.001930 0.024706    
 425 
 
220 224 0.765  Alternative 256 0.069015 0.851771    
50% Null 319 0.001930 0.024706    
 Alternative 246 0.182768 0.885632    
75% Null 322 0.001930 0.024706    
 Alternative 247 0.321049 0.889006    
 
Table D.1.6. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the conditional power method 
and O’Brien-Fleming decision boundaries. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
183 
 
186 
 
0.746 
25% Null 241 0.001930 0.024706 
Alternative 174 0.068805 0.779716 
 426 
 
50% Null 261 0.001930 0.024706 
 Alternative 173 0.182171 0.815679    
75% Null 275 0.001930 0.024706 
 Alternative 190 0.320094 0.846261    
 
 
550 
 
 
558 
 
 
0.845 
25% Null 616 0.001930 0.024706 
 Alternative 481 0.069643 0.740230    
50% Null 642 0.001930 0.024706 
 Alternative 481 0.184371 0.782292    
75% Null 654 0.001930 0.024706 
 Alternative 534 0.323890 0.807523    
   25% Null 406 0.001930 0.024706 
 427 
 
341 346 0.807  Alternative 303 0.069385 0.755569    
50% Null 429 0.001930 0.024706 
 Alternative 307 0.183666 0.796379    
75% Null 440 0.001930 0.024706 
 Alternative 340 0.322716 0.825099    
 
 
220 
 
 
224 
 
 
0.765 
25% Null 281 0.001930 0.024706 
 Alternative 205 0.069015 0.772559    
50% Null 302 0.001930 0.024706 
 Alternative 205 0.182768 0.810128    
75% Null 315 0.001930 0.024706 
 Alternative 226 0.321049 0.840671    
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Table D.1.7. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with effect-size ratio method and 
Pocock decision boundaries. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
183 
 
186 
 
0.746 
25% Null 269 0.016078 0.021698    
Alternative 198 0.226595 0.751778 
50% Null 280 0.016078 0.021698    
 Alternative 188 0.430316 0.826512    
75% Null 283 0.016078 0.021698    
 Alternative 195 0.605391 0.875019    
 
550 
 
558 
 
0.845 
25% Null 637 0.016078 0.021698    
 Alternative 510 0.228383 0.687093    
 429 
 
50% Null 650 0.016078 0.021698    
 Alternative 484 0.433748 0.75865    
75% Null 654 0.016078 0.021698    
 Alternative 512 0.609326 0.797284    
 
341 
 
346 
 
0.807 
25% Null 427 0.016078 0.021698    
 Alternative 333 0.227844 0.709340  
50% Null 439 0.016078 0.021698    
 Alternative 316 0.432635 0.783473    
75% Null 442 0.016078 0.021698    
 Alternative 333 0.608126 0.826463    
   25% Null 306 0.016078 0.021698    
 430 
 
 
220 
 
224 
 
0.765 
 Alternative 230 0.226992 0.737624    
50% Null 318 0.016078  0.021698    
 Alternative 218 0.431123 0.812622    
75% Null 320 0.016078 0.021698    
 Alternative 228 0.606380 0.859731    
 
Table D.1.8. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the conditional power method 
and Pocock decision boundaries. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Rejection 
probability 
 
 
 
 
 
 
25% Null 263 0.016078 0.021698    
Alternative 202 0.226595 0.760786    
 431 
 
183 186 0.746 50% Null 275 0.016078 0.021698    
 Alternative 188 0.430316 0.829126    
75% Null 281 0.016078 0.021698    
 Alternative 193 0.605391 0.871070   
 
 
550 
 
 
558 
 
 
0.845 
25% Null 640 0.016078 0.021698    
 Alternative 514 0.228383 0.691205    
50% Null 650 0.016078 0.021698    
 Alternative 489 0.433748 0.764274    
75% Null 654 0.016078 0.021698    
 Alternative 512 0.609326 0.797284    
   25% Null 428 0.016078 0.021698    
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341 
 
346 
 
0.807 
 Alternative 338 0.227844 0.716711    
50% Null 438 0.016078 0.021698    
 Alternative 320 0.432635 0.789683    
75% Null 443 0.016078 0.021698    
 Alternative 333 0.608126 0.826491    
 
 
220 
 
 
224 
 
 
0.765 
25% Null 303 0.016078 0.021698    
 Alternative 234 0.226992 0.746794    
50% Null 314 0.016078 0.021698    
 Alternative 220 0.431123 0.817145    
75% Null 320 0.016078 0.021698    
 Alternative 227 0.606380 0.858074    
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D.2. Results for Simulation study 2 
Table D.2.1. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the effect-size ratio method, O’Brien-
Fleming efficacy boundaries and Pocock futility boundary. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25% Null 54 0.00195 0.875893 0.018734 
Alternative 103 0.067891 0.408571 0.550792 
50% Null 95 0.00195 0.875893 0.018734 
 Alternative 145 0.179291 0.210752 0.744654 
75% Null 132 0.00195 0.875893 0.018734 
 Alternative 167 0.315418 0.107176 0.834594 
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Table D.2.2. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the conditional power method, O’Brien-
Fleming efficacy boundaries and Pocock futility boundary. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25% Null 50 0.00195 0.875893 0.018734 
Alternative 74 0.067891 0.408571 0.486881 
50% Null 89 0.00195 0.875893 0.018734 
 Alternative 114 0.179291 0.210752 0.667259 
75% Null 128 0.00195 0.875893 0.018734 
 Alternative 147 0.315418 0.107176 0.777358 
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Table D.2.3. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the effect-size ratio method, Pocock efficacy 
boundaries and Pocock futility boundary. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25% Null 53 0.015956 0.875933 0.020321 
Alternative 85 0.224141 0.408891 0.506438 
50% Null 94 0.015956 0.875933 0.020321 
 Alternative 126 0.425881 0.211056 0.714582 
75% Null 131 0.015956 0.875933 0.020321 
 Alternative 154 0.600368 0.107371 0.834428 
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Table D.2.4. Adaptive sample size re-estimation design for binary outcome applied to the reverse marker-based strategy design with the conditional power method, Pocock 
efficacy boundaries and Pocock futility boundary. 
Fixed sample 
size 
Difference in response 
rates between strategy 
arms 
Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
156 
 
0.15 
25% Null 56 0.015956 0.875933 0.020321 
Alternative 88 0.224141 0.408891 0.517662 
50% Null 95 0.015956 0.875933 0.020321 
 Alternative 125 0.425881 0.211056 0.716136 
75% Null 131 0.015956 0.875933 0.020321 
 Alternative 152 0.600368 0.107371 0.828347 
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Table D.2.5. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the effect-size ratio method, O’Brien-
Fleming efficacy boundaries and Pocock futility boundary. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
183  
 
186 
 
0.746 
25% Null 68 0.001950 0.875893 0.018734 
Alternative 123 0.068890 0.405581 0.554985 
50% Null 115 0.001950 0.875893 0.018734 
 Alternative 171 0.182105 0.207649 0.746814 
75% Null 157 0.001950 0.875893 0.018734 
 Alternative 196 0.319987 0.104713 0.833836 
 
550 
 
558 
 
0.845 
25% Null 196 0.001950 0.875893 0.018734 
 Alternative 367 0.069634 0.403354 0.556305 
 438 
 
50% Null 324 0.001950 0.875893 0.018734 
 Alternative 476 0.184386 0.205221 0.730834 
75% Null 447 0.001950 0.875893 0.018734 
 Alternative 534 0.323629 0.102877 0.796348 
 
341 
 
346 
 
0.807 
25% Null 123 0.001950 0.875893 0.018734 
 Alternative 229 0.069406 0.404002 0.556719 
50% Null 205 0.001950 0.875893 0.018734 
 Alternative 303 0.183680 0.205953 0.738352 
75% Null 282 0.001950 0.875893 0.018734 
 Alternative 343 0.322485 0.103446 0.813330 
   25% Null 81 0.001950 0.875893 0.018734 
 439 
 
220 224 0.765  Alternative 148 0.069069 0.405015 0.555808 
50% Null 136 0.001950 0.875893 0.018734 
 Alternative 202 0.182708 0.207027 0.744688 
75% Null 186 0.001950 0.875893 0.018734 
 Alternative 231 0.320885 0.104289 0.828374 
 
Table D.2.6. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the conditional power method, 
O’Brien-Fleming efficacy boundaries and Pocock futility boundary. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
183 
 
186 
 
0.746 
25% Null 56 0.001950 0.875893 0.018734 
Alternative 88 0.068890 0.405581 0.489414 
 440 
 
50% Null 102 0.001950 0.875893 0.018734 
 Alternative 135 0.182105 0.207649 0.670295 
75% Null 148 0.001950 0.875893 0.018734 
 Alternative 175 0.319987 0.104713 0.780193 
 
 
550 
 
 
558 
 
 
0.845 
25% Null 170 0.001950 0.875893 0.018734 
 Alternative 264 0.069634 0.403354 0.491318 
50% Null 310 0.001950 0.875893 0.018734 
 Alternative 403 0.184386 0.205221 0.671262 
75% Null 444 0.001950 0.875893 0.018734 
 Alternative 509 0.323629 0.102877 0.766529 
   25% Null 105 0.001950 0.875893 0.018734 
 441 
 
341 346 0.807  Alternative 164 0.069406 0.404002 0.490766 
50% Null 191 0.001950 0.875893 0.018734 
 Alternative 251 0.183680 0.205953 0.671945 
75% Null 277 0.001950 0.875893 0.018734 
 Alternative 321 0.322485 0.103446 0.775550 
 
220 
 
224 
 
0.765 
25% Null 67 0.001950 0.875893 0.018734 
 Alternative 106 0.069069 0.405015 0.489909 
50% Null 123 0.001950 0.875893 0.018734 
 Alternative 162 0.182708 0.207027 0.670911 
75% Null 179 0.001950 0.875893 0.018734 
 Alternative 210 0.320885 0.104289 0.780054 
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Table D.2.7. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the effect-size ratio method, Pocock 
efficacy boundaries and Pocock futility boundary. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
183 
 
186 
 
0.746 
25% Null 67 0.015956 0.875933 0.020321 
Alternative 101 0.226404 0.405947 0.511271 
50% Null 113 0.015956 0.875933 0.020321 
 Alternative 147 0.429997 0.207989 0.715421 
75% Null 155 0.015956 0.875933 0.020321 
 Alternative 180 0.605401 0.104909 0.829909 
 
550 
 
558 
 
0.845 
25% Null 190 0.015956 0.875933 0.020321 
 Alternative 301 0.228085 0.403724 0.511912 
 443 
 
50% Null 320 0.015956 0.875933 0.020321 
 Alternative 406 0.433466 0.205600 0.687413 
75% Null 444 0.015956 0.875933 0.020321 
 Alternative 487 0.609359 0.103043 0.774560 
 
341 
 
346 
 
0.807 
25% Null 120 0.015956 0.875933 0.020321 
 Alternative 188 0.227524 0.404389 0.512879 
50% Null 202 0.015956 0.875933 0.020321 
 Alternative 260 0.432332 0.206358 0.699500 
75% Null 280 0.015956 0.875933 0.020321 
 Alternative 313 0.608132 0.103625 0.796938 
   25% Null 79 0.015956 0.875933 0.020321 
 444 
 
 
220 
 
224 
 
0.765 
 Alternative 122 0.226785 0.405382 0.512214 
50% Null 134 0.015956 0.875933 0.020321 
 Alternative 174 0.430812 0.207408 0.711023 
75% Null 184 0.015956 0.875933 0.020321 
 Alternative 212 0.606405 0.104468 0.820300 
 
Table D.2.8. Adaptive sample size re-estimation design for time-to-event outcome applied to the reverse marker-based strategy design with the conditional power method, 
Pocock efficacy boundaries and Pocock futility boundary. 
Fixed number 
of events 
Fixed sample 
size 
Hazard ratio Information 
fraction 
Hypothesis Adaptive Average 
sample size 
Efficacy stopping 
probability 
Futility stopping 
probability 
Rejection 
probability 
 
 
 
 
 
 
25% Null 60 0.015956 0.875933 0.020321 
Alternative 105 0.226404 0.405947 0.520468 
 445 
 
183 186 0.746 50% Null 107 0.015956 0.875933 0.020321 
 Alternative 148 0.429997 0.207989 0.717937 
75% Null 153 0.015956 0.875933 0.020321 
 Alternative 178 0.605401 0.104909 0.825912 
 
550 
 
558 
 
0.845 
25% Null 186 0.015956 0.875933 0.020321 
 Alternative 305 0.228085 0.403724 0.515823 
50% Null 318 0.015956 0.875933 0.020321 
 Alternative 412 0.433466 0.205600 0.693019 
75% Null 445 0.015956 0.875933 0.020321 
 Alternative 487 0.609359 0.103043 0.77456 
   25% Null 114 0.015956 0.875933 0.020321 
 446 
 
341 346 0.807  Alternative 193 0.227524 0.404389 0.519999 
50% Null 199 0.015956 0.875933 0.020321 
 Alternative 264 0.432332 0.206358 0.705671 
75% Null 279 0.015956 0.875933 0.020321 
 Alternative 313 0.608132 0.103625 0.796938 
 
 
220 
 
 
224 
 
 
0.765 
25% Null 73 0.015956 0.875933 0.020321 
 Alternative 126 0.226785 0.405382 0.521006 
50% Null 129 0.015956 0.875933 0.020321 
 Alternative 176 0.430812 0.207408 0.715495 
75% Null 183 0.015956 0.875933 0.020321 
 Alternative 211 0.606405 0.104468 0.818615 
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D.3. R codes 
R codes for Simulation Study 1 and Simulation Study 2 are presented in D.3.1. 
and D.3.2 respectively. The following R codes are created based on examples and 
codes found in: 
1. Chang M. Adaptive Design Theory and Implementation Using SAS and R, 
Second Edition. 2nd ed. London: CRC Press; 2014. 
2. Francesca G, Luigi M. Two-stage re-estimation adaptive design: a simulation 
study. 2013; doi:10.2427/8862. 
In D.3.3 we provide the R codes for the type I error probabilities derived 
with the O’Brien-Fleming and Pocock method. 
D.3.1. Simulation study 1 
#Binary Endpoint 
#O’Brien-Fleming efficacy boundaries 
# Conditional power method 
 
 
 
cp=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
            ry=0.57,n1=78,diff=0.15,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=1/sqrt(2),cP=0.8){ 
 
 
 
set.seed(1736) 
 
FSP=0; ESP=0; nmean=0; power=0  
 
 
 
nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
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nmax=nclassic+100 
 
 
r=(rx+ry)/2 
  
sigma=sqrt(r*(1-r)) 
 
 
 
 
for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
     
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
     
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
 449 
 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2) 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2) 
     
    p2=1-pnorm(z2) 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  nmean=nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=1,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=1,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
   
 
 
## For rx=0.74 and ry=0.57 
 
 
 450 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=1,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.74, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=1,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
#Binary Endpoint 
#O’Brien-Fleming efficacy boundaries 
 
# Effect size ratio method 
 
 
es=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
          ry=0.57,n1=78, n0=156, diff=0.15,alpha1=0.0026, alpha0=1, 
          alpha2=0.0240){ 
   
   
  set.seed(1736) 
   
  FSP=0; ESP=0; nmean=0; power=0  
   
   
   
  nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
   
   
  nmax=nclassic+100 
   
  r=(rx+ry)/2 
   
  sigma=sqrt(r*(1-r)) 
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  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(n0, (er^2)*n0)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    nmean=nmean+nfinal/nsim 
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  } 
  
   return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
   
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.57, 
            ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.002, alpha0=1, 
            alpha2=0.0240) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.002, alpha0=1, 
   alpha2=0.0240) 
 
 
 
#### Similar codes for 25% and 75% Information Fraction 
 
#Survival Endpoint 
#O’Brien-Fleming efficacy boundaries 
# Conditional power method 
 
 
cp=function(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=0.70711,cP=0.9){ 
 
 
 
 
set.seed(1736) 
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FSP=0; ESP=0; Nmean=0; power=0  
 
 
m.strategy=(k*ma.pos+(1-k)*mb.neg) 
m.reverse=(k*mb.pos+(1-k)*ma.neg) 
 
 
 
 
nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
 
 
hr=m.strategy/m.reverse 
 
prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
 
prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-tAcr))-
exp((-(log(2)/m.reverse))*tStd))) 
 
 
 
Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
 
n1=Nclassic*f 
 
nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
 
rx=log(2)/m.strategy 
ry=log(2)/m.reverse 
 
diff=rx-ry 
 
if (case=="null"){rx=ry} 
 
r=(rx+ry)/2 
 
expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
  
sigma=r*(1+expTerm)^(-0.5) 
 
 
 
 
for(iSim in 1:nsim){ 
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  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2); 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2); 
     
    p2=1-pnorm(z2); 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  Nmean=Nmean+(n1+n2)/nsim  
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} 
 
return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
} 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.024,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% 
 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% 
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## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75%  
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% information fraction 
 
#Survival Endpoint 
#O’Brien-Fleming efficacy boundaries 
# Effect size ratio method 
 
es=function(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
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            w=0.70711,cP=0.9){ 
   
   
  set.seed(1736) 
   
 
  FSP=0; ESP=0; Nmean=0; power=0  
   
   
  m.strategy=(k*ma.pos+(1-k)*mb.neg) 
  m.reverse=(k*mb.pos+(1-k)*ma.neg) 
   
   
   
   
  nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
   
   
  hr=m.strategy/m.reverse 
   
  prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
   
  prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-
tAcr))-exp((-(log(2)/m.reverse))*tStd))) 
   
   
   
  Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
   
  n1=Nclassic*f 
   
  nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
   
  rx=log(2)/m.strategy 
  ry=log(2)/m.reverse 
   
  diff=rx-ry 
   
  if (case=="null"){rx=ry} 
   
  r=(rx+ry)/2 
   
  expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
   
  sigma=r*(1+expTerm)^(-0.5) 
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  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(Nclassic, (er^2)*Nclassic)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    Nmean=Nmean+nfinal/nsim 
     
  } 
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   return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
   
} 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
   
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% information fraction 
 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
####Similar codes for 50% and 75% information fraction 
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## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
 
#### Similar codes for 50% and 75% information fraction 
 
 
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.002,alpha0=1,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% information fraction 
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#Binary Endpoint 
#Pocock efficacy boundaries 
# Conditional power method 
 
 
 
cp=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
            ry=0.57,n1=78,diff=0.15,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=1/sqrt(2),cP=0.8){ 
 
 
 
 
set.seed(1736) 
 
FSP=0; ESP=0; nmean=0; power=0  
 
 
 
nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
 
nmax=nclassic+100 
 
r=(rx+ry)/2 
  
sigma=sqrt(r*(1-r)) 
 
 
 
 
for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
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  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2); 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2); 
     
    p2=1-pnorm(z2); 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  nmean=nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
} 
 
 
## For rx=0.72 and ry=0.57 
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#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=1,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=1,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% information fraction 
 
 
 
## For rx=0.74 and ry=0.57 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=1,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.74, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=1,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Similar codes for 50% and 75% information fraction 
 
 
#Binary Endpoint 
#Pocock efficacy boundaries 
# Effect size ratio method 
 
 
 
es=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
          ry=0.57,n1=78, n0=156, diff=0.15,alpha1=0.0026, alpha0=1, 
          alpha2=0.0240){ 
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  set.seed(1736) 
   
  FSP=0; ESP=0; nmean=0; power=0  
   
   
   
  nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
   
  nmax=nclassic+100 
   
  r=(rx+ry)/2 
   
  sigma=sqrt(r*(1-r)) 
   
   
   
  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(n0, (er^2)*n0)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
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        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    nmean=nmean+nfinal/nsim 
     
  } 
  
   return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
   
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.57, 
            ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.016, alpha0=1, 
            alpha2=0.009) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.016, alpha0=1, 
   alpha2=0.009) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
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#Survival Endpoint 
#Pocock efficacy boundaries 
# Conditional power method 
 
 
 
cp=function(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=0.70711,cP=0.9){ 
 
 
 
 
set.seed(1736) 
 
FSP=0; ESP=0; Nmean=0; power=0  
 
 
m.strategy=(k*ma.pos+(1-k)*mb.neg) 
m.reverse=(k*mb.pos+(1-k)*ma.neg) 
 
 
 
 
nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
 
 
hr=m.strategy/m.reverse 
 
prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
 
prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-tAcr))-
exp((-(log(2)/m.reverse))*tStd))) 
 
 
 
Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
 
n1=Nclassic*f 
 
nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
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rx=log(2)/m.strategy 
ry=log(2)/m.reverse 
 
diff=rx-ry 
 
if (case=="null"){rx=ry} 
 
r=(rx+ry)/2 
 
expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
  
sigma=r*(1+expTerm)^(-0.5) 
 
 
 
 
for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
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    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2); 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2); 
     
    p2=1-pnorm(z2); 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  Nmean=Nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
} 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
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#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
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#### Similar codes for 50% and 75% Information fraction 
 
 
#Survival Endpoint 
#Pocock efficacy boundaries 
# Effect size ratio method 
 
 
es=function(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=0.70711,cP=0.9){ 
   
   
  set.seed(1736) 
   
 
  FSP=0; ESP=0; Nmean=0; power=0  
   
   
  m.strategy=(k*ma.pos+(1-k)*mb.neg) 
  m.reverse=(k*mb.pos+(1-k)*ma.neg) 
   
     
  nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
   
   
  hr=m.strategy/m.reverse 
   
  prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
   
  prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-
tAcr))-exp((-(log(2)/m.reverse))*tStd))) 
   
   
   
  Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
   
  n1=Nclassic*f 
   
  nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
 471 
 
   
  rx=log(2)/m.strategy 
  ry=log(2)/m.reverse 
   
  diff=rx-ry 
   
  if (case=="null"){rx=ry} 
   
  r=(rx+ry)/2 
   
  expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
   
  sigma=r*(1+expTerm)^(-0.5) 
   
   
   
   
  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(Nclassic, (er^2)*Nclassic)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
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        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    Nmean=Nmean+nfinal/nsim 
     
  } 
  
   return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
   
} 
 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
   
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
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es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
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es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.016,alpha0=1,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 505 and 75% Information fraction 
 
 
 
D.3.2. Simulation study 2 
  #Binary Endpoint 
#O’ Brien-Fleming efficacy boundaries 
# Conditional power method 
 
 
 
cp=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
            ry=0.57,n1=78,diff=0.15,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=1/sqrt(2),cP=0.8){ 
 
 
 
 
set.seed(1736) 
 
FSP=0; ESP=0; nmean=0; power=0  
 
 
 
nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
 
 
nmax=nclassic+100 
 
 
r=(rx+ry)/2 
  
sigma=sqrt(r*(1-r)) 
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for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
     
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
     
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2) 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2) 
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    p2=1-pnorm(z2) 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  nmean=nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=0.124,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=0.124,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For rx=0.74 and ry=0.57 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=0.124,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.74, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.002,alpha0=0.124,alpha2=0.0240, 
   w=1/sqrt(2),cP=0.8) 
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#### Similar codes for 50% and 75% Information fraction 
 
 
 
#Binary Endpoint 
#O’ Brien-Fleming efficacy boundaries 
# Effect size ratio method 
 
 
 
es=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
          ry=0.57,n1=78, n0=156, diff=0.15,alpha1=0.0026, alpha0=1, 
          alpha2=0.0240){ 
   
   
  set.seed(1736) 
   
  FSP=0; ESP=0; nmean=0; power=0  
   
   
   
  nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
   
   
  nmax=nclassic+100 
   
  r=(rx+ry)/2 
   
  sigma=sqrt(r*(1-r)) 
   
   
   
  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
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    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(n0, (er^2)*n0)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    nmean=nmean+nfinal/nsim 
     
  } 
  
   return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
   
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.57, 
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            ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.002, alpha0=0.124, 
            alpha2=0.0240) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.002, alpha0=0.124, 
   alpha2=0.0240) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
#Survival Endpoint 
#O’ Brien-Fleming efficacy boundaries 
# Conditional power method 
 
 
 
cp=function(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=0.70711,cP=0.9){ 
 
 
 
 
set.seed(1736) 
 
FSP=0; ESP=0; Nmean=0; power=0  
 
 
m.strategy=(k*ma.pos+(1-k)*mb.neg) 
m.reverse=(k*mb.pos+(1-k)*ma.neg) 
 
 
 
 
nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
 
 
hr=m.strategy/m.reverse 
 
prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
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prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-tAcr))-
exp((-(log(2)/m.reverse))*tStd))) 
 
 
 
Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
 
n1=Nclassic*f 
 
nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
 
rx=log(2)/m.strategy 
ry=log(2)/m.reverse 
 
diff=rx-ry 
 
if (case=="null"){rx=ry} 
 
r=(rx+ry)/2 
 
expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
  
sigma=r*(1+expTerm)^(-0.5) 
 
 
 
 
for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
  } 
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  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2); 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2); 
     
    p2=1-pnorm(z2); 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  Nmean=Nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
} 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.024,w=(1/sqrt(2)),cP=0.8) 
 
 
 482 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
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## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
#Survival Endpoint 
#O’ Brien-Fleming efficacy boundaries 
# Effect size ratio method 
 
 
 
es=function(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=0.70711,cP=0.9){ 
   
   
  set.seed(1736) 
   
 
  FSP=0; ESP=0; Nmean=0; power=0  
   
   
  m.strategy=(k*ma.pos+(1-k)*mb.neg) 
  m.reverse=(k*mb.pos+(1-k)*ma.neg) 
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  nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
   
   
  hr=m.strategy/m.reverse 
   
  prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
   
  prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-
tAcr))-exp((-(log(2)/m.reverse))*tStd))) 
   
   
   
  Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
   
  n1=Nclassic*f 
   
  nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
   
  rx=log(2)/m.strategy 
  ry=log(2)/m.reverse 
   
  diff=rx-ry 
   
  if (case=="null"){rx=ry} 
   
  r=(rx+ry)/2 
   
  expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
   
  sigma=r*(1+expTerm)^(-0.5) 
   
   
   
   
  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
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    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(Nclassic, (er^2)*Nclassic)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    Nmean=Nmean+nfinal/nsim 
     
  } 
  
   return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
   
} 
 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
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es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
   
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75%  
 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
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#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.002,alpha0=0.124,alpha2=0.0240,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% Information fraction  
 
 
#Binary Endpoint 
#Pocock efficacy boundaries 
# Conditional power method 
 
 
 
 
cp=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
            ry=0.57,n1=78,diff=0.15,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=1/sqrt(2),cP=0.8){ 
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set.seed(1736) 
 
FSP=0; ESP=0; nmean=0; power=0  
 
 
 
nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
 
nmax=nclassic+100 
 
r=(rx+ry)/2 
  
sigma=sqrt(r*(1-r)) 
 
 
 
 
for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
  } 
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  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2); 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2); 
     
    p2=1-pnorm(z2); 
     
    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  nmean=nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=0.124,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=0.124,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
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## For rx=0.74 and ry=0.57 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.57, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=0.124,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,alpha=0.025, beta=0.2, ni=0,rx_0=0.74,ry_0=0.57,rx=0.74, 
   ry=0.57,n1=39,diff=0.15,alpha1=0.016,alpha0=0.124,alpha2=0.009, 
   w=1/sqrt(2),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
 
#Binary Endpoint 
#Pocock efficacy boundaries 
# Effect size ratio method 
 
 
 
es=function(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
          ry=0.57,n1=78, n0=156, diff=0.15,alpha1=0.0026, alpha0=1, 
          alpha2=0.0240){ 
   
   
  set.seed(1736) 
   
  FSP=0; ESP=0; nmean=0; power=0  
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  nclassic=(((qnorm(1-alpha)+ qnorm(1-beta))^2)*(rx_0*(1-rx_0)+ry_0*(1-
ry_0)))/((diff)^2) 
   
  nmax=nclassic+100 
   
  r=(rx+ry)/2 
   
  sigma=sqrt(r*(1-r)) 
   
   
   
  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(n0, (er^2)*n0)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
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        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    nmean=nmean+nfinal/nsim 
     
  } 
  
   return(cbind(nclassic,nmean,power,FSP,ESP)) 
 
   
} 
 
 
## For rx=0.72 and ry=0.57 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.57, 
            ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.016, alpha0=0.124, 
            alpha2=0.009) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,alpha=0.025, beta=0.2, ni=0, rx_0=0.72,ry_0=0.57,rx=0.72, 
   ry=0.57,n1=39, n0=156, diff=0.15,alpha1=0.016, alpha0=0.124, 
   alpha2=0.009) 
 
 
 
#### Similar codes for 505 and 75% Information fraction 
 
 
#Survival Endpoint 
#Pocock efficacy boundaries 
# Conditional power method 
 
 
 
cp=function(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
            w=0.70711,cP=0.9){ 
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set.seed(1736) 
 
FSP=0; ESP=0; Nmean=0; power=0  
 
 
m.strategy=(k*ma.pos+(1-k)*mb.neg) 
m.reverse=(k*mb.pos+(1-k)*ma.neg) 
 
 
 
 
nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
 
 
hr=m.strategy/m.reverse 
 
prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
 
prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-tAcr))-
exp((-(log(2)/m.reverse))*tStd))) 
 
 
 
Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
 
n1=Nclassic*f 
 
nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
 
rx=log(2)/m.strategy 
ry=log(2)/m.reverse 
 
diff=rx-ry 
 
if (case=="null"){rx=ry} 
 
r=(rx+ry)/2 
 
expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
  
sigma=r*(1+expTerm)^(-0.5) 
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for(iSim in 1:nsim){ 
   
   
  rx1=rnorm(1,rx,sigma/sqrt(n1)) 
   
  ry1=rnorm(1,ry,sigma/sqrt(n1)) 
   
   
  t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma;  
   
  p1=1-pnorm(t1) 
   
   
  if (p1>alpha0){ 
     
    FSP=FSP+1/nsim 
    n2=0 
  } 
   
   
  if (p1<=alpha1){ 
     
    power=power+1/nsim 
    ESP=ESP+1/nsim 
    n2=0 
  } 
   
   
  if (p1>alpha1 & p1<=alpha0) { 
     
    eSize=diff/sigma 
     
    Cfun=(qnorm(1-alpha2)-w*qnorm(1-p1))/w 
     
    n2=min(nmax-n1,2*((Cfun-qnorm(1-cP))/eSize)^2); 
     
    rx2=rnorm(1,rx,sigma/sqrt(n2)) 
    ry2=rnorm(1,ry,sigma/sqrt(n2)) 
     
    t2=(rx2-ry2+ni)*sqrt(n2/2)/sigma 
     
    z2=(t1+t2)/sqrt(2); 
     
    p2=1-pnorm(z2); 
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    if (p2<=alpha2) {power=power+1/nsim} 
     
  } 
   
  Nmean=Nmean+(n1+n2)/nsim  
   
} 
 
return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
} 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7,mb.neg=4.3, mb.pos=4.3, ma.neg=6,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
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#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.3,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
cp(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3,mb.neg=4.3, mb.pos=4.3, ma.neg=6.6,  
   f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
#Survival Endpoint 
#Pocock efficacy boundaries 
# Effect size ratio method 
 
 
es=function(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=12,tStd=36,ma.pos=6,mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.5,alpha1=0.0026,alpha0=1,alpha2=0.0240, 
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            w=0.70711,cP=0.9){ 
   
   
  set.seed(1736) 
   
 
  FSP=0; ESP=0; Nmean=0; power=0  
   
   
  m.strategy=(k*ma.pos+(1-k)*mb.neg) 
  m.reverse=(k*mb.pos+(1-k)*ma.neg) 
   
   
   
   
  nclassic=2*((qnorm(1-alpha)+ qnorm(1-beta))^2)/((log(m.strategy/m.reverse))^2) 
   
   
  hr=m.strategy/m.reverse 
   
  prob.strategy=1-((1/((log(2)/m.strategy)*tAcr))*(exp((-(log(2)/m.strategy))*(tStd-
tAcr))-exp((-(log(2)/m.strategy))*tStd))) 
   
  prob.reverse=1-((1/((log(2)/m.reverse)*tAcr))*(exp((-(log(2)/m.reverse))*(tStd-
tAcr))-exp((-(log(2)/m.reverse))*tStd))) 
   
   
   
  Nclassic=nclassic/(0.5*prob.strategy+0.5*prob.reverse) 
   
  n1=Nclassic*f 
   
  nmax=Nclassic+100    ####### Allow recruitment of additional 100 patients  
   
  rx=log(2)/m.strategy 
  ry=log(2)/m.reverse 
   
  diff=rx-ry 
   
  if (case=="null"){rx=ry} 
   
  r=(rx+ry)/2 
   
  expTerm=exp(-r*tStd)*(1-exp(r*tAcr))/(tAcr*r) 
   
  sigma=r*(1+expTerm)^(-0.5) 
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  for(iSim in 1:nsim){ 
     
     
    rx1=rnorm(1,rx,sigma/sqrt(n1)) 
     
    ry1=rnorm(1,ry,sigma/sqrt(n1)) 
     
     
    t1=(rx1-ry1+ni)*sqrt(n1/2)/sigma; 
     
    p1=1-pnorm(t1) 
     
     
    if (p1>alpha0){FSP=FSP+1/nsim; nfinal=n1} 
   
    if (p1<=alpha1){power=power+1/nsim; ESP=ESP+1/nsim; nfinal=n1} 
     
    if (p1>alpha1 & p1<=alpha0) { 
       
      if (diff*(rx1-ry1+ni)<0) {nfinal=n1} 
       
      er=diff/(abs(rx1-ry1)+0.0000001) 
       
      nfinal=min(nmax, max(Nclassic, (er^2)*Nclassic)) 
       
      if (nfinal>n1) { 
         
        rx2=rnorm(1,rx,sigma/sqrt(nfinal-n1)) 
         
        ry2=rnorm(1,ry,sigma/sqrt(nfinal-n1)) 
         
        t2=(rx2-ry2+ni)*sqrt((nfinal-n1)/2)/sigma 
         
        z2=(t1+t2)/sqrt(2) 
         
        p2=1-pnorm(z2) 
         
        if (p2<=alpha2) {power=power+1/nsim} 
         
      } 
       
    } 
     
    Nmean=Nmean+nfinal/nsim 
 499 
 
     
  } 
  
   return(cbind(nclassic,Nclassic,hr,Nmean,power,FSP,ESP)) 
 
   
} 
 
 
 
## For ma.pos=6, ma.neg=6.7, mb.neg=4.3, mb.pos=4.3 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
   
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.7, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Similar codes for 50% and 75% Information fraction 
 
## For ma.pos=6.7, ma.neg=6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.7, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
## For ma.pos=6.6, ma.neg=6.3, mb.neg=4.3, mb.pos=4.3 
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#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.6, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.3, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
#### Similar codes for 50% and 75% Information fraction 
 
 
 
## For ma.pos=6.3, ma.neg=6.6, mb.neg=4.3, mb.pos=4.3 
 
 
#### Test null hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="null",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
#### Test alternative hypothesis__Information fraction=25%__No futility stopping 
es(nsim=1000000,case="alternative",alpha=0.025, beta=0.2, 
ni=0,k=0.2,tAcr=104.28,tStd=116.28,ma.pos=6.3, 
   mb.neg=4.3, mb.pos=4.3, ma.neg=6.6, 
f=0.25,alpha1=0.016,alpha0=0.124,alpha2=0.009,w=(1/sqrt(2)),cP=0.8) 
 
 
 
#### Similar codes for 50% and 75% Information fraction 
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D.3.3. Type I error probabilities 
 
The type I error probabilities derived from O’Brien-Fleming and Pocock type 
spending functions for a two-stage design with one-sided 0.025 significance level can 
be calculated in R software by the following codes: 
2-2*pnorm(qnorm(1-0.025/2)/sqrt(1/2)) # O’Brien-Fleming type boundary in stage 1 
0.025-(2-2*pnorm(qnorm(1-0.025/2)/sqrt(1/2))) # O’Brien-Fleming boundary in stage 
#2 
0.025*log(1+((exp(1)-1)*(1/2))) # Pocock boundary in stage in stage 1 
0.025-(0.025*log(1+((exp(1)-1)*(1/2)))) # Pocock boundary in stage 2 
In case of two-sided 0.05 significance level, the aforementioned one-sided 
stopping boundaries would be multiplied by 2. Additionally, the aforementioned 
calculations can be performed by the package GroupSeq in R statistical software 
which computes probabilities regarding group sequential designs including the 
O’Brien-Fleming and Pocock type spending functions. 
 
 
 
